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Abstract 
Malaria kills over one million people per year and has devastating social and economic 
effects on endemic countries. It is caused by the Plasmodium parasite which has a history of 
developing resistance to anti-malarial drugs, meaning new therapeutics are urgently required. 
A key event in the Plasmodium life cycle is the invasion of human erythrocytes. The force for 
this invasion is derived from an actomyosin motor located inside the parasite plasma 
membrane. This molecular motor consists of a type XIV myosin, Myosin A (MyoA), bound 
to myosin tail interacting protein (MTIP). The MTIP/MyoA protein-protein interaction is a 
potential anti-malarial drug target; disruption of this complex should stall erythrocyte 
invasion and kill the parasite. 
In the work discussed in this thesis the MyoA tail was mimicked using short chain peptides 
for the study of MTIP/MyoA binding in vitro. Development of fluorescence assays for the 
analysis of MyoA peptide binding to MTIP and the screening of potential inhibitors of this 
complex is described, together with the application of these assays to identify novel binding 
motifs at the MTIP/MyoA interface. In combination with peptide arrays, these fluorescence 
assays were also used to investigate MTIP binding to Myosin B (MyoB), another 
Plasmodium myosin of unknown function. No binding partners of MyoB have yet been 
identified in vivo, but results reported here show that MTIP can bind MyoB peptides in vitro.  
CD spectroscopy and protein NMR experiments were used to investigate the structures of 
MTIP/MyoA and MTIP/MyoB peptide complexes in solution, and indicate that MTIP 
undergoes a large conformational change upon myosin peptide binding. These structural 
techniques together with the fluorescence assays provide a platform for future drug discovery 
efforts targeting MTIP/MyoA.  
Finally, the information obtained concerning the MTIP/MyoA interaction was used to design 
and synthesise α-helix mimetic compounds of MyoA. These compounds were examined for 
inhibition activity against MTIP/MyoA using fluorescence assays, and appear to be able to 
disrupt MTIP/MyoA complex formation in vitro. This provides a starting point for future 
anti-malarial drug development and is a further step towards the chemical validation of 
MTIP/MyoA as a drug target. 
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Chapter 1   Introduction 
 
This thesis details investigations targeting the MTIP/MyoA protein-protein interaction that is 
involved in the invasion motor of Plasmodium parasites, and is therefore a potential anti-
malarial drug target. In order to understand the context of this work, this chapter provides an 
introduction to malaria, the MTIP/MyoA complex and modulation of helix-protein 
interactions using small molecules. 
The global burden of malaria is briefly described, followed by a closer look at the 
Plasmodium parasite focussing on the invasion of erythrocytes and the composition of 
apicomplexan actomyosin molecular motors. A brief discussion of motion generated by 
actomyosin motors precedes an in-depth analysis of the MTIP and Myosin A proteins in 
terms of their function in Plasmodium and similarities across the apicomplexan phylum. 
X-ray crystallography data for the MTIP/MyoA tail peptide complex suggests that MTIP 
wraps around the MyoA tail α-helix, forming a high-affinity interaction.  
The final section of this literature review concerns protein-protein interactions as drug 
targets, including the properties of protein-protein interfaces and how these may be 
modulated using molecular mimics of protein α-helices. Finally, the evidence for 
MTIP/MyoA as a drug target is summarised, concluding with an outline of the project aims 
and objectives.  
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1.1. Malaria overview 
Malaria is a potentially fatal disease caused by several species of the genus Plasmodium, 
eukaryotic, single-celled protozoan that are transmitted by the bites of female Anopheles 
mosquitoes. It infects 200–300 million people each year and kills almost 800,000,1 most of 
whom are pregnant women and young children due to their weaker immune systems. Within 
the genus Plasmodium there are four species that can affect humans: P. falciparum, P. vivax, 
P. malariae and P. ovale.2 Recently, there have also been reports of human infection by 
P. knowlesi (a species that normally causes non-human primate malaria) in South-East Asia.3 
Of these species, P. falciparum is by far the most deadly, accounting for 95% of all malaria-
related deaths.4 Socially, malaria can have severe long-term effects on the cognitive 
development and education of those children who survive the disease,5 and it is also linked to 
low birth weights and hindered foetal development when it infects pregnant women.6 These 
effects, combined with poor record keeping and diagnosis in many malaria-endemic 
countries, suggest that the number of people dying due to malaria-related factors is likely to 
be much higher than the quoted figure of 800,000. 
1.1.1. Global distribution 
Malaria is endemic in 108 countries across the globe, putting over 40% of the world’s 
population at risk.7 It mainly occurs in developing countries in equatorial and sub-tropical 
regions, as shown in Figure 1. Many factors influence the distribution of malaria 
transmission, relating to the parasite, the vector species and the environment. Environmental 
conditions, such as rainfall, temperature and humidity influence the abundance and survival 
of mosquitoes. The optimal temperature for Plasmodium sporogony is between 20–30 °C, 
and below this temperature the parasite is unable to develop,8 meaning malaria thrives in hot, 
tropical regions. Approximately 60 species of Anopheles are able to transmit malaria under 
natural conditions, and of these, around 30 are of major importance due to their high vectorial 
capacity (the efficiency with which mosquitoes carry malaria from one human to another).9 
Anopheles gambiae is the most efficient vector, and this is found exclusively in sub-Saharan 
Africa, indicating why this area has the greatest number of malaria cases; almost 90% of 
malaria deaths occur in this region.10 P. falciparum, the deadliest form of the parasite, is also 
prevalent in this area, contributing to the high death toll.  
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Figure 1: Map showing the global distribution of malaria transmission risk.11 Malaria is found in 
developing countries in equatorial regions of the globe. 
It may be noted from Figure 1 that malaria is dominant in poor countries. In addition to the 
high death rate, malaria also carries a devastating social and economic burden, meaning 
malaria and poverty are intimately related.12 It is estimated that malaria costs Africa more 
than US$12 billion annually,9 due to both direct expenditure on attempted prevention and 
disease control methods, and indirect expenditure, such as working days lost due to ill health. 
It can also be difficult to find ways to recoup this money, as malaria is likely to discourage 
foreign investment and tourism in endemic regions; between 1965–1990 the economic 
growth rates of malarious countries were 1.3% lower than those that were malaria-free.12  
1.1.2. The life cycle of the parasite 
The malaria parasite has an extremely complex life cycle, involving both a vertebrate and an 
insect host, as illustrated in Figure 3. Sporozoites are injected into the human bloodstream 
when an infected mosquito takes a blood meal. These travel to the liver where they penetrate 
hepatocyte cells. In order to reach hepatocytes, sporozoites must transverse the sinusoidal 
layer which is believed to involve migration through Kupffer macrophage cells (Figure 2). 
Plasmodium parasites do not contain the motile organelles cilia or flagella, and so this occurs 
through gliding motility, a substrate-dependent form of locomotion during which the parasite 
maintains a fixed shape.13 On reaching the liver, the sporozoite migrates through several 
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hepatocytes before productive invasion to cause infection (Figure 2).14 This cell transversal 
occurs by disruption of the host cell membrane; the membrane is broken but is quickly 
repaired by the hepatocyte. In contrast, successful sporozoite invasion of hepatocytes occurs 
via invagination; the hepatocyte membrane folds in on itself to enclose the sporozoite in a 
parasitophorous vacuole.13 The mechanism of this invasion is not well understood, nor the 
triggers which lead to active invasion rather than migration. The circumsporozoite protein 
and thrombospondin-related adhesive protein (TRAP) receptors on the sporozoite surface 
appear to mediate invasion through interaction with heparan sulphate proteoglycans on the 
hepatocyte surface.15 It is postulated that migration through hepatocytes prior to invasion 
activates sporozoites for invasion, possibly due to molecules in the host cell cytosol 
triggering signalling pathways.16  
 
Figure 2: Plasmodium sporozoite invasion of hepatocyte cells.17 Sporozoites enter the bloodstream 
(1) and upon reaching the liver make contact with heparan sulfate proteoglycans (HSPG) on liver cell 
surfaces (2). This acts as a signal to invade and the sporozoite crosses the sinusoidal layer between the 
bloodstream and the liver, likely through Kupffer cells (3), to access hepatocytes. The sporozoite 
migrates through several hepatocytes (4) before productive invasion, which is associated with the 
formation of a parasitophorous vacuole (5).17 
Once inside the hepatocyte, the sporozoites mature and multiply into merozoites over a 
period of 9–16 days, in a process known as exo-erythrocytic schizogony. Tens of thousands 
of merozoites are generated in this time.18 In P. vivax and P. ovale, a proportion of 
sporozoites develop into hypnozoites which may remain dormant in the liver for weeks, 
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months, or even years before they undergo exo-erythrocytic schizogony, leading to relapsing 
malaria. This cannot happen for P. falciparum or P. malariae. Instead, the liver cells burst 
and the merozoites are released into the bloodstream. Here, each merozoite immediately 
(within minutes) enters a red blood cell to initiate intra-erythrocytic schizogony. Asexual 
division begins and the parasite develops through ring and trophozoite stages before forming 
a schizont, which contains approximately 20 new merozoites (Figure 3).19 Erythrocyte lysis 
results in these merozoites being released back into the bloodstream where they can invade 
further red blood cells. This cycle of invasion-multiplication-egression takes about 48 hours, 
occurring synchronously. The eruption of the erythrocyte stimulates the production of tumour 
necrosis factor, triggering an immune response.9 This is responsible for the cyclic symptoms 
associated with malaria, such as fever, shivering, headache and vomiting. 
 
Figure 3: The life cycle of the Plasmodium parasite.20 The complex life cycle involves both a 
vertebrate (in this case human) and an insect (mosquito) host. 
Intra-erythrocytic schizogony modifies the outer red blood cell surface, causing it to become 
sticky due to parasite expressed proteins, meaning it can adhere to host endothelial cells, 
preventing them being cleared by the spleen. This is predominantly observed in P. falciparum 
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malaria, and can lead to fatal complications when these parasite-infested red blood cells are 
sequestered in the brain (cerebral malaria) or the placenta (placental malaria).21  
During merozoite replication, some merozoites differentiate into micro- and 
macrogametocytes (male and female respectively), the reproductive forms of the parasites. It 
is unclear what triggers this event. These may be taken up by an uninfected mosquito when it 
takes a blood meal, so propagating the life cycle. Once inside the mosquito’s midgut, these 
develop into micro- and macrogametes, which fuse and undergo fertilisation to form a 
zygote. Within 18–24 hours, these zygotes transform into motile ookinetes, which are able to 
pass through a cell wall in the midgut, and develop into an oocyst. Thousands of sporozoites 
are created inside the oocyst, which migrate to the salivary glands upon cell lysis. Ten to 24 
days after initial infection, the mosquito is ready to infect another susceptible victim upon 
taking a blood meal, so perpetuating the life cycle.19 
1.1.3. Current control and treatments 
Despite the high death toll, malaria is both preventable and curable, but there are many 
obstacles associated with this. Several charities have been set up in recent years to coordinate 
and develop these methods, including the World Health Organisation (WHO) Roll Back 
Malaria programme, the Medicines for Malaria Venture and The Global Fund to Fight AIDS, 
TB and Malaria. In 2007 the Bill and Melinda Gates Foundation announced their ambitious 
goal to work towards the eradication of malaria.22 This will require a combination of all 
current prevention and treatment methods, in addition to concentrating research on 
developing new tools and techniques.23 
1.1.3.1. Prevention 
Vector control is the main measure used to reduce malaria transmission, the aim of which is 
to protect individuals from infectious mosquito bites. There are currently two methods for 
achieving this; indoor residual spraying (IRS) and insecticide-treated mosquito nets (ITNs). 
IRS consists of the application of approved insecticides to the inside surfaces of homes in 
endemic areas. It can be incredibly effective when applied properly to sufficient houses in an 
area (>80%), and can last up to 6 months.2 However, this requires strong infrastructure and 
organisation at both national and local levels, which is not always feasible. Other significant 
issues include the development of mosquito resistance against the insecticides used, and the 
toxicity of insecticides to other organisms, including humans.  
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Comprehensive distribution of ITNs is the other way in which the intensity of malaria 
transmission is being reduced, in particular by the use of long-lasting insecticidal nets 
(LLINs), which can last up to 5 years without the need for re-treatment. Again though, there 
are difficulties ensuring entire populations own one, and that they are used correctly. In 2010 
it was estimated that 42% of African households owned at least one net, an increase from 
17% in 2006, but still much lower than the WHO target of 80%.1,7 
The most potent way to control infectious diseases is through vaccination, but there are 
several problems associated with development of a vaccine against malaria, although there is 
much ongoing research into this area. As yet there are no examples of vaccines against 
parasites, only viruses and bacteria. This is largely due to the complexity of parasitic species, 
which makes it difficult to identify possible vaccine targets.4 In addition, the Plasmodium life 
cycle is extremely complicated and incorporates several distinct forms (Figure 3), all of 
which express different antigens with high levels of variability, making design of a vaccine 
that can target all phases of the parasitic life cycle extremely challenging.24 The parasite also 
travels quickly around the body and spends its time inside host cells where it is hidden from 
the host immune system. However, there are indications that a vaccine may one day be 
successful; namely, that populations living in endemic areas have been shown to develop 
natural acquired immunity against malaria; although carrying the parasite, they are able to 
tolerate it so that clinical disease does not occur.25 Over the past 15 years, several vaccine 
candidates have been tested in clinical trials, mainly against sporozoite and liver stages of the 
life cycle. Although some have been shown to provide a degree of immunity, it is not 
generally as strong or long-lasting as is desired,26 meaning it is likely to be several years, if 
ever, until a malaria vaccine is commonplace. 
Another recent advancement towards vector control is the genetic modification (GM) of 
Anopheles mosquitoes so that they are no longer able to sustain or transmit Plasmodium. This 
may overcome problems such as that of mosquito resistance to pesticides, but generates 
further ethical considerations of its own over the prolonged fitness, spread and maintenance 
of GM mosquitoes in the wild.27 
1.1.3.2. Treatment 
The lack of a vaccine and problems associated with the various prevention methods mean that 
reliable treatments are vital in the fight against malaria. The first specific treatment for 
malaria was found during the 18th century, from the bark of the Cinchona tree. The active 
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ingredient was later identified to be quinine, and this led to the synthesis of chloroquine, a 
derivative of quinine, consisting of a 4-amino-quinoline scaffold (Figure 4).28 Chloroquine 
was inexpensive and highly effective, and was used extensively in the malaria eradication 
programme of the 1940’s and 1950’s, even being added to table salt in some places, to ensure 
widespread coverage. However, it is likely that this overuse led to the appearance of 
Plasmodium resistance to this compound in the late 1950s. This resistance is believed to arise 
due to a mutation in the chloroquine resistance transporter protein (PfCRT), which promotes 
chloroquine efflux and prevents the drug from accumulating at its site of action, the 
Plasmodium food vacuole.29 Today, chloroquine-resistant strains of P. falciparum are found 
all over the world, leaving it redundant in many areas, particularly in Africa.30 
 
Figure 4: The structures of existing antimalarial drugs.30 
In an attempt to overcome this resistance, several more compounds based on the 4-amino-
quinoline or the similar aryl amino alcohol scaffolds were synthesised, including 
amodiaquine, mefloquine and halofantrine (Figure 4). It is generally accepted that this class 
of compounds acts by interference of the degradation of haemoglobin by the parasite.31 
During the intra-erythrocytic cycle, haemoglobin is ingested into the parasite, where it is 
Chloroquine Amodiaquine Mefloquine Halofantrine
Sulfadoxine Pyrimethamine Proguanil Atovaquone
Artemisinin Artemether Artesunate
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metabolised. The haem moiety is potentially toxic to the parasite, so is converted to 
haemozoin crystals which are stored in the food vacuole. The quinoline-based drugs are 
thought to prevent this process occurring. However, use of these compounds has been limited 
due to the occurrence of dangerous side-effects, such as agranulocytosis (amodiaquine), 
neuropsychosis (mefloquine), and heart arrhythmia (halofantrine).30 There have also been 
cases of parasite resistance.32  
The second class of antimalarials are the antifolates, the best known examples of which are 
sulfadoxine and pyrimethamine (Figure 4), which are generally given in a combination 
therapy (known as Fansidar). This combination acts synergistically against parasitic folate 
synthesis by inhibiting the enzymes dihydropteroate synthase and dihydrofolate reductase. 
Again, there have been incidences of parasitic resistance against this therapy, particularly in 
South-East Asia and East Africa.32 
Proguanil also targets dihydrofolate reductase upon formation of cycloproguanil, but has low 
efficacy when used as a monotherapeutic. Instead it is used in tandem with atovaquone 
(together known as Malarone, Figure 4). Atovaquone inhibits mitochondrial electron 
transport when used alone, but resistance develops quickly due to a mutation in the 
corresponding mitochondrial gene. Remarkably though, when used synergistically, 
atovaquone-proguanil antimalarial activity is potent, although it is not known how these 
species interact. Importantly, they are able to target the liver stage of the parasite, meaning it 
is commonly used as a prophylactic, as it prevents the blood stage and associated symptoms 
developing.30 
Currently, the most widely used treatments for malaria are artemisinin derivatives such as 
artesunate and artemether (shown in Figure 4), which are derived from the Artemisia Annua 
tree. These are all metabolised to the active agent dihydroartemisinin, which is thought to act 
by the formation of free radicals as a result of cleavage of the peroxide bond, which interfere 
with parasitic haem degradation. This drug class can act against gametocytes in addition to 
merozoites, so reducing transmission as well as rapidly clearing parasites from the blood.30 
Artemisinins are given in combination with another anti-malarial as artemisinin combination 
therapies (ACTs), in an effort to prevent the development of resistance. However, recently 
there have been early signs of P. falciparum developing resistance against these compounds 
on the Thai-Cambodian border.33 Were this to become as widespread as chloroquine 
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resistance, the results would be catastrophic. Research into new anti-malarials and possible 
Plasmodium drug targets is therefore urgently required. 
1.1.4. Model systems used to study malaria 
The phylum Apicomplexa contains over 5000 species,34 all of which are defined by the 
presence of an apical complex consisting of specialised secretory organelles, the micronemes, 
rhoptries and dense granules. These are shown in a Plasmodium merozoite in Figure 5. 
Apicomplexa are also characterised by a three-layered pellicle comprised of the plasma 
membrane closely associated with the inner membrane complex, a parallel lattice formed by 
aligned intramembranous particles, supported by subpellicular microtubules.35 Each of these 
features has evolved to promote the unusual gliding motility and active energy-dependent cell 
invasion pathways observed in these species. Apicomplexa do not possess classical means of 
motility such as flagella or cilia, but are able to invade a wide variety of host cells using a 
unique actin-based motion.36  
 
Figure 5: Diagram of a Plasmodium merozoite.37 The labelled organelles and cellular structures are 
characteristic of apicomplexan parasites. 
Within Apicomplexa, P. falciparum is the species most deadly to humans, but it can be 
difficult to study, particularly the blood stages, which survive only transiently outside red 
blood cells. However, important information about this species can be inferred through the 
study of related Apicomplexa, in particular the model organism Toxoplasma gondii, which 
causes Toxoplasmosis, a life-threatening infection in immunocompromised patients.38 Both 
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the P. falciparum and T. gondii genomes have been sequenced, but T. gondii is more readily 
susceptible to genetic modifications than Plasmodium, providing important insights into 
equivalent Plasmodium proteins. The Toxoplasma life cycle is shown in Figure 6. As for 
Plasmodium it involves two different hosts, although in this case both are vertebrates. The 
asexual Toxoplasma tachyzoites are morphologically similar to Plasmodium sporozoites, 
particularly in terms of their motility, and the tachyzoites invade mammalian cells to form a 
parasitophorous vacuole in which they replicate, as is the case for Plasmodium merozoites.39 
Many experiments have initially been carried out on Toxoplasma tachyzoites, and later 
applied to Plasmodium sporozoites and merozoites. However, there are significant variations 
across Apicomplexa, for example host range and transmission, which must be taken into 
account when applying T. gondii data to Plasmodium. 
 
Figure 6: The life cycle of Toxoplasma gondii. In the definitive host (feline), bradyzoites undergo 
schizogony and gametogenesis to form unsporulated oocycts in the intestine. These are released into 
the environment in faeces. Sporogony occurs outside the host to form an infectious, mature oocyst 
containing sporozoites. These may be ingested by the intermediate host (human) where they 
differentiate into tachyzoites, the rapidly replicating, motile form of the parasite that causes acute 
Toxoplasmosis. Tachyzoites develop into bradyzoites, which form tissue cysts. These are immediately 
infectious and can be ingested by another intermediate host or the definitive host to restart the life 
cycle.38,40 Figure adapted from Black et al.40  
Although only five species of Plasmodium are known to infect humans, there are several 
others that infect mammalian hosts, and may be utilised as models to study malaria. 
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Specifically, P. berghei, P. chabaudi and P. yoelii, rodent forms of malaria, are regularly 
used as model organisms in order to study disease behaviour inside an animal host. 
1.2. Plasmodium merozoite invasion of red blood cells 
1.2.1. The mechanism of erythrocyte invasion 
A key event in the parasitic life cycle is the invasion of red blood cells. Once inside, the 
parasite is able to drain the erythrocyte of nutrients whilst remaining protected from the 
host’s immune system. Merozoites are only able to survive extracellularly in the bloodstream 
for approximately 30 minutes; the parasite is therefore vulnerable if erythrocyte entry is 
impeded.34 Plasmodium invasion may be divided into four stages; (1) Initial recognition of 
the erythrocyte by the merozoite (Figure 7A), (2) Reorientation and junction formation 
(Figure 7B), (3) Invagination of the erythrocyte membrane around the merozoite to allow it 
entry into a parasitophorous vacuole (Figure 7C, D), (4) Sealing of the erythrocyte orifice 
(Figure 7E).41  
 
Figure 7: Merozoite invasion of red blood cells.37 The merozoite initially recognises the erythrocyte 
(A) and reorients to form a tight junction between the merozoite apical region with the erythrocyte 
membrane (B). The tight junction is pushed towards the rear of the merozoite as it forces itself into 
the red blood cell (C, D). Finally, the erythrocyte membrane seals around the merozoite, enclosing it 
in a parasitophorous vacuole (E). 
The merozoite initially recognises and attaches itself to an erythrocyte. Primary attachment 
can occur anywhere on the merozoite surface, is generally of low affinity and is reversible.37 
The merozoite then reorients itself so that its apical region forms an irreversible tight junction 
with the erythrocyte membrane, as shown in Figure 7B. The primary contacts are thought to 
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involve interactions between glycosylphosphatidylinositol (GPI) anchored proteins on the 
merozoite surface with erythrocyte receptors. Merozoite surface protein-1 (MSP-1) is the 
most abundant protein on the merozoite surface, and is thought to play a key role at this 
stage; this protein is therefore thought to be a major candidate for malaria vaccine 
development.42 Several proteins, such as the apical membrane antigen (AMA-1), are also 
released from the apical organelles, the micronemes and rhoptries at this time to strengthen 
the initial interactions. It is currently believed that microneme protein secretion is controlled 
by Ca2+ signalling.43 
Once the tight junction is formed invasion is activated, and the junction is pushed towards the 
rear of the merozoite, allowing it to move forwards into the erythrocyte. The erythrocyte 
membrane is not broken during invasion, but folds in on itself through a process known as 
invagination.41 This also occurs during Plasmodium sporozoite invasion of hepatocyte cells. 
Two families of proteins, the Duffy binding-like (DBL) family, and the P. falciparum 
reticulocyte binding protein homologue (PfRh or PhRBL) are thought to be important in 
forming secondary interactions with erythrocyte receptors. There are a wide variety of these 
proteins, each of which mediates different ligand-receptor interactions between the merozoite 
surface and the erythrocyte.44 These interactions define alternative invasion pathways;45 the 
parasite therefore has several different mechanisms at its disposal with which to gain entry 
into red blood cells, meaning it is able to adapt to evade the immune response. As the 
merozoite forces itself further into the erythrocyte, its protein surface coat is shed, via the 
action of the rhomboid family of serine proteases. Finally, the erythrocyte membrane is 
sealed behind the parasite, enclosing it in a parasitophorous vacuole from where it may 
undergo intra-erythrocytic schizogony. The entire invasion process takes approximately 30 
seconds.41  
1.2.2. The Plasmodium actomyosin invasion motor 
The force for this erythrocyte invasion is derived from an actomyosin molecular motor, 
located at the periphery of the parasite, sandwiched between the plasma membrane and the 
inner membrane complex (IMC, Figure 5). This motor was first described in T. gondii 
tachyzoites,46 but is conserved across Apicomplexa, and the proteins involved have also been 
identified in Plasmodium merozoites and sporozoites.47-50 In merozoites the extracellular 
receptor merozoite thrompospondin related anonymous protein (MTRAP) is linked via 
aldolase to actin filaments just inside the plasma membrane (PM). These bind to an unusual 
myosin, Myosin A (MyoA), which in turn forms a complex with myosin tail-domain 
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interacting protein (MTIP, known as myosin light chain 1 (MLC1) in Toxoplasma). This is 
linked to gliding associated proteins GAP45 and GAP50, which anchor the motor to the IMC.  
 
Figure 8: Diagram of the invasion motor in Plasmodium.51 
The tetrameric complex MyoA-MTIP-GAP45-GAP50 is known as the glideosome and is at 
the core of the motor, providing the essential link between the extracellular components and 
the stable anchorage of the IMC (Figure 8). It is generally assumed that these proteins form a 
1:1:1:1 complex,52-54 although there is not yet conclusive evidence for this. Co-
immunoprecipitation experiments are able to pull down all four of these protein species, 
demonstrating that they form a high affinity complex in vivo.48 Expression of each of these 
proteins has been shown to peak around 40 hours post-invasion, just before the release of new 
invasive merozoites, and immunofluorescence staining has shown that they all localise to the 
periphery of the parasite, strongly suggesting a role in invasion.48-50 It also appears that 
MTIP, GAP45 and GAP50 all bind to the IMC, rather than the plasma membrane.46,50,55 
Recently, a fifth member of the glideosome has been identified in T. gondii, GAP40, a 
polytopic IMC protein which is highly conserved across Apicomplexa.56 As for the other 
glideosome proteins, GAP40 localises to the periphery of parasites, and expression of the 
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gene in P. falciparum peaks in late schizonts. GAP40 co-immunoprecipitates with GAP45, 
suggesting it also acts to anchor the motor complex in the IMC.56 This discovery of a new 
protein suggests that further investigations are required before the Plasmodium invasion 
motor can be fully understood.   
The energy required to drive invasion is derived from the hydrolysis of ATP by the MyoA 
head domain. When this occurs, MyoA undergoes a conformational change that results in the 
release of previously bound filamentous (F-) actin, and translocates actin towards the rear of 
the parasitic cell.57 Due to the aldolase linker, this also has the effect of translocating the 
extracellular receptors towards the rear of the cell, and so the parasite is able to propel itself 
forwards to penetrate the erythrocyte. 
The glideosome is an extremely complex system, implying careful regulation must be 
required to organise the correct assembly and activity of the motor, but the exact regulatory 
mechanisms are not yet clear. It appears that Ca2+ signalling, phosphorylation, and actin 
polymerisation all play a significant role. It has been established that glideosome assembly in 
the IMC occurs in two steps; MyoA, MTIP and GAP45 form an initial trimeric complex in 
the cytosol, and this is transported to the IMC where GAP45 binds to GAP50 (an integral 
membrane protein that appears to be co-translationally inserted into the parasite endoplasmic 
reticulum and translocated to the IMC) to anchor the motor in the IMC.46,50 GAP45 contains 
both a myristoylation and a palmitoylation site at its N-terminus. 35S Pulse-chase experiments 
reported by Holder et al.58 indicated that GAP45 is co-translationally N-myristoylated and 
post-translationally palmitoylated. Co-translational N-myristoylation is able to promote 
membrane interaction, but is insufficient to provide a stable anchorage.59 Holder et al. 
therefore proposed that GAP45 myristoylation targets the trimeric complex 
MyoA-MTIP-GAP45 to the IMC, where it is palmitoylated to strengthen IMC association.58 
Palmitoylation is a reversible process,60 and so it is postulated that this may contribute to the 
regulation of complete glideosome formation.53 However, data recently reported by the 
Soldati group56 indicates that N-terminal acylation of GAP45 in T. gondii actually anchors it 
to the plasma membrane, and it is the C-terminus (also predicted to be palmitoylated) that 
links GAP45 to the IMC, although it is not known whether these interactions occur 
simultaneously (Figure 9). In addition to recruiting MTIP-MyoA to the IMC and regulating 
glideosome formation, it seems that GAP45 provides structural cohesion to the pellicle 
during invasion by maintaining a fixed distance and tight connection between the PM and 
IMC. This is illustrated in Figure 9. 
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Figure 9: The alternative arrangement of the apicomplexan glideosome proposed by Soldati et al.56 In 
contrast to the earlier model shown in Figure 8, in this case GAP45 is linked to both the inner 
membrane complex (through its C-terminal domain, CTD) and the plasma membrane (through 
acylations of the N-terminal domain, NTD). This may help maintain the structural integrity of the 
inner membrane complex and plasma membrane pellicle, although it is unclear whether these 
interactions occur simultaneously. 
It has recently been shown that GAP45 and MTIP may be phosphorylated in vitro by 
calcium-dependent protein kinase 1 (CDPK1).61 CDPK1 expression peaks in mature 
schizonts, and it is thought to be located in the plasma membrane, in close proximity to the 
glideosome.53 Inhibitors of this protein have been shown to arrest development at the schizont 
stage, suggesting it plays a key role during invasion.62 Although there is strong evidence for 
GAP45 being phosphorylated in vivo,63 phosphorylated MTIP has not yet been identified in 
parasite lysates. However, it appears that the phosphorylation state of GAP45 could play a 
key role in regulating motor formation. Certainly, in T. gondii, mutation of the 
phosphorylated serine residues 163 and 167 in TgGAP45 to glutamate (to mimic 
phosphorylated serine) prevents the association of the trimeric MyoA-MTIP-GAP45 complex 
with GAP50 in the IMC, indicating that GAP45 may be dephosphorylated for the final stage 
of glideosome assembly.64 It has also been determined that the release of intracellular Ca2+ is 
required for host cell invasion in T. gondii,65 possibly partly due to the key role of CDPK1 in 
this process, although there may be other calcium-dependent kinases or signalling pathways 
that have yet to be identified. 
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Early studies of apicomplexan motility found that host-cell invasion could be halted upon 
treatment with cytochalasin D, a known inhibitor of actin polymerisation, indicating that actin 
polymerisation and depolymerisation is vital during erythrocyte invasion.66 Despite this, it 
has been extremely difficult to isolate filamentous actin, apparently due to the inherent 
instability of the filaments,67 or possibly reflecting the transient nature of the fully intact 
motor complex. There are however, mechanisms within the parasite to promote actin 
polymerisation and nucleation, and these may also be significant during regulation of the 
invasion machinery, in particular the directionality and duration of motility. Formin is one 
such protein that has been implicated in the catalysis of fast actin filament assembly,68 while 
actin depolymerising factor (ADF) is a key actin sequestering protein.67  
Although there is still much uncertainty over the regulation and control of apicomplexan 
glideosome function and assembly, it is clear that it is essential for successful parasite 
invasion of host cells, and therefore parasite survival. This means it is of significant interest 
in terms of new anti-malarial drug development, and is an interesting target for further 
research. 
1.3. The MTIP/Myosin A protein complex 
1.3.1. Actomyosin motors and their myosin light chains 
Actomyosin motors are protein machines that convert chemical potential energy, derived 
from the hydrolysis of ATP, into mechanical work to produce force and movement. They 
participate in a broad range of cellular functions, including muscle contraction, vesicle 
transport and cell locomotion.69 Myosin proteins usually possess a molecular weight of at 
least 100 kDa, and generally consist of a head, a neck and a tail domain (Figure 10). The 
N-terminal head domain is responsible for both ATP hydrolysis and binding to actin 
filaments. The neck domain connects the head to the tail region, and sometimes acts as a 
lever-arm for motility, which may be regulated by the binding of this region to myosin light 
chains. This region usually incorporates one or more IQ motifs (the protein binding sequence 
IQxxxRGxxxR, where standard single letter amino acid abbreviations are used, and x is any 
natural amino acid70). Finally, the C-terminal tail domain may bind different cargoes, which 
often determine the specific localisation and function of the myosin motor.71 The myosin 
superfamily may be divided into classes (also known as types) by phylogenetic analysis of 
the head domain protein sequence. This region tends to be well conserved within a class, as 
the production of force and movement generally occurs via the same mechanisms. The tail 
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domain however may vary significantly, reflecting the role this region plays in determining 
how and where the motor is utilised in the cell. There are currently eighteen known myosin 
classes (Figure 12), which may be split into conventional muscle myosins, and 
unconventional myosins (those required for functions other than muscle contraction).72 
 
Figure 10: Structure of a typical myosin heavy chain in complex with its myosin light chains. The 
myosin molecule (skeletal muscle myosin heavy chain) is shown in blue, with the essential light chain 
(skeletal muscle isoform of myosin light chain 3) in pink and the regulatory light chain (skeletal 
muscle isoform of myosin regulatory light chain 2) in yellow.73 Both the essential and regulatory light 
chains bind to the myosin neck and tail region, while the head domain is responsible for hydrolysis of 
ATP and binding to actin. 
The actomyosin motor generates force by a cyclical process involving the step-wise binding 
of myosin to ATP and F-actin.74 When myosin binds ATP it is unable to form a complex with 
actin. However, upon ATP hydrolysis and the release of phosphate and ADP, a 
conformational change occurs in the myosin head domain, and it is able to form a tight 
complex with actin filaments, creating a sliding force as it does so. Myosin binding of a new 
molecule of ATP results in the dissociation of the actin-myosin complex, and the cycle 
begins again, propagating cell movement. This is illustrated in Figure 11. The rate of actin-
myosin association and dissociation can vary depending on the load of the myosin. The 
length of the lever-arm neck region can also determine the force and speed of movement 
generated.75 
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Figure 11: Actomyosin motors generate force by the cyclical binding of myosin to ATP and 
filamentous actin. Myosin is unable to bind actin when it is bound to ATP (1). Upon ATP hydrolysis, 
there is a conformational change in the myosin head domain which allows it to bind actin filaments 
(2). The release of ADP and phosphate from the myosin head domain causes the myosin power stroke 
through another conformational change which translocates the associated actin filaments (3). The 
cycle is repeated upon the binding of another molecule of ATP.74 Figure adapted from Pinder et al.76 
As mentioned above, the neck domain of myosins may bind to a myosin light chain, usually 
through an IQ motif. In conventional myosin motors, these light chains are small proteins of 
approximately 20 kDa, and are members of the calmodulin family. They are thought to 
stabilise the neck domain and may play a role in regulating motor activity. Calmodulin-like 
proteins generally consist of an N- and a C-terminal domain, containing four helix-loop-helix 
structures, known as EF hands (Figure 17). These regions are able to bind calcium, which 
changes the conformation of the protein allowing it to bind to myosin.77 Myosin light chain 
binding to its heavy chain myosin is therefore often calcium-dependent. Both the N- and C-
terminal domains of the myosin light chain fold around the myosin heavy chain to form a 
tight complex (Figure 17).78,79 
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Figure 12: A phylogenetic tree of the myosin superfamily.80 Type XIV myosins found in Apicomplexa (shown in red, highlighted) show high divergence 
from human muscle myosins (Type II, shown in purple, highlighted), indicated by the length and distance between the branches. PfMyoA is labelled as PfMA 
and PfMyoB is labelled as PfMB.
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1.3.2. Plasmodium myosins, Myosin A and Myosin B 
Studies of the P. falciparum genome have revealed the presence of six genes coding for 
putative myosins, all of which are unconventional myosins named MyoA–MyoF, and all 
seem to be active during the merozoite blood-stage of the life cycle. MyoA has so far been 
the most extensively characterised, and has been found to have similar structure, transcription 
and translation patterns to MyoB, both belonging to the unusual class XIV.81 Class XIV 
myosins represent a novel, divergent class of myosins that have so far been identified only in 
Apicomplexa. They are noticeably different from muscle myosins found in the human body 
(Figure 12). Both MyoA and MyoB are approximately 90 kDa, small proteins by myosin 
standards, and consist of a head domain with a short neck/tail region (in contrast to the two 
heads and long tail region found in type II muscle myosins); of the 818 residues in MyoA, 
only the final 56 amino acids make up the neck/tail domain.82 This MyoA neck/tail region 
contains a putative IQ motif, which implies that it is a short neck with no tail,53 although it is 
often referred to as a short tail with no neck in the literature.76 Analogues of MyoA and 
MyoB have also been isolated and studied in greater detail in T. gondii.67,83 The other four 
myosins identified in Plasmodium appear to be more conventional, being both larger in size 
and containing distinct neck and tail regions.81 Although the myosin light chain binding 
partner for MyoA has been identified and characterised in Plasmodium and Toxoplasma, very 
little is known about the binding partners of other myosins in these species. Recently, 
Frenal et al.84 identified an interaction between T. gondii MyoD (TgMyoD) and myosin light 
chain 2 (TgMLC2), which is bound to the plasma membrane of Toxoplasma tachyzoites. It 
appears that the C-terminal domain of TgMLC2 binds to MyoD and the N-terminal directly 
localises with the membrane, likely through palmitoylation. Surprisingly, no other proteins 
were co-immunoprecipitated with this complex, suggesting it is a two-component complex 
only. The function of this motor is yet to be determined, but the localisation with the PM, 
rather than anchorage in the IMC, indicates that it may have a different role to that of MyoA 
and suggests that the Plasmodium myosins may all have varying functions. 
As described in Section 1.2.2, Plasmodium MyoA forms part of the glideosome and is found 
in all life stages of the parasite. Protein expression peaks in late schizonts and disappears after 
invasion is complete, and immunofluorescence staining has shown that it is located at the 
pellicle around the periphery of the merozoite (the merozoite pellicle is shown Figure 5), 
probably indirectly bound to the IMC.47 Equivalent proteins are present in all Plasmodium 
species, and there is high conservation across the phylum. Knock-out experiments of the 
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MyoA gene in T. gondii have indicated that it is essential for parasite survival.85 TgMyoA 
also binds a myosin light chain (TgMLC1), is located around the periphery of the parasite, 
and is vital for cell invasion.86 TgMyoA and PfMyoA share 63% sequence identity,87 with 
TgMyoA also lacking a neck region and possessing an unusually short tail domain (only 57 
of its 831 amino acids form the tail83), which it uses to bind to TgMLC1. 
Neck regions of myosins usually contain at least one IQ motif, that is utilised to bind to the 
myosin light chain. In P. falciparum MyoA however, it seems that only a partial IQ motif is 
present in the C-terminal region, consisting of residues 807–817 (Figure 13). Residues Q808 
and R812, representing the 2nd glutamine residue and 6th arginine residue of the canonical IQ 
motif are completely conserved across apicomplexan species, but no other required residues 
for an IQ motif are present, and notably the glycine residue usually found in the 7th position 
of the IQ motif has been replaced by lysine in all Plasmodium species. This casts doubt as to 
whether this sequence accurately represents an IQ motif at all. The MyoA tail is however 
highly basic, which is also the case for some other unconventional myosins, in particular 
those that are linked to membranes.83   
 
Figure 13: The sequences of the partial IQ motif in the tail region of several apicomplexan species. 
Conserved residues are written in red, completely conserved residues are highlighted in red. Non-
conserved residues are written in black.88 
All myosins contain a conserved DALAK sequence in the motor head domain, as is the case 
for MyoA and MyoB, and most myosins contain a phosphorylatable residue (threonine or 
serine), or a negatively charged residue (glutamic or aspartic acid) at a site 16 residues 
upstream from the conserved DALAK motif. This is known as the TEDS rule.89 The TEDS 
site is in a region of the myosin head domain that is believed to make significant contact with 
actin when it is negatively charged; phosphorylation at this site may regulate the actomyosin 
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motor.53 It is interesting to note that while Plasmodium does follow this rule, containing a 
threonine residue at the stipulated site, TgMyoA does not, suggesting that despite the 
similarity between the glideosomes and invasion motors in these species, they may be 
regulated by different mechanisms.83 However, it is unclear whether the TEDS site in 
PfMyoA is phosphorylated in vivo.  
Although there has been increasing data available to provide insights into Plasmodium MyoA 
and its associated proteins in recent years, very little is known about MyoB. It is 801 residues 
in length, giving rise to an 88 kDa protein, 17 residues shorter than MyoA in the head 
domain. The minimum length required for myosin motility is 782-786 residues, so it is 
possible that it is also part of a molecular motor that contributes to parasite movement.90  
Using an antibody raised against a bacterially expressed partial sequence of PfMyoB, data 
reported by the Pinder group90 indicated that P. falciparum MyoB is expressed during late-
stage schizonts and merozoites, as is MyoA, suggesting that MyoB may also be important 
during merozoite invasion of erythrocytes. Immunofluorescence images suggest that PfMyoB 
is located towards the anterior of the parasite, possibly with an additional presence in 
subcellular organelles.90 No binding partners have yet been determined for MyoB, and it is 
unclear exactly what its role is within the parasite. It does however, have high basicity in the 
tail region, as does MyoA, and there is possibly a partial IQ motif at the C-terminus (residues 
Q788 and R792 of the MyoB tail are conserved with MyoA and may represent the residues Q 
in the 2nd position and R in the 6th position of the putative IQ motif (Figure 14)), suggesting 
that binding to a myosin light chain may occur. Interestingly, the equivalent MyoB protein in 
T. gondii appears to be significant during cytokinesis of tachyzoites into daughter cells.91 In 
this species two myosins, TgMyoB and TgMyoC, are encoded by the same gene, which gives 
two alternatively spliced mRNAs leading to two proteins of ~110 kDa, with identical head 
regions, but two distinct tails. TgMyoB is the smaller protein, with only 21 residues in its tail 
region, compared to 118 in the tail of TgMyoC, and it has been shown that it is these tail 
domains that determine the localisation of the proteins. TgMyoB was found to localise 
throughout the cytoplasm, and TgMyoC dominates at the posterior end of the parasite, in 
contrast to TgMyoA and PfMyoA localisation, which occurs around the periphery of the 
parasite. Overexpression of TgMyoB resulted in the slowing down of cell division, and the 
presence of residual bodies lacking an IMC and key organelles, which reduced the virulence 
of infection in mice.91 Taken together, these results indicate that this protein is important 
during T. gondii cell division. Similar experiments in Plasmodium have not yet been carried 
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out, but this data suggests that PfMyoB could also be significant during intra-erythrocytic 
schizogony, and malaria propagation.  
 
Figure 14: Sequence alignment of P. falciparum MyoA and MyoB.92 The green box highlights the 
neck/tail myosin domains, all other residues belong to the head region. The blue stars indicate the 
conserved residues MyoA Q808 and R812 and MyoB Q788 and R792, which represent Q in the 
second position and R in the 6th position of the putative IQ motif. 
**
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1.3.3. Plasmodium MTIP 
As for MyoA, the myosin light chain P. falciparum MTIP has homologues throughout 
Apicomplexa. It is a 27 kDa protein of 204 residues, split into N-terminal (residues 1–140) 
and C-terminal (141–204) domains that are connected via a flexible linker. MTIP was first 
identified in T. gondii (known as TgMLC1),86 and has since been detected in a variety of 
Plasmodium species. The proteins are well-conserved, with PfMTIP showing 69% homology 
with P. yoelii MTIP, and 43% homology with TgMTIP.55 The sequence alignment of these 
proteins is shown in Figure 15.  
 
Figure 15: Sequence alignment of P. falciparum MTIP, P yoelii MTIP and T. gondii MLC1. 
Conserved residues are shown in green and completely conserved residues in red. The N-terminal 
domain is shown by a blue bar and the C-terminal domain with a yellow bar. The N-terminal 
extension (MTIP[1-60]) is indicated with a purple bar above the sequences. Alignment was performed 
using Clustal X software.93 
Results reported by Green et al. show that MTIP is present throughout the intra-erythrocytic 
cycle, with expression peaking at 40–45 hours post-invasion,49 and it is found in a tetrameric 
complex with MyoA, GAP45 and GAP50, which is attached to the IMC.50 MTIP shows 
distant sequence homology (24%) to the calmodulin family,55 but binding to MyoA appears 
to be independent of Ca2+ ions in vitro.49 Calmodulin-like light chains commonly contain 
EF-hand motifs that usually require Ca2+ ions to bind to their heavy chain target. An EF-hand 
is a helix-loop-helix structural domain; two perpendicular helices are linked by a Ca2+ 
chelation loop (the EF-hands of apo-calmodulin bound to a murine myosin V peptide are 
Pfalciparum ---MKQECNVCYFNLPDPESTLGPYDNELNYFTWGPGFEYEPEPQRKPLS---IEESFEN 54
Pyoelii ---MEQQCHACYFELPDPKTTIGPYDSELNYFMWGPGFEWKPEPVVSQIS---GEDTYDE 54
Tgondii MSKVEKKCPVCYQKLPNPADVLGPMDKELNYFMWMPGFEWRPEPKVGEYDGACESPSCRE 60
::::* .** :**:*  .:** *.***** * ****:.***     .    . :  :
Pfalciparum SEESEESVADIQQLEEKVDESDVRIYFNEKSSGGKISIDNASYNARKLGLAPSSIDEKKI 114
Pyoelii TEESEESEHGFDELDEKVNKDDRKRYFDEKSSGGKISIENASHNARRLGLAPSSKDEEKI 114
Tgondii GGRPAADEDMQEALEEMVEADEMYARFNARASGGKVSTGDAMILARQLGLAPSYADKQAF 120
..  .    : *:* *: .:    *: ::****:*  :*   **:******  *:: :
Pfalciparum KELYGDNLTYEQYLEYLSICVHDKDNVEELIKMFAHFDNNCTGYLTKSQMKNILTTWGDA 174
Pyoelii RELYGDNLTYDQYLEYLSMSIHDKDNAEQLVKMFAYFDTNTTGYLTKNQMKNILITQGDA 174
Tgondii EEKSGDNLDYASFQKFVGTSTHPEDNIEDLVEAFAYFDVSKHGYLTRKQMGNILMTYGEP 180
.*  **** * .: :::. . * :** *:*:: **:** .  ****:.** *** * *:.
Pfalciparum LTDQEAIDALNAFSSEDNIDYKLFCEDILQ--- 204
Pyoelii LTEDEAMNALNAFSNDDKIDYKLFCEDILQ--- 204
Tgondii LTTEEFNALAAEYFTSDQIDYRQFCKAMLERRE 213
** :*       : ..*:***: **: :*:   
P. falciparum MTIP
P. oelii MTIP
T. ndii MLC1
P. alciparum MTIP
P. oelii MTIP
T. ndii MLC1
P. alciparum MTIP
P. oelii MTIP
T. ndii MLC1
P. falciparum MTIP
P. oelii MTIP
T. ndii MLC1
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shown in Figure 17). The EF-loop is generally rich in glutamate and aspartate residues as 
these contain oxygen atoms in their side-chains that can coordinate Ca2+. EF-hand motifs 
almost always occur in pairs and the binding of Ca2+ results in a conformational change to 
allow protein complex formation to occur.94 This can be utilised to regulate myosin light 
chain binding to the myosin heavy chain. X-ray crystallography studies of P. falciparum 
MTIP in complex with 15 amino acids from the tail of P. yoelii MyoA revealed that MTIP 
forms four EF-hands, two in the C-terminal and two in the N-terminal domain,88 but none 
appear to bind Ca2+ at physiological pH. 
Although MTIP has been shown to localise to the IMC, it does not appear to contain a 
membrane-spanning domain or potential lipid attachment sites, implying that it is held in the 
IMC by a linker protein.95 Co-immunoprecipitation experiments indicate that MTIP and 
GAP45 form a complex in late-stage parasites,50 but there has not yet been any data reported 
concerning the nature or structure of this protein interaction. However, it appears that only 
MTIP residues 61–204 are required for complex formation with MyoA,88 meaning the 
N-terminal extension of MTIP, residues 1–60, may be responsible for binding to GAP45. 
Green et al.61 recently published work demonstrating that PfMTIP may be phosphorylated in 
vitro by CDPK1 on residue S47, with a secondary phosphorylation site on S51, both of which 
are found in the N-terminal extension. Two-dimensional gel electrophoresis confirmed that 
MTIP is partially phosphorylated in vivo, existing in both a phosphorylated and non-
phosphorylated form in late schizonts. However, MTIP binding to MyoA is unaffected by 
phosphorylation,61 suggesting that phosphorylation of the N-terminal region of MTIP may 
regulate binding to GAP45, and therefore glideosome assembly. 
Interestingly, it has recently been proposed that MTIP may not only bind to MyoA and 
function during invasion, but may also contribute to another myosin motor involved during 
Plasmodium cytokinesis.96 A series of pull-down experiments using GST-tagged PfMTIP 
identified a transient interaction with PfRab11A. Rab11A is a small G-protein conserved in 
eukaryotes, which has been shown to regulate trafficking of plasma membrane receptors, and 
is required for correct plasma membrane localisation during plant cell division.97 In 
Apicomplexa it is believed to be involved in late stages of cell division and assembly of the 
glideosome during intra-erythrocytic schizogony. Rab11A has a variable distribution 
throughout the parasite during blood stages;96 it co-localises with merozoite surface protein-1 
(MSP-1) in trophozoites and early schizonts, and is found near GAP45 at the periphery of 
early and segmented schizonts, but in late-stage schizonts and merozoites it is situated in the 
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rhoptries (see Figure 5 for rhoptry location in a merozoite). This suggests a dynamic function, 
which may include the delivery of GAP45 to the IMC. Rab11AN126I, a dominant negative 
mutant of Rab11A, was expressed in T. gondii and found to be deleterious to the parasite.96 
On further analysis it was observed that TgMyoA, TgMLC1 and TgGAP45 were all less 
efficiently associated with the IMC in daughter cells of parasites containing this defect, 
implicating Rab11A in the correct assembly of the glideosome during cell division. 
Furthermore, overexpression of the TgMyoA tail in intracellular parasites resulted in a 
similar effect, namely a defect in IMC formation.96 Overexpression of the TgMyoA tail in 
extracellular parasites caused a significant block in invasion, presumably due to competition 
of this tail peptide with full-length TgMyoA, leading to TgMyoA displacement from 
TgMLC1, and dissociation of the invasion motor.96 The prevention of cell replication when 
this gene is expressed in intracellular parasites implies that this tail peptide is displacing a 
myosin protein from its light chain at this stage too, suggesting that there is at least one other 
myosin motor key to the Plasmodium life cycle which may also utilise MTIP. The number of 
putative myosin light chains in the T. gondii genome is less than the number of myosin heavy 
chains,84 implying some light chains may participate in more than one molecular motor. It is 
possible MTIP may be one such myosin light chain, and play an additional role in an as yet 
unidentified motor. Further studies into complex formation and protein binding involving 
MTIP are therefore of high interest. 
1.3.4. The structure of the Plasmodium MTIP/MyoA protein complex 
Yeast two-hybrid studies performed by Bergman et al. indicated that only the final 15 amino 
acids of the C-terminal tail of PyMyoA were necessary and sufficient to bind to PyMTIP;55 
PyMyoA[803-817] appeared to form a complex with PyMTIP but PyMyoA[742-802] did not. 
To this end, a crystal structure of PkMTIP[79–205] in complex with PyMyoA[803–817] was 
obtained by Bosch et al.54 in 2006 at pH 5.3. Remarkably, three different structures were 
found in the same unit cell; two unliganded molecules of PkMTIP (Figure 16, subunits 1 and 
2), and one bound to the tail of PyMyoA (Figure 16, subunit 3). PkMTIP was found to adopt 
an extended conformation, consisting of an N- and a C-terminal domain joined by a 28 
residue α-helix linker. The N-terminal domain showed little variation between the three 
structures, forming three α-helices, two of which form an EF-hand. The C-terminal domain 
however, showed marked differences. Surprisingly, even between the two unliganded forms, 
helices α5 and α8 can be seen to change their conformation with respect to the rigid α6-loop-
α7 structure, suggesting that the C-terminal domain of free MTIP is flexible in solution. 
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Figure 16: Three crystal structures found in the same unit cell of PkMTIP[79–205] with 
PyMyoA[803–817] obtained at pH 5.3.54 
Much larger conformational changes are observed when comparing unliganded PkMTIP to 
the structure of the protein bound to the PyMyoA tail peptide. Four of the α-helices in the 
C-terminal domain are observed to form two EF-hands in the unliganded structure, and one 
of the α-helices in each of these EF-hands (α5 and α8) undergoes dramatic movement to 
allow binding of the MyoA tail. It appears that MyoA is accommodated by the opening of 
two EF-hands in the MTIP C-terminal domain to form a deep hydrophobic groove. This 
results in the burying of 1389 Å2 of solvent-accessible surface area by the interaction of 10 
residues of the MyoA tail with 17 residues of MTIP. Both hydrophobic and hydrophilic 
interactions are involved in the binding, of particular note are the electrostatic interactions 
arising from PyMyoA residues R812 and R814. These form a dibasic motif, well conserved 
across Apicomplexa, which have been found to be key to the binding of TgMyoA with its 
light chain TgMLC1, and localisation to the IMC.87 These residues appear to be crucial for 
complex formation between MyoA and MTIP in Apicomplexa.  
It was unexpected to find only the C-terminal domain of PkMTIP interacting with the 
PyMyoA tail, as this is in contrast to other myosin light chains interacting with their heavy 
chains. For example, apo-calmodulin binds to the C-terminus of murine myosin V using both 
its C- and N-terminal domains (Figure 17). In addition, scallop muscle myosin essential light 
chain (ELC) is similar in structure to MTIP, in that several residues in the ELC C-terminal 
domain are in similar conformations to those in the PkMTIP complex.54,78 However, the 
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ELC-MHC complex has both domains of ELC binding to the MHC, surrounding it on all 
sides,78 whereas in the PkMTIP-PyMyoA complex the MTIP N-terminal domain does not 
participate in binding at all. It was thought that this was due to the presence of a lysine 
residue at position 813 of the PyMyoA tail, the 7th position of the putative IQ motif that 
usually requires glycine. The large lysine side chain was believed to prevent formation of a 
closed complex utilising both MTIP domains, due to unfavourable steric clashes that would 
occur if this were to happen. 
 
Figure 17: The structure of calcium-free calmodulin bound to an IQ motif in the C-terminal region of 
murine myosin V heavy chain (myosin residues 791-811, black).98 The four EF-hands are shown in 
green, yellow (in the N-terminal domain), pink, and red (in the C-terminal domain). The inter-lobe 
linker is shown in blue and the loops connecting the EF-hands in cyan. The side-chains of critical 
residues of the murine myosin V IQ motif are labelled and shown in red. Both the N- and C-terminal 
domains of calmodulin are involved in binding. 
Surprisingly, a year later, Bosch et al.88 reported the crystal structure of PfMTIP[60–204] in 
complex with PyMyoA[803–817] at neutral pH, which was found to be dramatically different 
from that reported earlier. In this structure, both domains of PfMTIP fold around the 
PyMyoA tail to bind in a clamp-like fashion (Figure 18A), burying 2107 Å2 of solvent-
accessible surface area, a significant favourable increase on the 1389 Å2 buried in the 
extended complex. The linker region between the N- and C-terminal domains, which 
previously formed a long α-helix, is now a flexible loop (between residues 
PfMTIP[135-140]), allowing the N-terminal domain to rotate by approximately 140° to 
contact the PyMyoA tail. This structure is very similar to that of apo-calmodulin binding to 
murine myosin V (Figure 17). Residue S108, located in the MTIP N-terminal domain, forms 
a hydrogen bond with D173 of the C-terminal domain to seal the clamp around the PyMyoA 
EF hand 1 EF hand 2
EF hand 3
EF hand 4
Inter-lobe linker
Q797
V796
R801
R806
C-terminal 
domain
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tail. The MTIP C-terminal domain broadly forms the same secondary structure as in the open 
PkMTIP complex, providing a deep groove to accommodate the hydrophobic side chains of 
the MyoA tail; the conformations of these residues L804, V807 and I811 are very similar in 
both complexes (Figure 18). The hydrophilic residues however, adopt strikingly different 
conformations, in particular R806, K813 and R814, which all form contacts with the 
relatively flat N-terminal surface (Figure 18). The hinge region of PfMTIP is now also able to 
interact with the MyoA tail, and forms a salt-bridge through residue D139 with MyoA R806, 
and a hydrogen bond with MyoA H810.  
Interestingly, although it was previously believed that the incorporation of a lysine residue 
(K813) in the 7th position of the partial IQ motif in the MyoA tail prevented formation of a 
closed complex, it in fact appears that this residue is crucial for closed complex formation at 
neutral pH. All atoms in the side chain of PyMyoA K813 are engaged in extensive 
interactions, resulting in the complete burial of this side chain,88 in contrast to the complete 
exposure of these atoms in the PkMTIP complex (Figure 18).  
 
Figure 18: (A) The closed crystal structure of PfMTIP[60-204] in complex with PyMyoA[803-817] 
obtained at pH 7.5,88 compared to (B) the open crystal structure of PkMTIP[79-205] in complex with 
PyMyoA[803-817] obtained at pH 5.3.54 The MTIP C-termini are shown in green, the N-termini in 
purple, and the MyoA tail in black. PyMyoA residues L804, V807 and I811 are shown in cyan. These 
maintain the same conformation in both complexes. PfMyoA residues R806, H810, K813 and R814 
are shown in red. The orientation of these side-chains varies markedly between the closed and the 
open structure. 
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It seems that there are two important factors for the formation of the more favourable closed 
complex observed in the more recent crystal structure. Firstly, this compact conformation was 
obtained at pH 7.5, whereas the initial open complex was generated at pH 5.3. In the closed 
complex, residue H810 of the PyMyoA tail forms two hydrogen bonds, one with the amino 
group of the MyoA K813 side-chain, and one with the carboxylate of PfMTIP D139. The 
imidazole functionality must be deprotonated for these to occur, which is likely to be the case 
at physiological pH, but not at pH 5.3, preventing the clamping of the MTIP N-terminal 
domain. Secondly, a longer construct was used in formation of the closed complex, 
PfMTIP[60–204] compared to PkMTIP[79–205] in the open crystal structure. The truncated 
PkMTIP construct is missing residue K71, which is seen to form a salt-bridge with D137 of 
the PfMTIP N-terminal domain, to stabilise the kinked conformation of the linker region. 
Both of these residues are conserved across Apicomplexa, implying the closed compact 
structure applies for all species, and is the likely conformation at physiological conditions. 
This compact conformation is also in agreement with all other known myosin interactions 
with their light chains, suggesting it is more likely to be the case in vivo. The occurrence of 
varying crystal structures however, shows the need for further structural studies of these 
proteins in solution. 
1.4. The Plasmodium MTIP/MyoA interaction as a drug target 
1.4.1. Protein-protein interfaces as drug targets 
Protein-protein interactions are ubiquitous in nature, involved in such diverse functions as 
cell signalling, immune response and apoptosis. For a protein-protein interaction to be a 
successful drug target by design, there are three steps that must be followed; identification of 
a suitable prospective target, in-depth investigation of its binding interface and properties, 
and the rational design of a corresponding ligand.99 This means that the system needs to be 
studied extensively using a variety of biological and biophysical techniques, which may 
include protein nuclear magnetic resonance (NMR), surface plasmon resonance (SPR), site-
directed mutagenesis and X-ray crystallography; this information may then be used to design 
a small molecule to modify the interaction. There are two possible ways that small molecule 
recognition may affect a protein-protein interaction, either through agonism or antagonism. In 
agonism, the small molecule binder will promote a biological response or mediate native 
protein oligomerisation, whereas in antagonism the small molecule will selectively bind to a 
protein involved in a complex to prevent association with its native binding partner, which 
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will inhibit the interaction and the corresponding biological event.100,101 For the Plasmodium 
MTIP/MyoA interaction the second approach is required, as inhibition of this complex should 
disrupt the invasion motor, stall erythrocyte invasion, and kill the parasite. 
Protein-protein interfaces consist of a combination of interacting secondary structures, 
including random coils, α-helices and β-sheets. The proteins involved show high 
complementarity, and bind through the synergistic effect of several weak, non-covalent 
interactions such as van der Waals, electrostatic and hydrophobic forces. Generally these 
occur between the side chains of the two proteins, although some backbone contacts may also 
be important. Protein-protein complex formation is believed to be driven by the burial of 
hydrophobic residues and the hydrophobic effect,102,103 although electrostatic interactions are 
also significant in increasing the rate of complex association.104 The hydrophobic effect arises 
due to the tendency of water molecules to exclude non-polar molecules. Proteins in solution 
are therefore surrounded by an organised cage of water molecules, but these are ejected from 
the binding site during protein-protein complex formation, resulting in a favourable increase 
in entropy to promote binding.105 Electrostatic interactions prolong the amount of time that 
two proteins remain close to one another in solution, which provides the opportunity for them 
to rotate into the correct binding orientation to form the initial encounter complex (also 
known as the transition state).104  
Dimeric protein-protein interactions may be homo- or heterodimeric. In general, homodimers 
form a tighter interaction, and mainly consist of hydrophobic interactions at the interface, in 
order to hide these residues from solution. In contrast, heterodimers are more hydrophilic at 
the binding interface, which reflects their ability to exist as a stable monomer in 
solution.106,107 Although protein-protein interactions have been the subject of much research 
in recent years, they are often avoided as drug targets due to a number of challenges, which 
are outlined below. 
The interacting proteins form a large, flat, shallow surface, burying up to 2000 Å2 of surface 
area.106 This can make it difficult to design a drug-like inhibitor as it may appear that a large 
area needs to be covered (small molecule drugs typically cover approximately 800 Å2 of 
molecular surface area),108 and there may not be an obvious cavity to accommodate a small 
molecule, as is the case for enzyme drug targets.101 Additionally, proteins involved in protein-
protein interactions do not often naturally bind small molecules, unlike enzymes and their 
substrates, meaning it can be challenging to identify a starting point when designing a 
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potential drug of this kind.109 It is unrealistic to expect a small molecule to force itself 
between two proteins and prise them apart. Instead, the most successful cases are likely to be 
those where there is a dynamic equilibrium between protein binding partners, allowing an 
inhibitor to bind to one of them. This may alter the topological and electrostatic properties of 
the interface significantly and prevent complex formation.106 Solvation also needs to be taken 
into account, as water molecules are frequently present at the protein-protein interface, which 
can act to stabilise the interaction through the formation of additional hydrogen bonds and 
charge complementarity.99 A potential small molecule drug may therefore also need to 
displace water molecules to be a potent inhibitor. 
1.4.1.1. Hot spots at protein-protein interfaces 
It has recently become apparent that a small-molecule may not need to cover the entire 
protein binding surface, as protein-protein interactions often contain a smaller region on each 
side of the interface which is key for binding, known as a hot-spot. Hot spots were discovered 
through alanine scanning mutagenesis studies; Clackson and Wells noted that single residues 
in a protein-protein binding interface can contribute large fractions of the binding energy,110 
while Bogan and Thorn reported that the binding energy of a protein-protein interaction is not 
evenly distributed across the protein-protein interface, but is concentrated in smaller areas 
known as hot spots.111 These regions are approximately 600 Å2, made up of non-contiguous 
residues and are likely to be highly complementary.100 Hot spot residues are defined as those 
that result in a change in the free energy of binding greater than 2 kcal/mol upon mutation to 
alanine.112 These are generally situated near the centre of the protein-protein interface so that 
they are protected from bulk solvent molecules. The exclusion of bulk solvent molecules 
from the interacting hot spot region is achieved through the presence of a group of residues 
that are energetically unimportant surrounding the hot spot, known as the “O-ring”.111 The 
O-ring shields hot spot residues from attack by solvent molecules, which increases the 
strength of electrostatic and hydrophilic interactions between complementary hot spots and 
reduces the rate of complex dissociation.111 Hot spots generally incorporate both hydrophobic 
(van der Waals) and hydrophilic (electrostatic and hydrogen-bonding) interactions, and so 
residues are favoured that can participate in both; tryptophan, tyrosine and arginine are 
frequently found in hot spots, whereas leucine, valine, serine, and threonine are 
disfavoured.111 A protein-protein interface may contain more than one binding hot spot, and 
these usually cluster together in a hot region.113 In general, larger interfaces will contain more 
hot spots. The same hot spot or hot region may be used to bind to multiple binding partners, 
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utilising the same residues each time, although structural changes may be observed such as 
the rotation of side chains, or the backbone in loop regions. This flexibility means that there 
may be binding sites available to bind small molecules which are not visible in crystal 
structures or other conformational studies.101,109  
1.4.2. Small molecule inhibitors of protein-protein interactions 
Despite the challenges outlined above, there has been some success in targeting protein-
protein interactions in recent years by focusing on the fundamental roles played by specific 
secondary structures at the binding interface, such as β-turns, β-sheets and α-helices. The 
MyoA tail is an α-helix that binds to MTIP at the glideosome, as discussed in Section 1.3.4. 
Methods of modulating protein-protein interactions involving α-helices are therefore of 
particular interest and there are several possible ways of doing this, many of which have 
shown success against proteins involved in cancer and other diseases.  
 
Figure 19: (A) Side-on view of an α-helix showing the positions of residues i, i+4 and i+7. These all 
align on the same face of the α-helix. (B) A helical wheel representation of an α-helix, showing the 
sequence of PfMyoA[803-818].114  
α-Helices are the most abundant secondary structure in proteins, and generally consist of 8–
10 amino acids which form two to three helical turns (Figure 19).115  This small size suggests 
that it may be possible to develop a drug to modulate this area. However, when excised from 
a protein, peptides of less than 15 residues do not generally form an α-helix at physiological 
conditions; instead, they adopt a variety of random conformations which can reduce their 
biological activity.116 In addition, peptides themselves do not tend to make good drugs due to 
proteolytic degradation and problems with cell permeability. Therefore, a common starting 
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point for α-helical interface drug design is to mimic this structural domain in solution, either 
by stabilising the peptide in an α-helical conformation, or by using a non-natural chemical 
scaffold as a helix surface mimetic. These techniques effectively pre-form the α-helix in 
solution, and so should lead to a more favourable entropy change upon complex formation. 
These are collectively known as α-helix mimetics.117  
Stapled peptides are one such technique used to hold a peptide in an α-helical conformation, 
and this may be achieved using a variety of methods. An α-helix contains 3.6 residues in each 
turn, which results in the residues i, i+4, i+7 and i+11 being situated on the same face (Figure 
19 (A)).118 Formation of covalent bonds between these residues can stabilise the helix, which 
is known as stapling (shown in Figure 20). This was initially achieved using lactam or 
disulfide bridges, but these functionalities are liable to degradation inside the cell via 
enzymatic hydrolysis or reduction respectively. More recently, hydrocarbon-stapled peptides 
have been described by the Verdine group119 which use an 11-carbon chain between residues 
i and i+7. These were synthesised by ruthenium catalysed ring-closing metathesis of two 
unnatural amino acids at positions i and i+7, both of which contained a primary alkene group 
in the side chain. This peptide exhibited greatly enhanced α-helicity in solution (measured 
using circular dichroism spectroscopy), in addition to showing a 40-fold increase in stability 
towards degradation by trypsin compared to the wild-type peptide. The Walensky group used 
the same technique to staple the i and i+4 residues of a peptide modelled on the BH3 domain 
of pro-apoptopic human BCL-2 family proteins (known as SAHB (stapled α-helix of BCL-2 
domains)).120 This peptide exhibited increased helicity in solution and a four-fold increase in 
binding affinity with the anti-apoptopic protein MCL-1 in vitro compared to the wild-type 
peptide. Interestingly, an X-ray crystal structure of SAHB in complex with recombinant 
MCL-1 revealed that the hydrophobic hydrocarbon staple interacts with the periphery of the 
MCL-1 binding site, suggesting that the increase in affinity for MCL-1 is a result of 
additional binding contacts, as well as an increase in peptide helicity.120 Promisingly, Verdine 
and Bradner have shown that stapled peptides utilising a hydrocarbon linker are able to enter 
cells and disrupt protein-protein interactions in vivo.121 They synthesised stapled peptides to 
mimic a fragment of MAML1, a key protein in the NOTCH transcription activation complex 
ICN-CSL-MAML. The successfully stapled peptide (SAHM) exhibited increased helical 
character in solution, was able to penetrate cells, and when immobilised on a bead could pull-
down the protein target from a mixture of proteins in cell lysates.121 Of greater interest, 
SAHM seemed able to reduce the expression of NOTCH target genes in NOTCH1-dependent 
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T-ALL cells (a leukaemia cell line), and treatment with this peptide reduced the proliferation 
of T-ALL cells in a murine model.121 This indicates the potential of stapled peptides and 
other stabilised α-helix compounds to be developed into drugs. 
Rather than a hydrocarbon staple, Woolley et al. described the use of a diaminoazobenzene 
cross-linker to stabilise peptidic α-helices, inserting it at the i, i+4, i, i+7 or i, i+11 positions 
of a short peptide through the mutation of these residues to cysteine (the sulphur group of the 
cysteine side-chain is used to introduce the diphenylazo cross-linker).122,123 The azobenzene 
group undergoes trans to cis isomerisation upon irradiation with light, which allows a 
reversible means of controlling α-helix formation; when in the i, i+4 or i, i+7 positions, the 
thermodynamically favoured trans azobenzene conformation generates an unfolded peptide 
and irradiation to give the cis linker promotes an α-helix, but when situated at the i, i+11 
positions, the thermally stable trans conformation generates an α-helix that becomes 
disordered following irradiation to the cis form. This has been applied by the Allemann group 
to modulate both protein-DNA124,125 and protein-protein interactions.126 They inserted an 
i, i+7 azobenzene cross-linker into a peptide sequence from the MyoD transcription factor. 
Fluorescence anisotropy assays revealed that the cis-azobenzene stapled peptide formed a 
more stable complex with its target oligonucleotide MCK-S, exhibiting a binding affinity 
approximately 2000-fold stronger than that of the corresponding non-alkylated peptide.125 
Similarly, azobenzene stapling of peptides derived from the Bak BH3 protein domain 
resulted in an increase in peptide helicity and higher affinities of these peptides for the Bcl-xL 
protein binding partner, compared to the corresponding unmodified peptides.126 Interestingly, 
the Bak peptide containing an azobenzene linker between residues i and i+11 displayed the 
largest differences in helicity between the trans and cis forms, and correspondingly showed 
the greatest increase in binding affinity with Bcl-xL (approximately 16-fold stronger than the 
parent peptide).126 Azobenzene cross-linked peptides have the added benefit of being able to 
be controlled by light pulses and so could effectively be turned on and off inside cells, 
although the in vivo activity of these compounds has not yet been reported. 
Another method to staple peptides in an α-helical conformation is to use hydrogen-bond 
surrogates. There is a key hydrogen bond between the backbone carbonyl oxygen atom of the 
ith residue, and the amino N-H hydrogen atom of the i+4th residue in an α-helix, which forms 
a 13-membered coiled macrocycle (Figure 20). The orientation of the four amino acids in this 
conformation to form a hydrogen-bond is believed to be the rate-determining step for helix 
formation;127 preorganisation of these atoms should initiate coiling of the helix. To this end, 
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Arora and co-workers reported the synthesis of a peptide containing a carbon-carbon bond in 
place of the hydrogen bond in this position, achieved using solid phase peptide synthesis to 
generate N-terminal bis-olefin peptides that then underwent ring closing metathesis.128 
Circular dichroism spectroscopy and X-ray crystallography confirmed that these peptides 
adopt an α-helical conformation,129,130 and they were observed to be more stable to chemical 
denaturants and protease cleavage than the corresponding unconstrained peptides.128,131 A 
selection of hydrogen-bond surrogate peptides were designed to mimic a 14 residue peptide 
that binds to a hydrophobic pocket of gp41, a protein involved in HIV-1 entry into cells.132 A 
fluorescence polarisation assay indicated that these constrained peptides were able to bind to 
the target protein IZN17, and one of them appeared to inhibit HIV cell-cell fusion with an 
EC50 of 43 µM.132 Although the reported binding activity was not particularly high, these 
compounds may be of use in modulating protein-protein interactions as the unnatural bond is 
formed within the backbone of the peptide (Figure 20), rather than on the solvent-exposed 
surface (as is the case for stapled peptides), which reduces the likelihood of interference with 
peptide side-chain functionalities required for protein binding.  
Rather than using a chemical staple to constrain an α-helical peptide in its active 
conformation, synthetic structures may be used to mimic the helix. This can be done using 
foldamers, oligomers that adopt well-defined three-dimensional structures in solution,133 a 
prominent example of which are β-peptides. β-Peptides may be synthesised on the solid 
phase using β-amino acids, which contain one extra backbone methylene unit. The additional 
carbon atom confers increased stability of the peptide to metabolism and proteolysis.134 As 
for α-helices, β-peptides contain a stabilising intramolecular hydrogen bond, in this case 
between the carbonyl oxygen of the residue i, and the amino hydrogen of the i+3 residue, to 
form a 14-membered coiled macrocycle (Figure 20).135,136 This promotes a stable α-helix like 
structure that retains some flexibility, and so can adapt its structure to be able to bind 
designated proteins. However, the side chains at positions i and i+3 all project in the same 
direction, which differs from an α-helix, where side chains at residues i and i+4 (which form 
one turn) project at a 40° angle from one another (Figure 19).137 This may cause problems 
when trying to mimic side-chain interactions of an α-helix at a protein-protein interface. 
Nevertheless, data reported by the Schepartz group revealed that a β-peptide designed to 
mimic an α-helix of p53 disrupted the HDM2-p53 protein complex with an IC50 of 95 µM, 
30-fold weaker than the wild-type peptide.138 However, the inhibition activity of this peptide 
was improved (IC50 of 3 µM) through the introduction of an unusual β-amino acid containing 
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3-chlorotryptophan as the side-chain, and a related β-peptide containing a 
3-trifluoromethylphenyl side-chain showed increased cell permeability compared to the 
corresponding α-amino acid peptide. This indicates that modified β-peptides may be able to 
modulate protein-protein interactions inside cells, although further data regarding in vivo 
activity and selectivity are required. 
 
Figure 20: The representative structures of several α-helix mimetic scaffolds. Adapted from 
Henchey et al.118 
The final group of key peptidomimetics involve synthetic backbones highly divergent from 
the peptide scaffold. Hamilton et al. have done much research in this area.139-141 Initially this 
was achieved using a terphenyl scaffold (Figure 20); although there is rotational flexibility 
about the aryl-aryl bond, an energetically favourable conformer projects the ortho aryl side 
chains in the same direction as the residues i, i+4 and i+7 of an α-helix.142 The ortho aryl 
substituents may therefore be varied to mimic the side-chain functionalities of these peptide 
residues.143 A series of papers was published reporting successive modifications of this 
scaffold to enhance the solubility, flexibility and synthetic accessibility of the molecules, 
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leading to the synthesis of oligobenzamide compounds containing an intramolecular 
hydrogen bond to help stabilise the required conformation.144 Hamilton’s scaffolds were used 
to mimic a helical Bak peptide of the Bcl-xL-Bak protein interaction, and were found to bind 
to Bcl-xL with Kd as low as 114 nM.145 However, all non-peptidic α-helix mimetic 
compounds reported to date have only included hydrophobic substituents, and so there are 
concerns that their high activity may be due in part to non-specific hydrophobic interactions. 
There have been scaffolds reported that mimic residues other than i, i+4 and i+7, such as i, 
i+4, i+8 and i+11 described by Restorp et al.146 which uses a heterocyclic piperazine-based 
scaffold. However, as for the terphenyl and oligobenzamide compounds these are able to 
mimic functionalities from one face of the wild-type α-helix only, which may lead to 
constraints on their use. These analogues will be discussed in further detail in Chapter 6. 
A popular way to identify small molecule modulators of a protein or enzyme is to use high 
throughput screening, as thousands of compounds can quickly be assessed for activity against 
the target protein to generate lead compounds. A similar, more design-guided system is 
fragment-based screening. Although this does not involve wild type structure-based design, 
as for α-helix mimetics, it has shown success in the discovery of inhibitors of protein-protein 
interactions involving α-helices.147,148 The method involves the screening of small organic 
compounds (typically less than 200 Da, the ‘fragments’) for binding to the protein of interest, 
and then the linking or optimisation of active molecules to combine and improve their 
function.149 The small size and typical low hydrophobicity of the fragments means that there 
is considerable scope for modification and enhancement of activity following the initial hits. 
The small size also reduces the likelihood of unfavourable functionalities on the fragment 
interfering with an otherwise attractive protein-ligand interaction.150 However, as a result of 
the small fragment size, binding is initially often weak meaning the identification of hits can 
be difficult.150 Highly sensitive techniques are therefore required for screening, such as 
structure activity relationship (SAR) by NMR, tethering (for example, the use of disulfide 
bond formation to capture fragments at a binding site engineered to contain a cysteine 
residue),151 or X-ray crystallography. A combination of these techniques was used to identify 
and develop a small molecule inhibitor of the helical Bcl-xL-Bak protein-protein interaction, 
which binds to Bcl-xL with Ki <1 nM and appeared to promote apoptosis of SCLC tumour 
cells with EC50 <1µM.147 This inhibition activity confirms the applicability of fragment 
screening to identify modulators of protein-protein interactions involving α-helical interfaces. 
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1.4.3. MTIP/MyoA as a drug target 
There has been much advancement in protein-protein modulation in recent years, but as yet 
this has not been applied to malaria drug development. The MTIP/MyoA complex therefore 
represents an interesting, novel drug target, and there is mounting data to suggest that specific 
modulation of this interaction with small molecules could be possible. 
Although genetic manipulation is extremely difficult in Plasmodium species, the MyoA gene 
has been shown to be essential for parasite motility and survival in Toxoplasma. 
Meissner et al.85 were able to generate a conditional knockout of TgMyoA, and it was found 
that these parasites were unable to invade or egress from host cells. They were also unable to 
cause infection in mice, proving that MyoA is an essential virulence factor. It is strongly 
likely that this is also the case in Plasmodium. There have not yet been any reports of the 
knockout of TgMLC or PfMTIP, but it seems that this would have the same effect as, like 
MyoA, these proteins appear to be required for glideosome assembly and actomyosin-based 
motility.49,50,96,152 
Overexpression of the MyoA tail in extracellular T. gondii parasites proved to be deleterious, 
which was found in turn to be due to a block in invasion.96 This suggests that the 
MTIP/MyoA interaction may be disrupted in vivo, although further experiments are required 
to confirm that the observed decrease in parasite invasion of erythrocytes was indeed due to 
interference with glideosome formation. Data reported by Bergman and Hol54 indicated that 
exogenously added PyMyoA[803-817] inhibited the growth of P. falciparum parasites in 
culture with an IC50 of 84 µM when parasitemia was measured using a [3H] hypoxanthine 
assay. This is somewhat surprising as the PyMyoA[803-817] peptide is highly charged and so 
it is unclear as to whether this peptide is able to penetrate the parasite cell membrane. If the 
observed inhibition of parasite growth was indeed due to the intracellular activity of 
PyMyoA[803-817], no data has yet been reported concerning the in vivo molecular target of 
this peptide. A control MyoA peptide containing R812A and K813A mutations (both residues 
appear to be key to MTIP/MyoA binding by yeast two-hybrid and crystallography data)55,88 
was unable to inhibit parasite growth in this assay indicating that the apparent activity of 
PyMyoA[803-817] may be specific, although conclusive evidence is still to be obtained.  
Similar results were obtained by Green et al.,82 although there were problems with their 
reproducibility. Parasite cell counting experiments and Giesma smears indicated that 
treatment of P. falciparum parasites with 50 µM of the PfMyoA tail peptide 
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PfCMyoA[803-818] (MyoA[803-818] with an additional cysteine residue at the N-terminus) 
resulted in the parasites becoming stuck on the outside of erythrocyte cell membranes, 
seemingly unable to invade (Figure 21 (A)). A control peptide consisting of a randomised 
sequence of PfMyoA[803–818] (ranCMyoA[803–818]) had no effect; the parasites invaded 
and matured into trophozoites as normal (Figure 21 (B)). Although this data seems to support 
that published by Bergman and Hol, analysis using a fluorescence-activated cell sorting assay 
(FACS) did not show a significant decrease in P. falciparum parasitemia following treatment 
with PfCMyoA[803-818].82 Taken together, the results obtained by Bergman and Hol54 and 
Green et al.82 indicate that it may be possible to modulate the MTIP/MyoA interaction in 
vivo, which provides a reason to further investigate this protein-protein complex. However, 
the difficulties in reproducing in vivo results implies that the parasites are highly sensitive to 
the assay conditions used and highlights the need for a reliable assay, both in vivo and in 
vitro, when validating drug targets.  
 
Figure 21: Apparent inhibition of P. falciparum invasion of erythrocytes upon treatment with a 
PfMyoA tail peptide. Giesma-stained films showing P. falciparum 3D7 parasites cultured in 2% 
haematocrit (A) with 50 µM CMyoA[803-818]. Following treatment with the MyoA tail peptide, the 
parasites appear to become stuck on the surface of the erythrocyte, seemingly unable to invade 
(shown by black arrows). (B) with 50 µM ranCMyoA[803-818]. The parasites invade and develop 
into ring stages and trophozoites as normal. However, this result was unable to be reliably 
reproduced.82 
Fortunately, there are already several assays available which may be used to study 
Plasmodium merozoite growth in blood cultures. Bosch et al.54 used a [3H] hypoxanthine 
incorporation assay to identify a peptidic inhibitor of cell growth. This involved treating late 
trophozoites/early schizonts with the peptide for 24 hours before adding [3H] hypoxanthine. 
The incorporation of [3H] hypoxanthine was measured using liquid scintillation, and the 
growth of parasites compared to a control treated only with DMSO to give growth values as a 
percentage. The FACS assay used by Green et al.82,153 also treated late trophozoites/early 
(A) (B)
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schizonts with the peptide, but in this case for 44–48 hours (through one full invasion cycle) 
before adding hydroethidine to fluorescently label parasitic DNA. The viability of 
PfCMyoA[803-818] treated parasites was measured using fluorescence, relative to a control 
culture treated only with DMSO (viable parasites give a high fluorescence signal). These 
assays offer a variety of methods with which to study P. falciparum growth, although the 
variation in results shows that optimisation may be required, and consistency in the timings 
of peptide addition and measurement of parasitemia is vital. Additionally, Green et al.49 have 
described the initial development of an in vitro fluorescence assay that may be used to screen 
potential inhibitors of the MTIP/MyoA protein complex before testing them against parasites. 
This is also an important consideration when choosing a target for drug design as it enables 
many compounds to be screened quickly and efficiently. 
The availability of structural data for the MTIP/MyoA complex is another valuable factor in 
choosing it as a drug target, as it provides a starting point for rational drug design. The 
variety in the structures observed suggests an innate flexibility in the complex which means 
that further structural studies may be required, although it also suggests that it could be easier 
to design a small molecule inhibitor as the protein may be able change conformation to 
accommodate it.  
A vital consideration in drug target validation is the requirement to gain high specificity. This 
is a particular issue with anti-malarials, as many of those currently available cause unpleasant 
side-effects. The glideosome is unique to Apicomplexa, so is a non-human target which 
should make specificity easier to achieve. Although there are actomyosin motors in muscle 
cells in the human body, these generally involve type II myosins that are highly divergent 
from type XIV MyoA in both structure and sequence (Figure 12). The binding interfaces with 
their light chains are therefore also different, implying it should be possible to differentiate 
between them using small molecules.  
Finally, in addition to MTIP/MyoA having several positive characteristics as a good drug 
target itself, it is also of significant interest as a protein-protein interaction. As yet there are 
currently no protein-protein interactions targeted in malaria therapeutics, and very few as 
drug targets in other diseases. It is therefore a novel intellectual challenge to synthesise a 
small molecule inhibitor of the MTIP/MyoA complex, which if successful, could have wider 
implications for drug design in general. Additionally, it is possible that the parasite would be 
less likely to develop resistance to a drug of this kind. Anti-malarial drug resistance 
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originates from Plasmodium chromosome mutations, which often lead to a mutation in the 
protein or enzyme targeted by the drug.154 For a protein-protein interaction, mutation of a 
residue in the binding site of one protein would probably also require a mutation at the 
complex interface of its partner protein. The need for two mutations may make it more 
difficult for parasite resistance to occur. This is of considerable importance in the 
development of antimalarials, as drug resistance is a huge problem. 
1.5. Project aims and objectives 
The main objective for this project was to provide chemical validation for MTIP/MyoA as a 
drug target. Evidence discussed in Section 1.4.3 suggests that MTIP/MyoA is an attractive 
target for the development of anti-malarial therapeutics, but biological manipulation in 
Plasmodium is notoriously difficult, meaning chemical validation is also required. It was 
therefore desirable to determine whether MTIP/MyoA is able to be inhibited or modulated by 
small molecules. If successful, these molecules may also have the potential to be developed 
into lead compounds for drug discovery. In order to achieve this there were several aims:- 
 Develop a robust, reproducible assay for the efficient study of MTIP/MyoA binding 
and the screening of potential inhibitors of this complex in vitro. This is discussed in 
Chapter 2. 
 Analyse the MTIP/MyoA binding interface to identify key interacting residues and 
the minimum binding region of MyoA. This is described in Chapters 3 and 4 through 
the results of MTIP/MyoA peptide binding and displacement assays. 
 Obtain structural information for the MTIP/MyoA complex, particularly in solution. 
Chapter 5 describes the use of CD spectroscopy and protein NMR for this purpose. 
 Use all the information gathered concerning MTIP/MyoA binding to design and 
synthesise small molecule modulators of this complex. Chapter 6 discusses the 
synthesis and inhibition activity of α-helix mimetic compounds against MTIP/MyoA.  
In addition to MTIP/MyoA, the methods described above may be applied to other 
Plasmodium protein-protein interactions. Another objective was to examine MTIP 
binding with another Plasmodium myosin, specifically MyoB, with a view to identifying 
previously unrecognised binding partners of MTIP. 
  
61 
 
 
 
 
 
 
 
 
Chapter 2   Fluorescence-based assay design and optimisation 
 
The MyoA tail may be mimicked in vitro using short chain peptides that can be labelled with 
fluorophores. Following the successful expression of two MTIP constructs and the synthesis of 
a series of MyoA peptides, this chapter describes the development of fluorescence-based 
assays to study MTIP/MyoA peptide binding in vitro using dansyl-tagged MyoA peptides. 
Solvatochromic fluorescence, fluorescence anisotropy and FRET techniques were investigated 
for this purpose.  
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2.1. The dansyl fluorescence intensity assay 
2.1.1. Assays to study protein-protein interactions 
In order to study a protein-protein interaction in vitro a reliable and accurate assay is required 
to quantify binding and screen potential inhibitors of complex formation. There are several 
biological and biophysical techniques that may be applied for this purpose. Biological assays 
such as the yeast two-hybrid system and co-immunoprecipitation experiments can be used to 
identify protein binding partners, but are unable to provide quantitative data and there are 
often problems concerning false positive or negative results.155 Therefore, biophysical 
methods such as surface plasmon resonance (SPR), scintillation proximity assays (SPA), 
enzyme-linked immunosorbent assays (ELISA), isothermal titration calorimetry (ITC) or 
fluorescence techniques are often preferred. 
SPR monitors the binding of a protein in solution (analyte) to a protein immobilised on a 
metal sensor chip surface by measuring the refractive index of surface plasmons adjacent to 
the surface. The refractive index varies with the mass of the surface layer, which reflects the 
amount of analyte on the chip. The association and dissociation constants of the two proteins 
can therefore be calculated by plotting the resonance signal against time.156 This technique is 
able to determine kinetic and thermodynamic parameters without the need for labelling, and it 
can cover a wide range of binding affinities. However, it can require significant optimisation 
of the coupling chemistries to the chip and conditions to regenerate the ligand-free surface, 
and it may suffer from non-specific binding.157 
The SPA technique relies on the radioactive decay of low energy isotopes such as 3H or 125I. 
In this assay one protein is bound to a scintillant bead and the other is labelled with the 
radioactive isotope. If the proteins bind, the energy of the radioactive decay will excite the 
scintillant, which emits light to be measured. If the proteins do not bind the distance between 
the radioactive isotope and scintillant is too far, and water molecules dissipate the energy 
preventing the scintillant being excited so no light is emitted.158 SPA does not require a 
separation step or stringent washing which can disturb binding events, so it is suitable for 
high throughput and can detect relatively weak binding affinities. However, SPA is generally 
used to screen potential inhibitors of a protein-protein interaction, rather than studying and 
quantifying binding directly. Another problem associated with this technique is the need for a 
prolonged incubation period to ensure the system reaches equilibrium, which means all assay 
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components must be stable. There are also safety concerns associated with the use of 
radioactive isotopes.159  
Another assay which may be adapted to high throughput is ELISA. The protein of interest is 
immobilised to a plate well and the binding partner added, followed by a specific antibody for 
this binding protein. The antibody is typically detected using a secondary antibody linked to 
an enzyme, with detergent washes between each step to eliminate non-specific binding. 
Finally an enzyme substrate is added to produce a detectable signal, such as 
chemiluminescence.160 ELISAs are commonly used as immunoassays to determine antigen or 
antibody concentrations in a serum sample. This has been utilised to test for diseases such as 
HIV,161 but can also be adapted to study protein binding partners, in particular potential 
inhibitors of a protein complex. The assay displays high sensitivity as the secondary antibody 
and enzyme act as amplifiers, but the experiment contains many different components and 
binding is measured indirectly, meaning it can be subject to artefacts. It is unsuitable for 
studying weak binding interactions due to the multiple wash steps required. An additional 
problem is the need to immobilise one protein, which is unlikely to represent the conditions 
in vivo and may hinder binding.162 
In contrast to the assays described above ITC is not suited to high-throughput screening, but 
is a label-free technique that can give thermodynamic information about a protein-protein 
interaction. The macromolecule of interest is placed in solution in a sample cell and buffer is 
placed in a reference cell, both of which are connected by a circuit. The smaller protein 
binding partner is titrated into the sample cell, and heaters act to maintain the same 
temperature between all components in the system. For an exothermic reaction, the 
temperature in the sample cell will increase as binding occurs so the feedback power will be 
deactivated to cool the sample, and in an endothermic reaction the temperature will decrease, 
so the feedback circuit will increase power to maintain the temperature between the sample 
and the reference cell. By measuring the variability in the power input over time 
thermodynamic parameters such as the change in enthalpy (ΔH), the association constant (Ka) 
and the binding stoichiometry can be determined, and from these the change in Gibbs free 
energy (ΔG) and entropy (ΔS) may be calculated. ITC is very useful in this respect, and gives 
accurate data without the need to introduce a label, but it requires large concentrations and 
volumes of sample so solubility must be high, and it is not effective for weak binding 
events.163 
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The final common method for assaying protein-protein interactions measures fluorescence, 
which may either be intrinsic to the macromolecule or introduced by labelling the proteins 
with an extrinsic fluorophore. The main types of fluorescent assay suitable for protein-protein 
interactions include fluorescence intensity shift (solvatochromic fluorescence),164 
fluorescence anisotropy (or polarisation),165 fluorescence resonance energy transfer 
(FRET)166 and time-resolved fluorescence spectroscopy.167 Each of these techniques may be 
carried out homogenously in solution and can detect a wide range of binding affinities. They 
may be used to directly measure protein binding affinities or to screen potential inhibitors of 
a complex, and are frequently used in high-throughput screening.168 However, the presence of 
an extrinsic fluorophore label may interfere with complex formation in some cases, and the 
assay can be prone to artefacts due to fluorescence quenching or scattering, which may give 
misleading results. 
Assay type Advantages Disadvantages 
SPR 
 Label-free 
 Can calculate many kinetic and 
thermodynamic parameters 
 Requires immobilisation of 
one protein 
 May suffer from non-specific 
binding 
 Medium-throughput 
SPA  Can detect weak binding  High-throughput 
 Long incubation period 
requires high stability of all 
components 
 Requires radioactive isotope 
ELISA  Highly sensitive 
 Requires immobilisation of 
one protein 
 Contains many assay 
components – subject to 
artefacts 
ITC 
 Label-free 
 Can calculate thermodynamic 
parameters 
 Large volumes and 
concentrations required 
 Not suitable for weak binding 
events 
 Low-throughput 
Fluorescence 
 Can detect wide range of binding 
affinities 
 High-throughput 
 Homogenous solution assay 
 Requires label 
Table 1: The advantages and disadvantages of various assays suitable for the study of protein-protein 
interactions (SPR surface plasmon resonance, SPA scintillation proximity assay, ELISA enzyme-
linked immunosorbent assay, ITC isothermal titration calorimetry). 
The advantages and disadvantages of each of these techniques are summarised in Table 1. It 
is clear that each method has its own benefits and challenges, meaning careful consideration 
must be taken when choosing an assay for a particular system. A dansyl fluorescence-based 
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assay has previously been described for the study of P. falciparum MTIP/MyoA binding in 
vitro;49 fluorescence techniques will therefore be discussed in greater detail below. 
2.1.2. Fluorescence assay techniques 
2.1.2.1. Fluorescence 
Fluorescence is the absorption and emission of photons of energy. The absorption of a photon 
promotes an electron from the electronic ground state of a molecule, S0, to a higher energy 
orbital that relaxes to the lowest energy singlet excited state, S1 (Figure 22).  
 
Figure 22: Jablonski diagram showing the effects of solvent relaxation on the energy of the excited 
and ground states of a fluorescent molecule. The fluorophore is shown in green, with the arrow 
representing the dipole. Solvent molecules are shown in white with blue and red to represent the 
solvent molecule dipoles.164 
The excited singlet state can return to the ground state either by the emission of a photon 
(fluorescence), or through nonradiative quenching. Nonradiative processes include bond 
vibration, rotation and molecular collision. The system may also undergo electronically 
forbidden intersystem crossing (ISC) from the excited singlet state S1 to an excited triplet 
state, T1, that can decay to the ground state by emitting a photon, known as phosphorescence. 
The energy difference between S0 and excited energy levels determines the maximum 
absorption wavelength, λmax, of a molecule. The maximum emission wavelength, λem, is 
lower energy and so longer wavelength than λmax due to energy losses by solvent 
reorganisation or nonradiative processes. The difference between λmax and λem is known as 
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the Stokes shift (Figure 23). Fluorophores with small Stokes shifts may be susceptible to self-
quenching, so are best avoided.169 
 
Figure 23: Diagram of generic absorption and fluorescence emission spectra, showing the Stokes 
shift.169 
In addition to λmax and λem there are several other important fluorescence parameters such as 
the fluorescence lifetime, quantum yield and extinction coefficient. The fluorescence lifetime, 
τflu, is the time a molecule remains in its excited state, and may range from 0.1 ns to greater 
than 100 ns. It is particularly important in time-resolved and polarisation fluorescence 
experiments. The quantum yield, Φ, is the ratio of photons fluoresced to photons absorbed, so 
governs the efficiency of the fluorophore, while the extinction coefficient, ε, reflects the 
molecule’s ability to absorb a photon. The product of the quantum yield and extinction 
coefficient (Φ × ε) is a useful parameter to compare different fluorophores as it accounts for 
the amount of light absorbed and the efficiency, and so reflects the brightness of the dye. In 
addition to these fluorescent parameters, it is also essential to consider chemical properties 
when choosing a dye for a specific purpose, such as reactivity, solubility, pKa and stability.169 
There are several different types of fluorescent compounds that may be intrinsic or 
introduced extrinsically to the molecule of interest. In proteins, the most important 
endogenous fluorophores are the aromatic amino acids phenylalanine, tyrosine, and in 
particular tryptophan, which is the most fluorescent natural amino acid. These may be used to 
determine protein concentrations, in addition to being used to investigate a variety of 
biological processes including protein folding and ligand binding. However, the short 
wavelengths (280 nm) required for tryptophan excitation and the relatively high abundance of 
this amino acid in nature limit its applications.164,170 To this end, there has been much 
EmissionAbsorbance
Wavelength
Stokes shift
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research into the design, synthesis and application of other fluorescent molecules in biology. 
Green fluorescent protein (GFP) has been an important tool in recent years, as it can be fused 
to a protein of interest by cloning.171 It may be used to analyse the location and movement of 
proteins inside living cells, providing vital insights into protein function. GFP is an 
imidazoline dye surrounded by a protein adopting β-barrel tertiary structure. The protein 
casing acts to enhance fluorescence.172 Several analogues of GFP have been developed 
through protein mutations (such as yellow fluorescent protein YFP, and cyan fluorescent 
protein CFP)173 allowing different proteins to be imaged inside a cell at once. However, the 
size of these fluorescent tags can be a problem as they may interfere with protein folding or 
hinder protein function. Small molecule fluorophores are therefore also required, and there 
are numerous scaffolds available that all have different chemical and fluorescent properties. 
These generally consist of polycyclic aromatic compounds (Figure 24), such as naphthalene 
derivatives (dansyl, EDANS), indole or imidazole species (DAPI) and xanthene compounds 
(fluorescein and rhodamine dyes).169  
 
Figure 24: The structures of a selection of popular fluorophores; dansyl chloride, EDANS 
(5-((2-aminoethyl)amino)naphthalene-1-sulfonic acid), DAPI (4´,6-diamidino-2-phenylindole), 
fluorescein and rhodamine.169 
2.1.2.2. Fluorescence-based assays 
As mentioned in Section 2.1.1, there are four different fluorescence assays suitable for 
studying protein-protein interactions, each of which can provide quantitative data and may be 
adapted to high-throughput. The type of assay to be performed will influence the choice of 
Dansyl chloride EDANS DAPI
Fluorescein Rhodamine
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fluorophore. Fluorescence polarisation and FRET will be discussed in Sections 2.4 and 2.5 
respectively. Time-resolved fluorescence lifetime experiments rely on changes in the average 
time a molecule remains in its excited state. This is affected by factors such as solvent 
relaxation, quenching by exogenous agents, and changes in macromolecular conformation,167 
so can be used to study protein binding events. To monitor a protein-protein interaction, one 
protein is tagged with a fluorophore and the lifetime measured when this protein is free in 
solution or in complex with its binding partner. In general, the fluorescence lifetime will 
increase when the tagged protein is in complex, as this reduces the effects of external 
quenchers and solvent molecules, and stabilisation of the protein conformation can help keep 
the fluorophore in an excited state.174 
The simplest fluorescence method to measure protein-protein complex formation is to use a 
fluorescence intensity shift assay by utilising solvatochromic fluorophores. Solvatochromic 
dyes possess fluorescence properties that are highly sensitive to the local microenvironment, 
making them extremely useful tools to investigate biomolecular interactions. 
Solvatochromism arises from solvent polarity acting to stabilise the ground or excited 
electronic states, altering the energy difference between them.175 A molecule in solution is 
surrounded by a sphere of solvent molecules. When a fluorophore is excited, the electronic 
configuration is altered, which changes the dipole of the molecule. The solvent sphere 
therefore reorientates its dipoles to accommodate this new dipole (known as solvent 
relaxation), which stabilises the excited state and simultaneously destabilises the ground 
state, bringing them closer in energy (Figure 22). This means that the energy emitted on 
fluorescence is of lower energy than that absorbed, and so is at longer wavelengths. The 
degree of solvent relaxation increases with increasing solvent polarity, so polar solvents (or 
local environments) will stabilise the excited state more than non-polar environments. This 
means that fluorescence emission will be at longer wavelengths when a solvatochromic dye is 
in a polar environment. Additionally, polar solvents tend to increase the energy lost through 
nonradiative processes, meaning the quantum yield is decreased and fluorescence intensity is 
weaker. This can be used to investigate protein binding, as proteins tend to undergo 
conformational changes upon complex formation that may significantly alter the 
hydrophobicity of the local environment. Careful positioning of the fluorescent probe near 
the protein binding site should therefore result in the fluorescence varying depending on 
whether the tagged protein is monomeric or in complex. Examples of solvatochromic dyes 
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include tryptophan, dansyl, PRODAN and coumarin derivatives,164 the structures of which 
are shown in Figure 25. 
 
Figure 25: The structures of a selection of solvatochromic fluorophores; dansyl chloride, tryptophan, 
PRODAN (6-propionyl-2-(dimethylamino)naphthalene) and coumarin derivatives (EDG is an 
electron donating group OR or NR2).164 
2.1.3. The dansyl fluorescence shift assay for MTIP/MyoA 
As described above, fluorescence is a cheap and efficient assay method and so is a common 
starting point for preliminary assays to determine if two proteins bind. Green et al.49 
described the development of a fluorescence intensity shift assay for the MTIP/MyoA 
interaction using dansyl as the fluorescent tag. 
Dansyl is a solvatochromic naphthalene derivative (5-(dimethylamino)-naphthalene-1-
sulfonyl chloride), which becomes fluorescent upon conjugation to an amine. The structure is 
shown in Figure 26.  
 
Figure 26: The resonance structures of the dansyl fluorophore. 
H
N
COOH
H2N
OEDG O
Dansyl chloride Tryptophan
PRODAN Coumarin derivative
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Dansyl may be incorporated into a macromolecule by the sulfonation of a primary amine 
(Figure 27). The reaction usually proceeds in good yields and as dansyl is relatively cheap 
this makes it a popular choice for fluorescent assays. Dansyl has an absorption maximum at 
330 nm, and exhibits a large red shift in emission on going from a non-polar to a polar 
environment. The fluorescence lifetime and quantum yield have also been found to vary with 
solvent polarity, possibly due to an inversion of the two lowest excited singlet states.176,177 
 
Figure 27: The reaction of dansyl chloride with a nucleophile (Nu = nucleophile). 
In 2003, Bergman et al.55 suggested that only the final 15 amino acids of the Plasmodium 
MyoA C-terminal tail region are necessary and sufficient to bind to MTIP. This implies that 
MyoA can be mimicked by a 15 residue peptide when studying its binding to MTIP. 
Green et al.49 labelled this peptide with dansyl at the N-terminus (dmC-MyoA, Figure 30 
(A)). An additional N-terminal cysteine residue with maleimide linker was included to react 
with the dansyl group (dansyl was positioned on the cysteine side-chain, Figure 30 (B)). The 
system was excited at 330 nm and fluorescence emission recorded at 500 nm. Fluorescence 
was observed to increase with titration of MTIP (Figure 28), seemingly due to the dansyl 
group moving from a polar environment in solution to a more hydrophobic region in the 
MTIP binding site. The signal saturated at approximately 1.2 equivalents, indicating 
formation of a 1:1 complex, with a binding constant (Kd) of 48 ±5 nM. In addition, a 
displacement assay was carried out by titrating unlabelled C-MyoA into a solution containing 
1.3 equivalents MTIP and 1 equivalent dmC-MyoA. In this case, the emission at 500 nm 
decreased with increasing concentrations of C-MyoA peptide, as it displaced dmC-MyoA 
from the MTIP binding site into solution (Figure 28).  
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Figure 28: Fluorometric titration of MTIP into dmC-MyoA (Green et al.49) Inset: Displacement assay 
in which C-MyoA was titrated into a solution of dmC-MyoA and MTIP. Excitation was at 330 nm 
and emission read at 500 nm. 
It is clear that the dansyl group is located in such a position on the MyoA peptide to be able 
to undergo a sufficient environmental change to detect binding, but to not hinder complex 
formation. This is an ideal location for a fluorophore tag.178 With this in mind, it was decided 
to continue with this assay using dansyl as a reporter, as proof of principle had already been 
achieved and the assay had also been adapted to be able to screen potential inhibitors of the 
MTIP/MyoA complex. However, the assay was not particularly reproducible,82 likely due to 
a low fluorescence signal to noise ratio, so initial efforts were concentrated on the 
optimisation of these experiments.  
2.2. Synthesis of MTIP and d-GMyoA peptides 
Before any assays could be performed, MTIP and MyoA peptides had to be synthesised. 
P. falciparum MTIP and MyoA sequences were used, as this is the most deadly and 
widespread parasite species. The DNA construct for full-length MTIP was kindly donated by 
Dr Judith Green of the National Institute of Medical Research (NIMR). In this construct 
MTIP residues 1–204 had been cloned into the pET-46 Ek/LIC vector179 containing an 
N-terminal His6-tag and VDDDDK His-cleavage site between the tag and the first MTIP 
residue (Figure 29 (A)). This plasmid was transformed into BL21(DE3) cells and the protein 
expressed in LB media. The plasmid contains a lac operon, so isopropyl-β-D-1-
thiogalactopyranoside (IPTG) was used to induce expression. Following cell lysis, the protein 
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was purified by passing it through Ni-NTA (Ni-nitrilotriacetic acid) agarose beads, and the 
concentration was determined by measuring UV absorption at 280 nm (ε280 = 
28,800 M-1cm-1, calculated using ExPASy Protein Parameters tool website180). These 
conditions gave high yields of between 30–40 mg L-1. Previous studies suggested the His6-tag 
does not affect binding to MyoA,82 so it was not removed before use in binding assays. 
Recombinant MTIP was observed to run as a single band at the predicted molecular weight 
(27 kDa) when analysed using SDS-PAGE, as shown in Figure 29 (B).  
 
Figure 29: (A) The organisation of the MTIP pET46Ek/LIC construct. There is a His6-tag and 
His6-tag cleavage site at the MTIP N-terminus. The MTIP N-terminal domain (NTD) includes 
residues 1-140 and the MTIP C-terminal domain (CTD) residues 141-204. (B) Purified recombinant 
MTIP migrates as a single band on SDS-PAGE, at the predicted molecular weight. 
Automated solid phase peptide synthesis (SPPS) was used to synthesise a dansylated MyoA 
tail peptide. The same 16 C-terminal residues from the P. falciparum MyoA tail 
(MyoA[803-818]) as used by Green et al.49 were chosen, the sequence of which is shown in 
Figure 30. However, whilst the previous work incorporated an additional cysteine residue on 
the N-terminus and used a maleimide linker to bind to dansyl (dmC-MyoA, Figure 30 (B)), in 
this case a glycine linker was decided upon (d-GMyoA, Figure 30 (C)). This meant that 
dansyl could be directly reacted with the amine of the N-terminus of the MyoA peptide 
without introducing additional functionality or bulky groups. It was thought a linker residue 
would be required to ensure the dansyl group did not interfere with peptide binding to MTIP. 
Fmoc SPPS is currently the standard method for the synthesis of long-chain peptides.181 The 
use of a solid support allows a large excess of reagents to be used as they can easily be 
removed by wash steps, which is vital to obtain excellent yields. The N-terminal Fmoc 
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protecting group is preferred over Boc as it is base labile and so Fmoc deprotection 
conditions are chemically orthogonal to those required for side-chain deprotection. This 
removes the need to use potentially dangerous HF that is required for Boc SPPS. Pre-loaded 
glutamine Wang resin was chosen as the solid support for the synthesis of 
d-GMyoA[803-818], as it generates a peptide with a free acid at the C-terminus which best 
mimics the wild-type MyoA protein. Following automated synthesis of the MyoA peptide, 
the final N-terminal Fmoc group was removed, and the N-terminus dansylated manually 
using dansyl chloride. The peptide was cleaved from the resin and purified using high 
performance liquid chromatography (HPLC). The concentration of the stock solution was 
determined by measuring UV absorption at 330 nm (ε330 = 4,300 M-1cm-1).49 
 
Figure 30: (A) The sequences of dmC-MyoA and d-GMyoA[803-818] (B) Structure showing dansyl 
bound to a peptide via a cysteine maleimide linker (C) Dansyl bound to a peptide N-terminus via a 
glycine linker. 
2.3. Optimisation of the dansyl fluorescence intensity assay for MTIP binding 
studies 
2.3.1. Buffer optimisation 
Buffers must be used in protein-protein biophysical assays to mimic biological conditions and 
gain an insight into how the proteins may behave in vivo. The buffer used in the published 
development of the dansyl intensity assay for MTIP/MyoA included 25 mM Tris-HCl, 
(B) Dansyl with maleimide and cysteine linker (C) Dansyl with glycine linker
dmC-MyoA: dm-CSLLRVQAHIRKKMVAQ-OH
d-GMyoA[803-818]: d-GSLLRVQAHIRKKMVAQ-OH
(A) 
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100 mM KCl, and 1 mM EGTA, at pH 8.0.49 Tris and salt are required to maintain the pH 
and ionic strength, and prevent aggregation between protein molecules. EGTA 
(ethyleneglycoltetraacetic acid) is a chelating agent which binds Ca2+ ions. This prevents any 
metal ions present from the protein preparation interfering with complex formation 
(Green et al.49 have shown that Ca2+ is not required for MTIP binding to MyoA). This buffer 
was modified by using NaCl in place of KCl, as this is the standard salt used in Tris-buffered 
saline, and by the addition of 1 mM dithiothreitol (DTT). MTIP contains five cysteine 
residues, so is susceptible to aggregation through disulfide bond formation. DTT reduces 
disulfides so should prevent this. Fluorescence was measured at 37 °C rather than 20 °C used 
in the published method, as this is the biologically relevant temperature the proteins would be 
at inside the parasite when in the bloodstream.  
 
Figure 31: (A) Binding curves for MTIP/d-GMyoA[803-818] read at 0 mins, 5 mins and 10 mins 
after each MTIP titration.  MTIP was added in storage buffer (50 mM Tris, 200 mM NaCl, 20% 
glycerol, pH 8.0). Fluorescence appears to decrease over time. (B) Binding curves for 
MTIP/d-GMyoA[803-818] read at 0 mins, 5 mins and 10 mins after each MTIP titration. MTIP was 
incubated with 1 mM DTT for 30 mins at room temperature before starting the assay. Assays were all 
carried out at 1 µM d-GMyoA[803-818] in assay buffer (25 mM Tris, 100 mM NaCl, 1 mM 
EGTA, 1 mM DTT, pH 8.0) at 37 °C. Excitation = 330 nm, emission = 525 nm. Binding curves were 
generated by fitting the fluorescence data to Equation 2 (Chapter 3) using GraFit.182 
Initially, DTT was added to the assay buffer immediately before use and used to make a 
1 µM solution of d-GMyoA[803-818]. MTIP was added in small volumes, but it was 
observed that MTIP/d-GMyoA[803-818] fluorescence seemed to be decreasing over time 
(Figure 31 (A)). The MTIP storage buffer (50 mM Tris, 200 mM NaCl, 20% glycerol) did not 
contain any DTT, so MTIP was likely being titrated into d-GMyoA[803-818] as a dimer or 
higher aggregates and then being reduced by the DTT in the assay buffer, which could have 
caused the observed decrease in fluorescence signal. To solve this problem, 1 mM DTT was 
added to MTIP and kept at room temperature for 30 minutes before starting the assay. As 
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shown in Figure 31 (B), this resulted in stabilisation of the fluorescence signal, with readings 
taken at 0 mins, 5 mins and 10 mins after MTIP titration into d-GMyoA[803-818] all giving 
the same fluorescence values. 
The fact that fluorescence emission of the complex is the same whether measured 
immediately or after 10 minutes incubation time implies that the system has already reached 
equilibrium when the first reading is taken, so there is no need to allow extra time for an 
equilibration period. 
2.3.2. Concentrations of assay substituents 
The published assay for MTIP/dmC-MyoA used 2.65 µM dmC-MyoA and added up to two 
equivalents of MTIP. It was desirable to reduce the concentration of d-GMyoA[803-818] to 
conserve both peptide and protein. However, it is vital that the concentration of the 
fluorescent substituent in an assay provides a strong signal over background fluorescence to 
ensure conclusive, reliable results. To this end, a fluorescence emission scan of 
d-GMyoA[803-818] was carried out at various concentrations (in a cuvette). This is shown in 
Figure 32. 
 
Figure 32: Fluorescence emission scan of d-GMyoA[803-818] at various concentrations 
(excitation = 330 nm). Fluorescence was measured in assay buffer at 37 °C. 
The fluorescence emission of d-GMyoA[803-818] has a maximum at 550 nm, the intensity of 
which increases with increasing concentration. Although 2 µM and 5 µM 
d-GMyoA[803-818] have stronger emission peaks, 1 µM was chosen for binding assays with 
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MTIP as this gives greater than 4-fold increase over buffer fluorescence, so should not suffer 
from background interference and would not use too much of the starting materials.  
2.3.3. Fluorescence characterisation of the MTIP/d-GMyoA[803-818] complex 
Following buffer and assay component concentration optimisation, an excitation/emission 
scan was run on both 1 µM d-GMyoA[803-818] and a 1.2:1 ratio of 
MTIP/d-GMyoA[803-818] to determine the optimum wavelengths for fluorescence 
measurements (Figure 28 indicates that dmC-MyoA fluorescence is saturated in the presence 
of 1.2 equivalents MTIP). 
 
Figure 33: Contour plots showing the 3D excitation/emission scans of (A) 1 µM d-GMyoA[803-818] 
and (B) MTIP (1.2 µM)/d-GMyoA[803-818] (1 µM) complex.51 Both experiments were carried out at 
37 °C in assay buffer. 
As illustrated in Figure 33, λmax occurs at 330 nm for both d-GMyoA[803-818] in solution 
and in complex with MTIP, so this is the ideal wavelength for excitation. In solution 
d-GMyoA[803-818] has an emission maximum at 550 nm (Figure 33 (A)), but in complex 
(Figure 33 (B)) it is at 530 nm, and much more intense. Due to single read setting restrictions 
on the fluorescence spectrometer, emission measurements were taken at 525 nm (530 nm was 
not possible). 
Using these parameters, a binding assay was performed by titrating MTIP into 1 mL 
d-GMyoA[803-818] (1 µM) in 2 µL additions, to give a final MTIP concentration of 2 µM. 
The fluorescence was measured after each MTIP addition to create a binding curve that 
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saturates after the addition of 1.2 µM MTIP, as was the case for dmC-MyoA. The Kd was 
calculated to be 63±8 nM (the Kd was calculated as described in Chapter 3), very similar to 
that already published (48±5 nM) indicating the assay is accurate, and the error between 
repeat experiments is low confirming the reproducibility of the assay. This result also 
confirms that d-GMyoA[803-818] binds to MTIP with the same affinity as dmC-MyoA. 
 
Figure 34: Fitted curve for MTIP/d-GMyoA[803-818] binding assay to give  Kd 63±8 nM (data was 
fitted to Equation 2 (Chapter 3) using GraFit.182 The assay was carried out using 1 mL 
d-GMyoA[803-818] (1 µM) and adding MTIP in 2 µL additions up to 2 µM. Fluorescence was 
measured after each addition (excitation 330 nm, emission 525 nm) in a cuvette at 37 °C in assay 
buffer. 
As multiple data points are required to plot a binding curve and determine Kd, 
d-GMyoA[803-818] is repeatedly exposed to excitation light which can lead to 
decomposition of fluorophores, known as photobleaching. This can be a problem with dansyl, 
although usually only over long exposures to UV light, not the short exposures used in the 
dansyl fluorescence intensity assay described here.183 To confirm this, 
MTIP/d-GMyoA[803-818] was tested for photobleaching by repeatedly measuring the 
fluorescence after formation of the complex, which amounted to three times in 10 minutes. 
Each emission scan was the same with no observable decrease in fluorescence, ruling out the 
possibility of photobleaching on the timescale of this experiment.  
2.4. Fluorescence anisotropy binding assay 
2.4.1. Fluorescence anisotropy theory 
As mentioned in Section 2.1.2, fluorescence anisotropy (or fluorescence polarisation) is 
another popular fluorescence technique for studying protein-protein complex formation. This 
method does not rely on the solvent environment or the precise location of the fluorophore so 
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can be less susceptible to artefacts. Fluorescence anisotropy uses plane polarised light to 
excite a sample, whereby only molecules aligned with the direction of polarisation will be 
excited. One of two things may happen to these molecules; if the fluorescence lifetime of the 
molecule (τflu) is shorter than the rotational correlation time (τrot, the time taken for a 
molecule to rotate through one radian in solution) the molecules will remain aligned and so 
emitted fluorescence will remain polarised, giving a high polarisation signal.165 If τflu is 
longer than τrot, the molecules will have time to randomise their orientations in solution 
before fluorescence is emitted, so polarisation will be lost giving a low signal (Figure 35). 
The rotational correlation time is essentially how fast a molecule tumbles in solution, so 
depends on the size of the molecule in addition to solvent factors such as viscosity and 
temperature. In general, the larger the molecule the longer the rotational correlation time. 
This may be exploited in protein binding studies by fluorescently labelling the smaller protein 
and measuring its fluorescence anisotropy. Upon complex formation the dye becomes 
attached to a larger entity and so τrot will increase and anisotropy will be high. This may be 
applied to the MTIP/MyoA binding assay since the fluorescence anisotropy of 
d-GMyoA[803-818] will be expected to increase upon binding to MTIP, as a large protein 
complex is formed. 
 
Figure 35: Diagram to show the theory of fluorescence anisotropy. The blue circle is a ligand labelled 
with a fluorescent molecule (yellow), green is a larger protein binding partner. τrot rotational 
correlation time, τflu fluorescence lifetime.  
Polarised light
Rapid rotation
τrot <  τflu 
Slow rotation
τrot >  τflu 
Emitted light 
depolarised
Emitted light 
remains polarised
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2.4.2. d-GMyoA[803-818] in the anisotropy assay 
d-GMyoA[803-818] binding to MTIP was examined using a fluorescence anisotropy assay as 
this method can sometimes be more sensitive than fluorescence shift assays when studying 
protein-protein interactions. As for the fluorescence intensity binding assay, a 1 µM solution 
of d-GMyoA[803-818] was placed in a cuvette (400 µL) and MTIP (80 µM) was added in 
1 µL additions to give a final concentration of 2 µM. As predicted, the anisotropy was 
observed to increase with complex formation, and the data was fitted to give Kd 29±7 nM 
(Figure 36(A)). This value is close to that obtained in the MTIP/d-GMyoA[803-818] dansyl 
intensity assay, suggesting that it is possible to analyse this interaction using fluorescence 
anisotropy. However, there were problems with the reproducibility of this result, and it may 
be noted in Figure 36 (A) that the signal starts to saturate at only 0.5 equivalents of MTIP, 
which is earlier than expected. Dansyl is not the ideal fluorophore to use in anisotropy 
experiments, as the solvatochromic shift upon complex formation can interfere with 
polarisation measurements. It was therefore decided to re-synthesise fluorescently labelled 
MyoA[803-818] using a different dye. 
 
Figure 36: Fluorescence anisotropy binding assay results for (A) MTIP/d-GMyoA[803-818] (data 
were fitted with Kd 29±7 nM using GraFit182) (B) MTIP/f-GMyoA[803-818]. No change in anisotropy 
was observed upon MTIP titration with f-GMyoA[803-818]. All assays were carried out in assay 
buffer at 25 °C (the fluorescence anisotropy spectrometer used was unable to heat to 37 °C). 
2.4.3. f-GMyoA[803-818] in the fluorescence anisotropy assay 
Fluorescein is a xanthene dye which, unlike dansyl, is not very environmentally sensitive 
making it a common choice for use in anisotropy assays. It is cheap, readily available, and 
easily incorporated onto the N-terminus of peptides, so was chosen as an alternative to dansyl 
for labelling MyoA[803-818]. Fluorescein can exist in seven prototropic forms and is in 
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equilibrium between the open quinoid and closed lactone forms shown in Figure 37. Only the 
quinoid species is fluorescent.184  
 
Figure 37: The equilibrium between the open quinoid and closed lactone forms of fluorescein.169 
The dianion quinoid in Figure 37 is the predominant form at biological pH, and is the most 
fluorescent species with a λmax of 490 nm and λem 514 nm. It has extremely bright 
fluorescence with a quantum yield of 0.95.169 With this in mind, MyoA[803-818] was 
synthesised and reacted with carboxyfluorescein to give the N-terminally labelled peptide. As 
for d-GMyoA[803-818], glycine was used as a linker residue between the wild type peptide 
sequence and the fluorescent tag. This peptide was tested in the fluorescence anisotropy 
binding assay with MTIP using 1 µM f-GMyoA[803-818]. Surprisingly, no change in 
anisotropy was observed (Figure 36 (B)). This may be because the fluorescence lifetime of 
carboxyfluorescein (4.65 ns at pH 7–8)185 is too long for a protein complex of this size so 
polarisation is lost before fluorescence is emitted. Fluorescein is a larger molecule than 
dansyl, so it is also possible that it interferes with MyoA peptide binding to MTIP, meaning 
MTIP/f-GMyoA[803-818] complex formation does not occur. There are several fluorophores 
available, so it should be possible to find one suitable for development of a fluorescence 
anisotropy assay for the MTIP/MyoA interaction. However, it was decided to concentrate on 
the alternative fluorescence methods available rather than direct further time and resources 
towards an anisotropy assay.  
2.5. Development of a FRET binding assay for MTIP/MyoA 
2.5.1. Theory of FRET 
Fluorescence resonance energy transfer (FRET) is the radiationless transfer of energy from 
the excited state of one chromophore to another fluorophore in close proximity. Unlike the 
previously mentioned fluorescence techniques, FRET requires the presence of two 
± 2H+
Quinoid
(fluorescent)
Lactone
(non-fluorescent)
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fluorophores, a donor and an acceptor, and is highly dependent on the distance between them. 
The donor fluorophore is excited, and when close to the acceptor (10-80 Å)186 can transfer its 
energy. This occurs through long range dipole-dipole interactions, rather than photon 
emission and re-absorption, and so requires the overlap of the donor emission and acceptor 
absorption spectra. The acceptor is excited, and may return to the ground state by 
fluorescence. FRET can be monitored by measuring the quenching of the donor fluorescence 
(and accompanying decrease in its fluorescence lifetime) or the intensity increase of the 
acceptor fluorescence. The efficiency of this energy transfer is proportional to 1/r6 (r is the 
distance between the fluorophores), so FRET is highly sensitive to the distance between the 
chromophores. This can be used to analyse protein-protein interactions. One protein is 
labelled with the donor species, and the other with the acceptor. If the two proteins interact 
the fluorophores are brought into close proximity allowing FRET to occur, so acceptor 
emission is strong. If the proteins do not bind the fluorophores are too far apart to permit 
energy transfer, so the acceptor remains unexcited and no acceptor emission is observed 
(Figure 38). FRET is not reliant on the surrounding solvent shell of a chromophore so may 
provide additional information to that obtained by other fluorescence techniques, as solvent-
dependent events such as solvent relaxation, quenching and anisotropy are reduced.166,187  
 
Figure 38: Fluorescence resonance energy transfer. Proteins X and Y are labelled with a donor and 
acceptor fluorophore respectively. The donor fluorophore is excited: (i) if the proteins are free in 
solution the chromophores are far apart so the energy is emitted by the donor. The acceptor will not be 
excited. (ii) If the proteins bind, the donor and acceptor are brought within close proximity. Energy is 
transferred from the donor to the acceptor fluorophore, which then fluoresces.  
2.5.2. Development of a FRET assay for MTIP/MyoA 
MTIP contains two tryptophan residues, one in the N-terminal domain (W31) and one in the 
C-terminal domain (W171), and it was noted from the published crystal structure88 that W171 
is situated close to the MyoA peptide binding site (Figure 39 (B)). This residue is near the N-
(i) Proteins X and Y do not bind (ii) Proteins X and Y form a complex
Donor Acceptor
X Y
Donor Acceptor
FRET
X
Y
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terminus of the MyoA peptide, which is where the dansyl group is presumably located in 
d-GMyoA[803-818]. As mentioned in Section 2.1.2, tryptophan is fluorescent and when 
excited at 280 nm gives an emission peak with λmax at approximately 330 nm, which is where 
dansyl absorbs. Tryptophan and dansyl can therefore be used as a FRET pair. Experiments 
were carried out to determine if this was possible in the MTIP/d-GMyoA[803-818] complex. 
Initially, 1 µM MTIP was excited at 280 nm to check for intrinsic fluorescence arising from 
these tryptophan residues. There is a strong emission peak with a maximum at 340 nm, as 
shown in Figure 39 (D, dark blue spectrum).  
 
Figure 39: (A) Organisation of the MTIP[61-204] pQE30/pREP4 construct. (B) Space-filling 
structure of PfMTIP[60-204] (blue) in complex with PyMyoA[803-817] (green)88 with residue W171 
highlighted in red. (C) SDS-PAGE of purified MTIP[61-204] (D) Fluorescence emission spectra of 
MTIP (dark blue) and MTIP[61-204] (light blue) when excited at 280 nm. Spectra were obtained in a 
cuvette at 1 µM MTIP or MTIP[61-204] in assay buffer at 37 °C. 
It has previously been shown that MTIP residues 1–60 are not required for binding to 
MyoA55,88 (they are thought to bind instead to GAP45 or another membrane-linked protein) 
so  can be removed without adversely affecting MTIP/MyoA complex formation. Residue 
W31 is therefore unlikely to be affected by MyoA binding, so it was decided to remove this 
region and examine the intrinsic fluorescence of the shorter construct MTIP[61-204]. It was 
hoped that this would make any changes in the fluorescence of W171 easier to observe as 
there would be less background fluorescence. The MTIP[61-204] construct was provided by 
Dr Ernesto Cota, Imperial College London. MTIP[61-204] was cloned into the pQE30 
plasmid,188 which was transformed into BL21(DE3) cells along with the repressor plasmid 
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pREP4 (this plasmid is used to regulate pQE30 transcription, but does not contain the 
MTIP[61-204] gene sequence). The protein contains a His6-tag on the N-terminus, with a 
glycine linker residue between this tag and the first MTIP residue (S61). There is no His6-tag 
cleavage site in this protein (Figure 39 (A)). MTIP[61-204] was purified by passing the 
protein through Ni-NTA agarose beads, as for full-length MTIP, and was observed to run as a 
single band at the expected molecular weight (16 kDa) when analysed by SDS-PAGE (Figure 
39 (C)). MTIP[61-204] was tested in the dansyl fluorescence intensity binding assay with 
d-GMyoA[803-818] and was observed to form a 1:1 complex with Kd 63±4 nM, confirming 
that it behaves the same way as full-length MTIP in terms of binding to MyoA peptides. 
The fluorescence emission spectra of MTIP[61-204] has a strong peak with a maximum at 
330 nm when excited at 280 nm (Figure 39 (D), light blue spectrum). The intensity is much 
lower than that of the corresponding peak in full-length MTIP due to the removal of W31 and 
four tyrosine and four phenylalanine residues that are also likely to contribute to fluorescence 
emission when excited at 280 nm. Nevertheless, it is still a strong peak and gives a good 
fluorescence signal over background. Excitation/emission scans were run of this protein to 
determine the optimum wavelengths to measure FRET changes. The same buffer and 
concentrations were used as for the dansyl intensity assay; 1 µM MTIP[61-204] was 
measured both unliganded, and in the presence of 1.2 µM d-GMyoA[803-818] (1.2 µM was 
used to ensure total complex formation). The results are shown in Figure 40. It is clear that 
280 nm is the ideal excitation for this assay as all peaks have a maximum when excited at this 
wavelength. MTIP[61-204] has a strong emission peak at 330 nm (Figure 40 (A)), but upon 
complexation to d-GMyoA[803-818] this shifts to 315 nm, reflecting the solvatochromic 
behaviour of tryptophan residue W171. This peak is lower in intensity compared to free 
MTIP[61-204], and there is a new emission peak with a maximum at 525 nm (Figure 40 (B)). 
This is due to energy transfer between MTIP[61-204] residue W171 (which reduces the 
fluorescence at 330 nm) and d-GMyoA[803-818] (the dansyl group becomes excited and 
emits at 525 nm). 
The apparent solvatochromic shift of MTIP[61-204] residue W171 upon d-GMyoA[803-818] 
complex formation suggested that it might be possible to observe binding without the need to 
extrinsically label the MyoA peptide. To this end, unlabelled MyoA[803-818] was 
synthesised using automated SPPS and manually acetylated on the N-terminus (using acetic 
anhydride) to mimic the next amide bond of the MyoA tail. Following HPLC purification, 
this peptide was titrated into 1 µM MTIP[61-204] and emission scans taken at excitation 
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280 nm. Unfortunately, no significant changes in fluorescence were observed even at 
MyoA[803-818] concentrations up to 5 µM, suggesting that the dansyl group is responsible 
for the shift noted in the MTIP[61-204]/d-GMyoA[803-818] spectrum. 
 
Figure 40: 3D excitation/emission contour plots of (A) 1 µM MTIP[61-204] and (B) 
MTIP[61-204]/d-GMyoA[803-818] (1:1.2 µM) complex. Both spectra were obtained in assay buffer 
at 37 °C. The strong intensities in the upper left corners are due to interference from excitation light. 
A binding curve was generated for MTIP[61-204] with d-GMyoA[803-818]. 
d-GMyoA[803-818] was titrated into a 1 µM solution of MTIP[61-204] in 3 µL additions to 
give a final concentration of 2 µM. The fluorescence emission was measured at both 320 nm 
and 525 nm. As predicted, increasing concentrations of d-GMyoA[803-818] led to a decrease 
in the intensity at 320 nm, and an increase at 525 nm (Figure 41 (A) pink). However, neither 
curve seemed to saturate. A control experiment was performed to check the background 
fluorescence of d-GMyoA[803-818] when excited at 280 nm as it was thought that this may 
be contributing to the signal at 525 nm. As shown in Figure 41 (A, blue), this was found to be 
the case, although it was not a problem at emission 320 nm. To overcome this, the binding 
data at emission 525 nm was corrected for d-GMyoA[803-818] background fluorescence. 
The control experiment was performed in triplicate, the mean values calculated and a linear 
line of best fit applied to the data to obtain accurate values for d-GMyoA[803-818] 
fluorescence at the concentrations used in the binding assay (Figure 41 (A) blue). The 
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corrected binding curve was re-plotted and Kd calculated to be 597±173 nM (Figure 41 (B), 
red). The binding data obtained at emission 320 nm gave a Kd value of 1.3±0.4 µM (Figure 41 
(B), turquoise). In addition to the variation between these values, the Kd is higher than that 
calculated using the dansyl intensity assay (63±8 nM). This appears to be because the binding 
curves do not saturate properly, even after the addition of two equivalents of 
d-GMyoA[803-818], which is likely to be due to the background fluorescence of 
d-GMyoA[803-818] interfering with the binding fluorescence signals. It is difficult to 
determine how accurate the correction factor is. This suggests that the FRET assay is not 
ideal for analysing dansylated MyoA peptide binding to MTIP, although it does have a 
greater fluorescence signal over background and is more sensitive than the dansyl intensity 
assay, so may be preferred for other applications, such as displacement assays. 
 
Figure 41: FRET binding assay MTIP[61-204]/d-GMyoA[803-818] (A) Fluorescence emission of 
MTIP[61-204]/d-GMyoA[803-818] titration (pink, data fitted with Kd 957±315 nM) and background 
fluorescence of d-GMyoA[803-818] (blue) at emission 525 nm (B) Background corrected binding 
curve for MTIP[61-204]/d-GMyoA[803-818] at emission 525 nm (red, data fitted with Kd 
597±173 nM) and 320 nm (turquoise, data fitted with Kd 1300±417 nM)). Data at emission 320 nm 
has been normalised and inverted to give a binding curve. All assays were carried out with excitation 
280 nm in assay buffer at 37 °C using 1 µM MTIP[61-204]. Kd was calculated by fitting the data to 
Equation 2 (Chapter 3) using GraFit.182 
2.6. Summary 
This chapter has described the development of a robust, reproducible fluorescence assay for 
the study of MTIP binding to dansylated MyoA tail peptides. Although a dansyl intensity 
shift assay for MTIP/MyoA binding had been reported by Green et al.49 there were concerns 
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over its accuracy and consistency. Optimisation of the buffer, component concentrations and 
fluorescence parameters eliminated these problems, and a Kd value of 63±8 nM was 
calculated for the MTIP/d-GMyoA[803-818] interaction, which is in agreement with that 
already published. 
Attempts were made to develop novel fluorescence assays employing fluorescence anisotropy 
and FRET methodology. The fluorescence anisotropy assay was unconvincing due to a lack 
of consistency, suggesting further research into an appropriate fluorophore for the tagging of 
MyoA peptides was required. It was decided not to pursue this due to the success of the 
alternative methods.  
The tryptophan-dansyl FRET assay was highly sensitive and had better reproducibility than 
the dansyl intensity assay. It was applied to assess the binding of 
MTIP[61-204]/d-GMyoA[803-818], although the calculated Kd value (597±173 nM) was 
higher than expected, implying the increasing background fluorescence from 
d-GMyoA[803-818] may distort the results. However, FRET is a valuable technique as it can 
provide information on distances in a complex in addition to assessing binding interactions, 
so may have further applications in the future.  
In order to implement these assays, two constructs of MTIP were expressed; full-length 
MTIP and an N-terminal truncated construct MTIP[61-204]. Expression and purification 
conditions for both of these proteins were optimised to give yields in excess of 30 mg L-1 
with high purity, which means the screening of many d-GMyoA peptides or potential 
inhibitors should be feasible. MTIP[61-204] has not previously been isolated, so is a novel 
construct that may provide further insights into the behaviour of MTIP in Plasmodium. An 
effective method was also identified for the synthesis and purification of MyoA tail peptides 
with various functional groups on the N-terminus, which is vital for the characterisation of 
MyoA binding to MTIP. 
Development of these binding assays and the successful synthesis of the assay components 
paves the way for an in-depth study of the MTIP/MyoA protein-protein interface, which will 
be discussed in Chapters 3 and 4. 
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Chapter 3   MTIP-Peptide binding studies 
 
Chapter 2 described the development of dansyl fluorescence-based assays to examine the 
binding of dansylated MyoA peptides with MTIP. The present chapter discusses the use of 
these assays to quantify the binding affinity of several MyoA peptides with four different 
MTIP constructs to gain an insight into the binding motifs and protein domains required for 
MTIP/MyoA complex formation. Peptide arrays were also applied to probe the binding of 
MTIP with MyoA tail peptides. 
Fluorescence assays and peptide arrays were also used to determine whether MTIP is able 
to bind to peptides derived from the tail of MyoB, another Plasmodium myosin of unknown 
function, the results of which provide a starting point for future investigations. 
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3.1. The dissociation constant Kd 
As discussed in Chapter 2, in order to study a protein-protein interaction a reliable assay is 
required to quantify binding, and thus provide information about the binding interface. The 
standard parameter for assessing protein-protein binding affinities is the dissociation constant 
Kd. This is the form of the equilibrium constant (Equation 1) that reflects the propensity of a 
complex to dissociate into its individual components.189 It is equivalent to the ratio between 
the rate of dissociation (koff) and the rate of association (kon). In general, kon is similar for all 
protein complexes, but koff may display large variations due to the nature of the binding 
interface, and is therefore largely responsible for differences in binding affinities between 
protein complexes. 
 
Equation 1: The dissociation constant Kd. A and B are two proteins that form a complex AB. koff is 
the rate of dissociation of complex AB, and kon the rate of association.189 
In practical terms, Kd represents the concentration of ligand at which the binding site of a 
particular protein is half occupied; the concentration of ligand bound is equal to the 
concentration of ligand free in solution. This means that higher affinity interactions have 
lower Kd values. As for all equilibrium constants, Kd is related to the Gibbs free energy and 
so is influenced by both enthalpic and entropic factors, and varies with temperature             
(ΔG = –RTlnKd, where ΔG is the change in Gibbs free energy, R is the gas constant and T is 
temperature).189 Solution conditions also affect binding affinities as they can modify 
intermolecular interactions, so it is important to maintain constant conditions when 
comparing Kd values.190,191  
The previous chapter described the development and optimisation of the dansyl fluorescence 
intensity shift assay for studying MTIP/MyoA peptide binding. In this assay the fluorescence 
emission of d-GMyoA[803-818] increases when it binds to MTIP. Fluorescence emission at 
525 nm was plotted against MTIP concentration (amount of ligand bound plotted as a 
function of total ligand added) to give a single-site saturation curve (all fluorescence binding 
A + B AB
Kd =
A B
AB
=
kon
koff
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assays in this thesis were performed in triplicate and the mean values plotted). Kd was 
calculated by fitting the data to Equation 2 using non-linear regression analysis in GraFit 
software.182  
 
Equation 2: Equation to determine Kd values from the MTIP/d-GMyoA dansyl fluorescence intensity 
shift binding assay.182  
3.2. Binding of d-GMyoA peptides to MTIP 
3.2.1. Results using the dansyl fluorescence intensity shift assay 
3.2.1.1. Binding of d-GMyoA peptides to MTIP and MTIP[61-204] 
The MTIP/d-GMyoA dansyl fluorescence binding assay was developed using 
d-GMyoA[803-818] (P. falciparum sequence), which was found to bind to PfMTIP with a Kd 
of 63±8 nM (Chapter 2). This MyoA tail peptide is the equivalent of the P. yoelii 
MyoA[803-817] peptide crystallised in complex with PfMTIP.88 Yeast two-hybrid studies 
performed by Bergman et al.55 implied that this region was necessary and sufficient for 
MyoA binding to MTIP. However, Dr Judith Green and Dr Antony Holder at NIMR 
suggested that there may be additional interactions with MTIP from as yet unstudied MyoA 
residues.82 With this in mind, a range of MyoA peptides were synthesised (using solid-phase 
peptide synthesis) corresponding to different regions of the MyoA tail; d-GMyoA[803-818], 
d-GMyoA[799-818], d-GMyoA[791-818], d-GMyoA[781-818] and d-GMyoA[781-801], the 
sequences of which are shown in Figure 42. Peptides terminating with MyoA residue 818 
were synthesised with a free acid at the C-terminus, as is the case in vivo, whilst 
d-GMyoA[781-801] was synthesised with a C-terminal amide to mimic the next amide bond 
in the MyoA tail. Each peptide was dansylated on the N-terminus using a glycine linker, and 
tested for binding to MTIP using the dansyl fluorescence intensity shift assay.  
Total signal = (Max – Back)b + Back
b = (Kd + [MTIP] + [d-peptide]) - √{(Kd + [MTIP] + [d-peptide])2 – 4[MTIP][d-peptide]}
[MTIP] = Concentration of MTIP
[d‐peptide] = Concentration of d‐peptide
Max = Maximum fluorescence signal
Back = Background fluorescence signal
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Figure 42: The sequences of the d-GMyoA tail peptides synthesised. MyoA residues 803-818 are 
shown in blue. These were previously identified by crystallography and yeast two-hybrid experiments 
to bind to MTIP.55,88 Residues 781-802 are shown in orange and the dansyl group and glycine linker 
shown in green. 
The binding assay results for each of these peptides are shown in Figure 43. All d-GMyoA 
peptides containing residues 803–818 of the MyoA tail form a tight 1:1 complex with MTIP 
with similar low nanomolar dissociation constants. d-GMyoA[781-801] binds with much 
lower affinity (Kd 2.7±0.7 µM). It was previously thought that this region of the MyoA tail 
was not involved in binding to MTIP, but these assay results indicate that there may be 
additional interactions from these residues, although much weaker than MyoA[803-818]. The 
dansyl group is always located on the N-terminus of the MyoA peptide, so it is somewhat 
surprising that d-GMyoA[803-818], d-GMyoA[799-818], d-GMyoA[791-818] and 
d-GMyoA[781-818] all show the same fluorescent behaviour upon binding. It may have been 
expected that the varying locations of dansyl on the MyoA peptide would result in it being 
situated differently in the MTIP binding site. However, the increase in fluorescence is the 
same in each case, implying either that the dansyl moiety is moving into the same 
hydrophobic chemical environment whichever MyoA peptide binds to MTIP, or that there are 
multiple binding pockets that can accommodate dansyl but they all give rise to the same 
change in fluorescence.  
The same five d-GMyoA peptides were also tested for binding against MTIP[61-204]. This 
truncated construct does not contain N-terminal residues 1–60, which are not thought to be 
required for binding to MyoA. It would therefore be anticipated that this protein would be 
able to bind to d-GMyoA peptides in the same way as full-length MTIP. This was found to be 
the case for d-GMyoA[803-818], d-GMyoA[799-818], d-GMyoA[791-818] and 
d-GMyoA[781-818], which all give Kd values of the same magnitude with MTIP[61-204] as 
they do with MTIP (within error, Figure 43 (B)). This confirms that MTIP residues 1-60 are 
MyoA tail: ...VSVIEAAILKHKYKQKVNKNIPSLLRVQAHIRKKMVAQ-OH
d-GMyoA[781-801]: d-GVSVIEAAILKHKYKQKVNKNI-NH2
d-GMyoA[781-818]: d-GVSVIEAAILKHKYKQKVNKNIPSLLRVQAHIRKKMVAQ-OH
d-GMyoA[791-818]: d-GHKYKQKVNKNIPSLLRVQAHIRKKMVAQ-OH
d-GMyoA[799-818]: d-GKNIPSLLRVQAHIRKKMVAQ-OH
d-GMyoA[803-818]: d-GSLLRVQAHIRKKMVAQ-OH
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not required for MTIP binding to MyoA, suggesting that the N-terminal extension of MTIP 
may be utilised in binding to an inner membrane complex-linked protein, such as GAP45, 
instead (this has been proposed by Green et al.61 for Plasmodium and by Heaslip et al.152 for 
TgMLC1 in Toxoplamsa). The fluorescence increase of d-GMyoA[781-801] upon titration 
with MTIP[61-204] was too small to be able to calculate the Kd which suggests that the 
dansyl group may be in a slightly different environment compared to the other d-GMyoA 
peptides. It is possible that d-GMyoA[781-801] does not bind to MTIP[61-204], although this 
seems unlikely as MTIP residues 1–60 do not affect binding for any other MyoA peptides. It 
may be that binding of this peptide to MTIP[61-204] is too weak to be detected using the 
dansyl fluorescence intensity shift assay. 
 
Figure 43: (A) Binding curves of d-GMyoA peptides with MTIP (B) Kd values for the binding of 
several d-GMyoA peptides with MTIP and MTIP[61-204]. Kd could not be calculated for 
d-GMyoA[781-801] with MTIP[61-204]. Assays were all carried out at 1 µM d-peptide in assay 
buffer at 37 °C. Curves were plotted of fluorescence intensity at excitation 330 nm, emission 525 nm 
and fitted to Equation 2 using GraFit.182 Figure adapted from Thomas et al.51 
3.2.1.2. Binding of d-GMyoA peptides to MTIP NTD and CTD 
As discussed in Chapter 1 (Section 1.3.4.), the most recent crystal structure of 
PfMTIP[60-204] in complex with PyMyoA[803-817] obtained at neutral pH shows both the 
N- and C-terminal domains (NTD and CTD respectively) of MTIP wrapping around the 
MyoA tail in a “closed” conformation.88 However, the previous crystal structure of 
PkMTIP[79-205] in complex with PyMyoA[803-817] obtained at acidic pH showed only the 
MTIP C-terminal domain interacting with the MyoA tail peptide, with the N-terminal 
extended in an “open” conformation.54 To investigate the participation of the individual 
MTIP domains in MyoA binding, the NTD and CTD were expressed separately. DNA 
constructs were a gift from Dr Judith Green (NIMR). The N-terminal domain consists of 
MTIP residues 1–140 and the C-terminal residues 141–204. These were cloned individually 
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MyoA Peptide MTIP (nM) MTIP[61-204] (nM)
d-GMyoA[803-818] 63 ±8 63 ±4
d-GMyoA[799-818] 33 ±15 112 ±21
d-GMyoA[791-818] 82 ±18 113 ±47
d-GMyoA[781-818] 75 ±16 90 ±37
d-GMyoA[781-801] 2700 ±700 --
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into the pET-30 Xa/LIC vector192 and contain an S-tag (KETAAAKFERQHMDS) and 
His6-tag on the N-terminal, with a thrombin cleavage site (SSGLVPRGS) in between the 
tags; the proteins are of the form His-tag–cleavage-site-S-tag–MTIP-domain (Figure 44 (A)). 
The plasmids were transformed into BL21(DE3) cells and expressed in LB media, and 
following cell lysis the proteins were purified by passing over Ni-NTA beads. As illustrated 
in Figure 44 (B), SDS-PAGE analysis confirms that both domains migrate as single bands at 
the predicted molecular weights (NTD 21 kDa, CTD 12 kDa). 
 
Figure 44: (A) Organisation of the constructs for MTIP NTD and MTIP CTD. Both proteins contain 
a His6 and an S-tag on the N-terminus. (B) SDS-PAGE of MTIP NTD and CTD compared to full-
length MTIP. Both MTIP NTD and CTD migrate as single bands at the predicted molecular weights 
(NTD 21 kDa, CTD 12 kDa). (C) Kd values for MTIP CTD and NTD bound to d-GMyoA peptides of 
varying lengths. Kd values were determined using the dansyl fluorescence intensity binding assay 
which was carried out with 1 µM d-GMyoA in assay buffer at 37 °C. Fluorescence emission was 
measured at 525 nm with excitation 330 nm. Figure adapted from Thomas et al.51 
Both MTIP NTD and CTD were tested in the dansyl fluorescence intensity binding assay 
against each d-GMyoA peptide. The Kd values in Figure 44 (C) indicate that MTIP CTD is 
able to bind to each of the MyoA tail peptides, although with much weaker affinity than full-
length MTIP. The NTD only seems able to bind to the longest peptides d-GMyoA[781-818] 
and d-GMyoA[791-818], both with weaker affinities than CTD binding. This confirms that 
both the N- and C-terminal domains of MTIP participate in binding to MyoA at biological 
MyoA Peptide MTIP CTD (nM) MTIP NTD (nM)
d-GMyoA[803-818] 368 ±135 --
d-GMyoA[799-818] 336 ±202 --
d-GMyoA[791-818] 592 ±365 801 ±194
d-GMyoA[781-818] 654 ±67 1800 ±286
d-GMyoA[781-801] 5600 ±2900 --
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pH, and suggests that the greater contribution comes from the CTD. This supports the 
published crystallography data, as in the open complex structure it is the CTD which binds to 
the MyoA tail, with no interactions from the NTD.54 The observation that MTIP NTD does 
not bind to any of the short peptides suggests that this domain may interact with the hinge 
region of the MyoA tail (around residues 799–803), as it appears to require these residues to 
be in the middle of the peptide for binding to occur. 
3.2.1.3. The effect of varying the ionic strength on MTIP/d-GMyoA peptide binding 
The closed crystal structure obtained at neutral pH reveals a combination of hydrophobic and 
hydrophilic interactions between MTIP and the MyoA tail.88 The MTIP CTD forms a 
hydrophobic groove to accommodate MyoA residues L804, V807 and I811, while MyoA 
residues R806, H810 and K813 on the opposite face of the MyoA α-helix form electrostatic 
interactions with the MTIP NTD. Additionally, there are several electrostatic bridges, notably 
MTIP residues D137 of the hinge region and K71 of the NTD, which stabilise the closed 
MTIP conformation. To investigate the contributions of these binding motifs, the dansyl 
fluorescence intensity binding assay was carried out at different ionic strengths by varying 
the concentration of NaCl in the assay buffer. The assay was performed between full-length 
MTIP and d-GMyoA[791-818]. This longer d-GMyoA peptide was chosen rather than 
d-GMyoA[803-818] because it also includes interactions from the MyoA[781-801] region, so 
better represents full-length MyoA found in vivo, and it is easier to handle than the longest 
peptide d-GMyoA[781-818], which is prone to aggregation. The concentration of NaCl in the 
standard assay buffer is 100 mM. This was changed to 0 mM, 250 mM and 500 mM to assess 
the importance of electrostatic interactions in the MTIP/MyoA complex. All other buffer 
component concentrations were unchanged (25 mM Tris, 1 mM EGTA, 1 mM DTT, pH 8.0). 
The results shown in Figure 45 demonstrate that increased salt concentration reduces the 
binding affinity of the MTIP/d-GMyoA[791-818] interaction, reflected by the increase in Kd 
value, and confirm the importance of electrostatic interactions in the MTIP/MyoA tail 
complex. Protein ionic charges are solvated by salt ions in the buffer and this effect is larger 
at higher salt concentrations, reducing electrostatic contacts between the interacting proteins 
and decreasing protein binding affinity. The Kd values at 250 mM and 500 mM NaCl are 
approximately five times larger than at 100 mM NaCl, confirming that this has a strong effect 
on complex formation for MTIP/MyoA. Conversely, the Kd value obtained at 0 mM NaCl is 
only 16±10 nM and the binding curve for this assay is sharper than at 100 mM, indicating 
stronger protein binding in the absence of salt solvation. Interestingly, the Kd values obtained 
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at high salt concentrations are similar to those obtained for MTIP CTD binding to 
d-GMyoA[791-818] at 100 mM NaCl (Figure 44 (C)), implying that high salt may disrupt the 
electrostatic interactions of the MTIP NTD, preventing it from contacting MyoA. These 
results demonstrate the highly ionic nature of the MTIP/MyoA tail complex and suggest that 
preventing these interactions from occurring may be sufficient to hinder complex formation.  
 
Figure 45: Binding curves for MTIP/d-GMyoA[791-818] at various NaCl concentrations. Increased 
ionic strength results in a decrease in the affinity between MTIP and d-GMyoA[791-818]. Assays 
were carried out at 1 µM d-GMyoA[791-818] at 37 °C. Fluorescence emission was measured at 
525 nm with excitation 330 nm and the data fitted to Equation 2 using GraFit.182 
3.2.1.4. The effect of pH on MTIP/d-GMyoA peptide binding 
The strong participation of electrostatic interactions in the MTIP/MyoA complex implies that 
pH may have a large effect on complex formation, as this may alter the equilibrium 
protonation states of the various ionic amino acid residues involved. This has already been 
observed in the differences between the open and closed crystal structures. As discussed in 
Chapter 1 Section 1.3.4., the open crystal structure was obtained at pH 5.3, whereas the 
closed structure was obtained at pH 7.5. It was found that MyoA residue H810 must be 
deprotonated to allow the closed conformation to form,88 which is unlikely to be the case at 
acidic pH. The imidazole side-chain of histidine has a pKa of 6.0 (in the free amino acid),193 
meaning it is particularly susceptible to variations at biologically relevant pH. There are 
numerous other electrostatic interactions and hydrogen bonds involved in the MTIP/MyoA 
tail complex which also have the potential to be affected by pH variations. To investigate 
this, the binding assay between MTIP and d-GMyoA[791-818] was carried out across a range 
of defined pH. As for the assays assessing ionic strength variations described in Section 
3.2.1.3, full-length MTIP and d-GMyoA[791-818] were used to best mimic the wild type 
proteins. It was decided to assess binding at pH 6 and 7 as well as pH 8, at which the assay is 
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usually performed, as this would allow observation of binding under acidic conditions. 
However, the buffer range of Tris-buffer is 7.0–9.0, so it is unsuitable for studying binding at 
acidic pH.194 With this in mind, it was decided to use phosphate buffer (Na2HPO4/NaH2PO4) 
instead, which has a buffer range of 5.8–8.0.194 The assay was first carried out in 25 mM 
phosphate buffer at pH 8.0 to establish whether MTIP/MyoA behaves the same in this buffer 
as in Tris, and then at pH 7.0 and 6.0. As for the standard assay buffer, 100 mM NaCl, 1 mM 
EGTA and 1 mM DTT were also included. The results are illustrated in Figure 46. 
 
Figure 46: Binding curves for MTIP/d-GMyoA[791-818] in phosphate buffer at different pHs. 
Assays were carried out at 1 µM d-GMyoA[791-818] at 37 °C. Fluorescence emission was measured 
at 525 nm with excitation 330 nm and data were fitted to Equation 2 using GraFit.182 
In phosphate buffer at pH 8.0 MTIP binds to d-GMyoA[791-818] with very similar affinity 
(128±64 nM) as in Tris buffer (82±18 nM). The error is larger, possibly because it appears 
that d-GMyoA[791-818] is not as stable in phosphate buffer as it is in Tris; precipitation was 
observed at high stock concentrations. The same Kd value (within error) is calculated for 
MTIP/d-GMyoA[791-818] binding at pH 7.0, implying that there are no significant changes 
in protonation states at this pH. No variation in binding between pH 7.0–8.0, a biologically 
relevant pH range, suggests that binding observed in vitro under these conditions is likely to 
accurately reflect MTIP/MyoA binding in vivo. The Kd value is over four times larger for 
MTIP/d-GMyoA[791-818] at pH 6.0. This decrease in binding affinity supports the published 
crystallography data, and is possibly due to histidine residues being protonated and 
preventing key interactions occurring, although the change in pH may also cause alterations 
in the structure of MTIP which could have an adverse effect on binding. Interestingly, the 
background fluorescence of d-GMyoA[791-818] is higher at pH 6.0, leading to a larger 
fluorescence signal overall, suggesting that the protonation state of dansyl and its associated 
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peptide has a significant effect on dansyl energy states. This is unsurprising for a 
solvatochromic fluorophore. 
3.2.2. Results using the tryptophan-dansyl FRET assay 
The tryptophan-dansyl FRET assay described in Section 2.5 (Chapter 2) involves energy 
transfer between MTIP residue W171 and the dansyl group on the MyoA peptide, so is highly 
dependent on the location of the dansyl group in the MTIP binding site. Following analysis of 
MTIP/d-GMyoA peptide binding using the dansyl fluorescence intensity assay, each of the 
MyoA peptides d-GMyoA[803-818], d-GMyoA[799-818], d-GMyoA[791-818], 
d-GMyoA[781-818] and d-GMyoA[781-801] was examined for MTIP binding using the 
FRET assay in an attempt to gain further insights into the location and orientation of the 
dansyl group in the  MTIP/d-GMyoA complex. 
 
Figure 47: Background fluorescence of d-GMyoA peptides at excitation 280 nm, emission 525 nm. 
Measurements were taken in assay buffer at 37 °C. 
As discussed in Section 2.5, the dansyl FRET assay uses excitation at 280 nm and emission 
may be measured at 320 nm (which is expected to decrease with increased d-GMyoA 
binding) or 525 nm (which is expected to increase with d-GMyoA binding). However, each 
of the d-GMyoA peptides displays fluorescence emission at 525 nm when excited at 280 nm 
so control experiments were carried out to determine the background fluorescence at this 
wavelength. This was achieved by titrating each d-GMyoA peptide (150 µM) into assay 
buffer (with no MTIP) in 3 µL additions to give a final concentration of 2 µM. Fluorescence 
emission at 525 nm (excitation 280 nm) was measured after each addition. The results are 
shown in Figure 47. All d-GMyoA peptides show a linear increase in fluorescence with 
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increasing concentration, and all have similar fluorescence intensities when error is taken into 
account. 
The FRET binding assays were carried out by titrating the same volumes of d-GMyoA 
peptides (3 µL additions of 150 µM stock) into a 1 µM solution of MTIP[61-204] to give a 
final d-GMyoA peptide concentration of 2 µM. The fluorescence emission was measured at 
both 320 nm and 525 nm (excitation 280 nm). For each d-GMyoA peptide, the background 
fluorescence determined in Figure 47 was deducted from the overall signal at 525 nm. The 
mean corrected fluorescence for each peptide was plotted and Kd values calculated, as 
illustrated in Figure 48 (B) and (C). The fluorescence at emission 320 nm decreases with 
increasing d-GMyoA concentration, so the data were normalised and inverted to allow fitting 
to a binding curve. The results and associated Kd values are shown in Figure 48 (A) and (C). 
 
Figure 48: MTIP[61-204]/d-GMyoA FRET binding assay results. (A) Binding curves for 
MTIP[61-204]/d-GMyoA peptides obtained at emission 320 nm. Data were normalised and inverted 
before being plotted. (B) Binding curves for MTIP[61-204]/d-GMyoA peptides obtained at emission 
525 nm. (C) Table showing Kd values for d-GMyoA peptide binding to MTIP[61-204] obtained at 
emission 320 nm or 525 nm using the tryptophan-dansyl FRET assay. All assays were carried out at 
1 µM MTIP[61-204] in assay buffer at 37 °C with excitation 280 nm. Data were fitted to Equation 2 
using GraFit.182 
MyoA Peptide Kd (nM) Em 320 nm Kd (nM) Em 525 nm
d-GMyoA[803-818] 599±156 594±173
d-GMyoA[799-818] 465±95 402±179
d-GMyoA[791-818] 433±60 140±52
d-GMyoA[781-818] 312±34 177±38
d-GMyoA[781-801] --- 3000±600
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The binding curves obtained at emission 320 nm are of the same shape and intensity for all 
d-GMyoA peptides except d-GMyoA[781-801], and give similar Kd values of approximately 
400 nM. This is an order of magnitude higher than the values obtained using the dansyl 
fluorescence intensity assay (all approximately 80 nM) but all d-GMyoA peptides bind with 
similar affinities to each other, which corroborates the trend observed using the intensity 
assay. Kd could not be fitted for d-GMyoA[781-801], possibly because it binds too weakly, 
although when studying the dansyl emission data at 525 nm this peptide appears to bind to 
MTIP[61-204] with a Kd of 3.0±0.6 µM. Kd could not be calculated for d-GMyoA[781-801] 
binding with MTIP[61-204] using the dansyl intensity assay, but this is a similar value to Kd 
2.7±0.7 µM obtained for d-GMyoA[781-801] with full-length MTIP in the intensity assay.  
The results obtained in the FRET assay at 525 nm emission show more variation between 
d-GMyoA peptides than at 320 nm. d-GMyoA[781-818] and d-GMyoA[791-818] bind with 
177±38 nM and 140±52 nM affinities respectively (FRET assay), which are very similar to 
their Kd values with MTIP[61-204] calculated using the dansyl intensity assay (90±37 nM 
and 113±47 nM respectively). However, d-GMyoA[799-818] and d-GMyoA[803-818] both 
give higher Kd values from the FRET assay compared to the intensity assay (402±179 nM 
compared to 112±21 nM for d-GMyoA[799-818] and 594±173 nM compared to 63±4 nM for 
d-GMyoA[803-818]). This is probably a result of interference from d-GMyoA background 
fluorescence (Figure 47); the background fluorescence of d-GMyoA peptides is 
approximately 20% of the overall MTIP/d-GMyoA complex signal, which makes it difficult 
to accurately correct for and suggests that the tryptophan-dansyl FRET assay is not as reliable 
as the dansyl intensity assay for quantifying peptide binding to MTIP. With this in mind, 
MTIP binding to dansylated myosin tail peptides was analysed using only the dansyl intensity 
assay from this point forward.  
3.3. Binding assays using a peptide array on a cellulose membrane 
It was previously believed that MyoA[803-818] was the only region of the MyoA tail to bind 
to MTIP in the Plasmodium glideosome,55,88 but results from the dansyl fluorescence-based 
binding assays described above reveal there may be additional residues in the MyoA tail 
which contribute to complex formation. To fully understand the MTIP/MyoA interface the 
specific binding motif needs to be identified, meaning further peptide binding studies were 
required. This was investigated using a peptide microarray rather than synthesising numerous 
dansylated MyoA peptides, as this allows the screening of hundreds of peptides in parallel. 
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Peptide arrays are high-throughput devices used to study binding interactions, and consist of 
multiple peptides immobilised on a planar support surface. Currently, SPOT synthesis is the 
standard method used to create microarrays.195,196 Peptides are synthesised on a cellulose 
membrane by the spotting of small volumes of activated reagent solutions. The droplet is 
absorbed into the membrane and, provided that a non-volatile solvent is used, forms an open 
reactor to allow successive amino acid coupling, in the same manner as solid phase peptide 
synthesis. The peptides are synthesised from C- to N-terminus, meaning the C-terminus is 
tethered to the membrane. Hundreds of peptides may be simultaneously synthesised on the 
same membrane, and following side-chain deprotection these may be probed in parallel using 
a biological assay. This has been used to investigate enzyme active sites and protein-protein 
interactions.197 It is a particularly useful technique for the study of protein interactions in 
which one binding partner acts as a receptor by accommodating a relatively short peptide 
from the other protein into its binding pocket, as is the case for MTIP and MyoA. Although 
SPOT peptide arrays do not easily allow accurate Kd determination,198 they are quickly and 
efficiently able to evaluate whether binding occurs between a linear peptide sequence and a 
protein. The use of alanine scanning, epitope mapping and truncation in the peptide libraries 
synthesised can provide large amounts of information about the peptide binding motif.197  
For SPOT synthesis of the MTIP/MyoA complex, MyoA tail peptides were tethered to the 
membrane and probed with recombinant MTIP. This also provided an opportunity to assess 
MTIP binding with other myosins in P. falciparum. As discussed in Section 1.3.3. it is 
postulated that MTIP may be involved in another molecular motor associated with 
Plasmodium cytokinesis,96 but as yet there is no evidence that MTIP forms complexes with 
any proteins other than MyoA, GAP45 and those that comprise the glideosome. There are six 
myosin genes in P. falciparum (discussed in Section 1.3.2.), of which only MyoA and MyoB 
have been characterised. Very little is known about MyoB and no binding partners have yet 
been discovered, but as for MyoA it is expressed in late-stage schizonts and merozoites, 
suggesting a role during erythrocyte invasion.90 It has no neck and only a short tail region that 
is highly basic, with residues Q in the 2nd position and R in the 6th position of the putative IQ 
motif conserved, suggesting that it may bind a myosin light chain. TgMyoB has been found 
to be important in cell cytokinesis,91 so it is possible that PfMyoB may have a similar role. It 
was therefore decided to investigate whether PfMyoB is able to bind to PfMTIP. 
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3.3.1. SPOT synthesis of MyoA and MyoB peptide array on a cellulose support 
The Intavis ResPep LS automated SPOT peptide synthesiser is able to synthesise up to 600 
peptides on a single membrane. 200 peptides were synthesised in triplicate rather than 600 
individual sequences in order to allow repeat experiments to be performed. The entire MyoA 
tail (MyoA[762-818]) was split into overlapping 20-mers moving along the sequence one 
residue at a time (MyoA[762-781], MyoA[763-782] etc.), a process known as epitope 
mapping. An alanine scan was programmed for MyoA[799-818]. This region was chosen as 
it contains most of the MyoA residues key for complex formation. Peptides containing 
multiple alanine mutations of residues R806, H810 and K813 were also included. Yeast two-
hybrid studies and crystallography data both indicate that MTIP/MyoA complex formation is 
prevented in the absence of these residues,54,88 so these were to be used as negative controls. 
Region MyoA[799-818] was also truncated sequentially from both the C- and N-terminus to 
determine the minimum area required for MTIP binding. 93 MyoA peptides were synthesised 
in total (Figure 49). 
Unlike MyoA, nothing was known about MyoB binding to MTIP prior to this experiment, so 
peptides were required to probe the entire MyoB tail. MyoB[742-801] was split into 20-mers 
and 15-mers moving along the sequence one residue at a time. This resulted in a total of 87 
MyoB peptides (Figure 49). 
The peptides were synthesised on a cellulose membrane displaying an amino PEG linker, and 
all peptides were capped with acetic anhydride after each coupling step. This ensures that the 
only impurities present on the spot are truncated peptides of the desired sequence, rather than 
deleted peptide sequences. Peptides were also acetylated at the N-terminus after the final 
deprotection step in order to mimic the next amide bond in the native protein. The membrane 
was cut into three replicates following synthesis completion, and stored at –20 °C until 
required. They were then deprotected using standard peptide deprotection conditions in 
preparation for probing. 
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Figure 49: The layout of MyoA and MyoB peptides synthesised on Membrane 1. MyoA peptides are 
shown in shades of blue and MyoB peptides in shades of red. The membrane was split into three and 
180 peptides synthesised in triplicate (A, B, C) using SPOT technology.195 No peptides were 
synthesised on spots 181-200 of Membrane A (green). 
3.3.2. Optimisation of probe protocol for MyoA/MyoB peptide array 
There are numerous methods available to detect binding on microarrays. In general, the 
membrane is first blocked by incubation with protein blocking solutions such as bovine 
serum albumin (BSA) to minimise non-specific binding. It is then probed with solutions of 
the binding partner, for example an antibody, enzyme or recombinant protein. Detection may 
be carried out immediately if the interacting partner is labelled with a fluorescent tag or 
radioactive isotope, but in general the visualisation of protein bound to peptides is performed 
in an additional step.199 This is possible by the addition of a labelled moiety, usually an 
antibody, that recognises the interacting protein itself or an epitope tag. The antibody is 
detected by fluorescence, chemiluminescence or radioactivity. This label-based detection 
method was used for monitoring binding on the MTIP/Myosin tail peptide array.  
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Recombinant MTIP contains a His6-tag, so an anti-His6 antibody was used. A fluorescent 
anti-His6 antibody was chosen (AlexaFluor 488 anti-His6) as fluorescence is usually more 
readily quantifiable than chemiluminescence. A control experiment was initially carried out 
to determine the background fluorescence signal. Background fluorescence may arise from 
intrinsic fluorescence of the membrane and peptides themselves, or from non-specific 
antibody binding to the peptides. This was measured by blocking the membrane with 5% 
milk in TBS-Tween, washing, and then incubating with AlexaFluor 488 anti-His6, but no 
MTIP. The results are shown in Figure 50 (A).  
 
Figure 50: MTIP/Myosin tail peptide array Membrane 1A probed with AlexaFluor 488 anti-His6 (A) 
Background fluorescence: the membrane was blocked and probed with AlexaFluor 488 anti-His6 
(1:1000) (B) MTIP probed: the membrane was blocked, probed with 1 µM MTIP and detected with 
AlexaFluor 488 anti-His6 (1:1000). There is high background fluorescence when using this antibody. 
It is clear that there is high background fluorescence, both from the membrane itself and from 
most of the peptide sequences. Research into the literature revealed that this is a common 
problem when probing peptide arrays with fluorescent substrates.197,199 Nevertheless, the 
membrane was stripped and probed with MTIP to evaluate any differences. The membrane 
was stripped using two different stripping solutions (62.5 mM Tris, 100 mM 
β-mercaptoethanol, 2% SDS at 50 °C for 30 mins and 50% ethanol, 10% acetic acid in water 
at room temperature for 30 mins) to ensure complete removal of bound antibody and 
blocking protein.  
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The membrane was probed with 1 µM MTIP. First it was blocked using 5% milk, then 
washed with TBS-Tween and equilibrated with assay buffer. MTIP was added and incubated 
at 37 °C for 2 hours. The same assay buffer was used as for the dansyl fluorescence assays 
(25 mM Tris, 100 mM NaCl, 1 mM EGTA, 1 mM DTT, pH 8.0). Following probing, the 
membrane was washed thoroughly with assay buffer and re-equilibrated with TBS-Tween, 
before the addition of AlexaFluor 488 anti-His6 for 1 hour. The imaged results are shown in 
Figure 50 (B). It is immediately obvious that there are differences between this probed 
membrane and the background fluorescence, suggesting specificity of peptide binding to 
MTIP. However, due to the high background it is difficult to quantify these results, and the 
accuracy is questionable. The array was therefore probed using anti-His6 HRP (anti-His6 
conjugated to horseradish peroxidase) instead of AlexaFluor 488 anti-His6, as this is detected 
by chemiluminescence so should have lower background signal. This was originally 
attempted using Membrane 1A following a second stripping procedure, but the image was of 
low quality and it appeared that not all protein had been properly removed. Regeneration of 
the membrane to allow multiple screenings of the peptide array is a common problem 
associated with SPOT synthesis, so the same experiment was repeated using Membrane 1B.  
 
Figure 51: MTIP/Myosin peptide array Membrane 1B probed with anti-His6 HRP (A) Background 
chemiluminescence: membrane was blocked and probed with anti-His6 HRP (1:4000) only. (B) MTIP 
probed: membrane was blocked, probed with 5 µM MTIP and detected by anti-His6 HRP (1:4000). 
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As shown in Figure 51 (A), the background signal was much lower when binding was 
detected using chemiluminescence with anti-His6 HRP rather than fluorescence of 
AlexaFluor 488 anti-His6. It was also established that probing with 5 µM MTIP gives a much 
stronger signal and better variation between spots than 1 µM MTIP, so this was adopted as 
the standard probing concentration. These conditions generated reproducible result patterns 
between separate membranes containing the same sequences. 
3.3.3. MyoA peptide binding to MTIP 
The results shown in Figure 51 (B) were quantified using GeneSpotter software200 which 
calculates the mean intensity of each spot. These values were corrected for local background 
(the background signal surrounding each spot on the same membrane) and non-specific 
binding background (the mean intensities of the spot when probed with anti-His6 HRP only, 
as shown in Figure 51 (A)). The correction for non-specific binding background led to some 
spots with low signal becoming negative (Figure 52), however, the pattern of results was the 
same whether this correction was applied or not, suggesting that this is not significant. 
Figure 52 (A) shows the results for MyoA 20-mer peptide sequences. There is no apparent 
binding for the first 11 spots which correspond to MyoA[762-791], supporting the previous 
observation that MyoA binding to MTIP is mediated by the C-terminal region of MyoA. 
There are weak intensities for spots containing peptides of MyoA[775-812] suggesting some 
interactions from this area, but strong binding is only observed from MyoA[794-813] to 
MyoA[799-818]. This implies that MyoA[799-813] is vital for MyoA complex formation 
with MTIP. This sequence contains each of the residues identified to be involved in key 
interactions with MTIP via crystallography and yeast two-hybrid screening88 (L804, R806, 
V807, Q808, H810, K813). This result also supports data obtained from the dansyl 
fluorescence binding assays which confirmed that all MyoA peptides containing residues 
MyoA[803-818] bind to MTIP with high affinity.  
Similar information is gained by analysing the peptide array data for C- and N-terminal 
truncations of MyoA[799-818], as shown in Figure 52 (B). Optimum binding appears to 
occur with MyoA[800-818] and intensity decreases with sequential truncations from the N- 
or C-terminus. Very little binding is observed for peptides missing L804, reflecting the 
importance of this residue in MTIP complex formation. In the C-terminus, it appears that as 
long as K813 is present residues 814-818 may be truncated without a significant decrease in 
binding. However, there are some potential problems with this data, in that MyoA[800-817] 
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gives a very strong signal but MyoA[799-817] is approximately half, despite containing the 
same residues. This may in part be due to the artificial immobilisation of the peptide; the 
C-terminus is tethered to the membrane, which may hinder protein interactions with this 
region or cause artefacts. It seems that the peptide array is able to differentiate between those 
peptides that can bind strongly and those that do not bind at all, but more subtle differences 
may not be accurately reflected using this method. 
 
Figure 52: Peptide array MyoA peptide binding results (Membrane 1B) (A) Intensities of spots 
corresponding to MyoA 20-mers moving along the sequence MyoA[762-818] in one residue steps (B) 
Intensities of spots corresponding to different length peptides from the MyoA[799-818] region. 
Peptides labelled in green represent N-terminal truncations, pink show C-terminal truncations and 
blue show MyoA peptides with both N- and C-terminal truncations. (C) Intensities of spots 
corresponding to MyoA[799-818] alanine scan. Results were all obtained from the same membrane 
by probing with 5 µM MTIP followed by detection with anti-His6 HRP (1:4000). Data were 
quantified using GeneSpotter200 and normalised to the same maximum intensity (the value of the most 
intense spot). 
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The low sensitivity of the peptide array is also implied by the data for the alanine scan of 
MyoA[799-818] illustrated in Figure 52 (C). MyoA[799-818] containing alanine mutations at 
L804, Q808, I811 or R812 show a large decrease in intensity compared to wild-type 
MyoA[799-818], likely due to the critical importance of these residues, but other residues 
indicated to be key for MTIP/MyoA complexation by crystallography and yeast two-hybrid 
studies, such as R806, V807, H810 and K813 show no obvious decrease in binding activity. 
This is despite each of these residues preventing complex formation when mutated to alanine 
in yeast two-hybrid experiments. It appears that alanine scanning on a peptide array is subject 
to false positives and does not always provide an accurate negative control. This may be due 
to the high peptide density on spots of a cellulose supported array, which may reduce the 
effect of single point mutations.  
To confirm the above results, a second peptide array on a cellulose membrane was 
synthesised (Membrane 2). In this case there were 20 MyoA sequences repeated in triplicate. 
Following deprotection the membrane was stained with bromophenol blue which binds to 
amines and so indicates the amount of peptide present on each spot. As shown in Figure 
53 (A) peptide density is similar for all MyoA peptides, reflecting a successful synthesis. The 
membrane was destained using 20% piperidine in DMF, and the background signal assessed 
by probing the membrane with anti-His6 HRP (1:8000). A greater dilution was used than 
when detecting the previous membrane as the signal from MyoA peptide binding to MTIP 
was sometimes too strong and looked close to saturation which could distort results. As 
shown in Figure 53 (B) there is low background across the membrane. Spots 1 and 2 appear 
bleached, likely due to too much HRP in one place, as these spots both contain a His6-tag as 
positive controls and so bind very strongly to anti-His6 HRP antibody. The membrane was 
stripped and probed with 1 µM MTIP, then detected with anti-His6 HRP. A lower 
concentration of MTIP was used than previously to reduce over-saturation and better 
distinguish the degree of binding between spots. There are clear differences between this 
membrane and the background image, shown in Figure 53 (C). The results were quantified 
using GeneSpotter200 and corrected for local background and non-specific binding 
background.  
MyoA[779-818] was split into 20-mers moving along the sequence in 2-residue steps. The 
binding of these peptides is illustrated in Figure 53 (D). As seen previously, the maximum 
signal is observed for MyoA[797-818], further suggesting that this is the optimum MyoA 
region for MTIP binding. There is still some signal arising from peptides of the 
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MyoA[779-810] region suggesting that there are some interactions from this area, but they 
are only half as strong as those for MyoA[797-816] proving residues 811-816 are highly 
involved in complex formation. There are noticeable fluctuations between adjacent peptides 
of the MyoA[779-810] region which seems to reflect the artefacts of the peptide array, 
possibly due to non-specific binding.  
 
Figure 53: MyoA peptide array Membrane 2B (A) Membrane stained with bromophenol blue (B) 
Membrane background: the membrane was probed with anti-His6 HRP only (1:8000) (C) Membrane 
2B probed with 1 µM MTIP and detected with anti-His6 HRP (1:8000) (D) Quantified results for 
MyoA peptide 20-mers binding to MTIP (E) Quantified results for MTIP binding to MyoA peptide 
controls. The quantified results were obtained from (C) using GeneSpotter software.200 They were 
corrected for local background and non-specific binding background, then normalised to the same 
maximum intensity (the value of the most intense spot). 
Non-specific binding is also indicated by the array results for the positive and negative 
controls shown in Figure 53 (E). As expected, the positive controls containing a His6-tag both 
give strong signals and the negative control MyoA[762-781] gives very little signal, as in the 
previous membrane (Figure 52 (A)). However, the alanine mutated peptides are inconsistent. 
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MyoA[799-818]L804A, V807A, I811A gives a very low signal as predicted, but the four 
peptides containing mutations of R806, H810 or K813 show significant chemiluminescence. 
This suggests that the peptide array is not sensitive enough to accurately detect alanine 
mutations in MyoA peptides, as was the case for Membrane 1B (Figure 52 (C)). The 
consistently low signal of MyoA[762-781] allows this peptide to be used as a negative 
control, and indicates that the MTIP/MyoA peptide array is specific enough to distinguish 
between peptide binding and non-binding sequences for MTIP. 
3.3.4. MyoB peptide binding to MTIP 
In general, the peptide array data for MyoA peptides confirmed results obtained from the 
dansyl fluorescence intensity assay, suggesting the array method is able to distinguish 
between binding and non-binding peptides of MTIP. With this in mind, MyoB peptide data 
could be analysed. As for MyoA, spot intensities of Membrane 1B (Figure 51 (B)) were 
quantified using GeneSpotter200 and corrected for local background and non-specific binding 
background.  
 
Figure 54: Peptide array binding data for MyoB peptides (Membrane 1B) (A) Intensities for spots 
corresponding to 20-mers of MyoB[742-801] moving along the sequence in one residue steps. (B) 
Intensities for spots corresponding to 15-mers of MyoB[742-801] moving along the sequence in one 
residue steps. Data were obtained by probing Membrane 1B with 5 µM MTIP and detecting with 
anti-His6 HRP (1:4000). Spot intensities were quantified using GeneSpotter,200 corrected for local 
background and non-specific binding background, and normalised to the same maximum intensity 
(the value of the most intense spot). 
Figure 54 (A) shows the results for 20-mer peptides of the MyoB tail. There is a clear peak in 
intensity for spots corresponding to the MyoB region MyoB[756-782], in particular peptides 
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including MyoB[758-779], indicating strong binding to MTIP. This same region is implicated 
in the results for MyoB 15-mer peptides shown in Figure 54 (B). MyoB[761-775] appears to 
be the strongest binding 15-mer as it has the highest intensity, but peptides from the region 
MyoB[756-779] all seem to bind MTIP to some extent. This is very interesting as both sets of 
data support each other, but previously there has been no report in the literature of the 
possibility of MTIP binding to MyoB.  
Another MyoB peptide array was synthesised to confirm these preliminary results. This 
contained 49 peptides from MyoB[742-801]. The membrane was initially stained with 
bromophenol blue (Figure 55 (A)) to assess the efficiency of the peptide synthesis. Most of 
the spots are of similarly strong intensities, but spots 3, 4, 5 and 33 are all lighter than the 
others, suggesting that there is less peptide in each of these positions. The background signal 
was checked by probing the membrane with anti-His6 HRP only (1:4000), shown in Figure 
55 (B). Spots 17, 18, 19, 20 and 21 all show some chemiluminescence even without the 
presence of MTIP, implying non-specific binding to the antibody. It was possible to subtract 
this from the spot intensity value obtained following probing with 5 µM MTIP. Spot 33 
appears blank in both the background and MTIP probed images, suggesting there is not 
enough peptide on this spot to give an accurate result.  
The mean spot intensities for MyoB[742-801] 20-mers are displayed in Figure 55 (D). 
Although there are some fluctuations in the data, in general binding is strongest for peptides 
of the region MyoB[752-783] and binding seems to decrease for peptides further towards the 
C- or N-termini. This is the same area of the MyoB tail that showed the strongest binding in 
the previous membrane (Figure 54), confirming that the result is reproducible. The data for 
MyoB peptides MyoB[746-765], MyoB[748-767] and MyoB[750-769] correspond to 
membrane spots 3,4 and 5 which do not appear to contain much peptide (Figure 55 (A)) so 
these results cannot be relied on; indeed, the intensities for MyoB[748-767] and 
MyoB[750-769] are significantly lower than the surrounding peptides. The binding of the 
MyoB 15-mer peptides (Figure 55 (E)) also verify the previous membrane result shown in 
Figure 54, with peptides from MyoB[763-779] showing the strongest spot intensities and 
binding seeming to decrease moving further towards the C-terminus. As for MyoA peptides, 
this peptide array does not appear to be sensitive enough to accurately detect variations in 
binding due to single point alanine mutations. As illustrated by Figure 55 (F), there are no 
large fluctuations between spot intensities corresponding to alanine mutated peptides of 
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MyoB[763-778], meaning that specific residues that may be key to MyoB peptide binding to 
MTIP cannot be identified.  
 
Figure 55: MyoB peptide array Membrane 2B (A) MyoB peptide membrane stained with 
bromophenol blue (B) MyoB peptide membrane background: the membrane was probed with 
anti-His6 HRP (1:4000) only (C) MyoB peptides probed with 5 µM MTIP and detected using 
anti-His6 HRP (1:4000) (D) Quantified data for MyoB[742-801] 20-mers moving along the sequence 
in two residue steps (E) Quantified data for MyoB[763-788] 15-mers moving along the sequence in 
one residue steps (F) Quantified data for MyoB[763-778] alanine scan. The data in (C) were 
quantified using GeneSpotter software,200 corrected for local background and non-specific binding 
background, and normalised to the same maximum intensity (the value of the most intense spot) to 
create the column charts. 
It is interesting that MyoB peptides appear able to bind to MTIP, but also that the binding 
region is not the C-terminus but seems to be further towards the N-terminal region, in the 
middle of the MyoB tail. Additional experiments were required to further probe this potential 
interaction. 
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3.4. Binding of d-GMyoB peptides to MTIP 
A series of dansylated MyoB peptides were synthesised to examine MyoB binding to MTIP 
using the dansyl fluorescence intensity assay, in order to explore the peptide array results. 
The sequences of these peptides are displayed in Figure 56.  
 
Figure 56: (A) Sequence alignment of P. falciparum MyoA and MyoB tails.82 (B) Sequences of 
d-GMyoB peptides synthesised. MyoA residues 803-818 are shown in blue as these were identified by 
crystallography and yeast two-hybrid studies to bind to MTIP.88 MyoA[781-802] are shown in orange. 
The equivalent MyoB residues are shown in blue (MyoB[783-801]) and red (MyoB[763-782]). 
Dansyl and the linker glycine residue are shown in green.  
MyoB[763-778] seemed to bind strongly to MTIP in the peptide array, so 
d-GMyoB[763-778] was synthesised to confirm this result in solution. MyoB peptides were 
also chosen to correspond to the binding region of the MyoA tail by studying the alignment 
shown in Figure 56 (A) (this alignment was performed by Dr Judith Green, NIMR). Although 
this alignment contains many residue variations between MyoA and MyoB, it provided a 
starting point for comparison of the MyoA and MyoB tail domains. d-GMyoB[783-801], 
d-GMyoB[779-801] and d-GMyoB[771-801] are the corresponding MyoB peptides of 
d-GMyoA[803-818], d-GMyoA[799-818] and d-GMyoA[791-818] respectively, MyoA 
peptides that are all observed to bind to MTIP through the dansyl fluorescence intensity 
MyoA tail: ...VSVIEAAILKHKYKQKVNKNIPSLLRVQAHIRKKMVAQ-OH
MyoB tail: ...ITSALIMKIKKKRIVEENIKNLQLAQAYFRKYKYIKEHE-OH
d-GMyoB[763-788]: d-GITSALIMKIKKKRIVEENIKNLQLAQ-NH2
d-GMyoB[763-778]: d-GITSALIMKIKKKRIVE-NH2
d-GMyoB[771-801]: d-GIKKKRIVEENIKNLQLAQAYFRKYKYIKEHE-OH
d-GMyoB[779-801]: d-GENIKNLQLAQAYFRKYKYIKEHE-OH
d-GMyoB[783-801]: d-GNLQLAQAYFRKYKYIKEHE-OH
803 818799791
783 801771 779
(A)
(B)
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assay. d-GMyoB[763-788] was synthesised to include residues of both d-GMyoB[763-778] 
and d-GMyoB[771-801] to ensure that binding motifs were not eliminated by the truncation 
of these peptides. All peptides were synthesised using solid phase peptide synthesis and 
purified via liquid chromatography-mass spectrometry (LC-MS), and as for d-GMyoA 
peptides included a glycine linker between the dansyl group and MyoB peptide sequence.  
Each of the d-GMyoB peptides was examined for binding to MTIP using the dansyl 
fluorescence intensity assay with 1 µM d-GMyoB. Up to 5 µM MTIP was titrated in 4 µL 
additions to generate binding curves, illustrated in Figure 57 (A).  
 
Figure 57: (A) Binding curves for d-GMyoB peptides with MTIP (B) Kd values for d-GMyoB 
peptides binding with MTIP and MTIP[61-204]. d-GMyoB[779-801] and d-GMyoB[783-801] did not 
bind to MTIP and so were not tested with MTIP[61-204]. All assays were carried out at 1 µM 
d-GMyoB in assay buffer at 37 °C. Fluorescence data were obtained at excitation 330 nm, emission 
525 nm and fitted to Equation 2 using GraFit.182 
No binding was observed for d-GMyoB[783-801] or d-GMyoB[779-801] although these are 
the equivalent binding regions for MyoA. However, d-GMyoB[763-788] and 
d-GMyoB[763-778] were able to bind with strong affinity, giving Kd values of 27±17 nM and 
38±27 nM respectively, very similar to d-GMyoA peptides with MTIP. The fluorescence 
increase of d-GMyoB[763-788] on MTIP binding is much greater than that observed for 
d-GMyoA peptides, approximately a six-fold increase over background (compared to two-
fold for d-GMyoA). This suggests that the dansyl group is situated differently in the MTIP 
binding site. d-GMyoB[771-801] has a smaller fluorescence increase on binding, possibly 
because it is binding in the same way as d-GMyoA peptides, or because it binds less strongly 
than d-GMyoB[763-788] so the binding curve is not yet saturated. This seems the more likely 
explanation as the Kd is lower for this peptide (145±38 nM) than for d-GMyoB[763-788]. 
This implies that MyoB residues between 771-779 play a part in MTIP binding as 
MyoB Peptide MTIP (nM) MTIP[61-204] (nM)
d-GMyoB[763-788] 27±17 29±19
d-GMyoB[763-778] 38±27 25±15
d-GMyoB[771-801] 145±38 309±75
d-GMyoB[779-801] -- n/a
d-GMyoB[783-801] -- n/a
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d-GMyoB[771-801] appears able to form a complex with MTIP but d-GMyoB[779-801] does 
not. These results show strong correlation with those obtained from the MyoB peptide array, 
providing further evidence that MTIP is able to bind to MyoB tail peptides, but that the 
MyoB binding motif is further towards the N-terminal region of the tail compared to the C-
terminal binding motif observed in MyoA. This suggests that the alignment shown in Figure 
56 (A) may be inaccurate.   
d-GMyoB[763-788], d-GMyoB[763-778] and d-GMyoB[771-801] were also tested for 
binding with MTIP[61-204]. All were able to bind with similar affinities to their binding with 
full-length MTIP, suggesting that MTIP residues 1-60 do not participate in complex 
formation with MyoB peptides, as is the case for MyoA. Somewhat surprisingly, none of 
these peptides were able to bind to individual MTIP NTD or CTD implying that both MTIP 
domains participate heavily in d-GMyoB peptide binding.  
3.5. Summary 
Experiments described in this chapter investigated the binding of MTIP to peptides derived 
from the tail regions of two Plasmodium myosins, MyoA and MyoB, using three different 
assays; dansyl fluorescence intensity, tryptophan-dansyl FRET and a peptide array. It was 
previously believed that MTIP bound to MyoA purely through the MyoA C-terminal region, 
residues MyoA[803-818].55,88 However, fluorescence studies described here indicate that 
residues MyoA[781-801] may also play a part. All dansylated peptides containing residues 
MyoA[803-818] bind to MTIP and MTIP[61-204] with high affinity (Kd values of 
approximately 80 nM). This proves the formation of a tight binding complex between MTIP 
and MyoA, and supports the theory that MTIP residues 1–60 do not participate in binding to 
MyoA, but are likely utilised in binding to another protein of the glideosome. The individual 
MTIP NTD and CTD are able to bind to d-GMyoA peptides, although with weaker affinity 
than full-length MTIP, indicating that both domains are involved in MyoA binding. This 
supports the most recent crystal structure of MTIP/MyoA obtained at pH 7.5, which shows 
the NTD and CTD cooperatively wrapping around the MyoA tail.88 Affinity appears to be 
stronger for the CTD with d-GMyoA peptides than the NTD, suggesting greater interactions 
come from this domain. This may explain the open conformation observed in the crystal 
structure obtained at pH 5.3, where only the MTIP CTD binds to the MyoA tail peptide.54 
Fluorescence assays performed at various ionic strengths confirm the importance of 
electrostatic interactions at the MTIP/MyoA interface, and this is also reflected by assays 
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carried out at different pH; MTIP/MyoA binding is weakened in acidic conditions, probably 
due to the altering of protonation states of key amino acid side chains, as noted in 
crystallography.  
A novel method to study MTIP/Myosin peptide binding was developed, that of a cellulose 
supported peptide array. This was able to distinguish between binding and non-binding 
regions of the MyoA tail, but was not sensitive enough to accurately detect variations due to 
alanine mutations. This technique was particularly useful for preliminary investigations of 
MTIP interaction with MyoB. It is known that MyoB is expressed in late-stage schizonts and 
merozoites,90 but no binding partners have yet been identified. The peptide array indicated 
that MyoB tail peptides are able to bind to MTIP, but the optimum binding region appeared 
to be MyoB[761-783] which is further towards the N-terminal region of the MyoB tail than in 
MyoA. These results were supported by the synthesis of five d-GMyoB peptides, all of which 
were examined for binding to MTIP using the dansyl fluorescence intensity assay. No 
binding was observed for the C-terminal peptides d-GMyoB[783-801] or d-GMyoB[779-801] 
at the concentrations examined, but strong interaction was apparent for d-GMyoB[763-788] 
and d-GMyoB[763-778]. The increase in fluorescence upon binding of these peptides is 
much greater than for d-GMyoA peptides, suggesting a different mode of binding or location 
of the dansyl tag at the MTIP interface. These d-GMyoB peptides were both able to bind to 
MTIP[61-204] with similar affinity to full-length MTIP, indicating that the MTIP N-terminal 
extension is not required for MyoB complex formation. No binding was observed for either 
d-GMyoB peptide with the individual NTD and CTD domains (at the concentrations 
examined), implying that both MTIP domains contribute heavily to MyoB peptide binding. 
These results show that peptides from the tail region of MyoB are able to bind to MTIP in 
vitro, but whether this also occurs in vivo is unknown. Additional investigations were 
required to further map the binding interfaces of MTIP/MyoA and MTIP/MyoB and probe 
complex formation dynamics. 
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Chapter 4   Peptide competition studies targeting MTIP/Myosin peptide 
complexes 
 
The dansyl fluorescence intensity and FRET-based binding assays described in 
Chapters 2 and 3 were utilised to screen potential inhibitors of the MTIP/MyoA peptide 
complex. This chapter describes the optimisation of this displacement assay and adaption 
to a 96 well plate, followed by the screening of numerous MyoA peptides for inhibition 
of MTIP/d-GMyoA complex formation in order to provide information about the 
MTIP/MyoA binding interface. Some of these MyoA peptides were also examined for 
activity against Plasmodium parasites using a live cell FACS assay. 
In addition, the in vitro displacement assay was applied to the analysis of the 
MTIP/MyoB interface, to investigate the binding motif of the MyoB tail.  
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4.1. Development of dansyl fluorescence assays for studying inhibition of 
MTIP/Myosin tail peptide complexes 
As discussed in Chapter 2, assays are used to study binding and determine the affinity of a 
protein-protein interaction, but they can also be applied to screen potential inhibitors of a 
complex. This may generate information about the binding interface, as well as identify 
potential drug lead compounds. Green et al.49 adapted the dansyl fluorescence intensity 
binding assay to function as a displacement assay for MTIP/MyoA; unlabelled C-MyoA 
peptide was titrated into a preformed complex of 1.3 equivalents MTIP with 1 equivalent 
dm-CMyoA. Upon excitation at 330 nm, fluorescence emission at 500 nm decreased with 
increasing concentrations of C-MyoA, as dm-CMyoA was displaced into solution (Figure 28, 
Chapter 2). 
 
Equation 3: (A) 4-parameter equation used to calculate IC50 values. x = concentration of inhibitor, 
y = fluorescence signal, s = slope factor, range = the difference between fitted uninhibited signal and 
the background. The equation assumes that y decreases with increasing x. (B) Cheng-Prusoff equation 
for the conversion of an IC50 value to an inhibition constant, Ki.201 [L] is the concentration of labelled 
ligand used in the assay, Kd is the dissociation constant for the labelled ligand with the protein of 
interest.  
This displacement assay may be used to calculate IC50 values, which is a common parameter 
used to quantify inhibition. IC50 is the concentration required to give half the maximum 
inhibitory effect, so the lower the IC50 the stronger the inhibitor. IC50 values quoted in this 
thesis were calculated by fitting data (mean values of triplicate experiments) to the 4-
parameter equation shown in Equation 3 (A) using GraFit.182 The multiparameter fit used to 
determine IC50 means that it varies with concentration and so is not an absolute value; 
experiments must be performed under the same conditions and concentrations to accurately 
compare IC50. However, IC50 may be converted to the inhibition constant Ki using the Cheng-
Prusoff equation201 shown in Equation 3 (B). Ki is the binding affinity of an inhibitor, and 
may be thought of as the concentration at which the inhibitor would occupy 50% of the 
protein binding sites if no competing labelled ligand was present. The Cheng-Prusoff 
(A) (B)
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relationship takes into account ligand competition and therefore Ki is an absolute value which 
should not vary with concentration, but the equation is only valid for an inhibitor that binds in 
the same way as the labelled reporter ligand.   
4.1.1. Optimisation of the dansyl fluorescence intensity competition assay for 
MTIP/Myosin complexes 
4.1.1.1. Initial results in a cuvette 
Following the successful optimisation of the dansyl intensity assay for MTIP/MyoA binding 
studies described in Chapter 2 (Section 2.3.), the same conditions were applied to the dansyl 
intensity displacement assay. This assay was initially performed in a cuvette using 1 µM 
d-GMyoA[803-818] in complex with MTIP (1.2 µM MTIP was used to ensure a saturated 
complex was present) in assay buffer. Unlabelled MyoA[803-818] was titrated in 2 µL 
additions to give a final concentration of 150 µM, and the fluorescence emission was 
measured at 525 nm with excitation at 330 nm after each MyoA[803-818] addition. As 
expected, fluorescence was seen to decrease with increasing MyoA[803-818] (Figure 58).  
 
Figure 58: Displacement assay MTIP/d-GMyoA[803-818] + MyoA[803-818]; fluorescence emission 
at 525 nm decreases with increasing concentrations of MyoA[803-818]. Assay was carried out with 
1 µM d-GMyoA[803-818] and 1.2 µM MTIP in a cuvette, fluorescence was measured at excitation 
330 nm, emission 525 nm in assay buffer at 37 °C. Data have been corrected for d-GMyoA[803-818] 
background fluorescence. 
4.1.1.2. Adaption of the dansyl fluorescence intensity competition assay to a 96 well 
plate 
Having repeated the published result (the displacement of d-GMyoA[803-818] from MTIP 
using MyoA[803-818]), the displacement assay was adapted to a 96 well plate. This efficient 
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format allows multiple potential inhibitors to be screened in triplicate simultaneously, and 
requires smaller volumes than a cuvette so conserves assay components. It is also 
operationally easier to perform doubling dilutions of inhibitor in a microplate; doubling 
dilutions allow a greater distribution of data points on the Log scale used to calculate IC50 
compared to linear additions of inhibitor, and this should generate more accurate IC50 values. 
However, fluorescence emission in a cuvette is generally detected at 90° to the excitation 
light, but in a 96 well plate both excitation and emission are measured from the top of a well, 
often resulting in greater background interference. Initial fluorescence measurements of 
d-GMyoA[803-818] were taken at various concentrations to assess the optimum 
concentration to use in a plate: one that would give sufficient fluorescence above background, 
without using too much of the assay components. All fluorescence plate measurements were 
recorded on a Molecular Devices SpectraMax M2e plate reader. The manufacturers state that 
200 µL is the ideal volume per well to ensure that the fluorescence excitation beam hits the 
sample at the correct angle in the centre of the well to allow optimum emission detection, so 
this was used throughout.  
 
Figure 59: Optimisation of d-GMyoA[803-818] concentration: fluorescence emission spectra of 
d-GMyoA[803-818] at various concentrations in a 96 well plate (excitation 330 nm). Measurements 
were taken at 37 °C in plate assay buffer. 
Figure 59 shows that d-GMyoA[803-818] concentrations 10 and 5 µM give the sharpest, 
most intense peaks with maxima at 545 nm, but lower concentrations still give a large signal 
over background fluorescence, although the peaks are broader. There appears to be a shoulder 
at 470 nm, likely due to a meniscus effect or scattering of the excitation light. However, this 
10 uM
5 uM
2.5 uM
1.25 uM
0 uM
10 µM
5 µM
2.5 µM
1.25 µM
Buffer
Wavelength (nm)
400 420 440 460 480 500 520 540 560 580 600
Fl
uo
re
sc
en
ce
 in
te
ns
ity
0
200
400
600
800
1000
1200
l t  (n )
Fl
uo
re
sc
en
ce
 in
te
ns
ity
 (r
.f.
u.
)
119 
 
should not affect data collected at 525 nm, the required emission wavelength for the 
MTIP/d-GMyoA fluorescence assays. 1 µM was chosen as the standard d-GMyoA[803-818] 
concentration for displacement assays, as this gives a large signal above buffer background 
(so should not suffer from background interference) but conserved peptide and protein stocks.  
 
Figure 60: Non-binding surface plates drastically improve assay reproducibility. Fluorescence spectra 
for d-GMyoA[803-818] (1 µM) and MTIP/d-GMyoA[803-818] (1.3:1 µM) (A) in a standard white, 
round bottomed 96 well plate (B) in a non-binding surface, white, round bottomed plate. Note that the 
error is much lower when the assay is carried out in a non-binding surface 96 well plate. Fluorescence 
measurements were taken at excitation 330 nm in assay buffer at 37 °C. 
There are many different types of 96 well plates to choose from, including black or white 
surfaces, with round or flat bottoms. Tests found that white, round-bottomed plates gave the 
best signals for the MTIP/MyoA displacement assay, probably because this allows maximum 
reflection of fluorescence within the wells, and so amplifies the observed signal. The surface 
of the plate was also found to have a strong influence on the fluorescence signal, mainly in 
terms of the error between experiments. Originally, standard plates with a medium-binding 
surface were used, and although single-point measurements at emission 525 nm were used to 
calculate reproducible IC50 values, the emission scans contained large errors (Figure 60 (A)). 
These were much improved by the use of non-binding surface plates, and this also resulted in 
a greater fluorescence increase upon d-GMyoA[803-818] complexation with MTIP (Figure 
60 (B)). Non-binding surface plates are made from a polyethylene oxide-like material, such as 
polyethylene glycol (PEG), that prevents proteins sticking to the walls of the wells, meaning 
all assay components are free in solution. The large difference in fluorescence signal when 
using a non-binding surface compared to a standard plate suggests that the adsorption of 
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MTIP and d-GMyoA[803-818] was originally a significant problem, but was easily 
overcome. 
The error in fluorescence signal between repeat experiments was also improved by the 
addition of 0.1% Tween to the assay buffer. This detergent acts to flatten the meniscus of a 
solution and to reduce non-specific binding, which reduces background noise in the 
fluorescence spectra. This is particularly important when taking readings in a 96 well plate as 
both the excitation beam and emission detection are from the top of the well, so variations in 
the meniscus can have a large effect.  
To set up the MTIP/MyoA displacement assay in a 96 well plate, the unlabelled inhibitor 
peptide (MyoA[803-818]) was first added to the plate, and doubling dilutions performed in 
triplicate to give a concentration range of 1–64 µM. The MTIP/d-GMyoA[803-818] 
(1.3:1 µM) complex was pre-formed and incubated at 37 °C for 10 minutes to ensure total 
complex formation. This was then added to the wells containing various concentrations of 
MyoA[803-818].  
 
Figure 61: The fluorescence signal of the displacement assay MTIP/d-GMyoA[803-818] + 
MyoA[803-818] stabilises after approximately 20 minutes, indicating a steady state. Assays were 
carried out using 1 µM d-GMyoA[803-818], 1.2 µM MTIP and 8 µM MyoA[803-818]. 
Measurements were taken at excitation 330 nm, emission 525 nm in plate assay buffer at 37 °C. 
A time-course experiment was run to determine the optimum time after addition of 
MTIP/d-GMyoA complex to measure fluorescence. The results shown in Figure 61 indicate 
that a steady state is reached at 20–30 minutes after inhibitor addition to the MTIP/d-GMyoA 
complex. This is unlikely to be due to the complex formation and dissociation equilibrium, as 
MTIP/d-GMyoA binding experiments discussed in Chapter 3 implied that complex 
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association is very fast and equilibrium is reached in seconds. The decrease in fluorescence 
signal over time is therefore probably due to the assay solution taking time to reach a steady 
state, possibly due to variations in temperature (the MTIP/d-GMyoA[803-818] complex is 
added to the plate at room temperature and then placed in the spectrometer which is at 37 °C) 
or pH. From this point forward fluorescence was measured at 30 minutes to generate accurate 
IC50 curves.   
Experiments were also conducted to determine whether the order of addition of assay 
components had any effect on fluorescence signal or inhibition activity. MyoA[791-818] was 
used as the inhibitor peptide as binding studies described in Chapter 3 indicated that there 
may be additional interactions with MTIP from MyoA residues 791-802. In addition to the 
standard displacement assay of pre-forming MTIP/d-GMyoA[803-818] and adding this to 
various concentrations of MyoA[791-818], a reverse displacement assay was performed by 
pre-forming the MTIP/MyoA[791-818] complex at various MyoA[791-818] concentrations 
and adding to a fixed concentration of d-GMyoA[803-818]. A direct competition assay was 
also performed where d-GMyoA[803-818] was first mixed with various concentrations of 
MyoA[791-818] and this was then added to MTIP. Each assay gave the same fluorescence 
signal and very similar IC50 results (within error), shown in Figure 62, indicating that the 
MTIP/MyoA[791-818] complex equilibrium is reached each time, and the order of addition 
of assay components is not significant.  
 
Figure 62: The order of addition of displacement assay components leads to the same IC50 result. IC50 
curves and values are shown for the standard displacement assay (MTIP/d-GMyoA[803-818] + 
MyoA[791-818]), a reverse displacement assay (MTIP/MyoA[791-818] + d-GMyoA[803-818]) and a 
competition assay (MyoA[791-818]/d-GMyoA[803-818] + MTIP). Assays were carried out in plate 
assay buffer at 37 °C using excitation 330 nm and emission 525 nm, and data were fitted to Equation 
3 (A) using GraFit.182 All slope factors are between 0.8-1.3. 
MTIP/d-GMyoA[803-818]   +   MyoA[791-818]      IC50 = 1.9±0.2 µM
MTIP/MyoA[791-818]   +   d-GMyoA[803-818]      IC50 = 2.6±0.2 µM
MyoA[791-818]/d-GMyoA[803-818]   +   MTIP      IC50 = 3.1±0.5 µM
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As a final control experiment for the displacement assay, MyoA[803-818] and 
MyoA[791-818] were checked for background fluorescence. MyoA[803-818] does not 
contain any of the fluorescent amino acids (tryptophan, phenylalanine or tyrosine), and 
MyoA[791-818] contains only one tyrosine residue, Y793. Neither peptide showed any 
fluorescence emission between 400–600 nm when excited at 330 nm (data not shown), and 
therefore should not interfere with the observed fluorescence signal at 525 nm. This means 
that the decrease in fluorescence observed in the MTIP/d-GMyoA[803-818] + MyoA peptide 
competition assays should be due solely to the displacement of d-GMyoA[803-818], rather 
than quenching or fluorescence artefacts. 
Having optimised the MTIP/MyoA displacement assay to give reliable, reproducible results, 
the assay was repeated using lower concentrations of the assay components to further 
conserve peptide and protein stocks; this would also allow a greater excess of inhibitor to be 
used. Both 500 nM and 250 nM d-GMyoA[803-818] were used (with 600 nM and 300 nM 
MTIP respectively) but the error between experiments was high and the data could not be 
used to calculate accurate IC50 values. Therefore, 1 µM d-GMyoA[803-818] was used in 
future experiments. 
4.1.1.3. The use of different d-GMyosin probes in the MTIP/MyoA displacement 
assay 
The d-GMyoA binding results described in Chapter 3 indicated that peptide MyoA[781-801] 
also interacts with MTIP, likely in the region MyoA[791-801]. This implies that 
d-GMyoA[791-818] may be a better mimic of the MyoA tail than d-GMyoA[803-818], and 
so may be a more suitable probe in MTIP/MyoA displacement assays. d-GMyoA[791-818] is 
less prone to aggregation than d-GMyoA[781-818] so is easier to handle and less likely to 
cause assay artefacts. The displacement assay shown in Figure 63 (pink) was carried out 
using MTIP/d-GMyoA[791-818] + MyoA[791-818] under the same conditions as described 
in Section 4.1.1.2, and gave the same decrease in fluorescence and corresponding 
MyoA[791-818] IC50 value (within error) as for MTIP/d-GMyoA[803-818]. Therefore, 
d-GMyoA[791-818] was chosen as the standard dansylated probe in displacement assays as 
this should contain all key MyoA interactions with MTIP, and so better reflects the full 
MyoA tail which would need to be displaced in vivo.  
123 
 
 
Figure 63: Comparison of the displacement of d-GMyoA[803-818] (green) and d-GMyoA[791-818] 
(pink) peptides from MTIP using MyoA[791-818]. Assays were performed using 1 µM d-GMyoA 
peptide and 1.2 µM MTIP in plate assay buffer at 37 °C. Fluorescence was measured at excitation 
330 nm, emission 525 nm and data were corrected for d-GMyoA[803-818] or d-GMyoA[791-818] 
background fluorescence before being fitted to Equation 3 (A) using GraFit.182 All slope factors are 
between 0.8-1.3. 
Binding studies between MTIP and d-GMyoB peptides described in Chapter 3 (Section 3.4.), 
demonstrated that d-GMyoB[763-788] shows a much greater fluorescence increase 
(approximately 6-fold increase over background) upon complexation to MTIP than 
d-GMyoA[803-818] or d-GMyoA[791-818]. This could be of use in the displacement assay 
as there should be a greater change in fluorescence when this peptide is displaced into 
solution from the MTIP binding site. However, it was not known whether d-GMyoB peptides 
are located in the same binding site as d-GMyoA, or if MyoA peptides would be able to 
displace them. A trial assay was carried out using MTIP/d-GMyoB[763-788] + 
MyoA[791-818]. As anticipated, fluorescence decreased with increasing concentrations of 
MyoA[791-818] to allow calculation of an IC50 of 1.1±0.1 µM for MyoA[791-818], very 
similar to those obtained against MTIP/d-GMyoA[803-818] and MTIP/d-GMyoA[791-818]. 
This proves that MyoA peptides are able to displace d-GMyoB peptides from MTIP and 
suggests that MyoA and MyoB peptides are located in the same or an overlapping binding 
site. The assay with d-GMyoB[763-788] as fluorescent probe was more sensitive than with 
d-GMyoA peptides due to the greater change in fluorescence, meaning it could be performed 
accurately at lower concentrations (500 nM d-GMyoB[763-788]). This displacement assay 
was used in conjunction with MTIP/d-GMyoA[791-818] competition assays to probe 
MTIP/Myosin binding.  
MTIP/d-GMyoA[803-818]   +   MyoA[791-818]      IC50 = 1.9±0.2 µM
MTIP/d-GMyoA[791-818]   +   MyoA[791-818]      IC50 = 2.7±0.8 µM
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4.1.2. Optimisation of the tryptophan-dansyl FRET assay for MTIP/Myosin 
peptide competition studies 
The newly developed tryptophan-dansyl FRET assay was used to examine MTIP/d-GMyoA 
peptide binding (Chapter 3, Section 3.2.2.), but was not ideal for this purpose as the 
increasing concentrations of d-GMyoA meant that there was increasing background 
fluorescence at 525 nm. In the displacement assay however, the concentration of d-GMyoA 
remains constant so background fluorescence should not be a problem. The FRET assay was 
applied to examine the displacement assay MTIP[61-204]/d-GMyoA[791-818] + 
MyoA[791-818]. Emission at 525 nm should decrease if MyoA[791-818] is able to displace 
d-GMyoA[791-818], as this will prevent FRET occurring between MTIP[61-204] residue 
W171 and dansyl. The assay was performed in a 96 well plate, which was made up as for the 
dansyl intensity displacement assay but using MTIP[61-204] in place of full-length MTIP. As 
explained in Chapter 2 (Section 2.5), MTIP[61-204] is preferred to full-length MTIP in the 
FRET assay as it contains only one tryptophan residue, and so has lower background 
fluorescence than full-length MTIP that includes two tryptophan residues. Doubling dilutions 
of MyoA[791-818] were added to the plate first, followed by pre-formed 
MTIP[61-204]/d-GMyoA[791-818] complex (which had already been incubated at 37 °C for 
10 minutes to ensure complete complex formation). Fluorescence was measured at 
excitations 280 nm and 330 nm after 30 minutes at 37 °C to compare the FRET and dansyl 
intensity assays. The emission spectra are shown in Figure 64. It is immediately clear that in 
the FRET displacement assay (Figure 64 (A)) there is a greater fluorescence difference 
between free d-GMyoA[791-818] and MTIP[61-204]/d-GMyoA[791-818] complex than in 
the intensity assay (Figure 64 (B)), which leads to greater accuracy as changes in 
fluorescence are more easily measured. The background at 525 nm is lower for the FRET 
assay, making the assay more sensitive and reliable even at lower concentrations of assay 
substrates. The variance between repeat experiments was also smaller relative to overall 
signal for the FRET assay, likely due to less background interference. The same results were 
observed using d-GMyoB[763-788] as the fluorescent probe. Both the FRET and dansyl 
intensity assays were used to screen potential inhibitors of the MTIP/MyoA complex in order 
to probe the binding interface. 
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Figure 64: The tryptophan-dansyl FRET displacement assay is more sensitive than the dansyl 
intensity displacement assay. (A) FRET displacement assay MTIP[61-204]/d-GMyoA[791-818] + 
MyoA[791-818] (excitation 280 nm) (B) Dansyl intensity displacement assay 
MTIP[61-204]/d-GMyoA[791-818] + MyoA[791-818] (excitation 330 nm).  The FRET assay shows a 
greater fluorescence difference between d-GMyoA[791-818] and MTIP[61-204]/d-GMyoA[791-818], 
and has lower background at 525 nm. Assays were carried out in plate assay buffer at 37 °C using 
1 µM d-GMyoA[791-818] and 1.2 µM MTIP[61-204]. 
4.2. MyoA tail peptides in the MTIP/MyoA peptide displacement assay 
4.2.1. Initial MyoA peptide displacement results using the dansyl intensity assay 
As discussed in Chapter 3, d-GMyoA peptide binding studies indicated that there are residues 
in the region MyoA[791-802] of the MyoA tail that make previously unrecognised 
contributions to MTIP binding. The first experiments using the MTIP/MyoA peptide 
displacement assay concentrated on pinpointing the precise MyoA region and amino acids 
responsible for this additional binding. Unlabelled analogues of the dansylated peptides were 
synthesised: MyoA[803-818], MyoA[799-818], MyoA[791-818] and MyoA[781-801], as 
well as MyoA[795-818]. Two negative control peptides were included, 
MyoA[803-818]R806A and ranMyoA[803-818]. MyoA R806 appears to be crucial for 
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MTIP/MyoA binding as mutation of this residue to alanine prevents complex formation 
according to yeast two-hybrid studies.88 ranMyoA[803-818] contains the same residues as 
MyoA[803-818] but in a randomised order; this randomised peptide does not appear to bind 
to MTIP.82 These peptides should confirm whether any observed inhibition activity of MyoA 
peptides on the MTIP/d-GMyoA[791-818] complex is specific. Crystallography demonstrates 
that MyoA[803-818] is an α-helix when bound to MTIP, but proline has a tendency to break 
or “kink” α-helices due to its constrained ring conformation. It was therefore postulated that 
MyoA residue P802 may have a structural effect on the MyoA tail that may influence 
complex formation. The alanine mutated peptide MyoA[791-818]P802A was synthesised in 
order to investigate the effect of P802 on MTIP/MyoA binding. Each of these peptides were 
acetylated on the N-terminus to mimic the next amide bond of the wild-type protein, and 
were purified by HPLC before being tested against MTIP/d-GMyoA[791-818] in the dansyl 
intensity 96 well plate displacement assay (using 1 µM d-GMyoA[791-818]). The results are 
shown in Figure 65.  
MyoA[803-818] is a decidedly poor inhibitor with an IC50 of 38±2.6 µM, and is unable to 
fully displace d-GMyoA[791-818] at concentrations up to 64 µM. The apparent Ki is nearly 
3 µM, much higher than Kd 63±8 nM calculated for the direct binding of d-GMyoA[803-818] 
to MTIP. Although some variation in the values may be due to discrepancies between the 
binding and displacement assays, this implies that the dansyl group contributes to MTIP 
binding for d-GMyoA[803-818].  
Longer peptides MyoA[799-818], MyoA[795-818] and MyoA[791-818] show much stronger 
displacement activity against MTIP/d-GMyoA[791-818]; all are able to reduce 
d-GMyoA[791-818] fluorescence down to background levels with IC50 values as low as 
1.5±0.2 µM (this is at the lower limit of the dansyl intensity assay since d-GMyoA[791-818] 
concentration is 1 µM). The apparent Ki values for these longer MyoA peptides are 
approximately 200 nM, similar to the Kd values calculated for the equivalent dansylated 
peptides in the dansyl intensity binding assay. This provides further evidence that there are 
additional interactions between MyoA[791-802] and MTIP; in particular it appears that 
residues MyoA[799-802] are sufficient to enhance binding affinity. Interestingly, 
MyoA[781-801] did not show any inhibition activity at concentrations up to 64 µM, 
suggesting that the additional interactions from this region are significantly weaker than those 
from MyoA[803-818]. This was also indicated by the 40-fold difference in Kd values between 
d-GMyoA[781-801] and d-GMyoA[803-818], indicating that these preliminary MyoA 
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displacement activity results support those generated by the binding assays described in 
Chapter 3.  
 
Figure 65: Inhibition activity of initial MyoA peptides (A) Example IC50 profiles for MyoA peptides 
against MTIP/d-GMyoA[791-818]. (B) Table of IC50 and apparent Ki values for initial MyoA peptides 
tested for activity against MTIP/d-GMyoA[791-818] in the dansyl intensity displacement assay using 
1 µM d-GMyoA[791-818] and 1.2 µM MTIP. All slope factors are between 0.8-1.3. All assays were 
carried out in plate assay buffer at 37 °C in a 96 well plate, excitation 330 nm, emission 525 nm. Data 
were corrected for d-GMyoA[791-818] background fluorescence, then plotted and IC50 values 
calculated using GraFit.182 These values were converted to apparent Ki using the Cheng-Prusoff 
equation with Kd 82 nM for d-GMyoA[791-818] with MTIP. NI = No inhibition (up to 64 µM). Data 
have been published as Thomas et al.51 
As predicted, neither of the negative control peptides MyoA[803-818]R806A and 
ranMyoA[803-818] are able to displace d-GMyoA[791-818], confirming that the activity 
described above is due to specific MTIP/MyoA interactions, rather than fluorescence effects 
or non-specific binding events. The mutation of P802 to alanine does not seem to have any 
effect on MTIP/MyoA complex formation, with MyoA[791-818]P802A able to displace 
d-GMyoA[791-818] with an IC50 of 1.1±0.1 µM, the same as the wild-type peptide. This 
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MyoA peptide Sequence IC50 (µM)
Apparent Ki
(µM)
MyoA[803-818] VSVIEAAILKHKYKQKVNKNIPSLLRVQAHIRKKMVAQ 38.1±2.6 2.89
MyoA[799-818] VSVIEAAILKHKYKQKVNKNIPSLLRVQAHIRKKMVAQ 7.1±0.2 0.54
MyoA[795-818] VSVIEAAILKHKYKQKVNKNIPSLLRVQAHIRKKMVAQ 1.5±0.2 0.11
MyoA[791-818] VSVIEAAILKHKYKQKVNKNIPSLLRVQAHIRKKMVAQ 2.7±0.8 0.20
MyoA[781-801] VSVIEAAILKHKYKQKVNKNIPSLLRVQAHIRKKMVAQ NI --
MyoA[791-818]P802A VSVIEAAILKHKYKQKVNKNIASLLRVQAHIRKKMVAQ 1.1±0.1 0.08
MyoA[803-818]R806A VSVIEAAILKHKYKQKVNKNIPSLLAVQAHIRKKMVAQ NI --
ranMyoA[803-818] LKSRHLQKVIAVAMRQ NI --
(A)
(B)
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indicates that interactions from MyoA residues 799-802 are not adversely affected by the loss 
of this proline residue.  
4.2.2. Displacement assay results focussing on the region MyoA[799-818] 
Experiments were carried out to further probe the binding interface of 
MTIP/MyoA[799-818], as this MyoA peptide appeared to encompass all residues required 
for optimum binding, and peptide array data discussed in Chapter 3 (Section 3.3.3.) also 
indicated that this region of MyoA is highly involved in binding to MTIP. MyoA[799-818] 
was truncated from the N-terminus (up to MyoA[803-818]) and from the C-terminus (up to 
MyoA[799-813]), and each peptide was tested for displacement activity against 
MTIP/d-GMyoA[791-818] in a 96 well plate. These truncated peptides were synthesised by 
Ronald Howson (undergraduate project student in the Tate Group 2008-09) under the direct 
supervision of the author of this thesis. The inhibition results are shown in Table 2. From the 
N-terminus, removal of MyoA residue K799 reduced binding 3-fold compared to 
MyoA[799-818], suggesting that there may be some contacts with MTIP from this amino 
acid or it may have a structural effect. Removal of N800 does not appear to have a significant 
effect on binding, MyoA[801-818] showing the same IC50 as MyoA[800-818]. However, 
removal of I801 causes a dramatic loss of activity, implying that there are hydrophobic 
interactions with MTIP from this area of the MyoA tail. It may be that the dansyl group is 
able to mimic these contacts with MTIP to improve binding of d-GMyoA[803-818] compared 
to the corresponding unlabelled peptide.  
Truncations from the C-terminus suggest that Q818, A817 and V816 are not required for 
MTIP/MyoA binding, as the peptide missing these residues (MyoA[799-815]) is still able to 
displace d-GMyoA[791-818] with an IC50 of 10.2±1.1 µM. Activity decreases 4-fold on 
removal of M815, implicating this residue in MTIP complex formation. Inhibition activity is 
completely lost with the truncation of K814, confirming the importance of this residue. This 
was previously indicated by mutation of the corresponding residue R814 to alanine in the 
P. yoelii MyoA tail in a yeast two-hybrid screen performed by Bosch et al.,54 which 
prevented MTIP/MyoA complex formation. P. yoelii R814 was also observed to form 
electrostatic interactions with the C-terminal carboxylate of MTIP Q204 in the closed crystal 
structure.88 and it seems that K814 of P. falciparum MyoA behaves the same way. This 
residue is either lysine or arginine across Plasmodium spp.,54 suggesting it is critically 
important for MTIP/MyoA binding in all Plasmodium species. This is also evidenced by the 
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lack of inhibition activity of MyoA[799-818]K814A, which is unable to displace 
d-GMyoA[791-818] from MTIP at concentrations up to 64 µM. 
MyoA peptide Sequence IC50 (µM) 
Apparent 
Ki (µM) 
*MyoA[800-818] KNIPSLLRVQAHIRKKMVAQ 21.8±1.4 1.65 
*MyoA[801-818] KNIPSLLRVQAHIRKKMVAQ 23.4±1.7 1.77 
*MyoA[802-818] KNIPSLLRVQAHIRKKMVAQ 135±25 10.2 
*MyoA[799-817] KNIPSLLRVQAHIRKKMVAQ 2.3±0.5 0.17 
*MyoA[799-816] KNIPSLLRVQAHIRKKMVAQ 3.1±0.1 0.23 
*MyoA[799-815] KNIPSLLRVQAHIRKKMVAQ 10.1±1.1 0.77 
*MyoA[799-814] KNIPSLLRVQAHIRKKMVAQ 47.7±1.8 3.6 
*MyoA[799-813] KNIPSLLRVQAHIRKKMVAQ NI -- 
MyoA[799-818]N800A KAIPSLLRVQAHIRKKMVAQ 10.2±3.1 0.77 
MyoA[799-818]I801A KNAPSLLRVQAHIRKKMVAQ 71.0±15 5.38 
MyoA[799-818]L804A KNIPSALRVQAHIRKKMVAQ NI -- 
MyoA[799-818]R806A KNIPSLLAVQAHIRKKMVAQ NI -- 
MyoA[799-818]V807A KNIPSLLRAQAHIRKKMVAQ 128±53 9.7 
MyoA[799-818]Q808A KNIPSLLRVAAHIRKKMVAQ NI -- 
MyoA[799-818]H810A KNIPSLLRVQAAIRKKMVAQ 136±62 10.3 
MyoA[799-818]I811A KNIPSLLRVQAHARKKMVAQ NI -- 
MyoA[799-818]R812A KNIPSLLRVQAHIAKKMVAQ NI -- 
*MyoA[799-818]K813A KNIPSLLRVQAHIRAKMVAQ NI -- 
MyoA[799-818]K814A KNIPSLLRVQAHIRKAMVAQ NI -- 
Table 2: IC50 and apparent Ki values for truncated and alanine mutated peptides of MyoA[799-818] 
against MTIP/d-GMyoA[791-818] complex (using 1 µM d-GMyoA[791-818] and 1.2 µM MTIP). All 
slope factors are between 0.8-1.3. Values were obtained using the dansyl intensity displacement assay, 
with excitation 330 nm and emission 525 nm. Assays were carried out in plate assay buffer at 37 °C 
and data were corrected for d-GMyoA[791-818] background fluorescence, normalised and fitted to 
Equation 3 (A) using GraFit.182 Peptides labelled * were synthesised by Ronald Howson. NI = No 
inhibition (up to 64 µM). Data have been published as Thomas et al.51 
The alanine mutated peptides of MyoA[799-818] broadly support previously published data. 
Mutations of L804, R806, Q808, I811, R812, K813 and K814 all result in a total loss of 
inhibition activity compared to the wild-type peptide (up to 64 µM), proving that these 
residues are all vital for MTIP/MyoA tail peptide complex formation, as indicated previously 
by crystallography and yeast two-hybrid data.54,88 However, MyoA[799-818]V807A and 
MyoA[799-818]H810A show slight inhibition (although approximately 20-fold weaker than 
the wild-type peptide), despite mutation of these same residues apparently preventing 
complex formation in yeast two-hybrid experiments. Yeast two-hybrid studies do not provide 
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quantitative data so these effects may have been missed before. However, previously 
published data used P. yoelii MyoA[803-817], so it is also possible that the presence of the 
additional MTIP interactions from MyoA[799-802] is able to compensate slightly for the loss 
of activity due to mutations of V807 and H810. The inhibition activity of 
MyoA[799-818]N800A and MyoA[799-818]I801A support the above N-terminal truncated 
peptide displacement results, in that mutation of N800 has no significant impact on binding 
of the MyoA peptide, but mutation of I801 causes a 10-fold decrease in activity, suggesting 
that this residue participates in hydrophobic contacts with MTIP at the binding interface. 
4.2.3. Displacement activity of MyoA peptides containing α-helix capping residues 
As evidenced by both the open and closed crystal structures, the MyoA tail is a tight α-helix 
when in complex with MTIP.54,88 However, circular dichroism studies reported by 
Green et al.49 indicate it is a random coil when free in solution. This conformational change 
upon binding, from random coil to structured α-helix, is likely to result in an unfavourable 
entropy change. Therefore, pre-forming the α-helix in solution could lead to a more 
favourable entropy and Gibbs free energy change, and so enhance binding affinity. One 
method to pre-form α-helices is by the addition of helix-capping residues; individual amino 
acids have different propensities for forming α-helices in solution, particularly when they are 
located at the end (or cap) of the α-helix. This effect is generally due to the ability of the 
capping amino acid side-chain to form stabilising hydrogen bonds with amides of the helix 
backbone.202,203 With this in mind, Ronald Howson designed and synthesised three peptides 
containing various α-helix capping residues that were chosen as a result of a literature search 
for suitable capping motifs. These were tested against MTIP/d-GMyoA[791-818] for 
inhibition activity, the results of which are shown in Table 3. Displacement activity is 
reduced for AAEMyoA[803-818] and SEAAAMyoA[806-818] compared to the wild-type 
peptide MyoA[803-818]. This may be due to the introduced residues making unfavourable 
contacts with MTIP, or the helix capping residues interfering with the side-chains of key 
MyoA binding residues, such as R806. Interestingly, SPMyoA[806-818]G shows a 4-fold 
increase in displacement activity compared to MyoA[803-818]. It is not clear whether this is 
a structural effect (such as increased α-helicity) or due to the introduction of amino acids that 
can make additional contacts with MTIP. However, it is a promising result as it suggests that 
the wild-type MyoA peptide may be modified to increase binding affinity to MTIP, which is 
encouraging for drug design targeting the MTIP/MyoA interaction. 
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MyoA peptide Sequence IC50 (µM) 
Apparent 
Ki (µM) 
*SPMyoA[806-818]G SPRVQAHIRKKMVAQG 10.5±1.4 0.80 
*AAEMyoA[803-818] AAESLLRVQAHIRKKMVAQ NI -- 
*SEAAAMyoA[806-818] SEAAARVQAHIRKKMVAQ NI -- 
Table 3: IC50 and apparent Ki values for MyoA peptides containing N- and C-terminal α-helix 
capping residues. The slope factor for SPMyoA[806-818]G was 0.9±0.08.Assays were carried out 
against MTIP/d-GMyoA[791-818] (1 µM d-GMyoA[791-818] and 1.2 µM MTIP) in plate assay 
buffer at 37 °C. Fluorescence measurements were taken at excitation 330 nm, emission 525 nm and 
data were corrected for background d-GMyoA[791-818] fluorescence before being normalised and 
fitted to Equation 3 (A) using GraFit.182 Peptides labelled * were synthesised by Ronald Howson. 
NI = No inhibition (up to 64 µM). 
4.2.4. Displacement activity of MyoA peptides examined using the tryptophan-
dansyl FRET displacement assay 
A selection of alanine mutated MyoA[799-818] peptides were screened for displacement 
activity against MTIP[61-204]/d-GMyoA[791-818] using the tryptophan-dansyl FRET assay 
at 500 nM d-GMyoA[791-818]. The lower concentration of d-GMyoA[791-818] meant a 
greater excess of inhibitor peptide could be added (up to 500 µM MyoA peptide), which 
should provide more accurate information for those mutated peptides that display only slight 
inhibition activity.  
MyoA peptide Sequence IC50 (µM) 
Apparent 
Ki (µM) 
MyoA[799-818] KNIPSLLRVQAHIRKKMVAQ 4.4±1.2 0.62 
MyoA[799-818]N800A KAIPSLLRVQAHIRKKMVAQ 7.0±0.5 0.99 
MyoA[799-818]I801A KNAPSLLRVQAHIRKKMVAQ 38.8±8.4 5.47 
MyoA[799-818]H810A KNIPSLLRVQAAIRKKMVAQ 93.1±33 13.1 
MyoA[799-818]K813A KNIPSLLRVQAHIRAKMVAQ NI -- 
Table 4: IC50 and apparent Ki values for MyoA peptides tested in the tryptophan-dansyl FRET 
displacement assay against MTIP[61-204]/d-GMyoA[791-818] at 500 nM d-GMyoA[791-818] and 
600 nM MTIP[61-204]. All slope factors are between 0.8-1.3. Assays were carried out in a 96 well 
plate in plate assay buffer at 37 °C. Fluorescence measurements were taken at excitation 280 nm, 
emission 525 nm and data were corrected for d-GMyoA[791-818] background fluorescence before 
being normalised and fitted to Equation 3 (A) using GraFit.182 NI = No inhibition (up to 500 µM).  
The results are shown in Table 4. All IC50 values are lower than those calculated using 1 µM 
d-GMyoA[791-818] in the dansyl intensity assay, which is to be expected as the complex 
concentration is halved so less inhibitor is required to disrupt it. The apparent Ki of 
MyoA[799-818] is very similar to that calculated using the intensity assay at 1 µM 
d-GMyoA[791-818] (0.62 µM from the FRET assay compared to 0.54 µM) suggesting that 
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this is an accurate reflection of the binding affinity of this peptide with MTIP. 
MyoA[799-818]N800A shows similar activity to MyoA[799-818] in both the FRET and 
dansyl intensity assays, implying that N800 does not participate in significant contacts with 
MTIP. There is also good agreement for the displacement activity of MyoA[799-818]I801A, 
both the dansyl intensity and FRET assays generating 10-fold weaker IC50 values for this 
peptide than MyoA[799-818]. This strongly suggests that I801 makes important binding 
contacts with MTIP, and these may be largely responsible for the increased binding affinity 
observed for MyoA[799-818] compared to MyoA[803-818]. The negative control peptide 
MyoA[799-818]K813A is unable to displace d-GMyoA[791-818] from MTIP even at 
1000-fold excess over d-GMyoA[791-818], confirming the critical importance of this residue 
in MTIP/MyoA complex formation. This provides further evidence for the adoption of the 
closed, rather than open, conformation of MTIP in solution, as this residue does not 
participate in binding in the open MTIP/MyoA tail structure, but is completely buried in the 
binding site of the closed complex.54,88 MyoA[799-818]H810A shows weak inhibition 
activity when analysed by both the dansyl intensity and FRET displacement assays, further 
suggesting that the additional residues MyoA[799-802] help compensate for the loss of 
contacts from H810. 
4.2.5. Displacement activity of MyoA peptides against 
MTIP[61-204]/d-GMyoB[763-788] 
A selection of MyoA peptides were tested for inhibition activity against 
MTIP[61-204]/d-GMyoB[763-788] using the FRET displacement assay at 500 nM 
d-GMyoB[763-788]. As described in Section 4.1.1.3, d-GMyoB[763-788] displays a larger 
change in fluorescence upon MTIP complexation than d-GMyoA peptides, so may reveal 
more subtle differences in peptide displacement activity. Different length MyoA peptides 
(MyoA[791-818], MyoA[799-816] and MyoA[803-818]) were chosen for assessment using 
this assay to cover a wide range of binding affinities, and MyoA[799-818]K813A was also 
included as a negative control. A 64-fold excess of inhibitor peptide was used, fluorescence 
data were obtained at excitation 280 nm, emission 525 nm, and the IC50 values calculated 
using GraFit.182 These are shown in Table 5. It is immediately apparent that the Ki values 
calculated using this assay are up to 10-fold lower than those obtained against 
MTIP/d-GMyoA[791-818] (for example, 0.03 µM compared to 0.23 µM for 
MyoA[799-816]). This is due to differences in the IC50 values, which implies that 
d-GMyoB[763-788] is easier to displace from MTIP than d-GMyoA[791-818]. 
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MyoA[799-818]K813A is unable to disrupt the MTIP/d-GMyoA[791-818] complex, even at 
concentrations in 1000-fold excess of d-GMyoA[791-818], but it inhibits 
MTIP[61-204]/d-GMyoB[763-788] with an IC50 of 78.4±11.9 µM. This is despite both 
dansylated peptides giving similar Kd values when analysed using the dansyl intensity 
binding assay (Kd 82±18 nM for d-GMyoA[791-818], Kd 27±17 nM for d-GMyoB[763-788], 
Chapter 3). This suggests that there may be different modes of binding or inhibition activity 
for MyoA and MyoB peptides with MTIP. The difference in fluorescence intensity shifts for 
d-GMyoA and d-GMyoB peptides also indicates that there are differences in binding between 
them, although it is not yet clear what these variations might be. The IC50 and Ki values 
generated from the FRET displacement assay against MTIP[61-204]/d-GMyoB[763-788] do 
show the same trend as those obtained from the dansyl intensity and FRET displacement 
assays against MTIP/d-GMyoA[791-818], in that MyoA[791-818] and MyoA[799-816] show 
stronger activity than MyoA[803-818]. This provides further evidence that MyoA[799-818] 
is the optimal MyoA peptide for binding to MTIP, rather than MyoA[803-818]. 
MyoA peptide Sequence IC50 (µM) 
Apparent 
Ki (µM) 
MyoA[791-818] HKYKQKVNKNIPSLLRVQAHIRKKMVAQ 1.1±0.1 0.06 
MyoA[799-816] KNIPSLLRVQAHIRKKMVAQ 0.6±0.1 0.03 
MyoA[803-818] SLLRVQAHIRKKMVAQ 27.6±0.9 1.41 
MyoA[799-818]K813A KNIPSLLRVQAHIRAKMVAQ 78.4±11.9 4.02 
Table 5: IC50 and apparent Ki values for MyoA peptide displacement activity against 
MTIP[61-204]/d-GMyoB[763-788]. All slope factors are between 0.8-1.3. FRET displacement assays 
were performed in a 96 well plate at 500 nM d-GMyoB[763-788] and 600 nM MTIP[61-204]. 
Fluorescence measurements were taken at excitation 280 nm, emission 525 nm in plate assay buffer at 
37 °C and data were corrected for d-GMyoB[763-788] background fluorescence before being 
normalised and fitted to Equation 3 (A) using GraFit.182   
4.3. Live cell assay to assess inhibition activity of MyoA tail peptides in 
Plasmodium parasites 
Having identified MyoA peptides that are able to displace the MyoA tail from MTIP in 
laboratory protein assays, the next step was to examine their effects on the full Plasmodium 
invasion motor and parasite survival. As discussed in Chapter 1 (Section 1.4.3.), experiments 
performed by both Bosch et al.54 and Green et al.204 indicate that MyoA tail peptides may be 
able to disrupt the life cycle of Plasmodium parasites in blood culture (using P. yoelii 
MyoA[803-817] and P. falciparum CMyoA[803-818] respectively). These results were 
obtained using different assays, a [3H]-hypoxanthine incorporation assay by Bosch et al.54, 
134 
 
and a FACS assay in combination with Giesma smears by Green et al.204 Assays to examine 
MyoA peptide activity against Plasmodium described in this thesis were performed by Dr 
David Moss and Dr Judith Green (NIMR) using the FACS assay.  
4.3.1. The FACS assay 
Fluorescence activated cell sorting is a flow cytometry method which separates cells one at a 
time depending on their fluorescence or light scattering properties. For Plasmodium parasites, 
these properties are introduced by the staining of DNA, usually with hydroethidine or the 
incorporation of 3H-hypoxanthine. The FACS assay performed by Dr David Moss and Dr 
Judith Green uses hydroethidine as the stain. This method depends on the conversion of 
hydroethidine to ethidium which is catalysed by NADPH oxidase inside metabolically active 
parasites, so is a reliable indicator of parasite viability and growth.153 For analysis of MyoA 
tail peptides, synchronised parasite cultures were grown to trophozoite stages. The peptides 
were added and incubated for a whole parasite re-invasion cycle (48 hours), before live 
parasite DNA was labelled with hydroethidine and detected using FACS. Parasitemia was 
measured relative to a control labelled culture not containing any inhibitor. The FACS signal 
should be low for strong inhibitors, indicating parasite cell death. 
4.3.2. Inhibition activity of MyoA tail peptides using the FACS assay 
Four MyoA tail peptides were tested using the FACS assay. Treatment of parasites with 
CMyoA[803-818] (MyoA[803-818] with an additional cysteine residue at the N-terminus) 
previously appeared to inhibit parasite replication,82 so MyoA[803-818] was used as a 
positive control. It was hoped that MyoA[791-818] and MyoA[799-818] would show 
increased activity compared to MyoA[803-818], to reflect the stronger binding of these 
peptides with MTIP observed using the in vitro protein fluorescence assays. 
MyoA[803-818]R806A was included as a negative control. Unfortunately, no significant 
inhibition of parasite growth was observed for any of these peptides (Figure 66). This is not 
altogether surprising as peptide stability in blood serum is likely to be low, particularly over 
the extended time periods (48 hours) used here. However, it contrasts to the results reported 
by Bosch et al.54 which implied that PyMyoA[803-817] was able to inhibit parasite growth 
with an IC50 of 84 µM when examined using a 3H-hypoxanthine assay. This variation in 
results may be due to the difference in timings of peptide addition and parasite detection 
between the assays; the FACS assay used here measures parasitemia 48 hours after addition 
of the peptide, whereas the 3H-hypoxanthine assay used by Bosch et al. incubated parasites 
with the peptide for only 24 hours.54 However, Green et al. had problems reproducing their 
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own inhibition data82 (these results remain unpublished), suggesting that parasite inhibition is 
strongly dependent on the type of assay and conditions used, and the positive result reported 
by Bosch et al. may even be an assay artefact. Additionally, there are doubts over the ability 
of these MyoA tail peptides to penetrate the parasite membrane, which is required for access 
to the glideosome and MTIP/MyoA complex. MyoA tail peptides contain numerous charged 
residues, which often present problems when crossing the hydrophobic membrane lipid 
bilayer. This may also explain the lack of parasite growth inhibition observed using the 
FACS assay, despite the strong displacement activity of these peptides against MTIP/MyoA 
in protein assays. 
 
Figure 66: Live cell inhibition activity of MyoA peptides against P. falciparum. Data was obtained 
using a FACS assay which was performed by Dr David Moss (NIMR). Figure adapted from 
Thomas et al.51 
4.4. MyoB tail peptides as inhibitors of MTIP/Myosin peptide complexes 
4.4.1. Displacement activity of MyoB peptides against 
MTIP[61-204]/d-GMyoB[763-788] 
The dansyl intensity and FRET displacement assays were successfully used to identify the 
optimum MTIP binding peptide from the tail of MyoA, which prompted the application of 
the same techniques to probe the MyoB binding motif. By this stage, the tryptophan-dansyl 
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FRET assay had been fully developed, so this assay alone was used to study displacement 
activity of MyoB peptides, as it is more sensitive with lower error than the dansyl intensity 
assay. 
MyoB peptide Sequence IC50 (µM) 
Apparent 
Ki (µM) 
MyoB[783-801] LCCITSALIMKIKKKRIVEENIKNLQLAQAYFRKYKYIKEHE NI -- 
MyoB[779-801] LCCITSALIMKIKKKRIVEENIKNLQLAQAYFRKYKYIKEHE NI -- 
MyoB[771-801] LCCITSALIMKIKKKRIVEENIKNLQLAQAYFRKYKYIKEHE 2.8±0.4 0.14 
MyoB[763-788] LCCITSALIMKIKKKRIVEENIKNLQLAQAYFRKYKYIKEHE 6.1±0.3 0.31 
MyoB[763-778] LCCITSALIMKIKKKRIVEENIKNLQLAQAYFRKYKYIKEHE 64.6±8.1 3.31 
MyoB[763-777] LCCITSALIMKIKKKRIVEENIKNLQLAQAYFRKYKYIKEHE 24.2±1.0 1.24 
MyoB[763-776] LCCITSALIMKIKKKRIVEENIKNLQLAQAYFRKYKYIKEHE 22.8±0.8 1.17 
MyoB[763-775] LCCITSALIMKIKKKRIVEENIKNLQLAQAYFRKYKYIKEHE 19.9±1.2 1.02 
MyoB[763-774] LCCITSALIMKIKKKRIVEENIKNLQLAQAYFRKYKYIKEHE 28.2±0.8 1.44 
MyoB[760-775] LCCITSALIMKIKKKRIVEENIKNLQLAQAYFRKYKYIKEHE 10.6±0.4 0.54 
MyoB[760-774] LCCITSALIMKIKKKRIVEENIKNLQLAQAYFRKYKYIKEHE 19.2±0.9 0.98 
MyoB[761-774] LCCITSALIMKIKKKRIVEENIKNLQLAQAYFRKYKYIKEHE 19.9±0.8 1.02 
MyoB[760-778] LCCITSALIMKIKKKRIVEENIKNLQLAQAYFRKYKYIKEHE 21.6±0.8 1.11 
Table 6: IC50 and apparent Ki values for MyoB peptide displacement activity against 
MTIP[61-204]/d-GMyoB[763-788] using 500 nM d-GMyoB[763-788] and 600 nM MTIP[61-204]. 
All slope factors are between 0.8-1.3. Fluorescence data were obtained using the tryptophan-dansyl 
FRET assay at excitation 280 nm, emission 525 nm in plate assay buffer at 37 °C. Data were 
corrected for d-GMyoB[763-788] background fluorescence, then normalised and fitted to Equation 
3 (A) using GraFit.182 NI = No inhibition (up to 32 µM). 
Initial MyoB peptides examined using the FRET displacement assay were the unlabelled 
analogues of d-GMyoB peptides, that is MyoB[783-801], MyoB[779-801], MyoB[771-801] 
and MyoB[763-788], to confirm the results of the d-GMyoB dansyl intensity binding studies 
discussed in Chapter 3. Each of these MyoB peptides was acetylated on the N-terminus and 
purified using LC-MS, before being tested in the FRET displacement assay against 
MTIP[61-204]/d-GMyoB[763-788] using 500 nM d-GMyoB[763-788]. As shown in Table 6, 
MyoB[783-801] and MyoB[779-801] are unable to displace d-GMyoB[763-788] at 
concentrations up to 32 µM, supporting dansyl intensity binding results which indicated that 
these peptides do not bind to MTIP. MyoB[771-801] and MyoB[763-788] both show strong 
displacement activity with low µM IC50 values, which generate apparent Ki values of 140 nM 
and 310 nM respectively. This compares favourably to Kd 145±38 nM obtained for 
d-GMyoB[771-801] using the dansyl intensity binding assay, although 310 nM for 
MyoB[763-788] is somewhat weaker than Kd 27±17 nM obtained for d-GMyoB[763-788] 
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using the direct binding assay. Nevertheless, both MyoB peptides seem able to bind strongly 
to MTIP, although it seems to be with slightly weaker affinity than MTIP binding of MyoA. 
Stock solutions of MyoB[763-788] and MyoB[771-801] both aggregated over time, forming 
a gel-like substance for MyoB[771-801], and it is possible that this may have caused artefacts 
in the fluorescence displacement assays for inhibition activity. As a result, a selection of 
shorter MyoB peptides were synthesised to further probe the MTIP/MyoB binding interface. 
MyoB[771-801] seems to bind MTIP strongly, but MyoB[779-801] does not appear to 
interact at all, suggesting there are significant MTIP interactions from the region 
MyoB[771-778]. MyoB[763-788] was truncated to MyoB[763-778] to confirm this. 
Additionally, MyoB peptide array results (Chapter 3, Section 3.3.4.) suggested that 15-mer 
peptides from MyoB[760-779] form a complex with MTIP, so MyoB[760-778] was 
synthesised to encompass this region and assess the impact of residues MyoB[760-762]. This 
peptide was truncated from the N- and C-termini in an attempt to identify the smallest MyoB 
peptide able to bind to MTIP, and to investigate the effects of the removal of specific 
residues. The displacement activity of these peptides is shown in Table 6.  
Surprisingly, displacement activity of MyoB[763-778] appears to be approximately 10-fold 
weaker than MyoB[763-788], despite MyoB residues MyoB[779-788] seemingly not 
contributing to MTIP complex formation of MyoB[779-801]. This may be a result of 
glutamic acid residue E778 being unfavourable when in the C-terminal position of 
MyoB[763-778], which is also indicated by the increased displacement activity and lower 
apparent Ki of MyoB[763-777] compared to MyoB[763-778] (IC50 24.2±1.0 µM compared to 
IC50 64.6±8.1 µM respectively). It is also possible that MyoB[779-788] includes MTIP 
binding residues, but these may not be strong enough to form a complex unless they are 
associated with MyoB[763-778]. Peptides MyoB[763-777], MyoB[763-776] and 
MyoB[763-775] all give IC50 values of approximately 20 µM, suggesting that I776, V777 and 
E778 do not form key contacts with MTIP. Displacement activity is increased in the presence 
of MyoB residues MyoB[760-762] at the N-terminus, evidenced by the IC50 of 10.6±0.4 µM 
for MyoB[760-775] compared to 19.9±1.2 µM for MyoB[763-775]. Although this is only a 
two-fold difference in IC50, it implies that L760, C761 and C762 interact with MTIP in some 
way. L760 does not appear to be as important as C761 and C762, as this residue may be 
removed with no decrease in inhibition activity. R775 appears to play a role in complex 
formation, as MyoB[760-774] shows weaker displacement activity than MyoB[760-775], as 
does MyoB[763-774] compared to MyoB[763-775]. Taken together, these data suggest that 
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MyoB[761-775] is the minimum MyoB region required for complex formation with MTIP, 
although it is still unclear exactly which MyoB residues are responsible for MTIP 
interactions, or where this peptide is located in the MTIP binding pocket. 
4.4.2. Displacement activity of MyoB peptides against 
MTIP[61-204]/d-GMyoA[791-818] 
Competition studies with MyoA peptides indicated that d-GMyoB[763-788] is easier to 
displace from MTIP than d-GMyoA[791-818] (Section 4.2.5). To further investigate this, 
MyoB peptides were examined in the FRET displacement assay against 
MTIP[61-204]/d-GMyoA[791-818]. As for the competition experiments against 
MTIP[61-204]/d-GMyoB[763-788], this was performed at 500 nM d-GMyoA[791-818]. The 
results are displayed in Table 7.  
MyoB peptide Sequence IC50 
(µM) 
Apparent 
Ki (µM) 
MyoB[783-801] LCCITSALIMKIKKKRIVEENIKNLQLAQAYFRKYKYIKEHE NI -- 
MyoB[779-801] LCCITSALIMKIKKKRIVEENIKNLQLAQAYFRKYKYIKEHE NI -- 
MyoB[771-801] LCCITSALIMKIKKKRIVEENIKNLQLAQAYFRKYKYIKEHE 2.7±0.7 0.38 
MyoB[763-788] LCCITSALIMKIKKKRIVEENIKNLQLAQAYFRKYKYIKEHE 7.9±1.1 1.11 
MyoB[763-778] LCCITSALIMKIKKKRIVEENIKNLQLAQAYFRKYKYIKEHE 99.6±56 14.0 
MyoB[763-777] LCCITSALIMKIKKKRIVEENIKNLQLAQAYFRKYKYIKEHE 100±17 14.1 
MyoB[763-776] LCCITSALIMKIKKKRIVEENIKNLQLAQAYFRKYKYIKEHE 127±43 17.9 
MyoB[763-775] LCCITSALIMKIKKKRIVEENIKNLQLAQAYFRKYKYIKEHE 93.9±47 13.2 
MyoB[763-774] LCCITSALIMKIKKKRIVEENIKNLQLAQAYFRKYKYIKEHE 131±39 18.5 
MyoB[760-775] LCCITSALIMKIKKKRIVEENIKNLQLAQAYFRKYKYIKEHE 43.0±4.2 6.06 
MyoB[760-774] LCCITSALIMKIKKKRIVEENIKNLQLAQAYFRKYKYIKEHE 102±46 14.4 
MyoB[761-774] LCCITSALIMKIKKKRIVEENIKNLQLAQAYFRKYKYIKEHE 152±102 21.4 
MyoB[760-778] LCCITSALIMKIKKKRIVEENIKNLQLAQAYFRKYKYIKEHE 72.8±7.9 10.3 
Table 7: IC50 and apparent Ki values for MyoB displacement activity against 
MTIP[61-204]/d-GMyoA[791-818] (at 500 nM d-GMyoA[791-818] and 600 nM MTIP[61-204]). All 
slope factors are between 0.8-1.3. Fluorescence data were obtained using the tryptophan-dansyl FRET 
assay at excitation 280 nm, emission 525 nm in plate assay buffer at 37 °C. Data were corrected for 
d-GMyoA[791-818] background fluorescence, then normalised and fitted to Equation 3 (A) using 
GraFit.182 NI = No inhibition (up to 32 µM). 
The longer MyoB peptides show similar inhibition activity against 
MTIP[61-204]/d-GMyoA[791-818] as for MTIP[61-204]/d-GMyoB[763-788]; 
MyoB[783-801] and MyoB[779-801] are unable to displace d-GMyoA[791-818], but both 
MyoB[771-801] and MyoB[763-788] have low µM activity, giving apparent Ki values of 
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0.38 µM and 1.11 µM respectively. Once again, MyoB[763-778] shows weaker activity than 
MyoB[763-788], and peptides MyoB[763-777], MyoB[763-776], MyoB[763-775] and 
MyoB[763-774] all show similar IC50 values to each other. However, these IC50 values are all 
approximately 4-fold higher than those generated against MTIP[61-204]/d-GMyoB[763-788], 
providing further evidence that d-GMyoA[791-818] is more difficult to displace from MTIP 
than d-GMyoB[763-788], despite the similarity in their binding affinities obtained using the 
direct dansyl binding assay. MyoB[760-775], MyoB[760-774], MyoB[761-774] and 
MyoB[760-778] also exhibit lower IC50 values against MTIP[61-204]/d-GMyoB[763-788] 
that MTIP[61-204]/d-GMyoA[791-818]. Although the actual IC50 values vary, the activity 
trends of the MyoB peptides are the same whether obtained using assays against 
MTIP[61-204]/d-GMyoA[791-818] or MTIP[61-204]/d-GMyoB[763-788]. The lowest IC50 
against MTIP[61-204]/d-GMyoA[791-818] occurs with MyoB[760-775], which is 
approximately 3-fold smaller than that for MyoB[763-774], suggesting that MyoB residues 
C761, C762 and R775 interact with MTIP. The data again indicate that MyoB[761-775] is the 
minimum MyoB region required for MTIP/MyoB peptide complex formation, as was 
suggested by MyoB displacement assays against MTIP[61-204]/d-GMyoB[763-788]. 
4.5. Summary 
This chapter has described the development and optimisation of MTIP/Myosin peptide 
displacement assays, and the use of these to identify MyoA and MyoB tail peptides that bind 
strongly to MTIP. Both the dansyl intensity assay and tryptophan-dansyl FRET assay have 
been adapted to 96 well plate formats for the screening of potential inhibitors of 
MTIP/Myosin tail peptide interactions, and the FRET assay in particular gave robust, 
reproducible results with low error between repeat experiments. 
Displacement studies of MyoA peptides against MTIP/d-GMyoA[791-818] revealed that 
peptides incorporating residues MyoA[799-815] are much stronger inhibitors than 
MyoA[803-818], the peptide previously thought to be sufficient for MTIP complex 
formation. This indicates that there are additional MyoA contacts with MTIP than have been 
previously identified. In particular, MyoA residue I801 appears to enhance binding, 
suggesting that there may be hydrophobic interactions between this residue and MTIP. 
Additionally, MyoA peptide displacement experiments were used to validate data obtained by 
crystallography and yeast two-hybrid studies, which confirmed that MyoA residues L804, 
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R806, V807, Q808, H810, I811, R812, K813 and K814 are all required for MTIP/MyoA tail 
peptide complex formation in vitro. 
MyoA[803-818] is a poor inhibitor of the MTIP/d-GMyoA[791-818] complex, despite 
d-GMyoA[803-818] forming a tight interaction with MTIP (Kd 63±8 nM). In contrast, the 
apparent Ki for MyoA[803-818] is only 2.9 µM, suggesting that the dansyl group contributes 
significantly to MTIP binding of d-GMyoA[803-818]. Dansyl is at the N-terminus of 
MyoA[803-818], the same location as the additional MyoA residues MyoA[799-802]. It is 
postulated that the dansyl moiety may occupy the same MTIP binding pocket as these 
residues, however, further structural studies are required to confirm the exact location of 
dansyl and MyoA residues [799-802] in the MTIP binding site. The increased binding 
activity of d-GMyoA[803-818] and MyoA[799-818] compared to MyoA[803-818] is 
interesting in terms of future structure-based drug design targeting MTIP/MyoA, as it seems 
that potential inhibitors of the MTIP/MyoA interaction may be made more potent by taking 
this additional binding region into account. 
The difference in MTIP binding affinities between MyoA[799-818] and MyoA[803-818] was 
not reflected in parasite live cell assays; no parasite death was observed upon treatment with 
MyoA peptides. This is unfortunate but not entirely surprising due to the low serum stability 
of peptides, and their often poor cell permeability properties.205 Both of these factors make it 
unlikely that the MyoA peptides examined using the FACS assay were able to gain access to 
the full-length MTIP/MyoA proteins in the glideosome. It seems that the type of live cell 
assay used and the timing of additions of the peptides have a large impact on the observed 
results. The problems experienced here using the FACS assay show the difficulties 
encountered when using peptides as potential drugs, and suggest that structure-based design 
of drug-like, small molecule compounds for the inhibition of MTIP/MyoA may be a more 
productive route to follow. 
The FRET displacement assay was used to examine MyoB peptide binding to MTIP. Prior to 
this thesis, there were no indications in the literature that MTIP may bind MyoB, and no 
binding partners of MyoB have yet been identified in vivo. However, displacement assays 
using MyoB tail peptides confirm that MTIP is able to bind to the MyoB tail in vitro, 
supporting binding assay and peptide array results discussed in Chapter 3. MyoB[761-775] 
appears to be the minimum region required for MyoB binding with MTIP, which is 
interesting as this area is not the C-terminus of the MyoB tail (as is the case for MyoA 
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binding to MTIP), but is further towards the N-terminal region. No complex formation was 
observed for the C-terminus of MyoB (MyoB[779-801]), indicating that the binding observed 
for MyoB[761-775] and other peptides in this region is specific. However, it is not known if 
this interaction also occurs in vivo. Biological studies including co-immunoprecipitation are 
currently being performed by Dr Rob Moon and Dr Judith Green at NIMR to search for 
MyoB binding partners, which may provide further insight into the function and interactions 
of this protein.  
Although MTIP is able to form a complex with MyoB peptides as well as with MyoA, it is 
not clear whether the myosin tails are both located in the same MTIP binding site. 
Displacement assay data discussed in this Chapter indicates that MyoA peptides are able to 
displace d-GMyoB[763-788] from MTIP, and conversely, MyoB peptides may displace 
d-GMyoA[791-818], suggesting that the MyoA and MyoB tails bind in a similar way to 
MTIP. However, it appears that d-GMyoB is easier to displace than d-GMyoA, as both 
MyoA and MyoB peptides have lower IC50 values when tested against 
MTIP[61-204]/d-GMyoB[763-788] compared to testing against 
MTIP[61-204]/d-GMyoA[791-818]. This is surprising, as both d-GMyoA[791-818] and 
d-GMyoB[763-788] have low nanomolar Kd values with MTIP when assessed using direct 
binding assays, implying that they have the same binding affinities. It seems that the Kd 
obtained for d-GMyoB[763-788] with MTIP may be inaccurately low, although this peptide 
shows a much larger increase in fluorescence upon binding to MTIP than d-GMyoA peptides, 
which may mean it is in a slightly different binding location. Further structural studies are 
required to definitively establish how MyoB binds to MTIP and whether this occurs inside 
the parasite.  
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Chapter 5   Structural studies of MTIP/Myosin peptide complexes 
 
Having identified MyoA and MyoB tail peptides that bind tightly to MTIP, structural 
information for these complexes was desirable, particularly in solution. To this end, CD 
spectroscopy was used to analyse MTIP secondary structure, both unliganded and when 
bound to Myosin tail peptides, and protein NMR was applied to MTIP for the first time. 
Protein NMR experiments used 15N MTIP[61-204] to explore the differences in MTIP 
binding of MyoA[803-818] and MyoA[799-818] noted in Chapters 3 and 4. X-ray 
crystallography was also applied to examine the structure of MTIP[61-204] in complex 
with MyoA[799-818].  
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Fluorescence assays were used to thoroughly probe the binding interface of MTIP/Myosin 
peptide complexes and enabled the identification of tight binding peptides of MyoA and 
MyoB with MTIP. However, these experiments do not provide conformational or structural 
information, meaning additional structural techniques are highly beneficial when 
characterising a protein-protein interaction. Although there are X-ray crystallographic data 
available for PfMTIP[60-204] in complex with PyMyoA[803-817], crystallography can be 
prone to artefacts and the structures obtained are dependent on the crystallographic conditions 
used. This can lead to unnatural conformations, as evidenced by the differences between the 
open and closed crystal structures for MTIP/PyMyoA[803-817].54,88 Structural studies in 
solution are therefore highly desirable as they better represent physiological conditions. 
Circular dichroism (CD) spectroscopy and protein nuclear magnetic resonance (NMR) are 
currently two of the most popular methods available to probe protein conformation and 
structure in solution. Neither technique requires the introduction of an extrinsic chemical 
label, which is advantageous for MTIP/Myosin peptide studies as these methods may also be 
used to confirm the results of experiments with dansylated MyoA analogues (described in 
Chapters 3 and 4). 
5.1. CD spectroscopy studies 
Circular dichroism is the differential absorption of left- and right-handed circularly polarised 
light, which occurs for optically active chiral molecules.206 The vast majority of biological 
molecules are chiral, including 19 out of the 20 natural amino acids and protein secondary 
structures such as α-helices, meaning CD spectroscopy is particularly useful for the analysis 
of these species.207 The far-UV region of the CD spectrum (190–250 nm) contains 
information concerning the secondary structure of proteins. In this case the chiral 
chromophores are the peptide bonds. α-Helices, β-sheets and random coil structures each 
show a characteristic shape and magnitude of absorption of circularly polarised light (Figure 
67 (A)), which may be used to estimate the proportion of a protein in each conformation. 
However, it cannot determine which specific residues are involved in each structure type or 
where they are located within the molecule.206,208 The near-UV region (250–350 nm) of the 
CD spectrum may be used to analyse protein tertiary structure. In this case, the chromophores 
are the aromatic amino acids and disulfide bonds. Absorption in this region cannot be 
assigned to a particular three-dimensional structure, but can indicate the chemical 
environment and dipole orientations of these species.209,210 Visible CD spectroscopy detects 
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electronic transitions of metal ions in a chiral environment, so may be applied to the study of 
metal-protein interactions.211 In addition, CD spectroscopy can provide insights into the 
conformational stability of a protein under stress (thermal stability, pH stability and stability 
to denaturants), and can assess conformational changes due to protein-ligand binding 
events.206,210  
 
Figure 67: (A) Characteristic CD spectra for α-helix, β-sheet or random coil protein secondary 
structures (adapted from Alliance Protein Laboratories210). (B) Far-UV CD spectrum of MTIP 
reported by Green et al.49 (main image). Inset: a) Far-UV CD spectrum of MTIP in the presence of 
1 mM EGTA b) CD spectrum of MTIP in the presence of 1 mM Calcium c) the CD spectrum of 
MTIP + CMyoA[803-818] d) the spectrum of CMyoA[803-818].49 
5.1.1. CD spectroscopy studies of MTIP, MTIP[61-204], MTIP NTD and 
MTIP CTD 
For the MTIP/MyoA interaction, Green et al.49 performed far-UV CD studies on full-length 
MTIP in 20 mM phosphate buffer at pH 7.2, 20 °C, the spectrum of which was found to be 
characteristic of a protein with high α-helical content (38% α-helix, 13% β-sheet, 21% turn 
and 28% random coil, shown in Figure 67 (B)), as indicated by the published MTIP crystal 
structures.54,88 The secondary structure content was calculated using the methods described 
by Sreerama et al.212, the same as the CD spectroscopy data reported in this thesis. The CD 
spectrum for MTIP was reported to be independent of pH over the range 6.5–8.0, and 
independent of protein concentration between 2–30 µM.49  
CD spectra were obtained for MTIP, MTIP[61-204], MTIP NTD and MTIP CTD to further 
investigate the solution structures of the individual MTIP domains. Experiments were carried 
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out in assay buffer (25 mM Tris, 100 mM NaCl, 1 mM EGTA, 1 mM DTT, pH 8.0) to 
maintain the same conditions as used for dansyl fluorescence assays described in Chapters 3 
and 4. 3 µM MTIP was found to be sufficient to generate a strong, reproducible signal. The 
results are shown in Figure 68 (A).  
 
Figure 68: (A) Far-UV CD spectra for MTIP (blue), MTIP[61-204] (cyan), MTIP NTD (green) and 
MTIP CTD (pink). The orange spectrum is the sum of the experimental NTD and CTD spectra. (B) 
Structural analysis of MTIP, MTIP[61-204], MTIP NTD and MTIP CTD (calculated using the 
methods described by Sreerama et al.212). All experiments were carried out in assay buffer at 25 °C 
using 3 µM protein. CD spectroscopy data for MTIP reported by Green et al.49 is shown for 
comparison.  
It is immediately clear that the far-UV CD spectrum for MTIP looks very similar to that 
already published, suggesting that the results are reproducible and the data are reliable. 
Spectra are shown between 200-250 nm rather than the usual 190-250 nm for CD 
spectroscopy because the spectrometer used was unable to obtain data at wavelengths shorter 
than 200 nm. The values obtained for MTIP secondary structure content in Tris buffer are 
broadly in agreement with those reported by Green et al.49, confirming MTIP has high 
α-helix content. The small variations in percentages compared to Green’s data are likely due 
to differences in the conditions and equipment used, or a result of the slightly different 
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wavelengths covered. The spectrum for MTIP[61-204] is comparable to that of full-length 
MTIP (Figure 68 (A)), implying that MTIP residues 1-60 do not contribute to the overall 
structure of the protein. It seems that this region may be unstructured when in solution, 
implied by the decrease in the proportion of MTIP[61-204] which is random coil compared to 
full-length MTIP, and the corresponding increase in the fraction of α-helical content in 
MTIP[61-204]. MTIP[1-60] was not present in the published crystal structures of MTIP54,88 
so these CD data are the first indication of the conformation of these residues.  
The individual NTD and CTD seem to have a less well-defined secondary structure than full-
length MTIP, containing a greater proportion of random coil regions compared to α-helices, 
in particular for the CTD. The sum of these spectra is noticeably different from that obtained 
experimentally for full-length MTIP, seemingly due to greater unstructured regions. This 
implies that the domains adopt different conformations when in solution individually 
compared to the wild-type protein. It seems that both domains are required to ensure the 
correct folding of full-length MTIP. 
5.1.2. CD spectroscopy of MTIP/MyoA peptide complexes 
CD spectra were also obtained for three MyoA peptides and their complexes with MTIP. 
Figure 69 (A) shows the far-UV CD spectra for the MyoA peptides MyoA[803-818], 
MyoA[799-818] and SPMyoA[806-818]G, each of which is characteristic of a random coil. 
This supports the data published by Green et al.49 for CMyoA[803-818] (Figure 67 (B)). 
SPMyoA[806-818]G was found to exhibit increased displacement activity against 
MTIP/d-GMyoA[791-818] in the dansyl intensity displacement assays compared to 
MyoA[803-818] (Section 4.2.3, Chapter 4). It was postulated that this was due to an increase 
in the α-helicity of SPMyoA[806-818]G leading to a more favourable entropy change upon 
MTIP/MyoA peptide complex formation. However, there are no significant differences in the 
CD spectra or calculated α-helix content of this peptide compared to the wild-type MyoA 
peptides MyoA[803-818] and MyoA[799-818]. This may be because the helicity is too small 
to accurately measure using CD spectroscopy, or it may be that the peptide has an increased 
propensity to form an α-helix when in the presence of MTIP but is not helical itself when free 
in solution. It is also possible that the increased inhibition activity of this peptide is due to 
additional contacts with MTIP from the incorporated serine, proline and glycine residues, 
rather than the result of a structural effect. Further experiments, such as the synthesis and 
analysis of more α-helix promoting peptides, are required to confirm the cause of the 
apparent increased displacement activity of SPMyoA[806-818]G against MTIP/d-GMyoA. 
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The CD spectra and structural content analysis for MTIP/MyoA peptide complexes (shown in 
Figure 69 (B)) are all similar, suggesting that each peptide forms an analogous complex with 
MTIP, located in the same binding site each time. Interestingly, the MTIP/MyoA peptide 
complex spectra all show marked variation to that of unliganded MTIP, which is reflected in 
the increased α-helix content of the complexes (Figure 69 (C)). This is likely due to the 
contribution of the MyoA peptide to the secondary structure of the complex; X-ray 
crystallography data show that MyoA is an α-helix when bound to MTIP.54,88 
 
Figure 69: Far-UV CD spectra of MyoA and MyoB peptides and their MTIP complexes. (A) CD 
spectra of MyoA peptides MyoA[803-818] (red), MyoA[799-818] (blue), SPMyoA[806-818]G (cyan) 
and MyoB peptide MyoB[760-775] (green). (B) CD spectra of MTIP/MyoA peptide complexes; 
MTIP/MyoA[803-818] (red), MTIP/MyoA[799-818] (blue), MTIP/SPMyoA[806-818]G (cyan), 
MTIP/MyoB complex MTIP/MyoB[760-775] (green) and unliganded MTIP (black). (C) Structural 
analysis of MyoA and MyoB peptides and their MTIP complexes (calculated using the methods 
described by Sreerama et al.212) All experiments were carried out in assay buffer at 25 °C using 9 µM 
Myosin peptide and 3 µM MTIP. 
Peptide/Protein α-helix β-sheet Turn Unstructured
MyoA[803-818] 7% 35% 21% 37%
MyoA[799-818] 5% 39% 20% 36%
SPMyoA[806-818]G 3% 37% 24% 36%
MyoB[760-775] 5% 37% 24% 34%
MTIP/MyoA[803-818] 53% 6% 17% 24%
MTIP/MyoA[799-818] 50% 11% 17% 22%
MTIP/SPMyoA[806-818]G 49% 10% 17% 24%
MTIP/MyoB[760-775] 46% 11% 17% 26%
MTIP 43% 10% 19% 28%
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5.1.3. CD spectroscopy of MTIP/MyoB peptide complex 
CD spectra were also obtained for MyoB[760-775] and its complex with MTIP. 
Displacement assays described in Chapter 4 indicated that this peptide is the minimum region 
of the MyoB tail required for binding to MTIP. As for the MyoA peptides, the CD spectrum 
of MyoB[760-775] is characteristic of a random coil and the spectrum of 
MTIP/MyoB[760-775] reflects that of a protein complex with high α-helical content (Figure 
69). MTIP/MyoB[760-775] has higher α-helix content than unliganded MTIP suggesting that 
MyoB[760-775] is α-helical when bound to MTIP, as for the MyoA peptides. However, the 
α-helix content of MTIP/MyoB[760-775] is slightly lower than that of the MTIP/MyoA 
peptide complexes and there is a greater fraction of unstructured protein. This implies that the 
MTIP/MyoB peptide complex has a less well-defined secondary structure than MTIP/MyoA, 
possibly reflecting a more flexible interaction. This may explain the differences in binding 
affinities obtained for MyoB and MyoA peptide binding to MTIP; displacement assay results 
discussed in Chapter 4 indicated that MTIP/MyoA peptide binding is stronger than 
MTIP/MyoB. Additional structural studies were required to further investigate binding 
conformations of MTIP with MyoA and MyoB.  
5.2. Protein NMR studies of MTIP complexes 
The CD spectroscopy studies described above suggest that MTIP undergoes a conformational 
change upon MyoA binding to form a complex with well-defined secondary structure. 
However, CD spectroscopy is not able to show which residues or domains move or where the 
peptide is located in the MTIP binding site. More detailed information may be obtained using 
solution-phase protein NMR. 
5.2.1. Introduction to protein NMR 
5.2.1.1. Nuclear magnetic resonance 
Protein NMR uses multidimensional nuclear magnetic resonance experiments to obtain 
information about the structure and dynamics of a protein. NMR depends on the quantum 
mechanical spin angular momentum of a nucleus, the number of allowed angular momentum 
states being determined by the magnetic quantum number.213,214 The charge and spin of a 
nucleus generates a magnetic moment, and when placed in an external magnetic field these 
magnetic moments align themselves relative to the field. There are a discrete number of 
possible orientations because the energy states involved are quantised.215 1H, 15N and 13C 
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nuclei commonly used in protein NMR have magnetic quantum number (or spin) I = 1/2 
which means that there are only two permitted spin states (the number of allowed spin states 
is determined by 2I + 1). At equilibrium these have the same energy but when placed in an 
external magnetic field the energy levels are split, which may be thought of as the spins 
aligning parallel or antiparallel to the external magnetic field. The sample is irradiated with a 
pulse of radiofrequency energy corresponding to the difference in energy between the two 
spin states. This allows spins to switch between the two states, altering their occupation. 
Following the radiofrequency pulse the spins relax back to the equilibrium state (in the 
presence of an external magnetic field), emitting energy as they do so which is recorded as 
the NMR signal.213-216  Each NMR-active nucleus in a molecule will have a characteristic 
resonance frequency of decay depending on the type of nucleus involved and its local 
magnetic field. This local magnetic field is influenced by the interaction of the nucleus with 
the electrons surrounding it, so varies depending on the chemical environment.213,215 In 
addition, the magnetic moment of a nucleus is able to interact with the local magnetic field 
generated by neighbouring nuclei, which may be used to correlate different nuclei in a 
molecule with one another. This spin-spin interaction can occur directly through space or 
indirectly through bonds, and may occur between nuclei of different types (for example, 1H, 
15N and 13C).215 For 1D 1H NMR experiments this gives rise to a spectrum consisting of 
resonance signals (peaks) for each different 1H nucleus in the molecule. This is not suitable 
for the in-depth study of proteins due to the huge number of hydrogen atoms present in these 
macromolecules which would cause overlap of the signals and be very difficult to resolve.217 
This is overcome by the application of multidimensional NMR.  
5.2.1.2. Multidimensional NMR 
2D heteronuclear single quantum correlation (HSQC) detects coupled heteronuclear spins 
through a single bond and so identifies directly connected nuclei.215 For proteins this is 
usually measured between 1H and 15N or 13C, so requires the use of an isotopically enriched 
sample. Recombinant proteins generated in bacterial systems may be routinely isotopically 
labelled by expression in minimal media containing 15NH4Cl and 13C-glucose/glycerol as the 
sole nitrogen or carbon sources.218,219  
The labelled protein is placed in a magnetic field and a radiofrequency pulse applied to excite 
the spins. The spins are allowed to precess for time t1 to allow observation of the chemical 
shifts of the first nuclei (usually 1H), known as the evolution period. The magnetisation is 
then transferred from one nucleus type to the other (from 1H to 15N or 13C) in the mixing 
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period to allow correlation of the spins. Finally, there is a detection period t2 which measures 
the magnetisation of the second nucleus. A number of experiments are recorded with 
increasing evolution times t1 to yield a data matrix.215,220 Following a 2D Fourier transform a 
2D NMR spectrum is generated with 1H resonance frequencies represented on one axis and 
15N/13C on the other. For 1H-15N protein experiments this results in a distinct peak for each 
amide proton in the backbone of the protein. One peak is therefore expected for each amino 
acid residue in the protein (except proline which does not contain any amide protons). In 
addition, peaks may also be detected for those amino acids containing N-H bonds in their 
side-chains, notably tryptophan, asparagine, glutamine, and occasionally arginine and lysine. 
This results in a “fingerprint” of a protein.220  
These 2D HSQC experiments may be used to study protein binding events.221 As mentioned 
in Section 5.2.1.1, the NMR signal is largely influenced by the surrounding chemical 
environment, meaning that the spectrum of an isotopically labelled protein will be expected 
to change upon ligand binding. In particular, the chemical shifts of protein residues in contact 
with the ligand may shift positions in the spectrum, or may undergo broadening and reduced 
intensity due to enhanced relaxation of the nuclei involved. This is known as spectral 
perturbation mapping, and may be used to monitor protein-ligand binding and identify the 
interacting binding motifs.222 Information may also be obtained concerning complex kinetics, 
stoichiometry and affinity using this technique by monitoring how the protein amide peaks 
shift upon ligand titration.223 2D protein NMR is suitable for studying weak binding events 
which often preclude the use of X-ray crystallography.224 However, it must be remembered 
that in general only the backbone amides are observed, so structural information can be only 
indirectly inferred. Conformational changes in the protein may lead to the perturbation of 
residues that are not present at the binding interface, which can complicate identification of 
the protein binding region. Additionally, some signals for residues at the binding interface 
may be lost due to line-broadening which may occur due to enhanced relaxation upon 
protein-ligand binding.222 
Further information may be obtained by applying triple resonance 3D NMR experiments 
which also take into account correlations with a third nucleus, for proteins this is usually 13C. 
This allows the observation of amide N-H correlations with carbon nuclei of the protein 
backbone. The resonances of a 2D spectrum are spread into a third carbon dimension, which 
allows the sequential assignment of each peak in the 2D spectrum to a specific residue in the 
protein.220 This is useful for studying protein-ligand interactions via NMR as the resonances 
151 
 
that shift in a 2D HSQC spectrum upon ligand binding may be assigned to a specific amino 
acid and used to map the protein binding interface. 
Multidimensional NMR is currently routinely utilised for proteins up to approximately 
35 kDa molecular weight.217 However, there are problems associated with application to 
larger macromolecules due to signal overlap and broadening. This occurs due to enhanced 
relaxation which occurs with increasing molecular weight.  
5.2.2. Determination of the optimum MTIP construct to use for protein NMR 
studies 
2D NMR experiments were applied to MTIP to allow visualisation of MyoA peptide binding 
and give an indication of the structural changes and dynamics involved in MTIP/MyoA 
complex formation. The dramatic differences between the published open and closed crystal 
structures of MTIP in complex with a MyoA tail peptide54,88 imply that there is some 
flexibility in the complex. Protein NMR would be expected to supply further information 
about these effects in solution and provide an additional assay and structural template for 
future drug design. To this end, MTIP was labelled with 15N by transforming the MTIP 
pET-46 Ek/LIC plasmid into BL21(DE3) cells and growing them in minimal medium 
containing 15NH4Cl as the nitrogen source. Protein expression was induced with IPTG and 
following cell lysis the His6-tagged protein was purified by passing over Ni-NTA agarose 
beads. As for MTIP binding studies using dansyl fluorescence assays, the His6-tag was not 
removed prior to use. 
NMR is a relatively insensitive technique compared to other spectroscopic methods, meaning 
high concentrations of sample are required (usually between 50 µM and 1.5 mM).220 300 µM 
MTIP was used initially to assess the strength of the NMR signal. Another potential problem 
associated with protein NMR is the restrictions on suitable buffers. The resonance signals 
from proton-containing buffers such as Tris may swamp the protein resonances if the 
concentration is too high, so they are best kept between 0–50 mM. In addition, the 
conductivity of salt ions can interfere with the radiofrequency detection coil which increases 
background noise in the spectrum. There is therefore a balance between preserving the 
sensitivity of a high signal to noise ratio while maintaining protein stability and solubility.225  
For MTIP NMR studies, attempts were initially made to use phosphate buffer as this has 
minimal interference with protein signals. However, MTIP was unstable in this buffer at the 
high protein concentrations required; it tended to precipitate, seemingly due to the formation 
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of protein aggregates. Instead, SOFAST-HMQC experiments were performed in 20 mM Tris, 
50 mM NaCl, 5 mM DTT, pH 7.0. SOFAST-HMQC (band-Selective Optimised Flip-Angle 
Short-Transient Heteronuclear Multiple Quantum Coherence) experiments were chosen as 
this allows data to be acquired over a shorter timescale compared to HSQC (seconds rather 
than minutes) with an increased signal to noise ratio, although peaks at the periphery of the 
2D NMR spectrum tend to be reduced in intensity and may be lost. SOFAST-HMQC uses 
very short interscan time delays (which increases the speed of the experiment) and fewer 
radiofrequency pulses (which reduces the loss of signal due to pulse imperfections) than 
HSQC.226,227 As in the fluorescence assay buffer, Tris and NaCl were required to mimic 
biological conditions, maintain pH and stabilise the protein, but lower concentrations were 
used than in the fluorescence assay buffer to minimise buffer interference with the protein 
NMR signal. A higher concentration of DTT was used than in the fluorescence assay buffer 
to maintain reducing conditions over the long time periods sometimes required to acquire 
NMR data. A lower pH was necessary to ensure that the exchangeable amide protons were 
visible in the spectrum. In alkaline conditions the exchange of these protons with water is fast 
which can lead to the disappearance of resonances, so pH 8 (as used in fluorescence assays) 
is unsuitable. A pH lower than pH 7 was avoided since MTIP/MyoA complex formation 
appears to be hindered in acidic conditions, implied in the binding studies described in 
Chapter 3 together with the variation in crystal structures obtained at acidic compared to 
neutral pH54,88.  
The SOFAST-HMQC spectrum for full-length 15N MTIP is shown in Figure 70 (cyan). 
Protein NMR spectra shown in this thesis were obtained by Dr Ernesto Cota, Imperial 
College London, unless otherwise stated. There is high congestion in the centre of the 
spectrum and poor dispersion of resonances. This indicates the averaging of many different 
conformations, reflecting the presence of a large flexible region in the protein.228 This 
congested spectrum is inadequate for studying protein-ligand binding as changes in chemical 
shifts or peak intensities may be obscured. CD spectroscopy results shown in Figure 68 
suggested that MTIP[61-204] may have a more well-defined secondary structure than full-
length MTIP (indicated by the greater α-helix content and lower proportion of random coil in 
MTIP[61-204] compared to MTIP), and it was postulated that the MTIP N-terminal extension 
(MTIP[1-60]) may be disordered. A 2D NMR spectrum of MTIP[61-204] was obtained in an 
attempt to simplify the spectrum and assess the contribution of MTIP[1-60] to the overall 
protein conformation. As for full-length MTIP, MTIP[61-204] was 15N labelled by 
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transforming the MTIP[61-204] plasmids pQE30 and Prep4 into BL21(DE3) cells and 
expressing in minimal medium containing 15NH4Cl. The protein was purified by passing over 
Ni-NTA agarose beads, and the His6-tag was maintained. 
 
Figure 70: 15N SOFAST-HMQC NMR spectra of full-length MTIP (cyan) and MTIP[61-204] 
(black). The spectrum of MTIP[61-204] has improved dispersion of resonances and less congestion in 
the centre of the spectrum. Both experiments were performed in protein NMR buffer (20 mM Tris, 
50 mM NaCl, 5 mM DTT, pH 7.0) at 25 °C using 300 µM protein. Spectra were obtained by Dr 
Ernesto Cota, Imperial College London. Figure adapted from Thomas et al.51 
SOFAST-HMQC experiments were run using 300 µM 15N MTIP[61-204] in protein NMR 
buffer. The results are shown in Figure 70 (black). Although there is still some overlap in the 
centre of the spectrum this is much reduced compared to the spectrum of full-length MTIP 
and there are more resonances in the periphery regions of the spectrum. This greater 
dispersion represents amides in unique, well-folded chemical environments, implying that 
MTIP[61-204] adopts a better defined tertiary structure than MTIP and is less flexible. This 
also suggests that MTIP[1-60] does not fold independently and does not contribute to the 
overall structure of MTIP, as was implied by CD spectroscopy data. The higher quality of the 
MTIP[61-204] NMR spectrum meant that this construct was chosen for use in MyoA peptide 
binding studies by NMR. 
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5.2.3. 1D 1H spectra of MTIP, MTIP NTD and MTIP CTD 
1H spectra were obtained for full-length MTIP, MTIP NTD and MTIP CTD to gain an insight 
into the structural contributions from the individual NTD and CTD. MTIP NTD and CTD 
were not labelled with 15N so 2D SOFAST-HMQC experiments could not be performed, 
meaning the data are limited. CD spectroscopy data indicated that the individual MTIP NTD 
and CTD may adopt different conformations in solution compared to their conformations in 
full-length MTIP (Figure 68), so it did not seem worthwhile to express and 15N label these 
domains to obtain 2D NMR data. However, comparison of the 1D spectra was able to give 
basic indications of the MTIP NTD and CTD participation in the folding of full-length MTIP.  
 
Figure 71: The amide and aromatic region of 1D 1H spectra for MTIP, MTIP NTD and MTIP CTD. 
The dotted lines show that most dispersed resonances in full-length MTIP correspond to the NTD. 
Experiments were carried out in protein NMR buffer at 25 °C using 300 µM protein. Spectra were 
obtained by Dr Ernesto Cota, Imperial College London. Figure adapted from Thomas et al.51 
Figure 71 shows that as expected there is high overlap of resonances in the amide region of 
the spectrum, which reflects the need for two-dimensional studies. The dotted lines show that 
the dispersed peaks present in full-length MTIP are contributed by the NTD rather than the 
CTD. These are likely due to amides in the region MTIP[61-141], as CD studies and the 2D 
SOFAST-HMQC spectra described above indicate that MTIP[1-60] is unstructured and so 
would be unlikely to generate well-dispersed resonances. Although this implies that the 
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individual MTIP NTD adopts a more folded conformation than the CTD in solution, this may 
not be the case in the full-length protein. CD results described in Section 5.1.1 indicate both 
domains are required for the correct folding of full-length MTIP. 
Dansyl fluorescence intensity binding studies described in Chapter 3 suggested that MTIP 
CTD binds more strongly to MyoA tail peptides than MTIP NTD. This was also implied by 
the open crystal structure in which it is only the CTD of MTIP which binds to 
PyMyoA[803-817], the NTD does not participate.54 The low dispersion of resonances in the 
CTD NMR spectrum implies that it is flexible in solution and adopts many different 
conformations. A plausible scenario is that the CTD undergoes a large conformational change 
on MyoA binding which locks it in one conformation, whilst the NTD appears more rigid in 
solution. This may explain why NTD binding to MyoA peptides is weaker; it may be that the 
NTD is unable to alter its conformation to allow peptide binding unless it is associated with 
the CTD in full-length MTIP. However, further studies are required to test these hypotheses. 
5.2.4. 2D SOFAST-HMQC NMR spectra of MTIP[61-204] with MyoA peptides 
MyoA[799-818] was titrated into 15N MTIP[61-204] and SOFAST-HMQC spectra recorded 
to determine the extent of MTIP[61-204] conformational change upon MyoA peptide 
binding. As shown in Figure 72 (A), many peaks shift upon MyoA[799-818] addition 
indicating a large conformational change of MTIP[61-204] on complex formation. There are 
more peaks in the dispersed region of the spectrum for MTIP[61-204]/MyoA[799-818] 
compared to free MTIP[61-204] suggesting that the complex adopts a stable, well-folded 
structure. This implies that MTIP[61-204] is flexible in solution but is locked into one well-
defined conformation upon MyoA binding. The spectrum for free MTIP[61-204] contains too 
much congestion in the centre of the spectrum to accurately identify individual peaks, but 
automatic peak picking using NMR View (performed by Dr Ernesto Cota) identifies ~140 
distinct resonances in the spectrum of MTIP[61-204]/MyoA[799-818], indicating that most 
amides in the protein generate distinct peaks. This further illustrates the highly structured 
nature of the complex in solution.  
The results shown in Figure 72 (A) are broadly in agreement with published X-ray 
crystallography data in which the ‘open’ crystal structure contains three subunits in the same 
unit cell, two of which show unliganded MTIP and the third shows MTIP bound to the MyoA 
tail peptide through the CTD.54 There are variations in the CTD of the two unliganded 
structures, supporting the above NMR data by suggesting that MTIP is flexible in solution. 
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Dramatic differences are observed when comparing the MTIP crystal structure subunit bound 
to the MyoA peptide with the unliganded subunits; the α-helices of the MTIP CTD undergo 
significant movement to accommodate the MyoA tail. The large conformational change of 
MTIP[61-204] upon MyoA[799-818] indicated by the NMR spectra in Figure 72 (A) seems 
to be due to variations in the tertiary structure of the protein (such as the movement of 
α-helices), as CD spectroscopy results indicated that MTIP[61-204] has well-defined 
secondary structure when free in solution (Figure 68). The conformational change indicated 
by NMR may also reflect the movement of the CTD and NTD relative to one another; the 
closed crystal structure shows that both MTIP CTD and NTD make contacts with MyoA and 
they are joined by an unstructured linker region.88 This inter-lobe linker may allow relative 
motion of the CTD and NTD when free in solution.  
 
Figure 72: SOFAST-HMQC spectra of (A) MTIP[61-204] (grey) and 
MTIP[61-204]/MyoA[799-818] (blue). (B) MTIP[61-204]/MyoA[799-818] (blue) and 
MTIP[61-204]/MyoA[803-818] (green). The stars indicate the additional resonances in the dispersed 
region of the spectrum observed for MTIP[61-204]/MyoA[799-818] compared to 
MTIP[61-204]/MyoA[803-818]. All experiments were performed in protein NMR buffer at 25 °C 
using 300 µM MTIP[61-204] and 900 µM MyoA peptide. Spectra were obtained by Dr Ernesto Cota, 
Imperial College London. Figure adapted from Thomas et al.51 
SOFAST-HMQC spectra were also recorded for the titration of MTIP[61-204] with 
MyoA[803-818]. This MyoA peptide was previously believed to be sufficient for MyoA 
binding to MTIP,55 but displacement studies discussed in Chapter 4 indicated that 
MyoA[803-818] does not bind to MTIP as strongly as MyoA[799-818]. It was thought that 
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NMR experiments may identify differences in MTIP complexation with these two MyoA 
peptides. The spectrum for MTIP[61-204]/MyoA[803-818] is compared to that of 
MTIP[61-204]/MyoA[799-818] in Figure 72 (B). As for MyoA[799-818], the spectrum for 
MTIP[61-204]/MyoA[803-818] contains more resonances in the dispersed region of the 
spectrum than for unliganded MTIP[61-204] and peaks shift positions compared to the free 
protein. This suggests a large conformational change in MTIP[61-204] upon MyoA[803-818] 
binding and the formation of a stable, folded complex. The spectra for 
MTIP[61-204]/MyoA[803-818] and MTIP[61-204]/MyoA[799-818] are very similar, 
implying both peptides are located in the same MTIP binding site. However, there are more 
resonances in the dispersed region for MTIP[61-204]/MyoA[799-818] (labelled with stars in 
Figure 72 (B)) implying that this peptide makes additional contacts with MTIP and adopts a 
slightly different conformation. This may explain the increased binding affinity and 
displacement activity of MyoA[799-818] compared to MyoA[803-818].  
 
Figure 73: The effect of increasing concentrations of MyoA[799-818] and MyoA[803-818] on a 
selected resonance in the SOFAST-HMQC spectrum of 15N MTIP[61-204]. 
MTIP[61-204]/MyoA[799-818] exhibits slow exchange on the NMR timescale while 
MTIP[61-204]/MyoA[803-818] exhibits intermediate exchange. A greater concentration of 
MyoA[803-818] is required to generate a saturated complex, indicating weaker binding than 
MyoA[799-818]. Image generated by Dr Ernesto Cota, Imperial College London. Figure adapted from 
Thomas et al.51 
Figure 73 shows how a specific peak in the 15N MTIP[61-204] spectrum shifts upon the 
addition of increasing concentrations of MyoA[799-818] or MyoA[803-818]. 
MyoA[799-818] causes a systematic decrease in intensity of the peak for unliganded protein, 
and a corresponding increase in intensity for the peak in the bound state. This is indicative of 
slow-exchange on the NMR timescale, which occurs when the rate of exchange between free 
and bound protein states is much slower than the difference in the resonance frequencies.229 
This reflects a low rate of dissociation for the complex (koff) and so occurs for strong protein-
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ligand interactions; as ligand is added it all binds to the protein to give a peak corresponding 
to the bound protein frequency. This increases in intensity with increasing concentration of 
ligand until the complex is saturated, while the peak for unliganded protein decreases in 
intensity until it is all in the bound state.223 Slow-exchange is usually observed for 
interactions with sub-micromolar binding affinities.229 This supports information obtained for 
MTIP[61-204]/MyoA[799-818] using the dansyl fluorescence binding and displacement 
assays. 
Titration of MyoA[803-818] into 15N MTIP[61-204] causes the disappearance of the 
resonance of unliganded MTIP[61-204] which only reappears after the addition of 
1.5 equivalents MyoA[803-818], suggesting complex formation in the NMR intermediate 
exchange regime, which occurs for weaker interactions;229 the rate of complex dissociation is 
faster than for the slow exchange regime, which means that not all ligand is bound to protein. 
This intermediate exchange leads to line broadening that causes the initial disappearance of 
the peak in the MTIP[61-204]/MyoA[803-818] spectrum, although it reappears when there is 
sufficient ligand-bound protein to give a sharp signal.223 A saturated signal is not observed 
until the addition of three equivalents MyoA[803-818], indicating much weaker binding to 
MTIP[61-204] than MyoA[799-818]. Intermediate exchange is usually observed for 
interactions with micromolar Kd values, so the NMR data in Figure 73 further confirm the 
results obtained using the dansyl fluorescence displacement assays, and suggest that 
MyoA[799-818] is required for optimum MyoA complex formation with MTIP. 
A SOFAST-HMQC spectrum was recorded for MTIP[61-204]/d-GMyoA[803-818] to assess 
the impact of the dansyl fluorophore on MTIP/MyoA complexation. This spectrum is 
compared to the complex with the acetylated MyoA analogue 
MTIP[61-204]/MyoA[803-818] in Figure 74. The spectra are broadly similar, suggesting that 
both peptides MyoA[803-818] and d-GMyoA[803-818] locate in the same MTIP binding site. 
However, there are some differences between the spectra, namely the presence of additional 
peaks in the dispersed region of the MTIP[61-204]/d-GMyoA[803-818] complex compared 
to MTIP[61-204]/MyoA[803-818] (labelled with stars in Figure 74). These additional peaks 
in the MTIP[61-204]/d-GMyoA[803-818] spectrum likely reflect the accommodation of the 
dansyl moiety in the MTIP binding site, and indicate that the dansylated MyoA peptide forms 
a more stable, well-defined complex than the wild-type peptide. This was also suggested by 
fluorescence assay results; d-GMyoA[803-818] binding to MTIP has a Kd of 63±8 nM when 
measured directly using the dansyl intensity binding assay, however, MyoA[803-818] binds 
159 
 
with an apparent Ki of 2.89 µM when calculated indirectly using the IC50 value obtained via 
the dansyl displacement assay against MTIP/d-GMyoA[791-818].  
 
Figure 74: SOFAST-HMQC spectra of MTIP[61-204]/d-GMyoA[803-818] (red) compared to 
MTIP[61-204]/MyoA[803-818] (green). Stars indicate additional peaks in the dispersed region of the 
MTIP[61-204]/d-GMyoA[803-818] spectrum. The peak corresponding to the side-chain N-H of 
MTIP[61-204] residue W171 is labelled. This is not observable in the MTIP[61-204]/MyoA[803-818] 
spectrum. Spectra were recorded in protein NMR buffer at 25 °C using 300 µM MTIP[61-204] and 
900 µM MyoA peptide. Spectra were obtained by Dr Ernesto Cota, Imperial College London. Figure 
adapted from Thomas et al.51 
It is postulated that dansyl contributes to the binding of d-GMyoA[803-818] by mimicking 
the interactions of the N-terminal residues of MyoA[799-818] that are not present in 
MyoA[803-818]. The NMR data in Figure 74 support this hypothesis as the additional peaks 
present in the MTIP[61-204]/d-GMyoA[803-818] spectrum are in similar positions to those 
identified for MTIP[61-204]/MyoA[799-818] (labelled with stars in Figure 72 (B)). In 
particular, the side-chain N-H of tryptophan residues typically has a characteristic resonance 
in the lower left-hand corner of 2D HMQC NMR spectra. For MTIP[61-204] this peak 
corresponds to residue W171, which is located in the MyoA binding site near the N-terminus 
of the MyoA peptide (Figure 39 (B), Chapter 2). This peak is observable for MTIP[61-204] 
complexes with MyoA[799-818] and d-GMyoA[803-818] but disappears in the complex with 
MyoA[803-818] (W171 peak is labelled in Figure 74). This observation implies that 
MyoA[799-818] and d-GMyoA[803-818] are able to stabilise a region of MTIP near W171, 
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suggesting that the dansyl group is positioned in close proximity to this residue. This is also 
consistent with the high efficiency of the tryptophan-dansyl FRET assay. 
5.2.5. SOFAST-HMQC of MTIP[61-204]/d-GMyoB[763-788] 
Attempts were made to characterise MyoB binding to MTIP using 2D NMR. Initial efforts 
concentrated on the titration of d-GMyoB[763-788] into MTIP[61-204] measured by 
SOFAST-HMQC experiments. These spectra were obtained by Christopher Douse, Tate 
Group, Imperial College London. Unfortunately, the protein precipitated following the 
addition of one equivalent of d-GMyoB[763-788], meaning a completely saturated spectrum 
could not be obtained (this also occurred during the attempted titration of MyoA[791-818] 
into 15N MTIP[61-204]). The spectrum of MTIP[61-204]/d-GMyoB[763-788] before 
precipitation is shown in Figure 75.  
Many peaks have shifted positions compared to the spectrum for unliganded MTIP[61-204] 
(Figure 75 (A)) indicating a large conformational change in MTIP upon MyoB peptide 
binding. There are fewer peaks in the spectrum of MTIP[61-204]/d-GMyoB[763-788] 
compared to that of MTIP[61-204]/MyoA[799-818] (Figure 75 (B)), likely because the 
protein is not saturated with ligand. This disappearance of peaks implies that 
MTIP[61-204]/d-GMyoB[763-788] binds in the intermediate exchange regime, suggesting 
that d-GMyoB[763-788] binds to MTIP with an affinity more similar to MyoA[803-818] than 
MyoA[799-818]. Although d-GMyoB[763-788] appeared to bind to MTIP with Kd 27±17 nM 
when measured using the direct dansyl intensity binding assays, displacement assays against 
MTIP/d-GMyoB[763-788] suggested that d-GMyoB[763-788] is more easily displaced from 
MTIP than d-GMyoA[791-818], implying weaker binding. The NMR experiments described 
here may also indicate that d-GMyoB[763-788] affinity is somewhat weaker than 27±17 nM; 
if the complex is in the intermediate exchange regime on the NMR timescale, this indicates 
binding with micromolar rather than nanomolar affinity. However, this would mean that 
d-GMyoB[763-788] binding to MTIP is approximately 1000-fold weaker than determined by 
dansyl fluorescence assays which is unlikely. The disappearance of peaks in the 
MTIP[61-204]/d-GMyoB[763-788] NMR spectrum may therefore be a result of line 
broadening due to protein aggregation.  
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Figure 75: (A) SOFAST-HMQC spectra of MTIP[61-204]/d-GMyoB[763-788] (pink) compared to 
free MTIP[61-204] (black). There appears to be a large conformational change in MTIP[61-204] upon 
addition of d-GMyoB[763-788]. (B) SOFAST-HMQC spectra of MTIP[61-204]/d-GMyoB[763-788] 
(pink) compared to MTIP[61-204]/MyoA[799-818] (blue). MTIP[61-204]/d-GMyoB[763-788] 
precipitated after the addition of one equivalent d-GMyoB[763-788] so a saturated spectrum could not 
be recorded. Experiments were performed in protein NMR buffer at 25 °C using 300 µM 
MTIP[61-204] and 600 µM d-GMyoB[763-788] or 900 µM MyoA[799-818]. Spectra were obtained 
by Christopher Douse, Tate Group, Imperial College London. 
Further experiments are required to gain reliable information concerning the structure of the 
MTIP[61-204]/d-GMyoB[763-788] complex and determine whether MyoB and MyoA 
peptides are located in the same MTIP binding site; the missing peaks in the 
MTIP[61-204]/d-GMyoB[763-788] spectrum in Figure 75 (B) mean it is difficult to compare 
this spectrum directly to that of MTIP[61-204]/MyoA[799-818].  
It was thought that the precipitation observed on addition of d-GMyoB[763-788] to 
MTIP[61-204] may be caused by the length of the MyoB peptide used. This peptide contains 
26 residues, significantly longer than the maximum of 20 residues present in the successful 
MyoA peptide NMR experiments described in Section 5.2.4., and many of these residues are 
charged (Figure 56, Chapter 3) which may promote aggregation through electrostatic 
interactions between peptide molecules. Attempts were made to record SOFAST-HMQC 
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spectra using MyoB[760-775], the minimum region of MyoB required for binding to MTIP 
according to displacement assay results discussed in Chapter 4 (Section 4.4). However, this 
again led to protein precipitation upon titration with MTIP[61-204], meaning accurate spectra 
could not be obtained.  
5.3. X-ray crystallography of MTIP[61-204]/MyoA[799-818] 
Using the peptide MyoA[799-818] discovered and synthesised during the work described in 
this thesis, Christopher Douse (Tate Group, Imperial College London) obtained crystals of 
MTIP[61-204] in complex with MyoA[799-818] (Christopher Douse expressed 
MTIP[61-204] for this purpose and cleaved the His6-tag before use). Crystal growth was 
achieved under the same buffer conditions as successfully used by Bosch et al.,88 that is 
20 mM HEPES, 50 mM NaCl, 1 mM TCEP, pH 7.5. The X-ray crystal structure was solved 
by Dr Paula Salgado, Imperial College London. This is the first crystal structure obtained 
using both P. falciparum MTIP and P. falciparum MyoA sequences. The structure is overlaid 
with the PfMTIP[60-204]/PyMyoA[803-817] closed complex published by Bosch et al.88 in 
Figure 76 and the two complexes are compared in Figure 77. 
 
Figure 76: Overlay of the crystal structures of PfMTIP[61-204]/PfMyoA[799-818] (PfMTIP[61-204] 
is shown in blue and PfMyoA[799-818] in cyan) and PfMTIP[60-204]/PyMyoA[803-817] 
(PfMTIP[60-204] is shown in yellow and PyMyoA[803-817] in orange). The two complexes adopt 
very similar structures. The crystal structure of PfMTIP[61-204]/PfMyoA[799-818] was obtained by 
Christopher Douse and Dr Paula Salgado, Imperial College London, and the overlay was generated by 
Christopher Douse.230 
NTD
CTD
MyoA tail
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It is immediately apparent that PfMTIP[61-204]/PfMyoA[799-818] adopts the same closed 
conformation observed for PfMTIP[60-204]/PyMyoA[803-817] at pH 7.5. Both MTIP NTD 
and CTD contact MyoA[799-818], wrapping around the peptide in a clamp-like fashion. The 
α-helices of MTIP[61-204] are all oriented in the same directions in both complexes, 
confirming that PfMyoA[799-818] is located in the same MTIP binding site as 
PyMyoA[803-817]. There are slight variations in the random coil regions of MTIP, which is 
to be expected as unstructured regions of proteins are inherently flexible. 
MyoA residues L804, R806, V807, Q808, H810, I811, R812, K813 and K814 were all 
identified to be important for MTIP/MyoA tail peptide complex formation when analysed 
using the dansyl intensity displacement assay described in Chapter 4. Mutation of any of 
these residues to alanine dramatically decreases binding affinity and completely prevents 
MTIP/MyoA peptide complex formation in some cases, in agreement with published yeast 
two-hybrid studies.54,88 Figure 77 (A) and (B) show the orientations of MyoA R806, H810, 
K813 and K814 in the structures of PfMTIP[61-204]/PfMyoA[799-818] and 
PfMTIP[60-204]/PyMyoA[803-817] (MyoA residue 814 is lysine in P. falciparum but 
arginine in P. yoelii). These residues are all situated on the same face of the α-helix. Each 
side-chain is aligned in the same direction in both complexes and all appear to make the same 
contacts with MTIP, confirming the importance of these interactions. MyoA residues L804, 
V807, Q808, I811 and R812 are situated on the opposite face of the MyoA α-helix, and are 
highlighted in Figure 77 (C) and (D). These are also all oriented in the same way for both 
complexes PfMTIP[61-204]/PfMyoA[799-818] and PfMTIP[60-204]/PyMyoA[803-817], 
and participate in the same interactions with MTIP. 
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Figure 77: (A) Crystal structure of PfMTIP[61-204]/PfMyoA[799-818]. MTIP NTD is shown in 
blue, CTD in cyan and the MyoA tail peptide in yellow. (B) Crystal structure of 
PfMTIP[60-204]/PyMyoA[803-817] published by Bosch et al.88 MTIP NTD is shown in dark green, 
CTD in pale green, MyoA tail peptide in pale orange. MyoA side-chains of residues R806, H810, 
K813 and K814 (or R814 for PyMyoA[803-817]) are highlighted in red (from left to right (A) and 
(B)). (C) Crystal structure of PfMTIP[61-204]/PfMyoA[799-818]. MTIP NTD is shown in blue, CTD 
in cyan and the MyoA tail peptide in yellow. The N-terminal region of the MyoA peptide is in contact 
with an adjacent MTIP molecule in the crystal, so appears to be forced into an unnatural extended 
conformation. (D) Crystal structure of PfMTIP[60-204]/PyMyoA[803-817] published by 
Bosch et al.88 MTIP NTD is shown in dark green, CTD in pale green, MyoA tail peptide in pale 
orange. MyoA side-chains of residues R812, I811, Q808, V807 and L804 are highlighted in red (from 
left to right (C) and (D)). Both complexes PfMTIP[61-204]/PfMyoA[799-818] and 
PfMTIP[60-204]/PyMyoA[803-817] adopt extremely similar structures with MyoA side-chains 
oriented in the same directions. The crystal structure of PfMTIP[61-204]/PfMyoA[799-818] was 
obtained by Christopher Douse and Dr Paula Salgado, Imperial College London. 
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Dansyl displacement assay results discussed in Chapter 4 suggest that MyoA[799-818] binds 
to MTIP with higher affinity than MyoA[803-818]. It was proposed that this was due to 
additional contacts with MTIP from MyoA residues 799-802. In particular, I801 seemed to be 
significant; displacement activity of MyoA[799-818] noticeably decreased upon mutation of 
this residue to alanine. It was hoped that the crystal structure of 
PfMTIP[61-204]/PfMyoA[799-818] may provide further information about the binding of 
MyoA[799-818]. The N-terminal region of MyoA[799-818] is seen to form an additional turn 
of the α-helix compared to PyMyoA[803-817], and it is possible that the full MyoA tail is an 
α-helix in vivo. However, the final three residues of the N-terminus of MyoA[799-818] are 
forced into an extended conformation (Figure 77 (C)) and are contacting the next molecule of 
MTIP[61-204] in the adjacent crystal unit cell. This is likely an unnatural artefact of 
crystallography rather than an accurate representation of the complex in vivo, and it prevents 
reliable analysis of this region of the MyoA tail when in complex with MTIP. This highlights 
the need for the use of parallel solution methods in the investigation of the structure and 
conformation of MTIP/MyoA, such as the protein NMR experiments described above.  
5.4. Summary 
This chapter has discussed the results of experiments designed to probe the conformation of 
MTIP and associated MTIP/Myosin peptide complexes. CD spectroscopy confirmed that 
MTIP has high α-helix content even when unliganded, and suggested that the N-terminal 
extension of MTIP, MTIP[1-60], is unstructured. This is the first known indication of the 
structure of this region of MTIP. MTIP/MyoA and MTIP/MyoB peptide complexes appear to 
have higher α-helix content than unbound free MTIP, likely due to the contribution of the 
α-helical myosin peptide. However, there are differences between the spectra of MTIP/MyoA 
and MTIP/MyoB peptide complexes, implying that the MyoA peptide is more α-helical than 
that of MyoB, or that MyoB causes a change in the helix content of MTIP upon binding. CD 
spectroscopy is a limited technique and although it can be used to indicate the structural 
composition of proteins and identify binding-induced variations, it cannot show where the 
changes occur or which residues are involved. Protein NMR was utilised for these purposes.  
2D SOFAST-HMQC NMR experiments were run using 15N labelled MTIP and 
MTIP[61-204]. Comparison of the spectra of full-length MTIP and MTIP[61-204] indicates 
that MTIP[1-60] is unstructured, verifying CD spectroscopy data. Titrations of MTIP[61-204] 
with MyoA[799-818] and MyoA[803-818] confirmed that MTIP undergoes a large 
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conformational change upon MyoA complex formation. The spectrum of 
MTIP[61-204]/MyoA[799-818] contains more peaks in the dispersed region than that of 
MTIP[61-204]/MyoA[803-818], suggesting greater stability and the formation of a complex 
with a well-defined secondary and tertiary structure. These NMR data provide an insight into 
the enhanced inhibition activity displayed by MyoA[799-818] compared to MyoA[803-818] 
in dansyl displacement assays against MTIP/d-GMyoA[791-818] (Chapter 4). 2D NMR 
titration experiments of MyoA peptides with 15N MTIP[61-204] also revealed that residues of 
MTIP[61-204]/MyoA[799-818] are in the slow exchange regime on the NMR timescale 
(reflecting a high affinity complex), while the same residue in 
MTIP[61-204]/MyoA[803-818] is in intermediate exchange, indicating weaker binding. This 
provides further evidence for the enhanced affinity of MTIP for MyoA[799-818] over 
MyoA[803-818]. 
 
Figure 78: (A) SOFAST-HMQC spectra for MTIP[61-204]/MyoA[799-818] (blue) and 
MTIP[61-204]/MyoA[803-818] (green). The additional residues in the dispersed region of the 
spectrum for MTIP[61-204]/MyoA[799-818] are labelled in red with their corresponding 
MTIP[61-204] residue number (assignment of MTIP[61-204]/MyoA[799-818] spectrum was 
performed by Christopher Douse (Tate Group, Imperial College London)). (B) Crystal structure of 
PfMTIP[61-204]/PfMyoA[799-818] with the residues corresponding to the additional peaks in the 
dispersed region of the MTIP[61-204]/MyoA[799-818] SOFAST-HMQC spectrum labelled in red. 
These are all located near to the N-terminus of the MyoA[799-818] peptide. MTIP NTD is shown in 
dark blue, CTD in light blue and the MyoA peptide tail in black.  
The protein NMR experiments discussed in this chapter were the first known application of 
this technique to the MTIP/MyoA complex. Since then, Christopher Douse (Tate Group, 
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Imperial College London) has obtained 3D NMR data for 15N 13C MTIP[61-204] in complex 
with MyoA[799-818], and assigned the spectrum. Using this information, additional peaks in 
the dispersed region of MTIP[61-204]/MyoA[799-818] compared to 
MTIP[61-204]/MyoA[803-818] were identified as specific MTIP[61-204] residues. These 
were mapped onto the crystal structure of PfMTIP[61-204]/PfMyoA[799-818], as shown in 
Figure 78. It is interesting to note that each of these residues is located near the N-terminus of 
the MyoA peptide. This suggests that MTIP[61-204] alters its conformation in solution to 
accommodate the additional MyoA residues, providing an explanation for the enhanced 
binding affinity of MyoA[799-818] with MTIP compared to MyoA[803-818]. 
SOFAST-HMQC spectra were also obtained for MTIP[61-204] with d-GMyoA[803-818] and 
d-GMyoB[763-788]. d-GMyoA[803-818] appears to bind in the same location in the MTIP 
binding site as the unlabelled MyoA peptide, but there are additional peaks in the dispersed 
region of the spectrum compared to MTIP[61-204]/MyoA[803-818], indicating a stable 
complex with a well-defined structure. These peaks appear at similar chemical shifts to the 
additional peaks observed for MTIP[61-204]/MyoA[799-818], implying d-GMyoA[803-818] 
induces the same conformational changes in MTIP as MyoA[799-818]. This would explain 
the enhanced binding affinity of d-GMyoA[803-818] compared to wild-type MyoA[803-818] 
noted in Chapter 4; dansyl appears to participate in additional interactions with MTIP. 
Unfortunately, a saturated spectrum could not be obtained for 15N MTIP[61-204] with 
d-GMyoB[763-788] or the smaller MyoB peptide MyoB[760-775] due to protein 
precipitation on titration of the peptide, which prevents an accurate structural comparison of 
MTIP/MyoB peptide binding with MTIP/MyoA. However, MTIP[61-204] appears to 
undergo a significant conformational change upon d-GMyoB[763-788] addition, suggesting 
that it strongly interacts with this peptide. This supports peptide array results and dansyl 
fluorescence binding and displacement assay data, confirming that MTIP is able to bind to a 
MyoB peptide in vitro.  
The X-ray crystal structure of PfMTIP[61-204]/PfMyoA[799-818] obtained by Christopher 
Douse and Paula Salgado confirms that MyoA[799-818] is located in the same MTIP binding 
pocket as MyoA[803-818], and provides the first structure using both P. falciparum MTIP 
and MyoA sequences. This makes it a more reliable representation of the complex in vivo 
than those previously published using a combination of P. falciparum or P. knowlesi MTIP 
with P. yoelii MyoA. However, it does not provide an explanation for the increased binding 
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affinity of MyoA[799-818] because the N-terminal region of the MyoA[799-818] peptide is 
forced into an extended conformation due to contact with an MTIP molecule in the adjacent 
unit cell of the crystal. This demonstrates the advantage of using a multitude of structural 
techniques when examining protein-ligand binding, in particular those that are applied in the 
solution phase.                            
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Chapter 6   Design, synthesis and displacement activity of MyoA α-helix 
mimetic compounds 
 
The previous chapters have described experiments designed to probe the MTIP/MyoA 
binding interface. The present chapter describes how the information gained was applied 
to design α-helix mimetic compounds of the MyoA tail in an attempt to modulate the 
MTIP/MyoA peptide interaction using small molecules.  
A literature review of reported α-helix mimetic compounds is presented, followed by 
design of a scaffold for mimicry of three MyoA residues key to MTIP/MyoA complex 
formation. A range of potential MyoA α-helix mimetics were synthesised and tested for 
MTIP/d-GMyoA displacement activity using the fluorescence assays developed in the 
previous chapters. The results of these experiments are promising for future drug design 
targeting MTIP/MyoA.   
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The previous chapters have described the development and application of numerous 
biophysical assays to probe the MTIP/MyoA protein-protein interaction. As discussed in 
Chapter 1, MTIP/MyoA is a potential anti-malarial drug target. Therefore, having thoroughly 
investigated the MTIP/MyoA binding interface, it was desirable to use the information gained 
to design potential inhibitors of this complex.  
6.1. Design of MyoA α-helix mimetics 
There have been notable advances in recent years in the methods available for structure-based 
drug design targeting protein-protein interactions (as discussed in Chapter 1, Section 1.4.).  
For complexes involving an α-helix of one protein buried inside a larger binding pocket of 
another protein, many of these techniques have concentrated on stabilising or mimicking the 
α-helix secondary structure. Molecules such as stapled peptides,120 hydrogen-bond 
surrogates231 and β-peptides135 act to stabilise the α-helix, while α-helix mimetic compounds 
utilise a non-peptidic scaffold to mimic wild-type amino acid side-chain interactions.139 
MyoA peptides were inactive against P. falciparum parasites when tested using a FACS live 
cell assay (Chapter 4, Section 4.3.), and it was postulated that this was due to low stability in 
blood serum and likely difficulty in crossing the parasite cell membrane. Although stapled 
peptides and β-peptides often confer increased stability against proteases and can enhance 
cell penetrating properties of peptides, it was decided to move away from peptides and 
concentrate on an alternative scaffold in an attempt to improve these properties further. In 
addition, peptides are unlikely to be useful drugs for a disease endemic in developing 
countries due to high costs. Therefore, α-helix mimetic compounds were chosen for the 
development of inhibitors of MTIP/MyoA. α-Helix mimetic compounds provide a synthetic 
challenge and, to our knowledge, have not previously been utilised against Plasmodium 
protein targets. These compounds tend to have low molecular weight (so are more “drug-
like”)232 and may be modified to improve properties such as solubility, stability and 
absorption that are vital for drug development. 
6.1.1. α-Helix mimetic scaffolds 
As briefly mentioned in Chapter 1, Section 1.4.2., work in the field of α-helix mimetic design 
was pioneered by Hamilton and co-workers. In 2001, they published the synthesis and X-ray 
crystal structure of the terphenyl scaffold (Figure 79).139 The phenyl rings were observed to 
adopt a staggered conformation in the crystalline state, which results in the functionalities R1, 
R2 and R3 at the ortho ring positions projecting in similar directions to the side-chains of 
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residues i, i+3 and i+7 in an α-helix. Although there is likely to be significant rotation about 
the aryl-aryl bonds in solution, the crystal structure implies that the staggered conformation is 
energetically favourable and is easily accessible in the presence of a complementary protein 
recognition site.139  
This terphenyl scaffold was utilised for the structure-guided design of α-helix mimetic 
inhibitors targeting the Bcl-xL/Bak protein-protein interaction that is implicated in 
cancer.142,145 Mimetic design was based on the helical domains of Bak and Bad proteins 
which bind Bcl-xL, incorporating alkyl and aryl substituents at positions R1, R2 and R3. These 
compounds were tested using a fluorescence polarisation assay for the displacement of a 
fluorescein-labelled 16-mer Bak peptide from Bcl-xL. The most potent terphenyl mimetic 
contained isobutyl, 1-naphthylmethylene, isobutyl groups at R1, R2 and R3, inhibiting the 
Bcl-xL/Bak interaction with Ki 114 nM. Activity seemed to decrease with smaller, less 
hydrophobic substituents. Computational docking studies in combination with 15N HSQC 
NMR experiments suggest that the terphenyl mimetic binds to Bcl-xL in the same binding 
cleft as the wild-type Bak BH3 peptide.145 However, there is a risk that the high 
hydrophobicity of these molecules may result in non-specific binding to off-target proteins 
with hydrophobic binding pockets. These terphenyl derivatives were tested for inhibition 
activity inside live HEK293 cells.142 The mimetic containing isobutyl, 1-naphthylmethylene, 
isobutyl groups at R1, R2 and R3 was able to inhibit Bcl-xL/Bax complexation by 
approximately 50%, but surprisingly, a terphenyl mimetic containing isopropyl, methyl, 
methyl at R1, R2 and R3 showed 70% activity, in contrast to in vitro fluorescence polarisation 
results. This may be due to differences in cell uptake between the compounds, but may also 
indicate the risk of non-specific off-target effects.  
In similar studies, the same terphenyl α-helix mimetic scaffold was examined for binding 
activity targeting p53/HDM2, another protein-protein interaction linked to cancer.140,233 
HDM2 binds a helical region of p53 which includes key interactions from p53 residues F19, 
W23 and L26. A small library of terphenyl compounds containing various alkyl and aryl 
substituents in the R1, R2 and R3 positions was synthesised and tested for interaction with 
p53/HDM2 using a fluorescence polarisation assay.140 Interestingly, the most potent mimetic 
contained isobutyl, 2-naththylmethylene, isobutyl in the R1, R2 and R3 positions, very similar 
to the Bcl-xL/Bak interaction, despite the differences in the amino acids involved in the wild-
type α-helices of p53 and Bak. This suggests that there may be problems with non-specific 
binding when mimetics containing large hydrophobic surfaces are utilised; the high activity 
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may partly be due to generic hydrophobic interactions between the terphenyl mimetic and the 
HDM2 or Bcl-xL binding clefts. Nevertheless, terphenyl derivatives were examined for p53 
activation in HCT116 colon cancer cells. Somewhat unexpectedly, the mimetic containing 
isobutyl, 2-naththylmethylene, isobutyl in the R1, R2 and R3 positions was inactive, although 
terphenyl compounds containing smaller hydrophobic side-chains were able to activate p53 
transcription function, seemingly as a result of disrupting the p53/HDM2 interaction.233 As 
was the case for the Bcl-xL/Bak interaction, live cell results do not fully support in vitro 
fluorescence polarisation studies, suggesting that there may be problems with specificity or 
cell-uptake of these compounds. However, the apparent ability of terphenyl α-helix mimetics 
with small side-chains to enter cells and generate the expected effect indicates the potential 
for these molecules to modulate protein-protein interactions involved in disease. 
The Hamilton group followed these interesting results with the publication of a modified 
α-helix mimetic scaffold consisting of amide-linked pyridine units (Figure 79).141 
Preorganisation through hydrogen-bonding favours the conformation with the variable R1, R2 
and R3 groups projected on the same face of the molecule. X-ray crystallography studies 
show the aromatic-amide backbone to be quite planar, but the alkoxy side-chains are rotated 
out of the plane to allow the oxygen atom to participate in hydrogen bonding.141 This orients 
R1, R2, and R3 in similar directions as the side-chains of residues i, i+4 and i+7 in an α-helix. 
These functionalities are likely to be flexible in solution so may be able to adapt 
conformation to fit into protein binding clefts. This scaffold does not require formation of 
C-C bonds so is synthetically easier than the terphenyl scaffold. In addition, the presence of 
numerous polar substituents enhances solubility compared to terphenyl derivatives, which is 
vital for biological testing. The trispyridylamide mimetic was investigated for inhibition 
activity against Bcl-xL/Bak BH3 using a fluorescence polarisation assay141 (as for the 
terphenyl compounds above). Key residues involved in binding from the Bak BH3 domain 
include V74, L78 and I81, which were mimicked by incorporating isopropyl substituents at 
R1, R2 and R3 of the trispyridylamide scaffold. This compound was able to disrupt the 
Bcl-xL/Bak BH3 complex with a Ki of 2.6 µM, and molecular docking studies suggest that it 
binds in the same Bcl-xL binding site as the Bak BH3 peptide.141 Cell-based results have not 
yet been reported for this structure. 
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Figure 79: Reported α-helix mimetic scaffolds. R1, R2, R3 may be varied to mimic different amino 
acid side-chains. The terphenyl,139,145 trispyridylamide141 and terephthalamide234 scaffolds were 
reported by Hamilton and co-workers, the oxazole-pyrrole-piperazine scaffold by Rebek,235 the 
trisbenzamide scaffold reported simultaneously by the Boger236 and Wilson237 groups, and the 
simplified oligoamide structure reported by Boger.236  
Amongst other trispyridyl and terphenyl structures, Hamilton et al.234 have also reported the 
synthesis and inhibition activity of a simplified terephthalamide scaffold containing only one 
aryl ring (Figure 79). The carboxamide groups retain planar geometry with the aryl ring, 
assisted by hydrogen-bonding and the restricted rotation of amide bonds. This projects the 
variable R1, R2 and R3 groups in similar orientations to those on the terphenyl scaffold, 
mimicking residues i, i+4 and i+7 of an α-helix. As for the trispyridylamide scaffold, these 
compounds have a more straightforward synthesis and exhibit increased solubility in aqueous 
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solution compared to the terphenyl structure. The terephthalamide scaffold containing 
isobutyl, isopropyl, isopropyl, isopropyl in the R1, R2, R3 and R4 positions respectively 
showed high affinity for  Bcl-xL with Ki 780 nM, and 15N 2D NMR experiments indicate that 
it locates to the same hydrophobic binding site as the wild-type Bak peptide.234 Promisingly, 
this terephthalamide mimetic seemed able to disrupt approximately 80% of the Bcl-xL/Bax 
interaction at 100 µM inside HEK293 cells,234 significantly higher activity than the terphenyl 
derivative discussed above. This suggests that the terephthalamide compounds are able to 
penetrate cell membranes and can survive in a cellular environment.  
Following on from Hamilton’s work, in 2009 both the Wilson144,237 and Boger236 groups 
published the synthesis and inhibition activity of an oligobenzamide α-helix mimetic (Figure 
79). As for Hamilton’s trispyridylamide structure, hydrogen-bonding promotes a 
conformation that projects the variable R1, R2 and R3 substituents in similar directions to i, 
i+4 and i+7 residue side-chains in an α-helix. X-ray crystallography and NMR studies 
confirmed an extended conformation including hydrogen-bonding to restrict rotation about 
the Ar-NH bond. However, free rotation about the Ar-CO bond appears possible, which may 
provide flexibility allowing the R side-chain mimics to adapt to the protein binding site of 
interest.237 Both Wilson and Boger examined these mimetics for binding activity targeting the 
p53/HDM2 interaction. The Wilson group used a fluorescein-labelled p53 peptide in a 
fluorescence polarisation assay to screen a series of trisbenzamides containing various 
hydrophobic groups in the R1, R2 and R3 positions.144 In general, they found that compounds 
with more and larger hydrophobic groups bound strongly, the most potent molecule 
containing isopropyl, 2-naphthylmethylene and phenylmethylene in the R1, R2 and R3 
positions respectively (IC50 of 1 µM for inhibition of p53/HDM2). These are very similar 
results to those obtained for Hamilton’s terphenyl scaffold against p53/HDM2,140 implying 
some specificity. However, the increase in activity with increasing hydrophobicity suggests 
that non-specific hydrophobic interactions may also play a part. The Wilson group have 
described the first modular solid phase synthesis of an α-helix mimetic compound to facilitate 
efficient library synthesis.238 This also utilises the trisbenzamide structure, but the R 
substituents are linked to the amide N atom via a methylene unit, rather than situated at the 
ortho ring position. These compounds bind to HDM2 with similar affinities to the standard 
trisbenzamide compounds, and appear to position themselves in the same HDM2 binding 
cleft as the wild-type p53 peptide.238  
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The Boger group took a slightly different approach, designing a small molecule α-helix 
mimetic library to incorporate all combinations of natural amino acid side-chains.236 This 
library has the potential to be used to screen any protein-protein interaction. Initially, the side 
chains of p53 residues F19, W23 and L26 were mimicked using different combinations of 
alkyl and aryl substituents as the R groups on the trisbenzamide scaffold (Figure 79). 
Variations were made to determine the optimum functionalities at the N- and C-termini of the 
molecules, and the position of the R side-chain mimic groups (2-alkoxymethyl compared to 
3-alkoxymethyl).236 These were tested against p53/HDM2 using an ELISA-based assay. 
Activity was only observed with carboxylic acids at the C-terminus, esters were inactive 
likely due to solubility issues. There was no significant effect for the N-terminus 
functionality; NH2, NO2 and NHBoc all showed similar activity. The 3-alkoxyaryl derivatives 
(-OR groups in the meta ring positions, as shown in Figure 79) were more potent than the 
equivalent 2-alkoxyaryl compounds (-OR in the ortho ring positions), suggesting that this 
arrangement orients the R side-chains in a conformation more similar to that of the i, i+4, i+7 
residue side-chains of an α-helix. Additionally, the mimetics were more effective when the 
side-chain functionalities were presented in the same order as the wild-type peptide (side-
chains in order N- to C-terminus), rather than in reverse; NH2-Ar(Phe)-Ar(Trp)-Ar(Leu)-OH 
was approximately 3-fold more active than NH2-Ar(Leu)-Ar(Trp)-Ar(Phe)-OH for the 
representation of p53 residues F19, W23, L26. This indicates that the mimetics bind 
preferentially in the same N- to C-terminus direction as the wild-type peptides. Surprisingly, 
structures containing only two benzamide subunits tended to show comparable activity to the 
trisbenzamide compounds, and the presence of natural amino acids either side of a 
functionalised aryl ring (Figure 79, Boger oligoamide structure) maintained or even improved 
activity. This suggests that the rigid trisbenzamide system may only be able to make two of 
the possible three effective side-chain contacts in the protein binding site, but the addition of 
the more flexible natural amino acids may allow all three interactions to occur. These 
simplified structures showed improved solubility with decreasing numbers of aryl subunits, 
and are easily accessible via modular peptide coupling.  
Following these observations, Boger et al. synthesised a combinatorial library of the 
oligoamide structure, containing all possible 20 natural amino acid functionalities at each of 
the side-chain positions R1, R2 and R3.236 This was achieved as 400 mixtures of 20 
compounds, with the final coupling step to the third amino acid performed with all 20 amino 
acids in one pot. These mixtures were tested for activity against p53/HDM2 and, following 
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the identification of successful mixtures, the 20 individual compounds were synthesised 
individually and re-screened. This method identified the NH2-Phe-Ar(Trp)-Leu-OH mimetic 
as the most potent inhibitor, as was the case for the trisbenzamide compounds. This was the 
expected outcome, as structure-guided design implicated p53 residues F19, W23 and L26 in 
binding to HDM2. This implies that the simplified oligoamide mimetic scaffold can behave 
in a similar manner to the trisbenzamide structures, effectively mimicking i, i+4 and i+7 side-
chain interactions of an α-helix. 
In addition to the benzyl-based scaffolds described here, the field of α-helix mimetics is 
expanding to include compounds based on novel heterocyclic units. These include the 
oxazole-pyrrole-piperazine structure reported by the Rebek group235 (shown in Figure 79), 
1,4-dipiperazino benzene compounds239 and oligooxopiperazines.240 However, although the 
syntheses of these species have been reported, there is not yet any published data for the in 
vitro or in vivo activity for these compounds, so these will not be discussed further here.  
6.1.2. Incorporation of MyoA residues into an α-helix mimetic 
A suitable scaffold was required to mimic the MyoA tail α-helix in order to design an 
inhibitor of the MTIP/MyoA interaction. It was desirable to use a previously validated 
structure that had shown inhibition activity against a specific protein-protein interaction to 
enhance the likelihood of success. Scaffolds for which there were no assay data available 
were therefore eliminated. Any MyoA mimetic synthesised was to be examined for activity 
against MTIP/MyoA using the dansyl fluorescence assays described in Chapters 2–4, so good 
aqueous solubility was vital. The terphenyl compounds were discounted due to the reported 
problems concerning their solubility and also their potentially difficult synthetic route. The 
oligoarylamides are more favourable for these reasons, which led to the decision to use 
Boger’s oligoamide structure236 (Figure 79). This scaffold contains numerous polar atoms to 
enhance aqueous solubility, and it appeared to be relatively easily to obtain via amide 
formation between the functionalised aromatic unit and two natural amino acids. Inhibition 
results reported by the Boger group also suggested that these compounds are more active than 
the corresponding trisbenzamide species (against p53/HDM2), possibly due to the greater 
flexibility they possess.236 A major aim of these MyoA mimetic experiments was to ascertain 
whether MTIP/MyoA can be modulated by α-helix mimetic compounds. This has not 
previously been reported for this complex, or in fact any Plasmodium protein-protein 
interaction. It was therefore sensible to use a relatively simple molecule to begin with, which 
has the potential to be modified and enhanced if preliminary results were encouraging.  
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Figure 80: The orientations of key residue side-chains in the MyoA tail α-helix when bound to MTIP. 
(A) Side-on view of MyoA α-helix. (B) View looking down the MyoA α-helix from the C-terminus, 
showing the staggered conformation of the amino acid side-chains. Hydrophilic side-chains are shown 
in red, hydrophobic side-chains in blue. Residues R806, H810 and K813 are situated on the same face 
of the MyoA α-helix in a staggered conformation. Hydrophobic residues L804, V807 and I811 are 
situated on the opposite face, also in a staggered conformation. Images were generated using data 
from the crystal structure of PfMTIP[61-204]/PfMyoA[799-818] (Chapter 5, Section 5.3).  
Having decided on an α-helix mimetic scaffold, the MyoA residues to be mimicked were 
considered. MyoA peptide alanine mutation studies discussed in Chapter 4 supported the 
published crystal structures and yeast two-hybrid data54,88 in identifying MyoA residues 
L804, R806, V807, Q808, H810, I811, R812, K813 and K814 as all being involved in 
significant interactions in the MTIP binding site. The chosen Boger oligoamide scaffold was 
designed to mimic residues i, i+3/i+4 and i+7 of an α-helix. Study of the 
PfMTIP[61-204]/PfMyoA[799-818] closed crystal structure revealed that the electrostatic 
residues R806, H810 and K813 fit the i, i+4 and i+7 sequence and all project on the same 
face of the MyoA tail α-helix, while the hydrophobic residues L804, V807 and I811 (i, i+3 
and i+7) project on the opposite face (Figure 80). This provided the option to mimic either 
the hydrophobic or hydrophilic face of MyoA. To date, all α-helix mimetics reported in the 
literature have incorporated hydrophobic side-chain functionalities,140,142,144,236 but there are 
concerns that the activity of these compounds may in part be due to generic hydrophobic 
interactions, meaning there may be problems achieving specificity. Indeed, the hydrophobic 
mimetics synthesised by Hamilton and Wilson (described in Section 6.1.1) generally do not 
include the exact chemical group of the wild-type residue side-chain, but instead use more 
MyoA tail:       ...KNIPSLLRVQAHIRKKMVAQ-OH
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hydrophobic moieties such as naphthalene and isopropyl,142,144 indicating that the observed 
activity may not be specific. Therefore, the functionalities of MyoA residues R806, H810 and 
K813 were chosen to be incorporated into the MyoA α-helix mimetic to participate in 
electrostatic interactions with MTIP. Positively charged mimetics have not previously been 
reported, so this provides a novel challenge and it was hoped that this would eliminate non-
specific hydrophobic interactions. Hydrophilic groups should also improve aqueous 
solubility, ensuring the synthesised mimetics can be tested for activity in the MTIP/MyoA 
dansyl fluorescence assays. The apparent ease of synthesis of the simplified Boger 
oligoamide scaffold should allow the side-chain groups to be mimicked more precisely, 
rather than using generic electrostatic chemical species, which may further contribute to 
specificity. Figure 80 (B) shows that MyoA residues R806, H810 and K813 adopt a staggered 
conformation when bound to MTIP. The use of natural amino acid residues in place of aryl 
subunits in the Boger oligoamide scaffold should provide a degree of flexibility, which may 
be important in allowing the side-chain mimics to attain this staggered conformation. The 
structure of the designed MyoA α-helix mimetic is illustrated in Figure 81. 
 
Figure 81: Design of MyoA α-helix mimetics. The orientations of the side-chains of MyoA residues 
R806 (red), H810 (green) and K813 (blue) are shown when the MyoA tail α-helix is bound to MTIP. 
These side-chains were incorporated into the Boger oligoamide α-helix mimetic structure. (A) MyoA 
α-helix mimetic with N-terminal amine and C-terminal carboxylic acid, NH2-Arg-Ar(His)-Lys-OH. 
(B) MyoA α-helix mimetic with acetylated N-terminus and C-terminal carboxamide to mimic the next 
amide bonds of the wild-type peptide, AcNH-Arg-Ar(His)-Lys-NH2. 
Results reported by Boger et al.236 indicated that the side-chain groups on the α-helix mimetic 
should be in the same order as in the wild-type peptide (N- to C-terminus). Therefore, 
arginine was chosen as the N-terminal amino acid, the histidine functionality was to be linked 
NH2-Arg-Ar(His)-Lys-OH(A) Ac-Arg-Ar(His)-Lys-NH2(B)
K813
H810
R806
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to the aromatic ring, and lysine was chosen as the C-terminal amino acid. The published 
oligoamide α-helix mimetic library reported by the Boger group contains free amines and 
acids at the N- and C-termini of the compounds respectively. In addition to the free termini 
mimetic for MyoA (NH2-Arg-Ar(His)-Lys-OH), it was decided to synthesise a mimetic with 
a capped N-terminus and C-terminal carboxamide to mimic the next amide bonds of the wild-
type peptide (AcNH-Arg-Ar(His)-Lys-NH2). Previous studies using α-helix mimetics to 
disrupt protein-protein interactions have found that acid termini are usually favoured, with 
esters reported to be inactive at the concentrations tested,236 presumably due to the lower 
aqueous solubility of esters compared to carboxylic acids. This is likely to have a high impact 
when dealing with largely hydrophobic compounds, such as the mimetics incorporating 
hydrophobic side-chains described in Section 6.1.1. Comparison of the activities of 
NH2-Arg-Ar(His)-Lys-OH and AcNH-Arg-Ar(His)-Lys-NH2 should indicate whether 
hydrophilic side-chains are sufficient to allow high solubility of α-helix mimetic compounds, 
and also provide an insight into the effect of introducing additional charged residues into the 
molecule. 
6.2. Synthesis of NH2-Arg-Ar(His)-Lys-OH and AcNH-Arg-Ar(His)-Lys-NH2 
Retrosynthetic analysis for NH2-Arg-Ar(His)-Lys-OH and AcNH-Arg-Ar(His)-Lys-NH2 is 
shown in Figure 82 and shows that the mimetics may be formed via standard peptide bond 
formation using protected arginine and lysine amino acids, which are commercially available, 
together with an aryl-histidine amino acid mimic. This histidine mimic may be synthesised by 
a nucleophilic aromatic substitution reaction between 3-fluoro-4-nitrobenzoic acid 
(commercially available) and N-protected 4-hydroxymethylimidazole. This was the approach 
reported by the Boger group.236 Their synthetic route was followed, as they used relatively 
simple peptide coupling chemistry which seemed to work for all combinations of side-chain 
functionalities.  
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Figure 82: Retrosynthesis of the MyoA α-helix mimetics Y-Arg-Ar(His)-Lys-X (Y is PGNH, X is 
OPG for the N-terminal amine and C-terminal carboxylic acid mimetic and Y is AcNH, X is NH2 for 
the N-terminal acetylated and C-terminal carboxamide mimetic). The mimetics may be divided into 
an aryl-histidine unit (NO2-Ar(His)-OH) and protected arginine and lysine amino acids. The aryl-
histidine unit may be formed from 3-fluoro-4-nitrobenzoic acid and N-protected 
4-hydroxymethylimidazole. PG = protecting group. 
The first step was to protect commercially available 4-hydroxymethylimidazole to mask the 
reactivity of the nitrogen atom of the imidazole ring. This was achieved using trityl chloride 
with triethylamine as the base in DMF. Trityl is a standard protecting group for imidazole 
derivatives, and is acid-labile so should be stable to the bases required throughout the 
synthesis. This reaction gave a yield of 66% and the product was found to be pure by TLC, 
meaning no additional purification step was required. The N-trityl protected 
4-hydroxymethylimidazole was used in a nucleophilic aromatic substitution reaction with 
3-fluoro-4-nitrobenzoic acid. Initially NaH was used as the base, as indicated by 
Boger et al.236 The reaction was carried out under a nitrogen atmosphere using dried 
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glassware to prevent water deactivating NaH. However, the reaction did not work well; a 
small quantity of product was identifiable by mass spectrometry, but numerous other 
compounds were present, including starting materials, and the mixture was so insoluble in 
organic and aqueous solvents that it was extremely difficult to purify. Correspondence with 
the Boger group revealed that they had in fact used sodium hexamethyldisilazide (NaHMDS) 
as the base for the synthesis of the aryl-histidine moiety. The reaction was repeated with 
NaHMDS under a nitrogen atmosphere using dry tetrahydrofuran (THF) as the solvent, and 
proceeded with a high yield of 85%. NaH is insoluble in organic solvents, so reaction must 
occur at the solid NaH surface. It is likely that the greater solubility of NaHMDS, compared 
to NaH, in THF increases the rate of deprotonation and allows the nucleophilic aromatic 
substitution to proceed. The protected NO2-Ar[His(Trt)]-OH amino acid mimic product is 
insoluble in most aqueous and organic solvents, meaning impurities could easily be removed 
by washing with aqueous HCl, diethyl ether, hexane and ethyl acetate.  
The nitro group of the NO2-Ar[His(Trt)]-OH amino acid mimic masked the amine 
functionality, meaning the carboxylic acid could be directly reacted with the amine of 
tert-butoxycarbonyl (Boc)-protected lysine (NH2-Lys(Boc)-X, where X is OtBu or NH2 for 
the C-terminal carboxylic acid or carboxamide mimetics respectively). Boc-protected lysine 
was used to ensure all protecting groups were acid-cleavable so could be removed in one 
final deprotection step. The peptide coupling reaction was achieved using 2,6-lutidine as the 
base, and HATU to form an activated ester from the carboxylic acid of 
NO2-Ar[His(Trt)]-OH, in DMF. HATU promotes rapid amide bond formation and reduces 
racemisation during peptide coupling, and is generally thought to be one of the most efficient 
amino acid activators for peptide synthesis.241,242 The coupling reaction did indeed work well 
in this case, the NO2-Ar[His(Trt)]-Lys(Boc)-X product (X is OtBu or NH2) obtained in yields 
up to 86%.  
The next step was to reduce the nitro group of NO2-Ar[His(Trt)]-Lys(Boc)-X to provide an 
amine for peptide bond formation with an arginine moiety. There are numerous methods 
available to reduce nitroaryls, including hydrogenation with palladium243 or Raney nickel244 
catalysts, and treatment with SnCl2245 or Fe/HCl.246 However, the Boger group developed a 
novel method using Zn nanopowder with ammonium chloride in aqueous acetone. This 
reaction was reported to occur extremely quickly at room temperature, with no adverse 
effects on protecting groups or other functionalities in the molecule.236 This therefore seemed 
like an ideal method to use, especially as it had already been performed successfully on these 
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oligoamide mimetic compounds. As predicted, reduction of the nitro group of 
NO2-Ar[His(Trt)]-Lys(Boc)-X occurred in only 20 minutes at room temperature and the 
reaction was extremely clean, the product not requiring additional purification. 
 
Figure 83: Synthesis of MyoA α-helix mimetic NH2-Arg-Ar(His)-Lys-OH. The mimetic 
AcNH-Arg-Ar(His)-Lys-NH2 was synthesised via the same route using NH2-Lys(Boc)-NH2 in place 
of NH2-Lys(Boc)-OtBu and AcNH-Arg(Pmc)-OH in place of BocNH-Arg(Mtr)-OH. 
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The resultant NH2-Ar[His(Trt)]-Lys(Boc)-X protected dipeptide mimetics underwent another 
peptide coupling reaction with BocNH-Arg(Mtr)-OH (for the N-terminal amine mimetic) or 
AcNH-Arg(Pmc)-OH (for the N-acetylated mimetic). This step was the most difficult part of 
MyoA mimetic synthesis. The reaction proceeded with just 31% yield, even after two days at 
room temperature, probably due to the poor nucleophilicity of the aniline moiety of 
NH2-Ar[His(Trt)]-Lys(Boc)-X in which the lone pair of electrons on the nitrogen atom is 
likely delocalised into the aryl ring, reducing its reactivity. Both HATU and HOAt with 
EDCI were utilised as activating agents, but there was no noticeable difference in yield. 
Despite the low yield of this reaction, sufficient product was obtained to be able to continue 
with the final synthetic stage, the removal of all protecting groups. Boger et al. used HCl in 
1,4-dioxane for the deprotection step,236 but it was decided to use standard peptide 
deprotection conditions of 95% trifluoroacetic acid (TFA) containing 2.5% water and 2.5% 
triisopropylsilane (TIS) by volume. This method is a reliable way to deprotect peptides; small 
quantities of water and TIS act as scavengers to ensure that the cleaved protecting groups do 
not interfere with the desired product. The reaction was monitored by LC-MS. Total 
deprotection was complete within one hour, except for compounds containing the Mtr 
arginine protecting group. These compounds required the addition of 5% thioanisole to the 
deprotection solution (90% TFA, 5% thioanisole, 2.5% water, 2.5% TIS) and a further one 
hour reacting time to ensure total protecting group cleavage. As for standard solid phase 
peptide synthesis, the tripeptide mimetic products were precipitated from the TFA solution 
using cold tert-butylmethyl ether (TBME), and were then purified by LC-MS and dissolved 
in water to be stored as 50 mM stocks at –20 °C. All MyoA α-helix mimetics synthesised 
were soluble at this concentration, confirming that the Boger oligoamide scaffold is 
applicable to aqueous assays, and implying that the mimicry of electrostatic residues 
improves solubility compared to hydrophobic side-chain mimics, as expected. 
In addition to the tripeptide mimetics NH2-Arg-Ar(His)-Lys-OH and 
AcNH-Arg-Ar(His)-Lys-NH2, the intermediate dipeptide mimetics 
NO2-Ar[His(Trt)]-Lys(Boc)-X and NH2-Ar[His(Trt)]-Lys(Boc)-X were isolated, deprotected 
and purified, as were the acetylated compounds AcNH-Ar[His(Trt)]-Lys(Boc)-X. These were 
synthesised by acetylating NH2-Ar[His(Trt)]-Lys(Boc)-X using acetic anhydride in the 
presence of pyridine, which proceeded with 68% yield. The structures of all the C-terminal 
carboxylic acid and carboxamide MyoA mimetics synthesised are shown in Figure 84. 
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Figure 84: The structures of synthesised MyoA α-helix mimetic compounds incorporating the side-
chains of MyoA residues R806, H810 and K813. The top row shows the C-terminal carboxylic acid 
mimetics, the bottom row shows the C-terminal carboxamide mimetics which incorporate the next 
amide bonds of the wild-type peptide sequence. The labels of the mimetic compounds are coloured to 
correspond to the graphs in Section 6.3. 
6.3. Displacement activity of MyoA α-helix mimetic compounds 
6.3.1. Absorption and fluorescence emission spectra of MyoA α-helix mimetic 
compounds 
Prior to testing for displacement activity against MTIP/MyoA, the MyoA mimetic 
compounds were examined for intrinsic absorbance and fluorescence. The presence of an 
aromatic ring suggested that this was likely, and it was possible that this may interfere with 
the dansyl fluorescence signal monitored in the MTIP/d-GMyoA displacement assays. The 
absorbance spectra between 250-600 nm for the C-terminal carboxylic acid and carboxamide 
mimetics are shown in Figure 85 (A) and (B) respectively. It is immediately apparent that all 
of the mimetic compounds absorb strongly with maxima at approximately 280-300 nm. This 
is characteristic of aromatic ring absorption.247 The nitro compounds NO2-Ar(His)-Lys-OH 
and NO2-Ar(His)-Lys-NH2 also exhibit a strong absorption band with a maximum at 
NH2-Arg-Ar(His)-Lys-OH AcNH-Ar(His)-Lys-OH NH2-Ar(His)-Lys-OH NO2-Ar(His)-Lys-OH
AcNH-Arg-Ar(His)-Lys-NH2 AcNH-Ar(His)-Lys-NH2 NH2-Ar(His)-Lys-NH2 NO2-Ar(His)-Lys-NH2
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approximately 420 nm due to the effects of the nitro group. This has previously been reported 
for para-substituted nitrobenzene derivatives.248   
 
Figure 85: Absorbance spectra at pH 8.0 of (A) C-terminal carboxylic acid MyoA mimetic 
compounds (B) C-terminal carboxamide MyoA mimetics. Spectra were obtained in plate assay buffer 
at 37 °C using 500 µM of each mimetic compound.  
The dansyl fluorescence assays for the study of inhibitors of MTIP/d-GMyoA require 
external excitation at 330 nm (for the dansyl intensity assay) or 280 nm (for the tryptophan-
dansyl FRET assay). With this in mind, fluorescence emission spectra were obtained for each 
mimetic compound at excitation 280 nm and 330 nm to assess mimetic background 
fluorescence. A compound concentration of 500 µM was used as this was to be the maximum 
concentration of mimetic used in the displacement assay against MTIP/d-GMyoA. The 
spectra for the C-terminal carboxylic acid and carboxamide MyoA mimetic compounds are 
shown in Figure 86. All MyoA mimetics except the nitro compounds show strong 
fluorescence emission when excited at both 280 nm and 330 nm. Fluorescence is strongest 
for the NH2- dipeptide mimetics, which show an intense peak with two maxima at 370 nm 
and 420 nm when excited at 280 nm. Emission is generally slightly lower when the 
compounds are excited at 330 nm, likely because absorption is less efficient at this 
wavelength (Figure 85). As described in previous chapters, the MTIP/d-GMyoA fluorescence 
displacement assays require excitation at 280 nm or 330 nm and emission is measured at 
525 nm. Although the emission maxima of the MyoA mimetic compounds occur between 
370-460 nm, the peaks are broad and so there appears to be residual fluorescence at 525 nm. 
This needed to be taken into account when analysing the fluorescence emission of the 
mimetic displacement assays against MTIP/d-GMyoA. 
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Figure 86: Fluorescence emission spectra of (A) C-terminal carboxylic acid mimetic compounds at 
excitation 280 nm (B) C-terminal carboxylic acid mimetics at excitation 330 nm (C) C-terminal 
carboxamide mimetics at excitation 280 nm (D) C-terminal carboxamide mimetics at excitation 
330 nm. Spectra were obtained using 500 µM of each compound in plate assay buffer at 37 °C.  
Both the dansyl intensity and tryptophan-dansyl FRET assays were used to assess 
displacement activity of the mimetic compounds against MTIP/d-GMyoA initially. It was 
unclear what effect mimetic background fluorescence would have on the assay results, so 
using both of the fluorescence assays allowed comparison of the two methods in order to 
determine the most reliable technique to use. The dansyl intensity and FRET assays were 
performed simultaneously by making up one displacement assay plate and measuring the 
fluorescence emission at 525 nm with both excitations 280 nm and 330 nm. This required the 
use of MTIP[61-204] rather than full-length MTIP to allow application of the FRET assay 
(Section 2.5, Chapter 2 ). d-GMyoA[791-818] was chosen as the d-GMyoA component to 
maintain consistency with the MyoA peptide displacement assays and because it better 
represents the full-length MyoA tail found in vivo than the shorter peptides 
d-GMyoA[803-818] or d-GMyoA[799-818]. It was desirable to use a very large excess of the 
(A) C-terminal carboxylic acid mimetics Excitation 280 nm (B) C-terminal carboxylic acid mimetics Excitation 330 nm
(C) C-terminal carboxamide mimetics Excitation 280 nm (D) C-terminal carboxamide mimetics Excitation 330 nm
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mimetic compounds compared to d-GMyoA[791-818], as it was not known how strongly, if 
at all, these species would bind to MTIP. Therefore, a d-GMyoA[791-818] concentration of 
500 nM was chosen, together with a maximum mimetic concentration of 500 µM (a 
1000-fold excess). Doubling dilutions of the mimetic compounds were carried out, as for the 
MyoA peptide displacement assays, covering mimetic concentrations between 8-500 µM.  
 
Figure 87: Background fluorescence of MyoA α-helix mimetic compounds at emission 525 nm at 
increasing concentrations. (A) C-terminal carboxylic acid mimetics at excitation 280 nm (B) 
C-terminal carboxylic acid mimetics at excitation 330 nm (C) C-terminal carboxamide mimetics at 
excitation 280 nm (D) C-terminal carboxamide mimetics at excitation 330 nm. Data were obtained at 
37 °C in plate assay buffer. 
Control experiments were performed first to assess the mimetic background fluorescence at 
the concentrations required for the MTIP/d-GMyoA displacement assay. Doubling dilutions 
of each mimetic were performed in triplicate in a 96 well plate in plate assay buffer only (no 
MTIP or d-GMyoA was present). The fluorescence emission was measured at 525 nm at both 
excitations 280 nm and 330 nm. The results are shown in Figure 87.  
Apart from the nitro- dipeptide mimetics, each mimetic compound displays significant 
fluorescence emission at 525 nm, which increases with increasing compound concentration. 
The nitro compounds absorb strongly but do not appear to fluoresce. The intensities of 
(A) C-terminal carboxylic acid mimetics Excitation 280 nm (B) C-terminal carboxylic acid mimetics Excitation 330 nm
(C) C-terminal carboxamide mimetics Excitation 280 nm (D) C-terminal carboxamide mimetics Excitation 330 nm
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emission are generally very similar for the equivalent C-terminal carboxylic acid and 
carboxamide mimetics, although AcNH-Ar(His)-Lys-NH2 exhibits stronger fluorescence than 
the corresponding carboxylic acid compound AcNH-Ar(His)-Lys-OH. It is not clear why a 
difference occurs for this compound but not the others; it would not be expected that the 
amide or acid terminus of the lysine residue would interfere significantly with the electron 
density of the aromatic ring (which is likely to be causing fluorescence). The variation may 
be due to discrepancies in the stock concentrations of the two compounds; the concentrations 
were determined by mass so may not be completely accurate. However, the same stocks were 
used for the background fluorescence control experiment as the displacement assays, so the 
difference in background fluorescence should not be a problem when analysing the results of 
the displacement assays. 
The emission intensity at 525 nm is generally of similar values whether excited at 280 nm or 
330 nm, but surprisingly the increase with increasing concentration is not linear when excited 
at 280 nm (although it is at excitation 330 nm). This implies that there may be a quenching 
effect at high mimetic concentrations which causes lower fluorescence than anticipated. This 
is not ideal as it is possible that this could result in the quenching of the d-GMyoA signal in 
the mimetic displacement assays. However, these background fluorescence values were used 
as a correction factor for each MyoA mimetic compound before analysis of the displacement 
assay results in an attempt to eliminate mimetic interference with the monitored fluorescence 
emission. 
6.3.2. Displacement activity of MyoA α-helix mimetics against 
MTIP[61-204]/d-GMyoA[791-818] 
MyoA α-helix mimetic compounds were initially tested for displacement activity against 
MTIP[61-204]/d-GMyoA[791-818] using 500 nM d-GMyoA[791-818] and 600 nM 
MTIP[61-204] to ensure the presence of a saturated complex. The assays were carried out in 
a 96 well plate, as for the MyoA peptide displacement assays described in Chapter 4. 
Fluorescence emission at 525 nm was recorded using excitations of 280 nm (for the 
tryptophan-dansyl FRET assay) and 330 nm (for the dansyl intensity assay). The mean 
background fluorescence intensity values for each mimetic at each concentration (Figure 87) 
were deducted from the total signals observed (in triplicate for each mimetic compound). A 
correction was also made for d-GMyoA[791-818] background fluorescence. These corrected 
values were averaged and the mean values fitted to the IC50 equation shown in Equation 3 (A)  
(Chapter 4) using GraFit.182 The IC50 curves generated for the C-terminal carboxylic acid 
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MyoA mimetic compounds at both excitations 280 nm and 330 nm are displayed in Figure 
88.  
 
Figure 88: Displacement assay results for C-terminal carboxylic acid MyoA mimetic compounds 
against MTIP[61-204]/d-GMyoA[791-818] (A) IC50 curves generated using the tryptophan-dansyl 
FRET assay (excitation 280 nm, emission 525 nm). All slope factors are between 0.8-1.3. (B) IC50 
curves generated using the dansyl intensity assay (excitation 330 nm, emission 525 nm). (C) Table 
showing the IC50 and apparent Ki values obtained using both the tryptophan-dansyl FRET assay and 
the dansyl intensity assay. The FRET assay gives more reliable results than the dansyl intensity assay. 
Fluorescence data were obtained at 37 °C in plate assay buffer using 500 nM d-GMyoA[791-818] and 
600 nM MTIP[61-204] with a maximum mimetic inhibitor concentration of 500 µM. IC50 values were 
calculated by fitting the data to Equation 3 (A) (Chapter 4) using GraFit,182 and apparent Ki values 
were determined from the IC50 values using the Cheng-Prusoff equation with Kd d-GMyoA[791-818] 
113 nM. 
It is clear that the data obtained using the tryptophan-dansyl FRET assay contain lower error 
and give much better IC50 curves than that generated using the dansyl intensity assay. The 
FRET assay shows a decrease in fluorescence emission of d-GMyoA[791-818] with 
increasing concentrations of each MyoA mimetic allowing IC50 values to be calculated with 
good accuracy. In contrast, the data from the dansyl intensity assay for NH2-Ar(His)-Lys-OH 
and NO2-Ar(His)-Lys-OH could not be fitted to the IC50 equation as fluorescence increases 
above the value for the MTIP[61-204]/d-GMyoA[791-818] complex. The dansyl intensity 
assay has lower signal to noise than the FRET assay, meaning the background fluorescence 
values are of greater significance compared to the overall signal. This means that the mimetic 
background fluorescence is likely to cause greater interference with this assay than the FRET 
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method, which makes the correction factor less accurate. There is also greater error between 
triplicate repeats of the same experiment for the dansyl intensity assay meaning it is less 
reproducible. With this in mind, the FRET assay was chosen for the analysis and comparison 
of mimetic inhibition activity against MTIP/Myosin tail peptide complexes. 
Figure 88 (A) shows that all of the C-terminal carboxylic acid mimetics 
NH2-Arg-Ar(His)-Lys-OH, AcNH-Ar(His)-Lys-OH, NH2-Ar(His)-Lys-OH and 
NO2-Ar(His)-Lys-OH cause a decrease in fluorescence emission at 525 nm with increasing 
concentration, implying that they are able to displace d-GMyoA[791-818] from the 
MTIP[61-204] binding site. NH2-Arg-Ar(His)-Lys-OH appears to be the most active 
compound with an IC50 of 109±10 µM. This was predicted as it was thought that the arginine 
functionality would be able to engage in additional contacts with MTIP compared to the 
smaller dipeptide His-Lys mimetic compounds. Although AcNH-Ar(His)-Lys-OH and 
NH2-Ar(His)-Lys-OH seem able to displace d-GMyoA[791-818] with similar activities, 
NO2-Ar(His)-Lys-OH demonstrates notably weaker affinity than these compounds. There 
may be unfavourable interactions between the nitro group and MTIP residues. The apparent 
Ki of 20.1 µM calculated for NH2-Arg-Ar(His)-Lys-OH seems promising; MyoA peptide 
displacement assays suggested that MyoA[803-818] binds to MTIP with Ki of approximately 
3 µM (Chapter 4, Section 4.2.1.). The tripeptide mimetic NH2-Arg-Ar(His)-Lys-OH contains 
just three of the amino acid side-chain functionalities found in MyoA[803-818], so would be 
expected to bind to MTIP with weaker affinity. A seven-fold difference is a reasonable 
starting point for future optimisation. 
Following these preliminary results, a control mimetic compound was synthesised, 
AcNH-Ala-Ar(His)-Lys-NH2, containing a methyl alanine side-chain in place of the arginine 
functionality (Figure 89). This compound was synthesised using the same synthetic route as 
for the other C-terminal carboxamide MyoA mimetic species (Figure 83), using 
AcNH-Ala-OH in place of AcNH-Arg(Pmc)-OH for the final peptide coupling step. It was 
thought that this mimetic compound would show similar displacement activity against 
MTIP[61-204]/d-GMyoA[791-818] as the dipeptide mimetic species, rather than the 
tripeptide mimetics. AcNH-Ala-Ar(His)-Lys-NH2 was purified using LC-MS and examined 
for displacement activity against MTIP[61-204]/d-GMyoA[791-818] using the FRET assay 
along with the other C-terminal carboxamide MyoA mimetic compounds 
AcNH-Arg-Ar(His)-Lys-NH2, AcNH-Ar(His)-Lys-NH2, NH2-Ar(His)-Lys-NH2 and 
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NO2-Ar(His)-Lys-NH2. The results are compared to those for the C-terminal carboxylic acid 
MyoA mimetic compounds in Figure 90.  
 
Figure 89: The structure of the control tripeptide mimetic AcNH-Ala-Ar(His)-Lys-NH2. 
As for the C-terminal carboxylic acid mimetic compounds, all of the C-terminal carboxamide 
MyoA mimetics cause a decrease in fluorescence emission at 525 nm that increases with 
increasing mimetic concentration. The IC50 values are generally slightly lower for the 
C-terminal carboxamide species compared to the C-terminal carboxylic acid mimetics. The 
carboxamide species better mimic the wild-type MyoA protein fragment by containing an 
amide bond at the termini of the molecules and it is possible that the additional negative 
charge of the –COOH group introduced in the C-terminal carboxylic acid mimetics causes 
electrostatic clashes in the MTIP binding site. However, the difference in IC50 values is 
relatively small, so this does not appear to be a significantly unfavourable effect. As for the 
C-terminal carboxylic acid mimetic compounds, the nitro species NO2-Ar(His)-Lys-NH2 
shows the weakest affinity for MTIP of the C-terminal carboxamide mimetics, further 
suggesting that the nitro group interacts unfavourably in the MTIP binding pocket.  
Surprisingly, there does not appear to be a notable difference in displacement activity 
between the tri- and dipeptide C-terminal carboxamide mimetics, implying that the arginine 
functionality does not make an overall positive or negative contribution to the binding 
energy. This is further indicated by the IC50 of 114±11 µM obtained for 
AcNH-Ala-Ar(His)-Lys-NH2; mutation of arginine to alanine in the C-terminal carboxamide 
MyoA α-helix mimetic does not seem to impede binding to MTIP. Although the chosen 
Boger α-helix mimetic scaffold contains greater flexibility than the alternative tribenzyl ring 
AcNH-Ala-Ar(His)-Lys-NH2
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scaffolds,236 it may not allow the required orientation of all three of the side-chain groups to 
mimic the interactions of the wild-type MyoA residues R806, H810 and K813 in binding to 
MTIP. The data shown in Figure 90 suggest that only the histidine and lysine side-chains of 
the MyoA α-helix mimetic compounds may be interacting with MTIP.   
 
Figure 90: (A) IC50 curves for the displacement activity of C-terminal carboxamide MyoA α-helix 
mimetic compounds against MTIP[61-204]/d-GMyoA[791-818]. All slope factors are between 
0.8-1.3. (B) IC50 and apparent Ki values for the displacement activity of C-terminal carboxamide 
MyoA α-helix mimetic compounds against MTIP[61-204]/d-GMyoA[791-818]. (C) IC50 and apparent 
Ki values for the displacement activity of C-terminal carboxylic acid MyoA α-helix mimetic 
compounds against MTIP[61-204]/d-GMyoA[791-818]. All data were obtained using the tryptophan-
dansyl FRET assay with excitation 280nm, emission 525 nm. Fluorescence was recorded at 37 °C in 
plate assay buffer using 500 nM d-GMyoA[791-818] and 600 nM MTIP[61-204]. The fluorescence 
signal was corrected for both mimetic and d-GMyoA[791-818] background fluorescence before being 
fitted to Equation 3 (A) using GraFit.182 Apparent Ki values were determined from the IC50 values 
using the Cheng-Prusoff equation with Kd d-GMyoA[791-818] 113 nM. 
6.3.3. Displacement activity of MyoA α-helix mimetics against 
MTIP[61-204]/d-GMyoB[763-788] 
 Each of the MyoA α-helix mimetic compounds was also examined for displacement activity 
against MTIP[61-204]/d-GMyoB[763-788]. The change in fluorescence of 
d-GMyoB[763-788] upon complex formation with MTIP is approximately 3-fold larger than 
that of d-GMyoA[791-818] (Chapter 3, Section 3.4.1.). This suggested that the background 
fluorescence of the mimetics would be less significant compared to the overall signal, so 
should reduce interference with the observed emission at 525 nm to give more accurate 
results. In addition, it was hoped that mimetic displacement activity against 
MTIP[61-204]/d-GMyoB[763-788] would provide further insights into the binding mode of 
d-GMyoB[763-788] and MyoB peptides with MTIP.  
Mimetic compound 
(C-terminal carboxamide)
IC50 (µM)
Apparent Ki
(µM)
AcNH-Arg-Ar(His)-Lys-NH2 109±14 20.1
AcNH-Ar(His)-Lys-NH2 92±44 17.0
NH2-Ar(His)-Lys-NH2 111±9 20.5
NO2-Ar(His)-Lys-NH2 174±12 32.1
AcNH-Ala-Ar(His)-Lys-NH2 114±11 21.0
Mimetic compound 
(C-terminal carboxylic acid)
IC50 (µM)
Apparent Ki
(µM)
NH2-Arg-Ar(His)-Lys-OH 109±10 20.1
AcNH-Ar(His)-Lys-OH 164±20 30.2
NH2-Ar(His)-Lys-OH 153±7 28.2
NO2-Ar(His)-Lys-OH 382±8 70.4
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Figure 91: MyoA mimetic displacement activity against MTIP[61-204]/d-GMyoB[763-788]. (A) IC50 
profiles for C-terminal carboxylic acid MyoA mimetics displacement activity against 
MTIP[61-204]/d-GMyoB[763-788]. All slope factors are between 0.8-1.3. (B) IC50 profiles for 
C-terminal carboxamide MyoA mimetics displacement activity against 
MTIP[61-204]/d-GMyoB[763-788]. All slope factors are between 0.8-1.3. (C) Table of IC50 and 
apparent Ki values for C-terminal carboxylic acid and carboxamide MyoA mimetics against 
MTIP[61-204]/d-GMyoB[763-788]. Apparent Ki values are shown for displacement activity against 
MTIP[61-204]/d-GMyoA[791-818] for comparison. Data were obtained using the tryptophan-dansyl 
FRET assay at excitation 280 nm, emission 525 nm. Fluorescence was recorded at 37 °C in plate 
assay buffer and data were corrected for mimetic and d-GMyoB[763-788] background fluorescence 
before being fitted to Equation 3 (A) using GraFit.182 Apparent Ki values were determined from IC50 
values using the Cheng-Prusoff equation with Kd d-GMyoB[763-788] 29 nM. 
The C-terminal carboxylic acid and carboxamide MyoA mimetic compounds were tested for 
displacement activity against MTIP[61-204]/d-GMyoB[763-788] using 500 nM 
d-GMyoB[763-788] and 600 nM MTIP[61-204], with a maximum final mimetic 
concentration of 500 µM. As for the mimetic displacement assays against 
MTIP[61-204]/d-GMyoA[791-818], the background fluorescence of the mimetic and of 
d-GMyoB[763-788] were deducted from the observed emission at 525 nm before the data 
Mimetic compound 
IC50 (µM) against 
d-GMyoB[763-788] 
complex
Apparent Ki (µM) 
against 
d-GMyoB[763-788] 
complex
Apparent Ki (µM) 
against 
d-GMyoA[791-818] 
complex
NH2-Arg-Ar(His)-Lys-OH 224±23 12.3 20.1
AcNH-Ar(His)-Lys-OH 249±28 13.7 30.2
NH2-Ar(His)-Lys-OH 212±17 11.6 28.2
NO2-Ar(His)-Lys-OH 381±5 20.9 70.4
AcNH-Arg-Ar(His)-Lys-NH2 212±24 11.6 20.1
AcNH-Ar(His)-Lys-NH2 219±29 12.0 17.0
NH2-Ar(His)-Lys-NH2 222±14 12.2 20.5
NO2-Ar(His)-Lys-NH2 274±12 15.0 32.1
AcNH-Ala-Ar(His)-Lys-NH2 214±11 11.7 21.0
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were averaged and used to calculate IC50 values. The IC50 and corresponding apparent Ki 
values are shown for all of the mimetics in Figure 91 (C) with IC50 curves shown in Figure 
91 (A) and (B). 
The trend in IC50 values is similar to that observed against 
MTIP[61-204]/d-GMyoA[791-818]. The activity of the tripeptide mimetics does not 
significantly differ from that of the NH2- and AcNH- dipeptide mimetic compounds and the 
NO2- species show weaker activity. In addition, AcNH-Ala-Ar(His)-Lys-NH2 binds with the 
same affinity as AcNH-Arg-Ar(His)-Lys-NH2, further suggesting that the arginine side-chain 
mimic in the tripeptide mimetic compounds does not participate in favourable interactions 
with MTIP. The equivalent C-terminal carboxylic acid and carboxamide mimetics show 
similar displacement activity, implying that the presence of additional charged groups at the 
termini of the molecules does not have a large impact on binding.  
The apparent Ki values calculated using the displacement assay against 
MTIP[61-204]/d-GMyoB[763-788] are lower than those calculated against 
MTIP[61-204]/d-GMyoA[791-818] for each of the mimetic compounds. This was also 
observed for MyoA and MyoB peptide displacement assays against 
MTIP[61-204]/d-GMyoB[763-788] and MTIP[61-204]/d-GMyoA[791-818] (Chapter 4), and 
implies that d-GMyoB[763-788] is easier to displace from MTIP than d-GMyoA[791-818].  
6.3.4. Displacement activity of MyoA α-helix mimetic compounds at pH 7 
6.3.4.1. Absorption and fluorescence emission spectra of MyoA α-helix mimetic 
compounds at pH 7 
The MyoA α-helix mimetic compounds all contain an imidazole ring linked to the aromatic 
unit to mimic the side-chain of histidine. The side-chain of histidine has a pKa of 6.0193 
which means that the protonation state may change with biologically relevant pH variations. 
Although MyoA peptide binding to MTIP appears to be consistent at pH 8 and pH 7 
(Chapter 3, Section 3.2.1.4.), it was not known whether this would also be the case for the 
MyoA mimetic compounds. To this end, the displacement activity of the synthesised MyoA 
mimetic compounds was examined at pH 7. The same plate assay buffer was used for these 
experiments as for the standard assays, that is 25 mM Tris, 100 mM NaCl, 1 mM EGTA, 
1 mM DTT, 0.1% Tween, but the pH was adjusted to pH 7.0 (the lower limit of the buffering 
range of Tris). As for displacement activity at pH 8, control experiments were initially 
performed to characterise the intrinsic absorbance and fluorescent properties of each of the 
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MyoA mimetic compounds at pH 7. The absorption spectra were very similar to those 
obtained for the C-terminal carboxylic acid and carboxamide mimetics at pH 8; all mimetics 
contain a strong absorption band with a maximum at 280-300 nm, and the NO2- compounds 
also exhibit absorbance at 420 nm (data not shown).  
 
Figure 92: Fluorescence emission of MyoA α-helix mimetic compounds at pH 7.0. (A) C-terminal 
carboxylic acid mimetics emission spectra at excitation 280 nm. (B) C-terminal carboxamide 
mimetics emission spectra at excitation 280 nm. (C) Background fluorescence of C-terminal 
carboxylic acid mimetics at increasing concentrations at excitation 280 nm, emission 525 nm. (D) 
Background fluorescence of C-terminal carboxamide mimetics at increasing concentrations at 
excitation 280 nm, emission 525 nm. All data were obtained at 37 °C in pH 7 plate assay buffer 
(25 mM Tris, 100 mM NaCl, 1 mM EGTA, 1 mM DTT, 0.1% Tween, pH 7.0). 
The fluorescence emission spectra at excitation 280 nm at pH 7 are shown in Figure 92 (A) 
and (B) for the C-terminal carboxylic acid and carboxamide mimetics respectively. All 
except the nitro compounds exhibit fluorescence, but the maxima are generally at shorter 
wavelengths than observed at pH 8 (NH2-Arg-Ar(His)-Lys-OH has a maximum at 
approximately 360 nm at pH 7 but at 420 nm at pH 8, AcNH-Ar(His)-Lys-NH2 exhibits a 
maximum at 360 nm at pH 7 but at approximately 450 nm at pH 8). This change in 
(A) C-terminal carboxylic acid mimetics Excitation 280 nm (B) C-terminal carboxamide mimetics Excitation 280 nm
(C) C-terminal carboxylic acid mimetics (D) C-terminal carboxamide mimetics
Wavelength (nm)
32
0
34
0
36
0
38
0
40
0
42
0
44
0
46
0
48
0
50
0
52
0
54
0
56
0
58
0
60
0
Fl
uo
re
sc
en
ce
 in
te
ns
ity
 (r
.f.
u.
)
0
2000
4000
6000
8000
10000
0
0
0
8000
000
Fl
uo
re
sc
en
ce
 in
te
ns
ity
 (r
.f.
u.
)
32 36 400 44 48 52 56 60
Wavelength (nm)
AcNH-Ar(His)-Lys-OH
NO2-Ar(His)-Lys-OH
NH2-Ar(His)-Lys-OH
NH2-Arg-Ar(His)-Lys-OH
AcNH-Ar(His)-Lys-OH
NO2-Ar(His)-Lys-OH
NH2-Ar(His)-Lys-OH
NH2-Arg-Ar(His)-Lys-OH
Wavelength (nm)
32
0
34
0
36
0
38
0
40
0
42
0
44
0
46
0
48
0
50
0
52
0
54
0
56
0
58
0
60
0
Fl
uo
re
sc
en
ce
 in
te
ns
ity
 (r
.f.
u.
)
0
2000
4000
6000
8000
10000
Fl
uo
re
sc
en
ce
 in
te
ns
ity
 (r
.f.
u.
)
32 36 40 44 48 52 56 60
Wavelength (nm)
AcNH-Ar(His)-Lys-NH2
NO2-Ar(His)-Lys-NH2
NH2-Ar(His)-Lys-NH2
AcNH-Arg-Ar(His)-Lys-NH2
AcNH-Ala-Ar(His)-Lys-NH2-Ala-Ar(His)-Lys-NH2
c -Arg-Ar(His)-Lys-NH2
2 i )- ys-NH2
2 i )- ys-NH2
c -Ar(His)-Lys-NH2
[Mimetic] (uM)
0 100 200 300 400 500
Fl
uo
re
sc
en
ce
 in
te
ns
ity
0
200
400
600
800
1000000
Fl
uo
re
sc
en
ce
 in
te
ns
ity
 (r
.f.
u.
)
0 100 200 300 400 500
[Mimetic] (µM)
AcNH-Ar(His)-Lys-OH
NO2-Ar(His)-Lys-OH
NH2-Ar(His)-Lys-OH
NH2-Arg-Ar(His)-Lys-OH
AcN - r( is)- y -
2-Ar(His)-Lys-OH
2-Ar(His)-Lys-OH
2-Arg-Ar(His)-Lys-OH
[Mimetic] (uM)
0 100 200 300 400 500
Fl
uo
re
sc
en
ce
 in
te
ns
ity
0
200
400
600
800
100000
Fl
uo
re
sc
en
ce
 in
te
ns
ity
 (r
.f.
u.
)
0 100 200 300 400 500
[Mimetic] (µM)
AcNH-Ar(His)-Lys-NH2
NO2-Ar(His)-Lys-NH2
NH2-Ar(His)-Lys-NH2
AcNH-Arg-Ar(His)-Lys-NH2
AcNH-Ala-Ar(His)-Lys-NH2- l - r( is)-Lys-NH2
c - rg- r( is)-Lys-NH2
2- r( 2
2- r( 2
c - r( is)-Lys-NH2
196 
 
fluorescence is likely due to a variation in the protonation state of the imidazole ring of the 
Ar(His) subunit altering the electron density of the aromatic ring. Although the emission 
peaks remain broad, the displacement of the maxima to shorter wavelengths means that 
fluorescence emission at 525 nm is drastically reduced at pH 7 compared to pH 8 (Figure 
92 (C) and (D)). This implied that there would be less interference of mimetic background 
fluorescence with the emission signal recorded in the MTIP/d-GMyoA displacement assays, 
providing more accurate results.  
Displacement assays were performed for all of the MyoA α-helix mimetic compounds against 
MTIP[61-204]/d-GMyoA[791-818] at pH 7. Concentrations of 500 nM d-GMyoA[791-818] 
and 600 nM MTIP[61-204] were used to maintain the same conditions as the assays 
performed at pH 8. Although mimetic background fluorescence at 525 nm is very small at 
pH 7, these values were deducted from the detected emission signal of 
MTIP[61-204]/d-GMyoA[791-818] at each mimetic concentration (along with 
d-GMyoB[791-818] background fluorescence at pH 7), before the data were averaged and 
IC50 values calculated. These results are shown in Figure 93. 
The results obtained at pH 7 are broadly similar to those observed at pH 8. For the C-terminal 
carboxylic acid mimetics, NH2-Arg-Ar(His)-Lys-OH shows similar displacement activity to 
AcNH-Ar(His)-Lys-OH and NH2-Ar(His)-Lys-OH, while NO2-Ar(His)-Lys-OH is a notably 
poorer inhibitor. Similar IC50 values are obtained for AcNH-Arg-Ar(His)-Lys-NH2 and 
NH2-Ar(His)-Lys-NH2 as for the equivalent C-terminal carboxylic acid compounds, as was 
the case at pH 8. However, binding appears to be weaker for NH2-Arg-Ar(His)-Lys-OH, 
AcNH-Arg-Ar(His)-Lys-NH2, AcNH-Ala-Ar(His)-Lys-NH2 and AcNH-Ar(His)-Lys-NH2 at 
pH 7 than at pH 8. It is unclear why a change in pH should affect the binding of these 
compounds but not the others. The arginine side-chain guanidinium group has a pKa of 12.5 
in the free amino acid,193 so the protonation state of this species should not alter between 
pH 7 and pH 8, although it may vary due to the surrounding chemical functionalities. The 
observed differences in mimetic displacement activity may be due to fluorescence effects, 
rather than binding affinity with MTIP, although it is also possible that variations in the 
protonation states of MTIP residues due to pH may have an impact on the binding affinity of 
some MyoA mimetic compounds.  
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Figure 93: Displacement activity of MyoA mimetics against MTIP[61-204]/d-GMyoA[791-818] at 
pH 7. (A) IC50 profiles for C-terminal carboxylic acid MyoA mimetics against 
MTIP[61-204]/d-GMyoA[791-818] at pH 7. All slope factors are between 0.8-1.3. (B) IC50 profiles 
for C-terminal carboxamide MyoA mimetics against MTIP[61-204]/d-GMyoA[791-818] at pH 7. All 
slope factors are between 0.8-1.3. (C) IC50 and apparent Ki values for the displacement activity of 
MyoA α-helix mimetic compounds against MTIP[61-204]/d-GMyoA[791-818] at pH 7.0. Data were 
obtained using the tryptophan-dansyl FRET assay with excitation 280 nm, emission 525 nm. 
Fluorescence was recorded at 37 °C in pH 7 plate assay buffer and corrected for background 
fluorescence before being fitted to Equation 3 (A) using GraFit.182 Apparent Ki values were calculated 
using the Cheng-Prusoff equation with Kd d-GMyoA[791-818] 113 nM. Apparent Ki values for MyoA 
mimetic displacement activity against MTIP[61-204]/d-GMyoA[791-818] at pH 8 are shown for 
comparison. 
6.4. Summary 
This chapter has described the design, synthesis and assessment of MyoA α-helix mimetic 
compounds for the inhibition of the MTIP/MyoA protein-protein interaction. Following 
analysis of previously published α-helix mimetic scaffolds, Boger’s oligoamide structure was 
decided upon due to its apparent high solubility in aqueous solutions and ease of synthesis. 
Although all reported α-helix mimetics have been based on the mimicry of hydrophobic 
amino acid side-chains, electrostatic MyoA residues R806, H810 and K813 were chosen for 
Mimetic compound IC50 (µM)
(pH 7)
Apparent Ki (µM)
(pH 7)
Apparent Ki (µM)
(pH 8)
NH2-Arg-Ar(His)-Lys-OH 165±32 30.4 20.1
AcNH-Ar(His)-Lys-OH 166±17 30.6 30.2
NH2-Ar(His)-Lys-OH 124±19 22.9 28.2
NO2-Ar(His)-Lys-OH 277±40 51.1 70.4
AcNH-Arg-Ar(His)-Lys-NH2 185±14 34.1 20.1
AcNH-Ar(His)-Lys-NH2 227±10 41.8 17.0
NH2-Ar(His)-Lys-NH2 122±10 22.5 20.5
NO2-Ar(His)-Lys-NH2 173±8 31.9 32.1
AcNH-Ala-Ar(His)-Lys-NH2 213±18 39.3 21.0
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incorporation into a MyoA mimetic in an attempt to improve selectivity and to provide a 
novel challenge. Nine MyoA α-helix mimetic compounds were successfully synthesised, 
including free NH2- and COOH- termini, and N-acetylated and carboxamide capped termini 
to mimic the wild-type peptide bonds. In addition to the tripeptide mimetic species 
NH2-Arg-Ar(His)-Lys-OH and AcNH-Arg-Ar(His)-Lys-NH2, the intermediate NO2-, NH2- 
and AcNH- dipeptide mimetic compounds were isolated and purified to test for inhibition 
activity against MTIP/MyoA. A control mimetic AcNH-Ala-Ar(His)-Lys-NH2 was also 
synthesised to assess the contribution of the arginine side-chain. The MyoA mimetics were 
generally obtained in good yields, and to our knowledge this is the first time that these 
compounds have been isolated and characterised. 
Preliminary control experiments revealed that all of the MyoA α-helix mimetics absorb 
strongly at approximately 280 nm, and are themselves fluorescent when excited at 280 nm 
and 330 nm, likely due to the behaviour of aromatic ring electrons. This intrinsic fluorescence 
was not ideal as the broadness of the mimetic fluorescence emission peaks means they 
interfere with the detected emission at 525 nm for the MTIP/d-GMyoA displacement assays. 
The displacement assay data were therefore corrected for background fluorescence at each 
mimetic concentration before being used to determine IC50 values. This appeared to be 
reasonably accurate for the tryptophan-dansyl FRET assay, as the mimetic background 
fluorescence was lower compared to the overall observed fluorescence signal than for the 
dansyl intensity assay. The dansyl intensity assay was unreliable, as even after correction for 
mimetic background fluorescence the signal was higher than the supposed maximum value 
for the MTIP[61-204]/d-GMyoA[791-818] complex. The FRET assay was also more 
reproducible than the intensity assay, and so this method was solely used for the 
characterisation and comparison of mimetic inhibition activity. It is somewhat surprising that 
many groups have used fluorescent assays to characterise inhibition activity of α-helix 
mimetic compounds, but intrinsic mimetic fluorescence has not previously been reported to 
be a problem. It is possible that this phenomenon does not have such a large impact on the 
fluorescence polarisation experiments utilised by the Hamilton and Wilson groups.140,144,145 
Initial displacement assay results against MTIP[61-204]/d-GMyo[791-818] were 
encouraging. All MyoA α-helix mimetics appeared able to displace d-GMyoA[791-818] from 
MTIP, indicated by a decrease in fluorescence emission at 525 nm with increasing mimetic 
concentration. The apparent Ki of 20.1 µM for AcNH-Arg-Ar(His)-Lys-NH2 is of the same 
order of magnitude as the corresponding wild-type peptide MyoA[803-818], suggesting that 
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this compound may be a good starting point for future drug design. There is no significant 
difference between the IC50 values of the equivalent C-terminal carboxylic acid or 
carboxamide mimetic compounds, suggesting that the introduction of additional charged 
groups NH2- and COOH- at the termini of these molecules does not have an adverse effect on 
binding. Similar activity was observed for the tripeptide mimetics NH2-Arg-Ar(His)-Lys-OH 
and AcNH-Arg-Ar(His)-Lys-NH2 as the dipeptide mimics AcNH-Ar(His)-Lys-OH, 
AcNH-Ar(His)-Lys-NH2, NH2-Ar(His)-Lys-OH and NH2-Ar(His)-Lys-NH2, implying that 
the arginine side-chain functionality may not participate in MyoA mimetic binding to MTIP. 
This was also indicated by the activity of AcNH-Ala-Ar(His)-Lys-NH2, which showed no 
difference to that of AcNH-Arg-Ar(His)-Lys-NH2. There is some precedent for this 
observation; Boger et al. noted that trisbenzamide α-helix mimetics often only seem able to 
form protein contacts with two of the three incorporated side-chains.236 In this case for MyoA 
mimetics, it seems that the mimicked His and Lys side-chains contact MTIP, but the arginine 
functionality does not, although further experiments are required to confirm this. 
In addition to d-GMyoA[791-818], the MyoA α-helix mimetic compounds also seemed able 
to disrupt d-GMyoB[763-788] binding to MTIP. MyoB peptide displacement assays results 
discussed in Section 4.4 (Chapter 4) indicated that d-GMyoB[763-788] is easier to displace 
from MTIP than d-GMyoA[791-818], and this was also implied by the apparent Ki values 
calculated for the MyoA mimetic compounds; all were approximately two-fold lower when 
determined against MTIP[61-204]/d-GMyoB[763-788] than 
MTIP[61-204]/d-GMyoA[791-818], suggesting that these d-GMyosin peptides bind slightly 
differently in the MTIP binding site.  
Fluorescence assay data reported in this chapter imply that the MyoA α-helix mimetic 
compounds synthesised can disrupt MTIP/MyoA peptide binding, but further experiments are 
required to confirm this as the decrease of fluorescence observed in the MTIP/d-GMyosin 
displacement assays could be due to MyoA mimetic absorbance quenching the monitored 
fluorescence signal, rather than the displacement of the d-GMyosin peptides. However, if this 
was the case it might be expected that the nitro compounds NO2-Ar(His)-Lys-OH and 
NO2-Ar(His)-Lys-NH2 would appear to be more active than they are, as they absorb very 
strongly (so should effectively quench dansyl fluorescence if this is occurring). In fact, these 
compounds consistently caused the lowest decrease in fluorescence and have higher IC50 
values than the other MyoA mimetics. In addition, the IC50 values for MyoA mimetic 
inhibition activity are similar (between 100-200 µM) when obtained at pH 7 or pH 8 and 
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against MTIP[61-204]/d-GMyoA[791-818] or MTIP[61-204]/d-GMyoB[763-788], but the 
fluorescence signal and mimetic background varies between these assays so the extent of 
quenching would also be expected to vary. The fluorescence data described here therefore 
support each other in suggesting that the MTIP/MyoA peptide complex may be modulated by 
MyoA α-helix mimetic compounds, but additional experiments are needed before future work 
can concentrate on optimisation of the MyoA α-helix mimetic compounds or assessment of 
their activity in vivo. Ideally, structural techniques such as protein NMR and X-ray 
crystallography would be used to prove that the MyoA mimetic compounds bind to MTIP 
and provide information concerning the mimetic binding site and orientation, but due to time 
constraints these have not yet been performed. In addition, a label-free assay that is not 
influenced by the absorbance or fluorescence of the mimetics would be extremely useful, 
such as ITC. If these were to be successful and MyoA α-helix mimetics can be proven to bind 
to MTIP, future work could concentrate on the optimisation of these compounds and the 
synthesis of control mimetics to determine binding selectivity.  
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Chapter 7   Conclusion 
 
Experiments reported in this thesis worked towards the validation of MTIP/MyoA as a 
drug target and the development of inhibitors of this complex. In this chapter the results 
are summarised in terms of technique and methodology development and MTIP/Myosin 
binding, and the implications both for Plasmodium biology and future anti-malarial drug 
discovery are discussed. 
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The experiments described in this thesis have been directed towards the validation of 
MTIP/MyoA as an anti-malarial drug target, and the development of inhibitors of this 
protein-protein interaction. Although this has not yet been achieved, significant advances in 
the study of MTIP/Myosin complex formation and its potential as a target for disruption have 
been made. 
7.1. Techniques and methodology 
Various constructs of P. falciparum MTIP were expressed and purified during this project, 
allowing experiments to be performed using MTIP[61-204], MTIP NTD and MTIP CTD in 
parallel with full-length MTIP. All were expressed in high yields, up to 30 mg/L. In addition 
to providing information concerning the MTIP/MyoA binding site, comparison between the 
protein domains revealed that MTIP[61-204] is more structured and less prone to aggregation 
than MTIP, meaning it is easier to handle. These characteristics mean that in the future, a 
wider variety of chemical and biophysical techniques are likely to applicable to 
MTIP[61-204] than to full-length MTIP, particularly those requiring long time periods for 
measurements. 
Initial experimental efforts focussed on the development of a reliable fluorescence assay to 
use in binding and displacement studies to probe the MTIP/MyoA interface and screen 
potential inhibitors of this complex. The dansyl fluorescence intensity assay reported by 
Green et al.49 was optimised for MTIP/d-GMyoA binding studies and adapted to a 96 well 
plate for the screening of the displacement activities of MyoA peptides. Of greater 
significance was the development of a novel tryptophan-dansyl FRET assay for the 
MTIP[61-204]/d-GMyoA system. This method may be applied to binding or inhibition 
studies, and has a larger signal to noise ratio than the dansyl intensity assay, resulting in 
greater reproducibility and more reliable results. The FRET method can be used at nanomolar 
protein concentrations, which allows a greater excess of inhibitor while conserving assay 
components. This assay therefore has the potential to be adapted for high throughput 
screening, should it be desirable for MTIP/MyoA inhibitors to be identified this way.  
Peptide arrays were applied to examine MTIP/Myosin binding and identify key binding 
motifs in the myosin tail. This method failed to reflect the effects of single-point alanine 
mutations in the myosin peptide, but could be used to identify specific myosin sequences that 
bind to MTIP for both MyoA and MyoB. The myosin binding motif data obtained from 
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peptide arrays supported that generated using the dansyl intensity and FRET fluorescence 
assays. This array technique was particularly useful when applied to the MyoB tail; it was not 
known that MTIP could bind to MyoB prior to this work, but peptide array experiments 
indicated that this is possible and provided rapid insights into the region of the MyoB tail 
most likely responsible for complex formation with MTIP. This may be applied to study 
other protein interactions within the Plasmodium glideosome in the future, such as MTIP 
with GAP45 (peptides from the N-terminal MTIP region MTIP[1-60] could be synthesised on 
the peptide array and probed with affinity-tagged recombinant GAP45). Additional MyoB 
binding partners might be identified using a MyoB peptide array, by probing with 
Plasmodium lysates and detecting binding proteins using specific antibodies.  
Protein NMR techniques were applied to MTIP for the first time. This required the 
expression of 15N-labelled MTIP and MTIP[61-204]. A protocol was developed for the 
expression of MTIP in minimal media for this purpose, which produced highly labelled 
15N MTIP in good yields (15 mg/L). The SOFAST-HMQC spectra produced the first 
structural information for MTIP/MyoA peptide complexes in solution, and provided 
additional insights into the results generated by dansyl fluorescence assays. Following on 
from these preliminary experiments, Christopher Douse (Tate Group, Imperial College 
London) has assigned the 2D 15N-1H NMR spectra of both free MTIP[61-204] and 
MTIP[61-204] in complex with MyoA[799-818]. This is extremely beneficial for future work 
on MTIP/MyoA and drug discovery efforts, as it may provide information concerning 
complex dynamics and can be used to identify the binding site of MTIP/MyoA inhibitors. CD 
spectroscopy and X-ray crystallography were also applied to examine the structure of 
MTIP/MyoA peptide complexes, providing additional methods with which to probe MTIP 
complexes in the future. 
In addition to the advances in biophysical and biochemical techniques mentioned above, 
organic synthetic methodology described in this thesis resulted in the isolation and 
characterisation of nine novel compounds that to our knowledge are the first examples of 
peptidomimetics incorporating positively charged side-chains.  
7.2. MTIP/Myosin binding 
This wide range of techniques was used to investigate the MTIP/MyoA binding interface. 
MyoA[799-815] was identified as the minimum region of the MyoA tail required for high 
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affinity complex formation with MTIP. This peptide contains four additional residues at the 
N-terminus compared to MyoA[803-818], the peptide previously believed to be sufficient for 
MyoA tail tight binding to MTIP. Residue I801 appears to contribute to the high affinity of 
MyoA[799-815]; mutation of this residue to alanine results in a ten-fold decrease in binding 
affinity compared to the wild-type peptide. Alanine mutation studies were also used to 
validate published X-ray crystallography data in solution, confirming that MyoA residues 
L804, R806, V807, Q808, H810, I811, R812, K813 and K814 all participate in binding to 
MTIP. Christopher Douse (Tate Group, Imperial College London) has recently conducted 
ITC experiments on MTIP[61-204] in complex with MyoA[799-818] and MyoA[803-818], 
the results of which confirm that MyoA[799-818] binds to MTIP with stronger affinity than 
MyoA[803-818] (Kd 91±4 nM for MTIP[61-204]/MyoA[799-818] compared to Kd 
352±14 nM for MTIP[61-204]/MyoA[803-818]).249 Interestingly, this appears to arise due to 
a more favourable enthalpic contribution for formation of MTIP[61-204]/MyoA[799-818] 
compared to MTIP[61-204]/MyoA[803-818], although the entropy change for 
MTIP[61-204]/MyoA[799-818] is more unfavourable; for MTIP[61-204]/MyoA[799-818] 
ΔH –71.2±0.2 kJ/mol, ΔS –30.3 kJ/mol, for MTIP[61-204]/MyoA[803-818] ΔH 
-45.0±0.2 kJ/mol, ΔS –16.4 kJ/mol).249 ITC is a label-free technique and it supports data 
obtained using dansyl fluorescence assays, suggesting that the dansyl tag on MyoA peptides 
does not have an adverse effect on MTIP/MyoA complex formation. Full-length recombinant 
MyoA is extremely difficult to express, meaning the MyoA tail peptide experiments 
described here are of significant use. However, future work could concentrate on confirming 
the MyoA peptide binding motif results for full-length MyoA and MTIP.  
Data reported in this thesis have indicated that MTIP is able to bind to peptides from the tail 
of another P. falciparum myosin, MyoB, in vitro. Binding was observed to occur in the 
region MyoB[760-788], further towards the N-terminus of the myosin tail compared to MTIP 
binding of MyoA (Figure 94). In particular, MyoB[761-775] appears to be the minimum 
region of MyoB able to form a tight complex with MTIP. Comprehensive structural data has 
not yet been obtained for MTIP in complex with MyoB, but it appears that MyoB binds in the 
same or a very similar MTIP binding site to MyoA, although the differences in the changes of 
fluorescence of d-GMyoB[763-788] and d-GMyoA[791-818] upon binding to MTIP suggest 
that MyoA and MyoB peptides may bind to MTIP in slightly different orientations. The 
observation that MTIP may bind MyoB peptides provides an exciting starting point for future 
investigations of MTIP binding to MyoB and potentially other myosins in Plasmodium.  
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Figure 94: The sequences of the MyoA and MyoB tails. MTIP binding motifs are shown in blue, with 
key binding residues highlighted in red. MTIP binds further towards the N-terminus of MyoB 
compared to MyoA.  
7.3. Implications for Plasmodium biology 
The information obtained concerning MTIP/Myosin peptide binding in vitro provides insights 
into and poses questions relating to Plasmodium biology, particularly the glideosome. It 
appears that the CTD of MTIP plays a larger role in MyoA binding than the NTD, although 
both domains are required for high affinity complex formation. Binding data generated using 
MTIP[61-204] revealed that the N-terminal extension of MTIP (residues 1–60) is not 
required for MyoA complexation. This raises the question: what is the function of this 
domain? It is proposed that this region provides the link between MTIP/MyoA and GAP45,61 
but further investigations are required to confirm this in Plasmodium; although MTIP and 
GAP45 consistently co-precipitate in co-immunopreciptation experiments on parasite 
lysates,48,50 the MTIP/GAP45 interaction has not yet been identified in vitro. This may be due 
to the required domain of recombinant MTIP or GAP45 not folding correctly, but it could 
also indicate the presence of an as yet unidentified adaptor protein in vivo, or there may be a 
post-translational modification that is required for MTIP and GAP45 to form a complex. Both 
MTIP (residues S47 and S51) and GAP45 can be phosphorylated by CDPK1 in vitro and a 
proportion of both proteins appear to be phosphorylated in Plasmodium schizonts,61 
suggesting that phosphorylation of MTIP[1-60] may be important in glideosome formation. 
MTIP[1-60] could therefore be involved in regulation of the glideosome and actomyosin 
motor activity. It has been shown in T. gondii that the N-terminal domain of MLC1 is 
responsible for the localisation of MLC1 with the IMC, but it is not clear whether this is 
through a direct interaction with the IMC or via an intermediate protein such as GAP45.56 A 
new member of the glideosome, GAP40, was recently identified in Toxoplasma but its 
function is unknown.56 This reflects the uncertainty that still surrounds the formation and 
exact composition of the apicomplexan actomyosin molecular motor. 
As shown in Figure 94, MTIP only seems to bind to the final 20 residues of the C-terminal 
region of the MyoA tail. This means that there are approximately 30 more residues of the 
MyoA tail: ...GAKILTKIQREKLVEWENCVSVIEAAILKHKYKQKVNKNIPSLLRVQAHIRKKMVAQ-OH
762 781 799 818
MyoB tail: ...AVHKIRDIINSNLKCYRNLCCITSALIMKIKKKRIVEENIKNLQLAQAYFRKYKYIKEHE-OH
742 763 779 801
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MyoA tail that have unknown function. These may act as a linker between the MyoA head 
domain responsible for ATP hydrolysis and actin binding, and the tail region bound to MTIP. 
However, in general the neck region of myosins forms a complex with a regulatory myosin 
light chain, while the myosin C-terminus binds protein cargoes which determine motor 
function and localisation.71 It is therefore possible that MTIP acts as the cargo of MyoA to 
ensure correct localisation and function, and there is another myosin light chain bound to 
residues MyoA[762-798] which may regulate myosin activity, as is the case for skeletal 
muscle myosin shown in Figure 10 (Chapter 1).  
MTIP is able to form a stable complex with MyoB tail peptides in vitro. This is extremely 
interesting as no MyoB binding partners have yet been identified in Plasmodium, and the 
function of this myosin is unknown. MTIP and MyoB are expressed at similar stages of the 
parasite life cycle (late schizonts and merozoites)49,90 so it is possible that they could interact 
in vivo. In contrast to MyoA, MyoB appears to binds to MTIP in the middle region of its tail, 
rather than at the C-terminus. This suggests that if MTIP does bind MyoB in vivo, it may act 
as the regulatory light chain and there could be an additional protein at the C-terminus to 
influence localisation. Biological validation is required to assess whether these molecules 
interact in Plasmodium. Affinity-tagged recombinant MTIP could be used to pull-down 
binding partners from Plasmodium lysates that could be identified using specific antibodies 
or proteomics. Rob Moon at NIMR has recently attempted similar experiments, but 
unfortunately there is currently no reliable antibody available for MyoB, meaning results 
have been inconclusive.250 If MTIP is found to bind to MyoB in vivo, this would indicate that 
there is another actomyosin motor present in Plasmodium. The MTIP/MyoA molecular motor 
is required for forward propulsion of the parasite into a red blood cell.48,76 It is possible that a 
separate motor may be used for a different movement of the parasite, such as spinning 
motility for merozoite reorientation upon parasite-erythrocyte recognition (Figure 7, 
Chapter 1). Interestingly, it has recently been proposed that MTIP may play a role in an 
actomyosin motor involved in cytokinesis in T. gondii96 which is yet to be confirmed, but 
could potentially include MyoB in Plasmodium.  
7.4. Implications for anti-malarial drug discovery targeting MTIP/MyoA 
As discussed in Chapter 1, Section 1.4.3., the MTIP/MyoA protein-protein interaction is a 
potential anti-malarial drug target. Investigations reported in this thesis have contributed data 
that may be useful in the future development of inhibitors of this complex. MyoA[799-818] 
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and d-GMyoA[803-818] bind to MTIP with higher affinity than MyoA[803-818], suggesting 
that there is an important binding pocket at the MTIP/MyoA interface which accommodates 
the dansyl group or MyoA residues MyoA[799-802]. FRET binding assays between 
MTIP[61-204] and d-GMyoA[803-818] indicate that this is located near tryptophan residue 
W171 in the CTD of MTIP. This potential binding pocket provides a possible target for small 
molecule modulators of the complex. In addition, the stronger binding affinity of MTIP CTD 
with MyoA peptides, compared to MTIP NTD, suggests that it may be possible to disrupt the 
MTIP/MyoA complex using molecules that bind to the CTD only, rather than having to 
consider both MTIP CTD and NTD interactions.  
MyoA peptide displacement studies against MTIP/d-GMyoA revealed the MyoA residues 
that participate in key interactions with MTIP and quantified their relative contributions to 
binding, which is crucial for future structure-guided inhibitor design. In addition, these 
experiments confirmed that MTIP/d-GMyoA can be potently and specifically inhibited using 
peptides, indicating that modulation of the MTIP/MyoA protein-protein interaction is 
possible. The MyoA α-helix mimetic compounds also appeared to displace d-GMyoA from 
MTIP, suggesting that small molecules may disrupt MTIP/MyoA. The numerous assays 
developed here pave the way for the application of traditional drug discovery methods, such 
as high throughput screening. Indeed, following on from the work reported in this thesis, 
members of the Tate Group, Imperial College London are currently performing a fragment 
screen targeting MTIP/MyoA, which may also identify lead compounds for anti-malarial 
drug development. It may be most productive to use a combination of structure-guided design 
and screening for the development of drug-like inhibitors of MTIP/MyoA. 
Evidence for the validation of Plasmodium MTIP/MyoA as a drug target is mounting. There 
are no reports in the literature of the successful knock-out of MTIP or MyoA genes in 
Plasmodium, possibly because they are essential, but experiments using T. gondii have shown 
that overexpression of the MyoA tail is deleterious to the parasite.96 Chemically, studies 
(including this one) have indicated that MTIP/MyoA may be disrupted in vitro using 
peptides, and probably small molecules, and data reported by the Bergman group implies that 
treatment of P. falciparum with a P. yoelii MyoA peptide can cause parasite cell death,54 
although the difficulties reproducing this result mean that this is not yet confirmed. The 
Bergman group have also published a group of pyrazole-urea compounds that appear to 
disrupt the motility of Plasmodium sporozoites and were synthesised following 
computational molecular docking studies targeting MTIP/MyoA.251 However, there is not yet 
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proof that the observed impairment of sporozoite motility is due to the disruption of 
MTIP/MyoA in vivo, and in fact the compounds were designed using the open crystal 
structure of PkMTIP[79-205]/PyMyoA[803-817] which is unlikely to accurately represent 
the complex in vivo. Future efforts for the chemical validation of MTIP/MyoA as a drug 
target could concentrate on the modification of MyoA peptides to improve cell uptake and 
confirm that they can target MTIP/MyoA in vivo, in parallel with screening for inhibitors of 
the MTIP/MyoA interaction.  
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Chapter 8   Experimental data 
 
This chapter details the materials and methods used in each experiment performed for 
this thesis, including protein expression, peptide synthesis, assay methodology and the 
synthesis and characterisation of all MyoA α-helix mimetic compounds reported. 
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8.1. General 
All chemicals and solvents were purchased from commercial suppliers (Sigma Aldrich or 
VWR) unless otherwise stated, and used without further purification. Ultrapure water was 
obtained from a MilliQ® Millipore water purification system. 
SDS-PAGE reagents were purchased from Invitrogen and gel-running equipment supplied by 
BioRad. 
Fluorescence measurements were recorded on a SpectraMax M2e Microplate Reader from 
Molecular Devices.  
Circular dichroism spectroscopy measurements were recorded using a Jasco J-715 
spectropolarimeter. 
Protein NMR was carried out on a Bruker 500 MHz spectrometer. 15NHCl was purchased 
from Cortecnet. 
UV absorption was measured using a WBA Biowave II spectrometer. 
Biological samples (proteins and cell cultures) were centrifuged using an Eppendorf 
Centrifuge 5810R. Chemical samples (peptide synthesis) were centrifuged using Jouan BR4 
apparatus. 
Peptide array detection by fluorescence was recorded using an EttanTM Dige Imager 
(Amersham Biosciences) and peptide array detection by chemiluminescence was recorded 
using a LAS-3000 Imaging system from Fujifilm. 
Solid-phase peptide synthesis was carried out on an Advanced ChemTech Apex 396 
automated multiple peptide synthesiser, or an Intavis ResPep LS automated synthesiser. 
Membrane-supported peptide arrays were synthesised using the Intavis ResPep LS 
synthesiser. All Fmoc-protected amino acids, resins, coupling reagents and solvents were 
purchased from Merck Chemicals, including peptide synthesis-grade DMF. Peptide mass 
spectrometric characterisation was carried out using MALDI-TOF recorded on a Micromass 
Autospec-Q spectrometer, or ESI using the Waters LC-MS system described below.  
LC-MS analysis and purification was performed on Waters HPLC system (Waters 2767 
autosampler for sample injection and collection; Waters 515 HPLC pump to deliver the 
mobile phase to the source; XBridge C18 column (Waters, 4.6 mm × 100 mm for analytical 
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and 19 mm × 100 mm for preparative); Waters 3100 mass spectrometer with ESI and Waters 
2998 Photodiode Array (detection over 200–600 nm)). All solvents used were supplemented 
with 0.1% formic acid and degassed with helium.  
Analytical HPLC was carried out on a Gilson system with 322 pumps, a 234 Autoinjector and 
151 UV/vis detector. Preparative HPLC was performed using a Gilson semi-preparative 
RP-HPLC system equipped with 306 pumps and a Gilson 151 UV/vis detector. Both systems 
were fitted with an ACE 5 C18 column (250 × 4.6 mm) and a SecurityGuard cartridge system 
(C18, 4.0 × 3.0 mm). HPLC-grade acetonitrile or methanol were supplied by VWR and all 
solvents were supplemented with 0.1% TFA and degassed with helium.  
Following purification, compounds were freeze-dried on an Alpha 2-4 LD Plus freeze-dryer 
(Christ). 
NMR spectra were recorded in 5 mm tubes calibrated to the stated residual solvent peak on 
Bruker AV-100, 400 or 500 spectrometers at room temperature. The data is presented as 
follows: chemical shift, integration, multiplicity (s = singlet, d = doublet, t = triplet, 
q = quartet, m = multiplet), coupling constant and assignment (HAm = amide proton, 
HAr = aryl proton, HMe = methyl proton). High resolution mass spectrometry (HRMS) was 
by ESI-TOF-MS on an Autospec P673 spectrometer. Thin-layer chromatography was 
performed on pre-coated Silica plates (Aluminium oxide 60 F254, Merck) and spots 
visualised by UV light at 254 nm. Compound purification by column chromatography was 
performed using a Biotage Isolera automated machine equipped with SNAP cartridge 
columns (Biotage) and a fraction collector. Peaks were detected at 245 nm and 280 nm.  
8.2. Buffers and bacterial cell culture media 
8.2.1. LB media for bacterial cell culture 
Powdered LB media was purchased from Fisher Scientific and dissolved in water as 
instructed. The solution was autoclaved before use.  
8.2.2. Minimal media for bacterial cell culture 
15N labelled minimal media was generated according to the recipe in Appendix A1. 
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8.2.3. Buffers 
Buffer Composition 
Assay buffer 
25 mM Tris,  
100 mM NaCl,  
1 mM EGTA,  
1 mM DTT,  
pH 8.0 
Plate assay buffer 
25 mM Tris,  
100 mM NaCl,  
1 mM EGTA,  
1 mM DTT,  
0.1% Tween,  
pH 8.0 
pH 7 Plate assay buffer 
25 mM Tris,  
100 mM NaCl,  
1 mM EGTA,  
1 mM DTT,  
0.1% Tween, 
pH 7.0 
Protein NMR buffer 
20 mM Tris,  
50 mM NaCl,  
5 mM DTT,  
pH 7.0 
Protein purification wash buffer 
50 mM Tris,  
200 mM NaCl,  
5 mM imidazole 
Protein purification elution buffer 
50 mM Tris,  
200 mM NaCl,  
500 mM imidazole 
MTIP storage buffer 
50 mM Tris,  
200 mM NaCl,  
20% glycerol,  
pH 8.0 
Table 8: The compositions of all buffers used in this thesis. All buffers were filtered through a 0.2 µm 
syringe filter (supplied by Nalgene) before use. MTIP storage buffer was used to store MTIP, 
MTIP[61-204], MTIP NTD and MTIP CTD. 
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8.3. Protein Expression 
8.3.1. Plasmids 
Protein Residues Plasmid Affinity tag 
MTIP 1-204 pET-46 Ek/LIC N-terminal His6-tag 
MTIP[61-204] 61-204 pQE-30 N-terminal His6-tag 
MTIP NTD 1-140 pET-30 Xa/LIC N-terminal His6 and S-tag 
MTIP CTD 141-204 pET-30 Xa/LIC N-terminal His6 and S-tag 
Table 9: Plasmids used for the expression of MTIP, MTIP[61-204], MTIP NTD and MTIP CTD. The 
vectors for MTIP, MTIP NTD and MTIP CTD were a gift from Dr Judith Green, NIMR and the 
vector for MTIP[61-204] was kindly donated by Dr Ernesto Cota, Imperial College London. 
8.3.2. General transformation protocol 
50 µL BL21(DE3) cells were thawed on ice and 1 µL DNA was added and mixed lightly. 
The cells were left on ice for 30 min, before being heat shocked by placing in a water bath at 
42 °C for 45 sec, then returned to ice for 5 min. After this time, the cells (50 µL) were added 
to 500 µL LB media and shaken at 225 rpm, 37 °C for 1 h. 200 µL of this cell suspension was 
plated out onto LB agar (Merck) plates containing the relevant antibiotics, and these were 
incubated at 37 °C for 18 h, after which time several colonies were present. 
8.3.3. MTIP expression 
30 mL LB media containing 100 μg/mL ampicillin was inoculated with a single colony of 
BL21(DE3) cells containing the pET-46 Ek/LIC plasmid (including a His6-tag on the MTIP 
N-terminus) to form a starter culture. This was incubated at 37 °C and shaken at 225 rpm 
overnight. 20 mL of this culture was added to 1 L fresh LB media containing 100 μg/mL 
ampicillin, and this was shaken at 37 °C for 2.5 h until optical density (OD600) measurements 
reached 0.5–0.6. IPTG (1 mL of 100 mM stock solution to give 0.1 mM final concentration) 
was added to the flask and it was shaken at 225 rpm, 37 °C for a further 3 h. The culture was 
centrifuged (4000 rpm, 4 °C, 15 min), the supernatant removed and the cell pellet frozen at 
−20 °C overnight.  
The cell pellet was defrosted on ice, to which a solution of 10 mL 1 × Bugbuster, 5 µL 
DNAse (Merck) and 1 Complete EDTA-free protease inhibitor tablet (Roche) was added. 
Once at room temperature, the solution was repeatedly inverted on a rotary mixer for 10 min, 
then left on ice for a further 10 min. The cells were centrifuged at 12,000 rpm, 4 °C for 
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40 min. The supernatant containing the protein was filtered through a 0.2 μm syringe filter 
(supplied by Nalgene) and retained for purification.  
8.3.4. MTIP[61-204] expression 
100 mL LB media containing 50 μg/mL ampicillin and 25 µg/mL kanamycin was inoculated 
with a colony of BL21(DE3) cells containing the pQE30 and pRep 4 plasmids (including a 
His6-tag on the MTIP[61-204] N-terminus) to form a starter culture. This was incubated at 
37 °C and shaken at 225 rpm overnight. 10 mL of this culture was added to 1 L fresh LB 
media containing 50 μg/mL ampicillin and 25 µg/mL kanamycin, and this was shaken at 
37 °C for 2 h until OD600 measurements reached 0.5–0.6. IPTG (1 mL of 100 mM stock 
solution to give 0.1 mM final concentration) was added to the flask and it was shaken at 
225 rpm, 37 °C for a further 3 h. The culture was centrifuged (4000 rpm, 4 °C, 15 min), the 
supernatant removed and the cell pellet frozen at −20 °C overnight.  
The cell pellet was defrosted on ice, to which a solution of 10 mL 1 × Bugbuster, 5 µL 
DNAse and 1 Complete EDTA-free protease inhibitor tablet (Roche) was added. Once at 
room temperature the solution was repeatedly inverted on a rotary mixer for 10 min, then left 
on ice for a further 10 min. The cells were centrifuged at 12,000 rpm, 4 °C for 40 min. The 
supernatant containing the protein was filtered through a 0.2 μm syringe filter (supplied by 
Nalgene) and retained for purification.  
8.3.5. MTIP NTD and CTD expression 
The same protocol was followed for expression of both MTIP NTD and CTD constructs. 
50 mL LB media containing 50 µg/mL kanamycin was inoculated with BL21(DE3) cells 
containing the pET-30 Xa/LIC vector (including both His6 and S-tags on the protein 
N-terminus) to form a starter culture which was incubated at 37 °C and shaken at 225 rpm 
overnight. 2.5 mL of this was added to 1 L LB media containing 50 μg/mL kanamycin, and 
this was shaken at 225 rpm, 37 °C for 2 h until the OD600 reached 0.5–0.6. IPTG (1 mL of 
100 mM stock solution to give 0.1 mM final concentration) was added, and the broth was 
shaken at 18 °C (225 rpm) overnight. The culture was centrifuged (4000 rpm, 4 °C, 15 min), 
the LB media removed, and the cell pellet washed three times with PBS (phosphate buffered 
saline) before being flash frozen in liquid nitrogen and stored at –80 °C. 
A solution of 10 mL 1 × Bugbuster, 5 μL DNAse and one Complete EDTA-free protease 
inhibitor tablet (Roche) was added to the cells after they had been defrosted on ice, and the 
mixture vortexed. Once at room temperature the solution was placed on a rotary mixer for 
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15 min, then placed on ice for 10 min. The lysed cells were centrifuged at 15,000 rpm, 4 °C 
for 30 min and the supernatant removed and filtered through a 0.2 μm syringe filter (supplied 
by Nalgene) ready for purification.  
8.3.6. 15N MTIP expression 
50 mL LB broth containing 100 μg/mL ampicillin was inoculated with BL21(DE3) cells 
containing the pET-46 Ek/LIC plasmid (including a His6-tag on the MTIP N-terminus). This 
was shaken (225 rpm) at 37 °C overnight, then 24 mL added to each of 2 × 1 L minimal 
media containing 100 μg/mL ampicillin. These were shaken at 225 rpm for 3 h until OD600 
reached ~ 0.5, and they were then induced with 0.1 mM (final concentration) IPTG. The cells 
were allowed to shake (225 rpm) at 37 °C for 3 h before the culture was centrifuged 
(4000 rpm, 4 °C, 15 min), the media removed, and the cells frozen at  –20 °C overnight. A 
solution of 10 mL 1 × Bugbuster, 5 µL DNAse and 1 Complete EDTA-free protease inhibitor 
tablet (Roche) was added to the cells, which were allowed to stand on ice for 10 min to 
defrost. The solution was repeatedly inverted on a rotary mixer for 15 min, and then placed 
on ice for 10 min. It was centrifuged at 12,000 rpm, 4 °C for 30 min and the supernatant 
removed and filtered through a 0.2 μm syringe filter (supplied by Nalgene) ready for 
purification.  
8.3.7. 15N MTIP[61-204] expression 
50 mL LB broth containing 50 μg/mL ampicillin and 25 μg/mL kannamycin was inoculated 
with BL21(DE3) cells containing the pQE30 and pRep4 plasmids (including a His6-tag on the 
MTIP[61-204] N-terminus). This starter culture was shaken (225 rpm) at 37 °C overnight, 
then 24 mL added to each of 2 × 1 L 15N minimal media containing 50 μg/mL ampicillin and 
25 μg/mL kannamycin. These cultures were shaken at 225 rpm for 3 h until OD600 reached ~ 
0.5, and they were then induced with 0.1 mM (final concentration) IPTG. The cells were 
allowed to shake (225 rpm) at 37 °C for 3 h before the culture was centrifuged (4000 rpm, 
4 °C, 15 min), the media removed, and the cells frozen at  –20 °C overnight. A solution of 
10 mL 1 × Bugbuster, 5 µL DNAse and 1 Complete EDTA-free protease inhibitor tablet 
(Roche) was added to the cells, which were allowed to stand on ice for 10 min to defrost. The 
solution was repeatedly inverted on a rotary mixer for 15 min, and then placed on ice for 
10 min. It was centrifuged at 12,000 rpm, 4 °C for 30 min and the supernatant removed and 
filtered through a 0.2 μm syringe filter (supplied by Nalgene) ready for purification.  
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8.4. Protein purification 
Protein purification was achieved by mixing the soluble lysate obtained from the cells with 
4 mL Ni-NTA agarose beads (50% suspension supplied by Qiagen) that had been washed 3 
times with wash buffer (50 mM Tris-Cl, 200 mM NaCl, 5 mM imidazole). The protein 
solution/Ni-NTA beads mixture was put on a rotary mixer and repeatedly inverted slowly at 
4 °C for 1 h. The liquid was filtered off and the beads washed three times with wash buffer. 
Elution from the beads was achieved by mixing them with 5 mL elution buffer (50 mM 
Tris-Cl, 200 mM NaCl, 500 mM imidazole). An SDS-PAGE gel was run to confirm protein 
purity, and it was then dialysed overnight into storage buffer (50 mM Tris-Cl, 200 mM NaCl) 
using a Slide-A-Lyzer 3500 MW dialysis cassette in 2 L buffer at 4 °C. Dialysis was 
performed twice more using the same conditions for 1 h each time. 20% glucose (v/v) was 
added to the protein in storage buffer after dialysis. 
8.5. Protein concentration determination 
Protein concentrations and yields were calculated by UV absorption spectroscopy using 
ε280 = 28,800 M-1 cm-1 for MTIP, ε280 = 17,545 M-1 cm-1 for MTIP[61-204],  
ε280 = 8,605 M-1 cm-1 for MTIP CTD and ε280 = 20,525 M-1 cm-1 for MTIP NTD. ε280 values 
were calculated using ExPASy Protein Parameters.180 
8.6. Solid phase peptide synthesis 
All peptides were synthesised using standard Fmoc-protected SPPS methods. Briefly, the 
chosen resin (25 μmol per well) was swelled in DMF for 1 h before deprotection of the 
N-terminal Fmoc protecting group with 20% piperidine (v/v) in DMF for 15 min. This was 
repeated three times. Five equivalents of the incoming N-Fmoc protected amino acid were 
added (as a 0.5 M solution in DMF), and HBTU (125 μmol, 250 μL) and DIPEA (125 μmol, 
250 μL) used to activate each amino acid. The resin was washed 3 times with DMF (1 mL), 
and the cycle of deprotection, DMF wash, amino acid coupling, DMF wash repeated for each 
amino acid in the peptide sequence. After the final amino acid coupling, the N-terminal Fmoc 
group was cleaved using 20% piperidine (v/v) in DMF. The protected resin-bound peptides 
were removed from the reaction block, and either dansylated or acetylated in a fritted syringe 
(see sections 8.6.1 and 8.6.2 ). Each peptide was then washed with 3 × 5 mL DMF, 3 × 5 mL 
dichloromethane, 3 × 5 mL methanol and 3 × 5 mL diethyl ether before being covered and 
dried in a vacuum desiccator overnight. The peptides were deprotected and cleaved from the 
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resin using a deprotection/cleavage mixture of 94% TFA, 2.5% water, 2.5% EDT, 1% TIS. 
1 mL of this mixture was added to each resin-bound peptide and they were shaken at room 
temperature for 3 h. The liquid was filtered and the resin washed with 500 μL more 
deprotection mixture. To each peptide solution was added 10 mL cold tert-butyl-methyl-ether 
(TBME) to give a precipitate. This was centrifuged (4000 rpm, 4 °C, 15 min) and the solid 
washed with 10 mL TBME three more times. The peptides were placed in a vacuum 
desiccator overnight before being purified by HPLC or LC-MS and freeze-dried. All peptides 
were stored in water at –20 °C. 
8.6.1. Dansylation of the N-termini of peptides 
Following removal of the peptides to a 5 mL syringe from the SPPS reaction block, the resin 
was swelled using 1 mL DMF shaking for 1 h. This was removed by filtration and 1 mL 
dansylation solution (1 mL DIPEA (0.5 M in DMF), 1 mL DMF, 70 mg dansyl chloride) 
added and shaken at room temperature for 1 h. The reagent solution was removed, the resin 
rinsed with DMF, and another 1 mL dansylation mixture added and shaken for 1 h (double 
coupling). The reagent mixture was removed and the peptides washed and deprotected as 
described in section 8.6. Stock concentrations were confirmed by UV absorption 
spectroscopy using ε330 = 4300 M–1cm–1. Characterisation data for these peptides are shown 
in Table 10 (d-GMyoA peptides) and Table 12 (d-GMyoB peptides). 
8.6.2. Acetylation of the N-termini of peptides 
Following standard SPPS the peptides were each placed in a 5 mL syringe and the resin 
swelled by addition of 1 mL DMF followed by shaking at room temperature for 1 h. This was 
removed by filtration, and 1 mL acetylation mixture (10% acetic anhydride, 20% DIPEA in 
DMF (v/v)) added and shaken at room temperature for 1 h. The reagent mixture was removed 
by filtration and the peptides washed and deprotected as described in section 8.6. 
Characterisation data for these peptides is shown in Table 11 (MyoA peptides) and Table 13 
(MyoB peptides). 
8.6.3. N-termini coupling of peptides to carboxyfluorescein 
Following removal of the peptides to a 5 mL syringe from the SPPS reaction block, the resin 
was swelled using 1 mL DMF shaking at room temperature for 1 h. This was removed and 
1 mL of the reagent mixture (125 μmol 5(6)-carboxyfluorescein, 125 μmol HOAt, 125 μmol 
HATU, 250 μmol DIPEA) added and shaken at room temperature for 1.5 h. The reagent 
solution was removed by filtration and the peptides washed and deprotected as described in 
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section 8.6. Stock concentrations were confirmed by UV absorption spectroscopy using 
ε492 = 80,000 M-1 cm-1. Characterisation data is shown in Table 10. 
8.6.4. MyoA peptide characterisation 
Peptide C-terminus PurificationMethod 
Rt 
(mins) 
MALDI-TOF 
or ES+ peaks 
Yield 
(%) 
d-GMyoA[803-818] -OH B 26.8 2170 (M+1) 14 
d-GMyoA[799-818] -OH B 27.5 2374 (M+1) 21 
d-GMyoA[791-818] -OH A 17.9 3648 (M+1) 11 
d-GMyoA[781-818] -OH A 19.4 4671 (M+1) 19 
d-GMyoA[781-801] -NH2 A 19.3 2714 (M+1) 38 
f-GMyoA[803-818] -OH A 19.7 2308 (M+1) 7 
Table 10: Characterisation data for N-terminal fluorescently labelled MyoA peptides. Peptides with 
C-terminal acid were synthesised using the appropriate pre-loaded Wang resin, peptides with 
C-terminal amide were synthesised using Rink Amide AM resin. Purification methods A = HPLC 2–
98% H2O/acetonitrile over 40 min B = HPLC 2–98% H2O/MeOH over 40 min. Peptides purified via 
methods A and B were analysed by MALDI-TOF. 
Peptide C-terminus 
Purification
Method 
Rt 
(mins) 
MALDI-TOF 
or ES+ peaks 
Yield 
(%) 
MyoA[791-818] -OH A 19.9 3401 (M+1) 22 
MyoA[791-816] -NH2 A 18.4 3200 (M+1) 11 
MyoA[795-818] -OH A 17.8 2844 (M+1) 4 
MyoA[799-818] -OH A 18.4 2373 (M+1) 35 
MyoA[800-818]* -OH A 18.6 2244 (M+1) 12 
MyoA[801-818]* -OH A 18.9 2130 (M+1) 23 
MyoA[802-818]* -OH A 18.7 2017 (M+1) 24 
MyoA[803-818] -OH A 18.3 1921 (M+1) 26 
MyoA[799-817]* -NH2 B 26.0 2243 (M+1) 18 
MyoA[799-816] -NH2 B 26.3 2174 (M+1) 32 
MyoA[799-815]* -NH2 B 25.4 2073 (M+1) 9 
MyoA[799-814]* -NH2 A 18.3 1943 (M+1) 18 
MyoA[799-813]* -NH2 A 18.2 1815 (M+1) 12 
MyoA[781-801] -NH2 A 18.8 2523 (M+1) 12 
MyoA[791-818]P802A -OH A 18.5 3374 (M+1) 10 
MyoA[799-818]N800A -OH C 6.9 
1166 (M/2+1), 
778 (M/3+1) 
28 
MyoA[799-818]I801A -OH C 6.2 
1166 (M/2+1), 
778(M/3+1) 
28 
MyoA[799-818]L804A -OH C 5.4 
1166 (M/2+1), 
778 (M/3+1) 
28 
MyoA[799-818]R806A -OH C 6.6 1145 (M/2+1), 20 
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764 (M/3+1) 
MyoA[799-818]V807A -OH C 5.9 
1173 (M/2+1), 
783 (M/3+1) 
15 
MyoA[799-818]Q808A -OH C 7.1 
1159 (M/2+1), 
773 (M/3+1) 
28 
MyoA[799-818]H810A -OH C 6.7 
1154 (M/2+1), 
770 (M/3+1) 
15 
MyoA[799-818]I811A -OH C 6.2 
1166 (M/2+1), 
778 (M/3+1) 
19 
MyoA[799-818]R812A -OH C 6.8 
1145 (M/2+1), 
763 (M/3+1) 
22 
MyoA[799-818]K813A* -OH B 25.7 2287 (M+1) 26 
MyoA[799-818]K814A -OH C 6.8 
1159 (M/2+1), 
773 (M/3+1) 
24 
MyoA[803-818]R806A -OH A 18.7 1836 (M+1) 37 
SPMyoA[806-818]G* -OH A 21 1848 (M+1) 3 
ranMyoA[803-818] -OH A 18.5 1921 (M+1) 26 
Table 11: Characterisation data for N-terminal acetylated MyoA peptides. Peptides with C-terminal 
acid were synthesised using the appropriate pre-loaded Wang resin, peptides with C-terminal amide 
were synthesised using Rink Amide AM resin. Purification methods A = HPLC 2–98% 
H2O/acetonitrile over 40 min B = HPLC 2–98% H2O/MeOH over 40 min C = LC-MS 5–98% 
H2O/MeOH over 15 min. Peptides purified via methods A and B were analysed by MALDI-TOF, 
method C with ES+. Peptides labelled * were synthesised by Ronald I. Howson. 
8.6.5. MyoB peptide characterisation 
Peptide C-terminus 
Purification
Method 
Rt 
(mins) 
MALDI-TOF 
or ES+ peaks 
Yield 
(%) 
d-GMyoB[763-778] -NH2 C 7.4 
1081 (M/2+1), 
721 (M/3+1) 
25 
d-GMyoB[763-788] -NH2 B 28.2 3315 (M+1) 15 
d-GMyoB[771-801] -OH B 27.3 4212 (M+1) 12 
d-GMyoB[779-801] -OH B 27.6 3219 (M+1) 27 
d-GMyoB[783-801] -OH B 28.4 2734 (M+1) 15 
Table 12: Characterisation data for N-terminal dansylated MyoB peptides. Peptides with C-terminal 
acid were synthesised using the appropriate pre-loaded Wang resin, peptides with C-terminal amide 
were synthesised using Rink Amide AM resin. Purification methods B = HPLC 2–98% H2O/MeOH 
over 40 min C = LC-MS 5–98% H2O/MeOH over 15 min. Peptides purified via method B were 
analysed by MALDI-TOF, method C with ES+.  
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Peptide C-terminus 
Purification
Method 
Rt 
(mins) ES+ peaks 
Yield 
(%) 
MyoB[763-788] -NH2 C 7.0 
1023 (M/3+1), 
767 (M/4+1) 
22 
MyoB[763-778] -NH2 C 6.4 
957 (M/2+1), 
639 (M/3+1) 
29 
MyoB[763-777] -NH2 C 7.1 
893 (M/2+1), 
596 (M/3+1) 
34 
MyoB[763-776] -NH2 C 6.7 
843 (M/2+1), 
562 (M/3+1) 
27 
MyoB[763-775] -NH2 C 6.6 
787 (M/2+1), 
525 (M/3+1) 
35 
MyoB[763-774] -NH2 C 6.8 
708 (M/2+1), 
473 (M/3+1) 
39 
MyoB[760-775] -NH2 C 7.5 
946 (M/2+1), 
631 (M/3+1) 
11 
MyoB[760-774] -NH2 C 7.6 
868 (M/2+1), 
579 (M/3+1) 
20 
MyoB[761-774] -NH2 C 6.7 
811 (M/2), 542 
(M/3+1) 
9 
MyoB[760-778] -NH2 C 7.5 
1117 (M/2+1), 
745 (M/3+1) 
22 
MyoB[771-801] -OH C 6.5 
1323 (M/3+1), 
992 (M/4+1) 
5 
MyoB[779-801] -OH C 6.6 
991 (M/3+1), 
743 (M/4+1) 
26 
MyoB[783-801] -OH C 6.9 
1243 (M/2+1), 
829 (M/3+1) 
18 
Table 13: Characterisation data for N-terminal acetylated MyoB peptides. Peptides with C-terminal 
acid were synthesised using the appropriate pre-loaded Wang resin, peptides with C-terminal amide 
were synthesised using Rink Amide AM resin. Peptides were purified using method C = LC-MS 5–
98% H2O/MeOH over 15 min, and analysed using ES+. 
8.7. Dansyl intensity binding assay in a cuvette 
MTIP was incubated with 1 mM DTT at room temperature for 30 min before starting the 
assay. 1 mL of 1 μM d-GMyosin peptide in assay buffer (25 mM Tris-Cl, 100 mM NaCl, 
1 mM EGTA, 1 mM DTT, pH 8.0) was added to a cuvette and the fluorescence emission 
spectrum taken between 400–600 nm, together with a single read taken at emission 525 nm 
(excitation 330 nm). MTIP (126 μM) was added 2 μL at a time and thoroughly mixed before 
each reading. Fluorescence readings were taken after each addition at 37 °C. 16 μL MTIP 
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(126 μM) was added in total to give a final MTIP concentration of 2 μM. The same procedure 
was followed for binding assays with MTIP[61-204], MTIP NTD and MTIP CTD. 
8.8. Fluorescence anisotropy binding assay in a cuvette 
400 μL of d-GMyoA or f-GMyoA peptide (1 μM) was added to a small quartz cuvette and 
the fluorescence anisotropy signal measured at emission 525 nm using excitation 330 nm. 
MTIP (80 μM) was added in 1 μL aliquots, the solution thoroughly mixed and fluorescence 
anisotropy measured each time. A total volume of 10 μL MTIP was added to give a final 
concentration of 2 μM. Measurements were taken at 25 °C. 
8.9. Dansyl intensity inhibition assay 
8.9.1. In a cuvette 
MTIP was incubated with 1 mM DTT at room temperature for 30 min before starting the 
assay. 3 mL d-GMyoA peptide (1 μM) in assay buffer was placed in a cuvette and the 
fluorescence emission scanned between 400–600 nm and a single read taken at emission 
525 nm (excitation 330 nm). 14.4 μL MTIP (250 μM) was added to give a final concentration 
of 1.2 μM, and the fluorescence emission measured again. Inhibitor peptide (15 mM) was 
added in 2 μL additions and fluorescence measured after each addition. A total volume of 
30 μL inhibitor peptide was added to give a final concentration of 150 μM. All readings were 
taken at 37 °C. 
8.9.2. In a 96 well plate 
Assays were carried out in triplicate in the same 96 well microplate, with four separate 
inhibitors able to be tested at the same time in one plate. A multi-channel pipette was used to 
add 150 µL plate assay buffer into wells B–G in rows 12, 9, 6 and 3. 300 µL of Inhibitor 1 
was placed in well A12, Inhibitor 2 in A9, Inhibitor 3 in A6 and Inhibitor 4 in A3.  Doubling 
dilutions using 150 µL of each of these inhibitors was carried out between wells A–G to give 
a concentration range between 1–64 µM. The multi-channel pipette was used to transfer 
50 µL from row 12 into rows 11 and 10, 50 µL from row 9 into rows 8 and 7, 50 µL from 
row 6 into rows 5 and 4, and 50 µL from row 3 into rows 2 and 1 to set up triplicate 
experiments (Figure 95). 50 µL plate assay buffer was added to wells 1–12 of column H 
which were to be used for controls.  
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7000 µL d-GMyoA[791-818] (2.6 µM) was mixed with 7000 µL MTIP (3.2 µM) and 500 µL 
d-GMyoA[791-818] (2.6 µM) was mixed with 500 µL plate assay buffer, and both of these 
solutions were incubated at 37 °C for 10 min along with the plate containing the various 
concentrations of inhibitor. 150 µL of the MTIP (1.6 µM)/d-GMyoA[791-818] (1.3 µM) 
complex was then added to wells A–G of rows 1–12 to give wells containing the preformed 
complex with various concentrations of inhibitor. 150 µL was also added to wells H1–H4 to 
be used as controls. The d-GMyoA[791-818] (1.3 µM) solution mixed with plate assay buffer 
was added (150 µL) to wells H5–H8, and 150 uL buffer was added to H9–H12 to complete 
the control lane. The layout the dansyl intensity assay in a 96 well plate is shown in Figure 
95. The plate was incubated at 37 °C for 30 min before the fluorescence emission was 
scanned between 400–600 nm (excitation 330 nm) and single point readings taken at 
emission 525 nm. Measurements were taken at 37 °C. 
 
Figure 95: Diagram showing the layout of the dansyl intensity inhibition assay in a 96 well plate. 
8.10. Dansyl FRET binding assay in a cuvette 
8.10.1. Background fluorescence of d-peptides – control experiment 
2 mL assay buffer was placed in a cuvette, and the fluorescence emission scanned between 
320–600 nm (excitation 280 nm, cutoff 325 nm), in addition to single point readings being 
taken at 37 °C at emission 320 nm (excitation 280 nm, no cutoff) and 525 nm (excitation 
A B C D E F G H
12
11
10
9
8
7
6
5
4
3
2
1
Inhibitor 1
Inhibitor 2
Inhibitor 3
Inhibitor 4
B
uffer
d-peptide
C
om
plex
223 
 
280 nm, cutoff 325 nm). d-GMyosin peptide (150 µM) was titrated into the buffer in 3 µL 
additions, and fluorescence readings taken each time. 27 µL d-GMyosin peptide was added in 
total to give a final concentration of 2 µM. The readings were taken in triplicate and the mean 
values plotted. A line of best fit was fitted to the data, and used to determine background 
fluorescence values at each concentration point, which was used to correct the FRET binding 
assay data obtained for d-GMyosin peptide binding to MTIP[61-204]. 
8.10.2. Binding assays of d-GMyosin peptides to MTIP[61-204] 
2 mL MTIP[61-204] (1 µM) was placed in a cuvette and the fluorescence emission scanned 
between 320–600 nm (excitation 280nm, cutoff 325 nm), in addition to single point readings 
being taken at 37 °C at emission 320 nm (excitation 280 nm, no cutoff) and 525 nm 
(excitation 280 nm, cutoff 325 nm). d-GMyosin peptide (150 µM) was added in 3 µL 
additions, and the fluorescence measured each time. 27 µL d-GMyosin peptide was added in 
total to give a final concentration of 2 µM. 
8.11. Dansyl FRET inhibition assay of peptidic inhibitors in a 96 well plate 
Assays were carried out in triplicate in the same 96 well microplate, with four separate 
inhibitors able to be tested at the same time in one plate. A multi-channel pipette was used to 
add 150 µL assay buffer into wells B–G in rows 12, 9, 6 and 3. 300 µL of Inhibitor 1 was 
placed in well A12, Inhibitor 2 in A9, Inhibitor 3 in A6 and Inhibitor 4 in A3.  Doubling 
dilutions using 150 µL of each of these inhibitors were carried out between wells A–G to 
give a concentration range between 1–64 µM. The multi-channel pipette was used to transfer 
50 µL from row 12 into rows 11 and 10, 50 µL from row 9 into rows 8 and 7, 50 µL from 
row 6 into rows 5 and 4, and 50 µL from row 3 into rows 2 and 1 to set up triplicate 
experiments (as shown in Figure 95). 50 µL plate assay buffer was added to wells 1–12 of 
column H which were to be used for controls.  
6950 µL d-GMyoA[791-818] (2.6 µM) was mixed with 6950 µL MTIP[61-204] (3.2 µM), 
350 µL d-GMyoA[791-818] (2.6 µM) was mixed with 350 µL plate assay buffer, and 350 µL 
MTIP[61-204] (3.2 µM) was mixed with 350 µL plate assay buffer. Each of these solutions 
was incubated at 37 °C for 10 min along with the plate containing the various concentrations 
of inhibitor. 150 µL of the MTIP[61-204] (1.6 µM)/d-GMyoA[791-818] (1.3 µM) complex 
was then added to wells A–G of rows 1–12 to give wells containing the preformed complex 
with various concentrations of inhibitor. 150 µL was also added to wells H1–H3 to be used as 
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controls. 150 µL of MTIP[61-204] (1.6 µM) mixed with plate assay buffer was added to 
wells H4–H6, and 150 µL d-GMyoA[791-818] (1.3 µM) mixed with assay buffer was added 
to wells H7–H9. 150 µL plate assay buffer was added to H10–H12 to complete the control 
lane. The plate was incubated at 37 °C for 30 min before the fluorescence was scanned 
between 320–600 nm (excitation 280 nm, cutoff 325 nm) and single point readings were 
taken at emission 320 nm (excitation 280nm, no cutoff) and 525 nm (excitation 280 nm, 
cutoff 325 nm). Measurements were taken at 37 °C. 
8.12. Peptide arrays on a cellulose support 
8.12.1. SPOTTM synthesis of peptide arrays on a cellulose support 
This was performed using an Intavis ResPep SL peptide synthesiser with SPOT module, on a 
cellulose membrane containing a PEG linker (M~500 g/mol) as a spacer between the 
membrane support and peptide. The membrane was soaked in DMF for 30 min at room 
temperature before being loaded onto the automated synthesiser. The amino acids (0.5 M) 
were dissolved in NMP and mixed with HBTU (1.1 M in NMP) and DIC (1.1 M in NMP) for 
20 min at room temperature to pre-activate, then they were placed in the machine. The 
membrane was washed with EtOH (2 × 15 s) and dried by extraction (900 s), then 0.22 µL of 
the activated amino acid spotted onto the membrane and allowed to react for 10 min. This 
coupling step was performed twice. The membrane was extracted for 30 s and capped with a 
2% (v/v) Ac2O solution in NMP for 10 min. The membrane was extracted (30 s), washed 
with DMF (8 × 5s) and EtOH (2 × 5 s), extracted (30 s), and the N-terminal Fmoc group 
cleaved using 20% piperidine (v/v) in DMF for 2 × 5 min. The membrane was extracted for 
30 s and washed with DMF (8 × 10 s) and EtOH (2 × 10 s) before being extracted for 900 s. 
This cycle of coupling, capping, wash, deprotection, wash was repeated for each amino acid 
in each peptide sequence. After the final coupling the N-terminal Fmoc was removed and the 
membrane capped with Ac2O to ensure all peptides were acetylated on the N-terminus. The 
membrane was removed from the synthesiser and dried in a vacuum desiccator overnight. 
8.12.2. Deprotection of peptide array side-chains on a cellulose membrane 
20 mL deprotecting solution (95% TFA, 3% TIS, 2% H2O) was added to the membrane and 
rotated slowly at room temperature for 1 h. The solution was drained and the membrane 
washed with 3 × 15 mL DCM, 3 × 15 mL DMF and 3 × 15 mL EtOH before being dried 
under N2 and placed in a vacuum desiccator overnight. 
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8.12.3. Staining with bromophenol blue 
20 mL bromophenol blue (100 µg/mL) was added to the membrane and shaken at room 
temperature for 5 min. The membrane was removed from solution and a photograph taken of 
the blue stained spots. It was destained by shaking with 20% piperidine (v/v) in DMF for 
3 × 5 min at room temperature, then washed with 3 × 15 mL DMF and 3 × 15 mL EtOH 
before drying in a vacuum desiccator overnight. 
8.12.4. Probing the peptide array using Alexa Fluor 488 anti-His6 antibody 
8.12.4.1. Determining the background 
The cellulose membrane was first equilibrated with TBS-Tween by washing with 3 × 15 mL 
TBS-Tween for 10 min each. It was blocked by rotating gently at room temperature with 5% 
skimmed milk in TBS-Tween (15 mL) for 1 h, before being washed again with 
3 × TBS-Tween. 10 mL Alexa Fluor 488 anti-His6 antibody was added (1:1000 dilution in 
TBS-Tween), and the membrane rotated at room temperature for 1 h. The membrane was 
washed with 3 × 15 mL TBS-Tween, before being imaged on the Cy2 channel (excitation 
480±30 nm, emission 530±40 nm) on an Ettan™ DIGE Imager (Amersham Biosciences). 
8.12.4.2. Probing the peptide array with MTIP 
The cellulose membrane was equilibrated with TBS-Tween by washing with 3 × 15 mL 
TBS-Tween for 10 min each. It was blocked by rotating gently at room temperature with 5% 
skimmed milk in TBS-Tween (15 mL) for 1 h, before being washed again with 2 × 15 mL 
TBS-Tween. The membrane was re-equilibrated by washing with 3 × 15 mL assay buffer 
(25 mM Tris, 100 mM NaCl, 1 mM EGTA, 1 mM DTT, pH 8.0), before addition of 10 mL 
MTIP (1 µM or 5 µM in assay buffer), which was rotated at 37 °C for 2 h. After this time, the 
MTIP solution was removed, and the membrane washed with 2 × 15 mL assay buffer and 
3 × 15 mL TBS-Tween. The membrane was probed with 10 mL Alexa Fluor 488 anti-His6 
antibody (1:1000 dilution in TBS-Tween) by rotating at room temperature for 1 h. The 
membrane was washed with 3 × 15 mL TBS-Tween, before being imaged on the Cy2 
channel (excitation 480±30 nm, emission 530±40 nm) on an Ettan™ DIGE Imager 
(Amersham Biosciences). 
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8.12.5. Probing the peptide array using anti-His6 HRP antibody 
8.12.5.1. Determining the background 
The cellulose membrane was equilibrated with TBS-Tween by washing with 3 × 15 mL 
TBS-Tween for 10 min each. It was blocked by rotating gently at room temperature with 5% 
skimmed milk in TBS-Tween (15 mL) for 1 h, before being washed again with 3 × 15 mL 
TBS-Tween. 10 mL anti-His6 HRP antibody was added (1:4000 dilution in TBS-Tween) and 
the membrane was rotated at room temperature for 1 h. The membrane was washed with 
3 × 15 mL TBS-Tween, before being imaged on a Fuji Film imager using Millipore 
chemiluminescence reagents. 
8.12.5.2. Probing the peptide array with MTIP 
The cellulose membrane was equilibrated with TBS-Tween by washing with 3 × 15 mL 
TBS-Tween for 10 min each. It was blocked by rotating gently at room temperature with 5% 
skimmed milk in TBS-Tween (15 mL) for 1 h, before being washed again with 
2 × 15 mL TBS-Tween. The membrane was re-equilibrated by washing with 3 × 15 mL assay 
buffer (25 mM Tris, 100 mM NaCl, 1 mM EGTA, 1 mM DTT, pH 8.0), before addition of 
10 mL MTIP (1 µM or 5 µM in assay buffer) which was rotated at 37 °C for 2 h. After this 
time, the MTIP solution was removed, and the membrane was washed with 2 × 15 mL assay 
buffer and 3 × 15 mL TBS-Tween. The membrane was probed with 10 mL anti-His6 antibody 
(1:4000 dilution in TBS-Tween) by rotating at room temperature for 1 h. The membrane was 
washed with 3 × 15 mL TBS-Tween, before being imaged on a Fuji Film imager using 
Millipore chemiluminescence reagents. 
8.12.6. Stripping the membrane 
After probing and imaging, the membrane was washed with 3 × 15 mL TBS-Tween, then 
rotated with 15 mL stripping solution 1 (62.5 mM Tris, 100 mM β-mercaptoethanol, 2% 
SDS) at 50 °C for 30 min. The stripping solution was removed and the membrane washed 
with 3 × 15 mL TBS-Tween, before being rotated at room temperature for 30 min with 
15 mL stripping solution 2 (50% EtOH, 10% glacial acetic acid in H2O). The membrane was 
then washed with 3 × 15 mL TBS-Tween. 
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8.13. Live parasite invasion assays – Fluorescence Activated Cell Sorting 
method (FACS) 
This assay was carried out by Dr David Moss of NIMR. Briefly, stock parasite cultures of 
P. falciparum were cultured in 2% haematocrit. To generate a synchronous staged parasite 
population, the parasites were first Percoll treated (centrifuged onto a 70% Percoll cushion) 
with the late trophozoite/schizonts (which accumulate at the media/Percoll interface) 
re-cultured for 3–5 hrs, taking smears to assay for merozoite release. Subsequently, cultures 
were Sorbatol treated to remove any remaining schizonts and generate a parasite culture 
staged within 3–5 hrs of invasion. The synchronised culture was grown overnight so the 
parasites matured to trophozoites.  
To set up the FACS assay cultures, parasitemia was first gauged using the FACS. In brief, 
500 µL hydroethidine (HE) fluorescence stain (50 µg/mL in PBS) was placed into a FACS 
tube to which 50 µL of the culture was added and the tube incubated at 37 °C for 20 min. 
Samples were removed and placed on ice in the dark for up to 2 h. HE labelling was detected 
using the FL2 detector (585/42 nm) and parasitemia calculated as a percentage. The FACS 
count for parasitemia was then used to set up an appropriately diluted culture, typically 1% 
parasitemia in 2% haematocrit for a one cycle assay. For each assay a 90 µL culture was 
placed into a well of a 96 well plate, and 10 µL inhibitor added at various concentrations to 
give a final assay volume of 100 µL. The inhibitor stock was diluted using a 10 × stock of 
DMSO media to give final inhibitor concentrations of 125 µM, 250 µM and 500 µM, all in 
media containing 0.5% DMSO.  All assays were carried out in triplicate. 
Plates were incubated at 37 °C for approx 44–48 h i.e. through one invasion cycle to the next 
trophozoite stage prior to reading. Parasitemia was then calculated using the FACS. 
This FACS assay is based on that described by Bergmann-Leither et al.153 
8.14. Circular dichroism spectroscopy 
MTIP was incubated with 1 mM DTT at room temperature for 30 min before starting the 
assay. 3 µM MTIP (350 µL) was placed in a quartz cuvette (with 1 mm path length) in assay 
buffer, and the CD spectrum recorded between 200-300 nm at 25 °C. MyoA or MyoB peptide 
was added to give a final concentration of 9 µM (6.3 µL of a 500 µM stock solution), the 
solution was thoroughly mixed and the CD spectrum of the complex recorded between 
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200-300 nm at 25 °C. The background signal was determined by obtaining a CD spectrum of 
assay buffer only (350 µL). 
8.15. 15N SOFAST-HMQC NMR 
500 µL 15N MTIP[61-204] (300 µM) was placed in an NMR tube in protein NMR buffer 
(20 mM Tris, 50 mM NaCl, 5 mM DTT, pH 7.0) and the SOFAST-HMQC spectra recorded 
at 600 MHz at 25 °C. Peptide (15 mM) was added in 3 µL additions and the spectra recorded 
after each addition. 30 µL was added in total to give a final peptide concentration of 900 µM. 
8.16. Bis-Tris gel electrophoresis 
Gels were poured into 1.0 mm Invitrogen cassettes in the compositions shown in Table 14 
and Table 15. 
Component  Volume (mL)  
30%  Acrylamide  4  
1.25 M Bis-tris (pH 6.7) 2.9  
dH2O  3  
10% Ammonium persulfate (APS)  0.1  
N,N,N',N'-tetramethylethylenediamine (TEMED)  0.004  
Table 14: Components of 12% resolving gel (10 mL) 
Component  Volume (mL)  
30%  Acrylamide  0.333 
1.25 M Bis-tris (pH 6.7) 0.714 
dH2O  1.453 
APS 0.0125 
TEMED 0.002 
Table 15: Components of 4% stacking gel (2.5 mL) 
All protein samples were made up in water and mixed with 4 × NuPAGE LDS sample buffer 
from Invitrogen. They were boiled at 100 °C for 5 min before being loaded onto the gel. 
Invitrogen SeeBlue prestained standard marker was used and electrophoresis run at 200 V in 
MES buffer using an Invitrogen XCell SureLock gel electrophoresis system with a BioRad 
power supply unit. 
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8.17. α-Helix mimetic synthesis 
8.17.1. Synthesis of NH2-Arg-Ar(His)-Lys-OH tripeptide mimetic 
8.17.1.1. Trityl protection of 4-hydroxymethylimidazole 1. 
 
To a stirred solution of 4-hydroxymethylimidazole (1.00 g, 7.43 mmol) and triethylamine 
(2.49 mL, 17.8 mmol) in DMF (5.0 mL) was added a solution of trityl chloride (2.28 g, 
8.17 mmol) in DMF (8.0 mL) at room temperature. The reaction mixture was stirred at room 
temperature for 18 h and resultant white solid recovered by filtration, dissolved in DCM, and 
washed with water (2 × 100 mL) and sat. NaCl(aq.) (2 × 100 mL), before drying over Na2SO4 
and filtering. The solvent was removed under vacuum to give 1 as a white solid (1.68 g, 
66%). The product was found to be pure by TLC analysis. Rf = 0.14 (DCM–MeOH, 19:1); 
δH/ppm (400 MHz, CDCl3), 7.52 (1H, s, H3), 7.37 (9H, m, trityl), 7.16 (6H, m, trityl), 6.82 
(1H, s, H2), 4.62 (2H, s, H1); δC/ppm (100 MHz, CDCl3), 142.3, 140.9, 139.1, 129.8, 128.1, 
118.8, 58.8; HRMS (ESI) found 363.1467 (C23H20N2NaO, [M+Na]+ requires 363.1473). 
8.17.1.2. Synthesis of protected Aryl(His) monomer (3-(hydroxymethyl-N-(trityl)-
imidazole)-4-nitro-benzoic acid) 2. 
 
This reaction was carried out under a N2 atmosphere. NaHMDS (5.88 mL of a 1 M solution 
in THF, 5.88 mmol) was added to 1 (1.00 g, 2.94 mmol), and the solution stirred for 10 min 
at room temperature. 3-fluoro-4-nitro-benzoic acid (453 mg, 2.45 mmol) was suspended in 
2 mL dry THF, and added dropwise to the reaction flask. The reaction mixture was stirred at 
room temperature for 18 h, after which time the solvent was removed under vacuum and the 
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resulting dark brown solid was washed with 0.1 M HCl(aq.) (3 × 20 mL), Et2O (3 × 20 mL), 
hexane (3 × 20 mL) and EtOAc (3 × 20 mL). All traces of solvent were removed under 
vacuum to give 2 as a pale yellow solid (1.06 g, 85%). The product was found to be pure by 
TLC analysis. Rf = 0.28 (DCM–MeOH–AcOH, 19:1:0.2); δH/ppm (400 MHz, d-DMSO), 
7.85 (1H, s, H6), 7.74 (1H, d, J = 8.3, H2), 7.53 (1H, d, J = 8.3, H1), 7.42 (1H, s, H3), 7.38 
(9H, m, trityl), 7.06 (6H, m, trityl), 7.00 (1H, s, H5), 5.14 (2H, s, H4); δC/ppm (100 MHz, 
d-DMSO), 167.2, 150.8, 142.5, 141.3, 139.0, 136.2, 129.7, 128.7, 128.5, 124.7, 121.8, 116.9, 
75.2, 66.0; HRMS (ESI) found 506.1724 (C30H24N3O5, [M+H]+ requires 506.1716). 
8.17.1.3. Synthesis of NO2-Aryl[His(Trt)]-Lys(Boc)-OtBu 3. 
 
To a stirred suspension of 2 (100 mg, 0.2 mmol) in 1 mL DMF was added H-Lys(Boc)-OtBu 
(80 mg, 0.24 mmol), followed by HATU (90 mg, 0.24 mmol) and 2,6-lutidine (115 µL, 
1 mmol). The reaction was stirred at room temperature for 18 h, then diluted with EtOAc 
(50 mL) and washed with 0.1M HCl(aq.) (2 × 50 mL) and sat. NaHCO3(aq.) (3 × 50 mL) before 
drying over Na2SO4 and filtering. The solvent was removed under vacuum to give 3 as a pale 
yellow solid (134 mg, 86%) which was pure by TLC analysis. Rf = 0.33 (DCM–MeOH, 
19:1); δH/ppm (400 MHz, CDCl3), 8.11 (1H, s, HA6), 7.87 (1H, d, J = 8.3, HAr), 7.68 (1H, s, 
HAr), 7.55 (2H, m, HAr, HB1), 7.37 (9H, m, trityl), 7.13 (6H, m, trityl), 7.04 (1H, s, HA5), 
5.38 (2H, s, HA4), 4.73 (1H, br m, HB7), 4.63 (1H, br m, HB2), 3.13 (2H, br m, HB6), 1.92 
(2H, br m, HB3), 1.46 (13H, m, HB4, HB5, HB8 or HB9)  1.41 (9H, s, HB8 or HB9); δC/ppm 
(100 MHz, CDCl3), 171.5, 165.2, 156.1, 151.7, 146.9, 141.9, 139.0, 138.8, 135.3, 129.7, 
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128.3, 128.2, 127.9, 127.2, 125.6, 122.1, 119.4, 115.8, 82.4, 79.1, 66.0, 53.3, 40.1, 32.1, 29.6, 
28.4, 28.0, 22.5;  HRMS (ESI) found 790.3814 (C45H52N5O8, [M+H]+ requires 790.3816). 
8.17.1.4. Synthesis of NH2-Aryl[His(Trt)]-Lys(Boc)-OtBu 4. 
 
To a stirred solution of 3 (60 mg, 0.08 mmol) in acetone-water (5:1, 1.37 mL) was slowly 
added Zn nanopowder (50 mg, 0.8 mmol), followed by NH4Cl (61 mg, 1.14 mmol), and the 
resulting suspension was stirred vigorously at room temperature for 20 min and then filtered. 
The filtrate was diluted with EtOAc (80 mL), washed with sat. NaHCO3 (3 × 50 mL), dried 
over Na2SO4 and filtered. The solvent was removed under vacuum to give 4 as a pale yellow 
solid (48 mg, 83%), which was found to be pure by TLC analysis. Rf = 0.16 (DCM–MeOH, 
19:1); δH/ppm (400 MHz, CDCl3), 7.68 (1H, s, HAr), 7.51 (1H, s, HAr), 7.38 (9H, m, trityl), 
7.31 (2H, m), 7.14 (6H, m, trityl), 6.94 (1H, s, HAr), 6.68, (1H, m), 5.12 (2H, s, HA4), 4.67 
(2H, m, HB2, HB7), 3.12 (2H, m, HB6), 1.93 (1H, m, HB3), 1.78 (1H, m, HB3), 1.49 (11H, 
m), 1.43 (11H, m); δC/ppm (100 MHz, CDCl3),172.1, 166.7, 156.0, 146.9, 145.4, 142.0, 
141.0, 139.0, 136.3, 129.7, 128.2, 128.1, 127.9, 127.2, 123.3, 121.1, 113.6, 112.8, 82.0, 79.0, 
65.1, 52.7, 40.3, 32.7, 29.6, 28.7, 28.4, 22.4; HRMS (ESI) found 760.4051 (C45H54N5O6, 
[M+H]+ requires 760.4074). 
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8.17.1.5. Synthesis of BocNH-Arg(Mtr)-Ar[His(Trt)]-Lys(Boc)-OtBu 5. 
 
This reaction was performed under a N2 atmosphere. To a stirred solution of 
BocNH-Arg(Mtr)-OH (77 mg, 0.16 mmol) in DMF (800 µL) was added HOAt (38 mg, 
0.28 mmol), EDCI (33 mg, 0.17 mmol), and 2,6-lutidine (93 µL, 0.80 mmol). The reaction 
mixture was stirred at room temperature for 10 min before a solution of 4 (100 mg, 
0.13 mmol) in DMF (500 µL) was added. The flask previously containing the solution of 4 
was rinsed with 2 × 100 µL DMF, which was also added to the reaction mixture to give a 
total DMF volume of 1.5 mL. The reaction was stirred at room temperature for 40 h, after 
which time the mixture was diluted with EtOAc (200 mL), and washed with 0.1 M HCl(aq.) 
(3 × 100 mL) and sat. NaHCO3(aq.) (3 × 100 mL), before drying over Na2SO4 and filtering. 
The solvent was removed under vacuum to give a crude yellow oil, which was purified via 
column chromatography on an Isolera machine, using DCM with a MeOH gradient of 0–6% 
over 20 column volumes, to yield 5 as an off-white solid (50 mg, 31%). Rf = 0.16 (DCM–
MeOH, 19:1); δH/ppm (400 MHz, CDCl3), 8.33 (1H, m, HAr), 7.57 (1H, m, HAr), 7.42 (7H, 
m), 7.37 (3H, m, trityl), 7.12 (6H, m, trityl), 7.03 (1H, m), 6.81 (1H, m), 6.52 (1H, s, HA9), 
6.26 (2H, m), 5.17 (2H, s, HB4), 4.66 (1H, m), 4.59 (1H, m), 4.44 (1H, m), 3.83 (3H, s, 
HA10), 3.12 (4H, m), 2.71 (3H, s, Mtr HMe), 2.63 (3H, s, Mtr HMe), 2.20 (3H, s, Mtr HMe), 
1.96 (4H, m), 1.77 (4H, m), 1.51 (11H, m), 1.43 (18H, s); δC/ppm (100 MHz, CDCl3), 171.7, 
158.3, 158.2, 156.4, 156.0, 146.9, 138.8, 138.6, 137.3, 136.5, 134.1, 129.7, 129.5, 128.9, 
128.6, 128.2, 127.9, 127.3, 124.5, 121.1, 120.6, 111.6, 82.4, 79.9, 60.4, 55.4, 53.0, 52.7, 40.2, 
233 
 
32.7, 32.4, 30.9, 30.6, 29.7, 28.4, 28.3, 28.1, 24.9, 24.1, 22.4, 21.0, 19.6, 18.3, 14.2, 11.9, 1.0; 
m/z (ES), 1229 ([M+H]+). 
8.17.1.6. Synthesis of NH2-Arg-Ar(His)-Lys-OH tripeptide mimetic 6. 
 
300 µL deprotecting solution (90% TFA, 5% thioanisole, 2.5% TIS, 2.5% H2O) was added to 
5 (42 mg, 0.03 mmol), and the solution was stirred at room temperature for 1.5 h, after which 
time an off-white precipitate was observed in the reaction flask. The remaining deprotecting 
solution was evaporated by flushing with N2, and the resultant solid was washed with 
4 × 2 mL cold TBME (stored at –20 °C). Solvent traces were removed under vacuum before 
the product was purified by LC-MS, using a 5–98% MeOH gradient in H2O over 15 min, to 
give 6 as a white solid (13 mg, 72%). Rt = 2.48 min; δH/ppm (400 MHz, D2O), 8.66 (1H, s, 
HB6), 7.67 (1H, d, J = 8.3 Hz, HB1/B2), 7.51 (1H, s, HB5), 7.46 (1H, s, HB3), 7.40 (1H, d, 
J = 8.3 Hz, HB1/B2), 5.26 (2H, s, HB4), 4.45 (1H, m, HC2), 4.18 (1H, t, J = 13 Hz, HA1), 
3.06 (2H, t, J = 14 Hz, HC6), 2.88 (2H, m, HA4), 1.90 (3H, m, 2HA2, HC3), 1.81 (1H, m, 
HC3), 1.60 (4H, m, 2HA3, 2HC4), 1.42 (2H, m, HC5); δC/ppm (100 MHz, D2O), 175.9, 
169.8, 168.5, 165.7, 149.5, 134.5, 131.9, 128.3, 128.0, 124.6, 121.0, 118.5, 112.2, 60.2, 53.4, 
53.1, 40.3, 39.1, 29.9, 28.0, 26.2, 23.4, 22.3; HRMS (ESI) found 518.2841 (C23H36N9O5, 
[M+H]+ requires 518.2839). 
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8.17.2. Synthesis of NO2-Ar(His)-Lys-OH dipeptide mimetic 7. 
 
350 µL deprotecting solution (95% TFA, 2.5% TIS, 2.5% H2O) was added to 3 (24 mg, 
0.03 mmol), and the solution was stirred at room temperature for 1 h, after which time a 
precipitate was observed in the reaction flask. The remaining deprotecting solution was 
evaporated by flushing with N2, and the resultant solid was washed with 4 × 2 mL cold 
TBME (stored at –20 °C). Solvent traces were removed under vacuum before the crude 
product was purified using LC-MS, with a 5–98% MeOH gradient in H2O over 15 min, to 
give 7 as a bright yellow solid (8.0 mg, 67%). Rt = 4.07 min; δH/ppm (400 MHz, D2O), 8.56 
(1H, s, HA6), 7.92 (1H, d, J = 8.4 Hz, HA1/A2), 7.66 (1H, s, HA3), 7.50 (1H, s, HA5), 7.44 
(1H, d, J = 8.4 Hz, HA1/A2), 5.35 (2H, s, HA4), 4.27 (1H, m, HB2), 2.90 (2H, t, J = 7.5 Hz, 
HB6), 1.83 (1H, m, HB3), 1.74 (1H, m, HB3), 1.61 (2H, m, HB5), 1.38 (2H, m, HB4); 
δC/ppm (100 MHz, D2O), 178.3, 169.0, 168.1, 150.6, 141.3, 139.8, 134.8, 126.3, 120.7, 
118.8, 115.2, 61.5, 55.6, 39.2, 30.9, 26.3, 22.3; HRMS (ESI) found 392.1564 (C17H22N5O6, 
[M+H]+ requires 392.1570). 
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8.17.3. Synthesis of NH2-Ar(His)-Lys-OH dipeptide mimetic 8. 
 
350 µL deprotecting solution (95% TFA, 2.5% TIS, 2.5% H2O) was added to 4 (28 mg, 
0.04 mmol), and the solution was stirred at room temperature for 1.5 h, after which time a 
precipitate was observed in the reaction flask. The remaining deprotecting solution was 
evaporated by flushing with N2, and the resultant solid was washed with 4 × 2 mL cold 
TBME (stored at –20 °C). Solvent traces were removed under vacuum before the crude 
product was purified using LC-MS, with a 5–98% MeOH gradient in H2O over 15 min, to 
give 8 as a pale orange solid (9.0 mg, 69%). Rt = 2.5 min; δH/ppm (400 MHz, D2O), 8.98 
(1H, s, HA6), 7.73 (1H, s, HA5), 7.57 (1H, s, HA3), 7.48 (1H, d, J = 8.4 Hz, HA1/A2), 6.87 
(1H, d, J = 8.4 Hz, HA1/A2), 5.31 (2H, s, HA4), 4.62 (1H, m, HB2), 2.96 (2H, t, J = 14.6 Hz, 
HB6), 2.05 (1H, m, HB3), 1.93 (1H, m, HB3), 1.76 (2H, m, HB5), 1.59 (2H, m, HB4); 
δC/ppm (100 MHz, D2O), 178.2, 169.6, 162.7, 147.8, 145.0, 140.1, 134.4, 122.4, 118.3, 
115.9, 112.7, 60.3, 54.7, 39.2, 30.8, 26.3, 22.3; HRMS (ESI) found 362.1821 (C17H24N5O4, 
[M+H]+ requires 362.1828). 
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8.17.4. Synthesis of AcNH-Ar(His)-Lys-OH dipeptide mimetic 
8.17.4.1. Synthesis of AcNH-Ar[His(Trt)]-Lys(Boc)-OtBu 9. 
 
To a stirred solution of 4 (24 mg, 0.03 mmol) in DCM (500 µL), were added pyridine 
(5.1 µL, 0.06 mmol) and acetic anhydride (6.0 µL, 0.06 mmol). The reaction mixture was 
stirred at room temperature for 5 h, then diluted with DCM (75 mL) and washed with 0.1 M 
HCl(aq.) (3 × 100 mL), H2O (1 × 100 mL) and sat. NaHCO3(aq.) (3 × 100 mL), before being 
dried over Na2SO4 and filtered. The solvent was removed under vacuum to isolate 9 as a 
yellow oil, which was found to be pure by TLC analysis (17 mg, 68%). Rf = 0.4 (DCM–
MeOH, 32:1); δH/ppm (400 MHz, CDCl3), 8.41 (1H, d, J = 8.3 Hz, HAr), 7.56 (1H, s, HAr), 
7.42 (8H, m), 7.31 (3H, m), 7.10 (6H, m, trityl), 7.03 (1H, s, HAr), 6.82 (1H, d J = 7.2 Hz), 
5.25 (2H, s, HA4), 4.67 (1H, m, HB2), 4.60 (1H, m, HB7), 3.13 (2H, m, HB6), 2.37 (3H, s, 
HA11), 1.96 (1H, m, HB3), 1.80 (1H, m, HB3), 1.51 (11H, m), 1.43 (11H, m); δC/ppm 
(100 MHz, CDCl3), 171.8, 169.1, 166.2, 156.0, 146.9, 146.8, 141.6, 138.8, 132.8, 129.6, 
128.4, 128.3, 127.9, 127.2, 121.3, 120.7, 119.7, 113.9, 82.3, 52.9, 40.2, 36.4, 32.5, 30.9, 29.6, 
28.4, 28.0, 24.9, 23.6, 22.4, 14.1; HRMS (ESI) found 802.4185 (C47H56N5O7, [M+H]+ 
requires 802.4180). 
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8.17.4.2. Synthesis of AcNH-Ar(His)-Lys-OH dipeptide mimetic 10. 
 
350 µL deprotecting solution (95% TFA, 2.5% TIS, 2.5% H2O) was added to 9 (17 mg, 
0.02 mmol), and the solution stirred at room temperature for 1.5 h, after which time a 
precipitate was observed in the reaction flask. The remaining deprotecting solution was 
evaporated by flushing with N2, and the resultant solid was washed with 4 × 2 mL cold 
TBME (stored at –20 °C). Solvent traces were removed under vacuum, before the crude 
product was purified using LC-MS, with a 5–98% MeOH gradient in H2O over 15 min, to 
give 10 as a white solid (6.0 mg, 70%). Rt = 2.96 min; δH/ppm (400 MHz, D2O), 8.55 (1H, s, 
HA6), 7.63 (1H, d, J = 8.3 Hz, HA1/A2), 7.48 (1H, s, HA5), 7.44 (1H, s, HA3), 7.38 (1H, d, 
J = 8.3 Hz, HA1/A2), 5.23 (2H, s, HA4), 4.26 (1H, m, HB2), 2.89 (2H, t, J = 15.2 Hz, HB6), 
2.06 (3H, s, HA8), 1.82 (1H, m, HB3), 1.73 (1H, m, HB3), 1.61 (2H, m, HB5), 1.37 (2H, m, 
HB4); δC/ppm (100 MHz, D2O), 173.1, 169.3, 163.2, 149.2, 131.4, 130.0, 123.8, 120.9, 
117.8, 114.9, 113.4, 46.6, 39.2, 38.7, 31.1, 26.3, 22.7, 22.3, 8.2; HRMS (ESI) found 
404.1928 (C19H26N5O5, [M+H]+ requires 404.1934). 
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8.17.5. Synthesis of AcNH-Arg-Ar(His)-Lys-NH2 capped tripeptide mimetic 
8.17.5.1. Synthesis of NO2-Ar[His(Trt)]-Lys(Boc)-NH2 11. 
 
To a stirred suspension of 2 (200 mg, 0.40 mmol) in DMF (2 mL) was added 
NH2-Lys(Boc)-NH2 (134 mg, 0.47 mmol), followed by HATU (181 mg, 0.47 mmol) and 
2,6-lutidine (230 µL, 1.98 mmol). The reaction mixture was stirred at room temperature for 
19 h and then diluted in EtOAc (200 mL), washed with 0.1 M HCl(aq.) (3 × 100 mL) and 
sat. NaHCO3(aq.) (3 × 100 mL), before drying over Na2SO4 and filtering. The solvent was 
removed under vacuum to give 11 as a yellow solid which was pure by TLC analysis 
(251 mg, 87%). Rf = 0.32 (DCM-MeOH, 19:1); δH/ppm (400 MHz, CDCl3), 8.14 (1H, d, 
J = 6.8 Hz, HB1), 7.95 (1H, s, HAr), 7.77 (1H, d, J = 8.3 Hz, HA1/A2), 7.49 (1H, d, 
J = 8.3 Hz, HA1/A2), 7.45 (1H, s, HAr), 7.35 (9H, m, trityl), 7.12 (6H, m, trityl), 7.01 (1H, s, 
HAr), 6.76 (1H, s, HB9), 6.13 (1H, s, HB9), 5.25 (2H, s, HA4), 4.84 (1H, m, HB7), 4.65 (1H, 
m, HB2), 3.10 (2H, m, HB6), 1.96 (1H, m, HB3), 1.85 (1H, m, HB3), 1.47 (4H, m, HB5, 
HB4), 1.40 (9H, s, HB8); δC/ppm (100 MHz, CDCl3), 174.5, 165.6 151.6, 146.9, 141.9, 
138.7, 135.4, 129.7, 128.3, 128.2, 127.9, 127.2, 125.4, 121.8, 119.8, 115.9, 66.1, 60.4, 53.7, 
39.8, 31.3, 29.5, 28.4, 22.7, 21.1, 14.2; HRMS (ESI) found 733.3342 (C41H45N6O7, [M+H]+ 
requires 733.3350). 
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8.17.5.2. Synthesis of NH2-Ar[His(Trt)]-Lys(Boc)-NH2 12. 
 
To a stirred solution of 11 (132 mg, 0.18 mmol) in acetone-water (5:1, 3 mL) were slowly 
added Zn nanopowder (118 mg, 1.80 mmol) and NH4Cl (145 mg, 2.70 mmol), and the 
resulting suspension stirred vigorously at room temperature for 20 min, and then filtered. The 
filtrate was diluted with EtOAc (100 mL) and washed with sat. NaHCO3(aq.) (3 × 100 mL) 
before drying over Na2SO4, and filtering. The solvent was removed under vacuum to give 12 
as a yellow oil (105 mg, 83%) which was pure by TLC analysis. Rf = 0.07 (DCM-MeOH, 
19:1); δH/ppm (400 MHz, CDCl3), 7.60 (1H, s, HAr), 7.55 (1H, s, HAr), 7.38 (10H, m), 7.13 
(6H, m, trityl), 6.93 (2H, m), 6.68 (1H, d, J = 8.2 Hz, HA1/A2), 6.55 (1H, s, HB9), 5.54 (1H, 
s, HB9), 5.11 (2H, s, HA4), 4.70 (1H, m, HB7), 4.63 (1H, m, HB2), 3.13 (2H, m, HB6), 1.99 
(1H, m, HB3), 1.81 (1H, m, HB3), 1.54 (2H, m, HB5), 1.43 (11H, m); δC/ppm (100 MHz, 
CDCl3), 174.7, 167.5, 146.9, 145.3, 142.1, 141.1, 139.0, 136.4, 129.7, 128.2, 128.1, 127.9, 
127.2, 122.7, 121.5, 121.1, 113.7, 112.7, 65.0, 53.0, 40.0, 31.6, 29.6, 28.4, 22.8; HRMS (ESI) 
found 703.3614 (C41H47N6O5 [M+H]+ requires 703.3608). 
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8.17.5.3. Synthesis of AcNH-Arg(Pmc)-Ar[His(Trt)]-Lys(Boc)-NH2 13. 
 
This reaction was carried out under a N2 atmosphere. To a stirred solution of 
AcNH-Arg(Pmc)-OH (40 mg, 0.08 mmol) in DMF (400 µL) were added HOAt (20 mg, 
0.14 mmol), EDCI (17 mg, 0.09 mmol) and 2,6-lutidine (49 µL, 0.42 mmol), and the mixture 
was stirred at room temperature for 10 min before a solution of 12 (48 mg, 0.07 mmol) was 
added in DMF (500 µL). The reaction was stirred at room temperature for 24 h and then 
monitored by LC-MS which showed some starting material remaining. Another equivalent of 
Ac-Arg(Pmc)-OH (33 mg, 0.07 mmol) was added, along with HOAt (19 mg, 0.14 mmol), 
EDCI (14 mg, 0.07 mmol) and 2,6-lutidine (24 µL, 0.20 mmol), and the reaction was stirred 
at room temperature for another 20 h, before being diluted with EtOAc (100 mL), washed 
with 0.1 M HCl(aq.) (3 × 100 mL) and sat. NaHCO3(aq.) (3 × 100 mL), dried over Na2SO4 and 
filtered. The solvent was removed under vacuum to give a crude yellow oil that was purified 
via column chromatography on an Isolera machine, using DCM with a MeOH gradient of 0–
10% over 30 column volumes, to yield 13 as an off-white solid (9.0 mg, 11%). Rf = 0.07 
(DCM-MeOH, 19:1); δH/ppm (400 MHz, CDCl3), 8.93 (1H, s), 8.09 (1H, s, HAr), 7.49 (1H, 
s, HAr), 7.47 (1H, s, HAr), 7.31 (10H, m, trityl, HAr), 7.07 (6H, m, trityl), 6.97 (1H, s), 6.44 
(1H, s), 6.30 (1H, s), 4.98 (2H, s, HB4), 4.87 (1H, m, HC7), 4.55 (2H, m, HA1, HC2), 3.07 
(4H, m, HA4, HC6), 2.58 (2H, m, HA12/A13), 2.52 (3H, s, Pmf HMe), 2.51 (3H, s, Pmf 
HMe), 2.16 (4H, m), 2.07 (3H, s, Pmf HMe), 1.90 (3H, s, HA15), 1.77 (2H, m, HA12/A13), 
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1.56 (4H, m), 1.38 (11H, m), 1.28 (6H, s, HA10, HA11); δC/ppm (100 MHz, CDCl3), 156.2, 
153.5, 142.0, 141.8, 139.3, 135.4, 134.8, 133.5, 129.6, 128.9, 128.4, 128.3, 128.2, 127.9, 
127.2, 123.9, 121.9, 117.9, 73.6, 49.4, 40.5, 40.0, 35.4, 32.8, 31.9, 31.4, 30.0, 29.7, 29.6, 
29.5, 29.3, 29.2, 29.1, 28.4, 27.0, 26.9, 26.8, 25.3, 24.9, 22.9, 22.7, 21.4, 18.5, 17.4, 14.1, 
12.1; m/z (ES), 1167 ([M+H]+). 
8.17.5.4. Synthesis of AcNH-Arg-Ar(His)-Lys-NH2 capped tripeptide mimetic 14. 
 
350 µL deprotecting solution (90% TFA, 2.5% TIS, 2.5% H2O, 5% thioanisole) was added to 
13 (9.0 mg, 0.01 mmol) and stirred at room temperature for 1 h, during which time the 
solution turned bright yellow and there was an immediate precipitate. The deprotecting 
solution was then evaporated under N2, and the dark orange solid washed with 4 × 2 mL cold 
TBME (stored at –20 °C). Solvent traces were removed under vacuum before the product was 
purified by LC-MS, using a 5–98% MeOH gradient in H2O over 15 min, to give 14 as a white 
solid (3.0 mg, 70%). Rt = 2.70 min; δH/ppm (400 MHz, D2O), 8.54 (1H, s, HB6), 7.63 (1H, d, 
J = 8.3 Hz, HB1/B2), 7.48 (1H, s, HB3), 7.47 (1H, s, HB5), 7.41 (1H, d, J = 8.3 Hz, 
HB1/B2), 5.22 (2H, s, HB4), 4.38 (1H, m, HC2), 4.31 (1H, m, HA1), 3.09 (2H, t, 
J = 14.3 Hz, HA4), 2.91 (2H, t, J = 15.3 Hz, HC6), 1.89 (3H, s, HA8), 1.82 (3H, m, HA2, 
HC3), 1.62 (5H, m, 2HA3, 2HC5, 1HA2/C3), 1.45 (2H, m, HC4); δC/ppm (100 MHz, D2O), 
176.8, 174.4, 172.9, 170.3, 169.9, 156.7, 149.8, 134.8, 131.7, 129.0, 124.6, 121.1, 118.5, 
112.7, 61.0, 54.2. 54.1, 40.5, 39.2, 30.4, 27.9, 26.3, 24.3, 22.3, 21.5; HRMS (ESI) found 
559.3105 (C25H39N10O5 [M+H]+ requires 559.3105). 
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8.17.6. Synthesis of NO2-Ar(His)-Lys-NH2 capped dipeptide mimetic 15. 
 
350 µL deprotecting solution (95% TFA, 2.5% TIS, 2.5% H2O) was added to 11 (23 mg, 
0.03 mmol) and stirred at room temperature for 1 h, during which time the solution turned 
bright yellow with an immediate precipitate. The deprotecting solution was then evaporated 
under N2 and the solid washed with 4 × 2 mL cold TBME (stored at –20 °C). Solvent traces 
were removed under vacuum before the product was purified using LC-MS, with a 5–98% 
MeOH gradient in H2O over 15 min, to give 15 as a bright yellow solid (8.0 mg, 67%). Rt = 
3.4 min; δH/ppm (400 MHz, D2O), 8.63 (1H, s, HA6), 7.92 (1H, d, J = 8.4 Hz, HA1/A2), 7.64 
(1H, s, HA3), 7.51 (1H, s, HA5), 7.44 (1H, d, J = 8.4 Hz, HA1/A2), 5.34 (2H, s, HA4), 4.38 
(1H, m, HB2), 2.90 (2H, t, J = 15.3 Hz, HB6), 1.82 (2H, m, HB3), 1.62 (2H, m, HB5), 1.43 
(2H, m, HB4); δC/ppm (100 MHz, D2O), 176.5, 168.6, 150.5, 150.0, 141.4, 139.0, 134.7, 
126.2, 120.6, 118.7, 115.2, 61.4, 54.3, 39.1, 30.3, 26.3, 22.2; HRMS (ESI) found 391.1750 
(C17H23N6O5 [M+H]+ requires 391.1730). 
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8.17.7. Synthesis of NH2-Ar(His)-Lys-NH2 capped dipeptide mimetic 16. 
 
350 µL deprotecting solution (95% TFA, 2.5% TIS, 2.5% H2O) was added to 12 (24 mg, 
0.03 mmol) and the reaction stirred at room temperature for 1 h, during which time there was 
an immediate yellow precipitate. The deprotecting solution was then evaporated under N2 and 
the solid washed with 4 × 2 mL cold TBME (stored at –20 °C). Solvent traces were removed 
under vacuum before the product was purified by LC-MS, using a 5–98% MeOH gradient in 
H2O over 15 min, to give 16 as a yellow solid (2.0 mg, 17%). Rt = 2.1 min; δH/ppm 
(400 MHz, D2O), 8.62 (1H, s, HA6), 7.48 (1H, s, HA5), 7.35 (1H, s, HA3), 7.30 (1H, d, 
J = 8.2 Hz, HA1/A2), 6.81 (1H, d, J = 8.2 Hz, HA1/A2), 5.20 (2H, s, HA4), 4.34 (1H, m, 
HB2), 2.89 (2H, t, J = 15.3 Hz, HB6), 1.81 (2H, m, HB3), 1.61 (2H, m, HB5), 1.42 (2H, m, 
HB4); δC/ppm (100 MHz, D2O), 177.2, 170.2, 144.9, 140.9, 134.4, 128.5, 122.9, 122.6, 
118.3, 115.5, 112.8, 60.3, 54.0, 39.2, 30.4, 26.3, 22.3; HRMS (ESI) found 361.1983 
(C17H25N6O3 [M+H]+ requires 361.1988). 
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8.17.8. Synthesis of AcNH-Ar(His)-Lys-NH2 capped dipeptide mimetic 
8.17.8.1. Synthesis of AcNH-Ar[His(Trt)]-Lys(Boc)-NH2 17. 
 
To a stirred solution of 12 (24 mg, 0.03 mmol) in DCM (500 µL) were added pyridine 
(5.5 µL, 0.07 mmol) and acetic anhydride (6.5 µL, 0.07 mmol). The reaction was stirred at 
room temperature for 2 h, diluted with DCM (100 mL) and washed with 0.1M HCl(aq.) 
(3 × 100 mL) and sat. NaHCO3(aq.) (3 × 100 mL) before drying over Na2SO4 and filtering. 
The solvent was removed under vacuum to yield 17 as a yellow solid (13 mg, 52%) which 
was pure by TLC analysis. Rf = 0.41 (DCM-MeOH, 32:1); δH/ppm (400 MHz, CDCl3), 8.58 
(1H, s), 8.43 (1H, d, J = 8.3 Hz, HA1/A2), 7.62 (1H, s), 7.49 (1H, s), 7.45 (1H, d, J = 8.3 Hz, 
HA1/A2), 7.36 (10H, m, trityl, HB1), 7.11 (6H, m, trityl), 6.88 (1H, s, HA5), 6.64 (1H, s, 
HB9), 5.75 (1H, s, HB9), 5.07 (2H, s, HA4), 4.80 (1H, m, HB7), 4.64 (1H, m, HB2), 3.11 
(2H, m, HB6), 2.19 (3H, s, HA11), 1.97 (1H, m, HB3), 1.81 (1H, m, HB3), 1.52 (2H, m, 
HB5), 1.42 (11H, m, 2HB4, 9HB8); δC/ppm (100 MHz, CDCl3), 174.2, 168.9, 166.9, 146.8, 
142.0, 139.2, 135.8, 132.8, 129.7, 128.3, 128.2, 127.9, 127.2, 121.3, 121.1, 119.3, 114.1, 
75.7, 66.4, 53.1, 39.9, 31.6, 31.0, 29.6, 28.4, 24.9, 22.7; HRMS (ESI) found 745.3726 
(C43H49N6O6 [M+H]+ requires 745.3714). 
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8.17.8.2. Synthesis of AcNH-Ar(His)-Lys-NH2 capped dipeptide mimetic 18. 
 
350 µL deprotecting solution (95% TFA, 2.5% TIS, 2.5% H2O) was added to 17 (13 mg, 
0.02 mmol) and stirred at room temperature for 1 h, during which time the solution turned 
bright yellow with an immediate precipitate. The deprotecting solution was evaporated under 
N2 and the solid washed with 4 × 2 mL cold TBME (stored at –20 °C). Solvent traces were 
removed under vacuum before the crude product was purified by LC-MS, using a 5–98% 
MeOH gradient in H2O over 15 min, to give 18 as an off-white solid (6.0 mg, 86%). 
Rt = 2.9 min; δH/ppm (400 MHz, D2O), 8.59 (1H, s, HA6), 7.65 (1H, d, J = 8.3 Hz, HA1/A2), 
7.46 (1H, s, HA3), 7.45 (1H, s, HA5), 7.39 (1H, d, J = 8.3 Hz, HA1/A2), 5.22 (2H, s, HA4), 
4.36 (1H, m, HB2), 2.89 (2H, t, J = 15.2 Hz, HB6), 2.06 (3H, s, HA8), 1.82 (2H, m, HB3), 
1.62 (2H, m, HB5), 1.43 (2H, m, HB4); δC/ppm (100 MHz, D2O), 176.9, 173.2, 169.8, 149.3, 
134.6, 131.1, 130.1, 128.3, 124.5, 121.4, 118.5, 113.3, 60.9, 54.1, 39.2, 30.4, 26.3, 22.7, 22.3; 
HRMS (ESI) found 403.2097 (C19H27N6O4 [M+H]+ requires 403.2094). 
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8.17.9. Synthesis of AcNH-Ala-Ar(His)-Lys-NH2 tripeptide mimetic 
8.17.9.1. Synthesis of AcNH-Ala-Ar[His(Trt)]-Lys(Boc)-NH2 19. 
 
This reaction was carried out under a N2 atmosphere. To a stirred solution of AcNH-Ala-OH 
(7.0 mg, 0.06 mmol) in DMF (400 µL) were added HOAt (13 mg, 0.10 mmol), EDCI (11 mg, 
0.06 mmol) and 2,6-lutidine (32 µL, 0.28 mmol) and the mixture was stirred at room 
temperature for 10 min before a solution of 12 (32 mg, 0.05 mmol) in DMF (450 µL) was 
added. The reaction was stirred at room temperature for 17 h and monitored by LC-MS which 
indicated there was still starting material remaining. Another equivalent of Ac-Ala-OH 
(6 mg, 0.05 mmol) was added, together with HOAt (12 mg, 0.09 mmol), EDCI (10 mg, 
0.05 mmol) and 2,6-lutidine (21 µL, 0.18 mmol) and the reaction was stirred for a further 
24 h before it was diluted with EtOAc (100 mL), washed with 0.1 M HCl(aq.) (3 × 100 mL) 
and sat. NaHCO3(aq.) (3 × 100 mL), dried over Na2SO4 and filtered. The solvent was removed 
under vacuum to give a crude yellow oil (10 mg, 27%). The product was difficult to separate 
from the remaining starting material, so was retained as a mixture for the next step (Section 
8.17.10). Rf = 0.38 (DCM-MeOH, 9:1); δH/ppm (400 MHz, CDCl3), 8.99 (1H, s, HAr/Am), 
8.35 (1H, m, HB1/B2), 8.03 (1H, s, HAr/Am), 7.59 (1H, s, HAr/Am), 7.46 (1H, m, HB1/B2), 
7.35 (10H, m, trityl, HC1), 7.10 (6H, m, trityl), 6.91 (1H, s, HAr/Am), 6.59 (1H, s, HC9), 
5.68 (1H, s, HC9), 5.03 (2H, s, HB4), 4.75 (1H, m, HC7), 4.63 (1H, m, HC2), 4.14 (1H, m, 
HA1), 3.11 (2H, m, HC6), 1.96 (4H, m, 3HA3, 1HC3), 1.80 (1H, m, HC3), 1.51 (2H, m, 
HC5), 1.42 (11H, m, 9HC8, 2HC4), 1.28 (3H, m, HA2); δC/ppm (100 MHz, CDCl3), 175.8, 
170.2, 166.7, 162.5, 156.2, 146.9, 141.4, 129.6, 128.4, 127.9, 127.2, 122.2, 121.3, 119.5, 
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82.0, 53.6, 49.9, 43.0, 39.9, 36.5, 31.9, 31.4, 29.7, 28.4, 25.3, 23.0, 22.8, 18.1, 14.1, 1.0; m/z 
(ES), 816 ([M+H]+). 
8.17.10. Synthesis of AcNH-Ala-Ar(His)-Lys-NH2 tripeptide mimetic 20. 
 
350 µL deprotecting solution (95% TFA, 2.5% TIS, 2.5% H2O) was added to 19 (10 mg, 
0.01 mmol) and stirred at room temperature for 1 h, during which time the solution turned 
bright yellow and gave an immediate precipitate. The deprotecting solution was evaporated 
under N2 and the solid washed with 4 × 2 mL cold TBME (stored at –20 °C). Solvent traces 
were removed under vacuum before the crude product was purified via LC-MS, using a 5–
98% MeOH gradient in H2O over 15 min, to give 20 as a pale yellow solid (2.0 mg, 34%). Rt 
= 3.1 min; δH/ppm (400 MHz, D2O), 8.64 (1H, s, HB6), 7.62 (1H, d, J = 8.3 Hz, HB1/B2), 
7.49 (1H, s, HB5), 7.45 (1H, s, HB3), 7.39 (1H, d, J = 8.3 Hz, HB1/B2), 5.22 (2H, s, HB4), 
4.36 (1H, m, HC2), 4.28 (1H, q J = 7.2 Hz, HA1), 2.89 (2H, t, J = 15.4 Hz, HC6), 1.86 (3H, 
s, HA3), 1.81 (2H, m, HC3), 1.61 (2H, m, HC5), 1.43 (2H, m, HC4), 1.29 (3H, d, J = 7.2 Hz, 
HA2); δC/ppm (100 MHz, D2O), 176.9, 174.3, 174.2, 169.9, 168.0, 134.5, 131.5, 129.2, 
128.2, 124.7, 121.2, 118.5, 112.8, 60.5, 54.1, 50.3, 39.1, 30.4, 26.3, 22.3, 21.4, 16.3; HRMS 
(ESI) found 474.2458 (C22H32N7O5 [M+H]+ requires 474.2465). 
8.18. Dansyl FRET inhibition assay for screening of mimetics 
Assays were carried out in triplicate in the same 96 well microplate, allowing four separate 
inhibitors able to be tested at the same time in one plate. A multi-channel pipette was used to 
add 150 µL assay buffer into wells B–G in rows 12, 9, 6 and 3. 300 µL of Inhibitor 1 was 
placed in well A12, Inhibitor 2 in A9, Inhibitor 3 in A6 and Inhibitor 4 in A3.  Doubling 
dilutions using 150 µL of each of these inhibitors was carried out between wells A–G to give 
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a concentration range between 1–64 µM. A multi-channel pipette was used to transfer 50 µL 
from row 12 into rows 11 and 10, 50 µL from row 9 into rows 8 and 7, 50 µL from row 6 into 
rows 5 and 4, and 50 µL from row 3 into rows 2 and 1 to set up triplicate experiments (as 
shown in Figure 95). 50 µL plate assay buffer was added to wells 1–12 of column H which 
was to be used for controls.  
7000 µL d-GMyoA[791-818] (1.3 µM) was mixed with 7000 µL MTIP[61-204] (1.6 µM), 
500 µL d-GMyoA[791-818] (1.3 µM) was mixed with 500 µL plate assay buffer, and both 
solutions were incubated at 37 °C for 10 min along with the plate containing the various 
concentrations of inhibitor. 150 µL of MTIP[61-204] (800 nM)/d-GMyoA[791-818]  
(650 nM) complex was then added to wells A–G of rows 1–12 to give wells containing the 
preformed complex with various concentrations of inhibitor. 150 µL was also added to wells 
H4–H6 to be used as controls. 150 µL d-GMyoA[791-818] (650 nM) mixed with assay buffer 
was added to wells H7–H9 and 150 µL plate assay buffer was added to H10–H12 to complete 
the control lane. The plate was incubated at 37 °C for 30 min before the fluorescence was 
scanned between 320–600 nm (excitation 280 nm, cutoff 325 nm) and single point readings 
were taken at emission 320 nm (excitation 280nm, no cutoff) and 525 nm (excitation 280 nm, 
cutoff 325 nm). Measurements were taken at 37 °C. 
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Appendix 
A1. Minimal medium components 
Minimal medium 
For 1 L: 
6 g Na2HPO4 
3 g KH2PO4 
0.5 g NaCl 
0.7 g 15NH4Cl 
 
The above mixture was pH adjusted to 7-7.4 and autoclaved, then the following filter 
sterilised and added. 
 
2 mL 1M MgSO4 
10 µL 1M CaCl2 
10 mL 20% glucose (or 2 g) 
1 mL Vitamins solution 
1 mL Micronutrients 
 
Micronutrients 
1000 × concentration 
3 × 10-6 M Ammonium molybdate 
4 × 10-4 M H3BO3 
3 × 10-5 M CoCl2 
1 × 10-5 M CuSO4 
8 × 10-5 M MnCl2 
1 × 10-5 M ZnSO4 
 
Vitamins solution 
Per litre (1000 × concentration) 
0.4 g Choline chloride 
0.5 g Folic acid 
0.5 g Pantothenic acid 
0.5 g Nicotinamide 
1.0 g Myo-inositol 
0.5 g Pyridoxal HCl 
0.5 g Thiamine HCl 
0.05 g Riboflavin 
1.0 g Biotin 
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A2. DNA plasmids 
MTIP pET-46 Ek/LIC vector 
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MTIP NTD and MTIP CTD pET-30 Xa/LIC vector 
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MTIP[61-204] pQE30 vector 
 
 
